PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sonnenschein, K				Sonnenschein, Kristina			No pain, no gain in PAD	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Editorial Material									[Sonnenschein, Kristina] Hannover Med Sch, Dept Cardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany		Sonnenschein, K (通讯作者)，Hannover Med Sch, Dept Cardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	sonnenschein.kristina@mh-hannover.de					Aboyans V, 2018, EUR HEART J, V39, P763, DOI 10.1093/eurheartj/ehx095; Dohmen A., 2016, VASA, V45, P1, DOI [10.1024/0301-1526/a000579, DOI 10.1024/0301-1526/A000579]; Fowkes FGR, 2013, LANCET, V382, P1329, DOI 10.1016/S0140-6736(13)61249-0; Frank U, 2019, VASA, V48, P7, DOI 10.1024/0301-1526/a000834; McDermott MM, 2021, JAMA-J AM MED ASSOC, V325, P1266, DOI 10.1001/jama.2021.2536	5	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	NOV	2021	50	6					483	483		10.1024/0301-1526/a000970			1	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6JL	34743588				2022-04-28	WOS:000753518900013
J	Bauersachs, R; Brodmann, M; Clark, C; Debus, S; De Carlo, M; Gomez-Cerezo, JF; Madaric, J; Mazzolai, L; Ricco, JB; Sillesen, H; Aboyans, V				Bauersachs, Rupert; Brodmann, Marianne; Clark, Christopher; Debus, Sebastian; De Carlo, Marco; Gomez-Cerezo, Jorge Francisco; Madaric, Juraj; Mazzolai, Lucia; Ricco, Jean-Baptiste; Sillesen, Henrik; Aboyans, Victor		EUROPAD Writing Grp	International public awareness of peripheral artery disease	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article							RISK-FACTORS; PREVALENCE	Background: Peripheral artery disease (PAD) of the lower limbs is a common condition with considerable global burden. Some country-specific studies suggest low levels of public awareness. To our knowledge public awareness of PAD has never been assessed simultaneously in several countries worldwide. Patients and methods: This was an international, general public, internet-based quantitative survey assessing vascular health and disease understanding. Questionnaires included 23 closed-ended multiple-choice, Likert scale and binary choice questions. Data were collected from 9,098 survey respondents from nine countries in Europe, North and Latin America during May-June 2018. Results: Overall, familiarity with PAD was low (57% of respondents were "not at all familiar", and 9% were "moderately" or "very familiar"). Knowledge about PAD health consequences was limited, with 55% of all respondents not being aware of limb consequences of PAD. There were disparities in PAD familiarity levels between countries; highest levels of self-reported awareness were in Germany and Poland where 13% reported to be "very" or "moderately" familiar with PAD, and lowest in Scandinavian countries (5%, 3% and 2% of respondents in Norway, Sweden and Denmark, respectively). There were disparities in awareness according to age. Respondents aged 25-34 were most familiar with PAD, with 12% stating that they were "moderately" or "very" familiar with the condition, whereas those aged 18-24 were the least familiar with PAD (7% "moderately" or "very" familiar with PAD). In the 45-54, 55-64 and 65+ age groups, 9% said they were "moderately" or "very" familiar with the term. There was no important gender-based difference in PAD familiarity.Conclusions: On an international level, public self-reported PAD awareness is low, even though PAD is a common condition with considerable burden. Campaigns to increase PAD awareness are needed to reduce delays in diagnosis and to motivate people to control PAD risk factors.	[Bauersachs, Rupert] Klinikum Darmstadt, Darmstadt, Germany; [Brodmann, Marianne] Med Univ, Div Angiol, Graz, Austria; [Clark, Christopher] Univ Exeter, Inst Hlth Serv Res, Primary Care Res Grp, Exeter, Devon, England; [Debus, Sebastian] Univ Heart & Vasc Ctr, Dept Vasc Med, Hamburg, Germany; [De Carlo, Marco] Azienda Osped Univ Pisana, Cardiothorac & Vasc Dept, Pisa, Italy; [Gomez-Cerezo, Jorge Francisco] Hosp Univ Infanta Sofia, Serv Med Interna, Madrid, Spain; [Madaric, Juraj] Comenius Univ, Clin Angiol, Nove Mesto, Slovakia; [Madaric, Juraj] Natl Inst Cardiovasc Dis, Nove Mesto, Slovakia; [Mazzolai, Lucia] Lausanne Univ, Heart & Vessel Dept, Angiol Div, Lausanne, Switzerland; [Ricco, Jean-Baptiste] Univ Hosp Poitiers, Dept Clin Res, Poitiers, France; [Sillesen, Henrik] Univ Copenhagen, Rigshosp, Dept Vasc Surg, Copenhagen, Denmark; [Aboyans, Victor] Dupuytren Univ Hosp, Dept Cardiol, Limoges, France		Bauersachs, R (通讯作者)，Klinikum Darmstadt, Angiol, Grafenstr 9, D-64283 Darmstadt, Germany.	bauersachs@em.uni-frankfurt.de	De Carlo, Marco/I-7973-2012	De Carlo, Marco/0000-0002-5763-9804; Madaric, Juraj/0000-0003-1326-2336	Bayer AG as part of the "My Vascular Health" disease awareness campaign; Bayer AGBayer AG	The survey was initiated and funded by Bayer AG as part of the "My Vascular Health" disease awareness campaign. The authors had full authority on the analysis and interpretation of the results, without any influence from the sponsor. The survey, data collection and fieldwork were carried out by the research consultancy Vitreous World, who were engaged by the survey sponsors, Bayer AG.	Aboyans V, 2017, KARDIOL POL, V75, P1065, DOI 10.5603/KP.2017.0216; Aboyans V, 2009, CAN J CARDIOL, V25, P545, DOI 10.1016/S0828-282X(09)70154-0; Bauerly BC, 2019, J LAW MED ETHICS, V47, P39, DOI 10.1177/1073110519857314; Bridgwood BM, 2020, VASC MED, V25, P263, DOI 10.1177/1358863X19893003; Campia U, 2019, AM J MED, V132, P1133, DOI 10.1016/j.amjmed.2019.04.043; Charasson M, 2018, VASA, V47, P465, DOI 10.1024/0301-1526/a000727; Criqui MH, 2015, CIRC RES, V116, P1509, DOI 10.1161/CIRCRESAHA.116.303849; Dasgupta A., 2018, E J CARDIOLOGY PRACT, V16; Fowkes FGR, 2013, LANCET, V382, P1329, DOI 10.1016/S0140-6736(13)61249-0; Frank U, 2019, VASA, V48, P7, DOI 10.1024/0301-1526/a000834; Gomez-Cano M, 2021, BRIT J GEN PRACT, V71, pE55, DOI 10.3399/bjgp20X713861; Grenon SM, 2013, VASC MED, V18, P176, DOI 10.1177/1358863X13493825; Hay SI, 2017, LANCET, V390, P1260, DOI 10.1016/S0140-6736(17)32130-X; Knuuti J, 2020, EUR HEART J, V41, P407, DOI 10.1093/eurheartj/ehz425; Kobayashi LC, 2015, J EPIDEMIOL COMMUN H, V69, P278, DOI 10.1136/jech-2014-204733; Lecouturier J., 2019, BJGP OPEN, V3; NHS Digital, 2020, QUALITY OUTCOMES FRA; Sigvant B, 2016, J VASC SURG, V64, P1009, DOI 10.1016/j.jvs.2016.03.429; Song PG, 2019, LANCET GLOB HEALTH, V7, pE1020, DOI 10.1016/S2214-109X(19)30255-4; Weragoda J, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3748-8	20	2	2	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JUL	2021	50	4					294	300		10.1024/0301-1526/a000945			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QY	33645232				2022-04-28	WOS:000695708700007
J	Rudolf, H; Kreutzer, J; Klaassen-Mielke, R; Timmesfeld, N; Trampisch, HJ; Krause, DMJ				Rudolf, Henrik; Kreutzer, Julia; Klaassen-Mielke, Renate; Timmesfeld, Nina; Trampisch, Hans-Joachim; Krause, Dietmar M. J.			Socioeconomic factors and the onset of peripheral artery disease in older adults Results from a prospective cohort study in a primary care setting (getABI)	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Peripheral artery disease; socioeconomic factor; incidence; older adults	POPULATION-DENSITY; RISK-FACTORS; MORTALITY; NEIGHBORHOOD; PREVALENCE; STROKE	Background: As evidence concerning the impact of socioeconomic factors on the risk of peripheral artery disease (PAD) is sparse, we assessed the association of education and area-level factors (population density, type of municipality and local unemployment rate) on the onset of PAD in older adults. Patients and methods: The analysis used data of the getABI study, a prospective cohort study with seven years of follow-up. Onset of PAD was determined by ankle brachial index (<0.9) or PAD symptoms. Cox regression analysis was employed. Results: Out of 5,444 primary care attendees without PAD at baseline, there were 1,381 participants with PAD onset (cumulative observation time 31,739 years), yielding an event rate of 43.5 (0.95 confidence interval [0.95 CI] 41.2-45.8) per 1,000 person-years. Multivariable Cox regression analysis showed an association of PAD onset with low education (hazard ratio 1.29; 0.95 CI 1.14-1.46: P<0.001), high population density (0.93; 0.89-0.98: P=0.002), small cities (compared to large cities) (0.71: 0.53-0.96: P=0.027) and high local unemployment rate (1.04; 1.00-1.07; P=0.032). The impact of low education on PAD onset was higher for men (2.11; 1.64-2.72) than for women (1.22: 1.07-1.40) (interaction term P=0.013). Conclusions: Socioeconomic factors, education as well as area-level socioeconomic indicators, make independent contributions to PAD onset in older adults.	[Rudolf, Henrik; Kreutzer, Julia; Klaassen-Mielke, Renate; Timmesfeld, Nina; Trampisch, Hans-Joachim; Krause, Dietmar M. J.] Ruhr Univ Bochum, Dept Med Informat Biometry & Epidemiol, Univ Str 105, D-44789 Bochum, Germany		Krause, DMJ (通讯作者)，Ruhr Univ Bochum, Dept Med Informat Biometry & Epidemiol, Univ Str 105, D-44789 Bochum, Germany.	gundi.krause@t-online.de		Rudolf, Henrik/0000-0001-9114-3805			Beenackers MA, 2018, HEALTH PLACE, V53, P79, DOI 10.1016/j.healthplace.2018.06.010; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3; Diederichs C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190441; Diehm C, 2009, CIRCULATION, V120, P2053, DOI 10.1161/CIRCULATIONAHA.109.865600; Ferguson HJM, 2010, EUR J VASC ENDOVASC, V40, P76, DOI 10.1016/j.ejvs.2010.03.008; Forsberg PO, 2018, HEALTH PLACE, V50, P1, DOI 10.1016/j.healthplace.2017.12.006; Gavurova B, 2016, HEALTH ECON REV, V6, DOI 10.1186/s13561-016-0099-1; Gerhard-Herman MD, 2017, J AM COLL CARDIOL, V69, P1465, DOI 10.1016/j.jacc.2016.11.008; Hooi JD, 2001, AM J EPIDEMIOL, V153, P666, DOI 10.1093/aje/153.7.666; Hurst JE, 2021, VASC MED, V26, P147, DOI 10.1177/1358863X20981132; Katz M, 2016, INT J CARDIOL, V224, P33, DOI 10.1016/j.ijcard.2016.08.309; Krause D, 2016, VASA, V45, P403, DOI 10.1024/0301-1526/a000556; Kroger K, 2009, VASC MED, V14, P289, DOI 10.1177/1358863X09102294; Kroger K, 2006, EUR J EPIDEMIOL, V21, P279, DOI 10.1007/s10654-006-0015-9; Lindroth M, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-825; Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4; McLennan D., 2011, ENGLISH INDICES DEPR; Meijer M, 2012, HEALTH PLACE, V18, P391, DOI 10.1016/j.healthplace.2011.12.001; OECD, 1999, CLASS ED PROGR MAN I; Pande RL, 2014, CIRC-CARDIOVASC QUAL, V7, P532, DOI 10.1161/CIRCOUTCOMES.113.000618; Pujades-Rodriguez M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104671; Roux AVD, 2001, NEW ENGL J MED, V345, P99, DOI 10.1056/NEJM200107123450205; Alzamora MT, 2016, BMC CARDIOVASC DISOR, V16, DOI 10.1186/s12872-015-0170-6; Vagero D, 2016, EUR J PUBLIC HEALTH, V26, P778, DOI 10.1093/eurpub/ckw053; Vart P, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004995; Velescu A, 2016, EUR J VASC ENDOVASC, V51, P696, DOI 10.1016/j.ejvs.2015.12.045	27	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	SEP	2021	50	5					341	347		10.1024/0301-1526/a000961			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6GV	34254830				2022-04-28	WOS:000753511900004
J	Biedermann, A; Beate, E; Monika, E; Gabriele, S; Bomba, A; Abdollah-Zadeh, YB; Peter, MR; Kroger, K				Biedermann, Annett; Beate, Eickmann; Monika, Eirich; Gabriele, Schwab; Bomba, Anja; Abdollah-Zadeh, Yannic Binan; Peter, Mertens R.; Kroeger, Knut		Deutscher Verband Podologie ZFD	A questionnaire survey study on nail disease prevalence in patients under podologic foot care	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Letter							ONYCHOMYCOSIS		[Biedermann, Annett] Podol Off, Strassfurt, Germany; [Beate, Eickmann] Podol Off, Hamm, Germany; [Monika, Eirich; Gabriele, Schwab] Podol Off, Friedberg, Germany; [Bomba, Anja] Fliedner Fachhsch, Med Informat Management, Dusseldorf, Germany; [Abdollah-Zadeh, Yannic Binan; Kroeger, Knut] HELIOS Klin, Clin Vasc Med, Krefeld, Germany; [Peter, Mertens R.] Otto von Guericke Univ, Univ Clin Nephrol & Hypertens Diabetol & Endocrin, Magdeburg, Germany		Kroger, K (通讯作者)，HELIOS Klin, Clin Vasc Med, Krefeld, Germany.	knut.kroeger@helios-kliniken.de					Baran R, 2011, CLIN DERMATOL, V29, P54, DOI 10.1016/j.clindermatol.2010.07.008; Dyachenko P, 2007, J EUR ACAD DERMATOL, V21, P340, DOI 10.1111/j.1468-3083.2006.01925.x; Fukunaga A, 2013, ACTA DERM-VENEREOL, V93, P747, DOI 10.2340/00015555-1576; Maddy AJ, 2018, CLIN DERMATOL, V36, P159, DOI 10.1016/j.clindermatol.2017.10.007; Pierard G, 2001, DERMATOLOGY, V202, P220, DOI 10.1159/000051640	5	0	0	1	1	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	NOV	2021	50	6					481	482		10.1024/0301-1526/a000967			2	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6JL	34743587				2022-04-28	WOS:000753518900012
J	Gombert, A; Kotelis, D; Ruckbeil, MV; Barbati, M; Martin, L; Marx, G; Grommes, J; Jacobs, MJ; Schalte, G				Gombert, Alexander; Kotelis, Drosos; Rueckbeil, Marcia V.; Barbati, Mohammad; Martin, Lukas; Marx, Gernot; Grommes, Jochen; Jacobs, Michael J.; Schaelte, Gereon			Increase of urinary TIMP-2 and IGFBP7 as potential predictor of acute kidney injury requiring renal replacement therapy and patients' outcome following complex endovascular and open thoracic abdominal aortic aneurysm surgery - a prospective observational study	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						TAAA-repair; AKI; biomarker; TIMP-2; IGFBP7; intensive care unit	SURGICAL REPAIR; FAILURE; IMPACT	Background: Acute kidney injury (AKI) as complication after open and endovascular repair of thoracoabdominal aortic aneurysm (TAAA) is one major predictor of mortality and postoperative complications. We evaluated tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) as combined early biomarker for AKI detection and predictor of patients' outcome. Patients and methods: Between 2014 and 2015, 52 patients have been enrolled in this observational study, of whom 29 (55.8%) underwent elective open repair and 23 (44.2%) endovascular repair. TIMP2 x IGFBP7 were measured until 48 hours after admission on intensive-care unit (ICU) and were analyzed regarding their predictive ability for AKI (defined according to the KDIGO criteria) requiring temporary renal replacement therapy (RRT) and 90-day mortality using ROC curves. Results: Mean patient age was 64.5 years (Min: 43, Max: 85), endovascular treated patients were older (p < 0.0001). 40.4% (n = 21) developed AKI, and 21.2% (n = 11) required renal replacement therapy. Inhospital and total mortality rates were 7.7% (n = 4) and 9.6% (n = 5), respectively. At no time a significant difference in TIMP2 x IGFB7 levels between patients undergoing open or endovascular surgery was observed. The predictive quality of the TIMP2 x IGFBP7 value on ICU admission was sound regarding AKI requiring temporary renal replacement therapy (sensitivity: 55.56% [38.1-72.1%], specificity: 90.91% [58.7-99.8%] with an area under the curve [AUC]: 0.694 [0.543-0.820]). Mean follow-up was 13.2 months (Min: 2, Max: 20), regarding the 90-day mortality, the predictive property of the TIMP2 x IGFBP7 value was not sufficient (sensitivity: 80% [28.4-99.5%], specificity: 52.38% [36.4-68%], and AUC: 0.607 [0.454-0.746]). Conclusions: TIMP2 x IGFBP7 level measured 6-12 hrs postoperatively may be useful as an early detectable biomarker for AKI requiring temporary renal replacement therapy. It seems not suited to predict patients' outcome following complex thoracoabdominal aortic surgery, regardless if performed by open or endovascular repair.	[Gombert, Alexander; Kotelis, Drosos; Barbati, Mohammad; Grommes, Jochen; Jacobs, Michael J.] Rhein Westfal TH Aachen, Univ Hosp Aachen, European Vasc Ctr Aachen Maastricht, Aachen, Germany; [Rueckbeil, Marcia V.] Rhein Westfal TH Aachen, Univ Hosp Aachen, Dept Med Stat, Aachen, Germany; [Martin, Lukas; Marx, Gernot] Rhein Westfal TH Aachen, Univ Hosp Aachen, Dept Intens Care & Intermediate Care, Aachen, Germany; [Schaelte, Gereon] Rhein Westfal TH Aachen, Univ Hosp Aachen, Dept Anesthesiol, Aachen, Germany		Gombert, A (通讯作者)，Univ Hosp Aachen, Dept Vasc Surg, European Vasc Ctr Aachen Maastricht, Pauwelsstr 30, D-52074 Aachen, Germany.	agombert@ukaachen.de	Barbati, Mohammad Esmaeil/F-5529-2016; Rückbeil, Marcia/P-1821-2018	Barbati, Mohammad Esmaeil/0000-0003-0709-8533; Rückbeil, Marcia/0000-0003-0277-1282; Gombert, Alexander/0000-0002-8451-2913			Barratt J, 2000, EUR J VASC ENDOVASC, V20, P163, DOI 10.1053/ejvs.2000.1078; Canyigit M, 2013, DIAGN INTERV RADIOL, V19, P244, DOI 10.5152/dir.2012.001; Clough RE, 2012, EUR J VASC ENDOVASC, V43, P262, DOI 10.1016/j.ejvs.2011.11.009; Coselli JS, 2016, J THORAC CARDIOV SUR, V151, P1323, DOI 10.1016/j.jtcvs.2015.12.050; CRAWFORD ES, 1974, ANN SURG, V179, P763, DOI 10.1097/00000658-197405000-00032; Drews JD, 2014, ANN THORAC SURG, V97, P2027, DOI 10.1016/j.athoracsur.2014.02.045; Gocze I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120863; Gombert A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31183-1; Gombert A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112374; Jacobs MJ, 2007, J CARDIOVASC SURG, V48, P49; Jacobs MJ, 2014, ANN CARDIOTHORAC SUR, V3, P325, DOI 10.3978/j.issn.2225-319X.2014.05.02; Jacobs MJ, 2002, ANN THORAC SURG, V74, pS1864, DOI 10.1016/S0003-4975(02)04154-1; Kashani K, 2013, CRIT CARE, V17, DOI 10.1186/cc12503; Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789; Lee HC, 2015, YONSEI MED J, V56, P904, DOI 10.3349/ymj.2015.56.4.904; Martin L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00681; Meersch M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093460; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Mommertz G, 2008, EUR J VASC ENDOVASC, V35, P181, DOI 10.1016/j.ejvs.2007.10.013; Murray PT, 2014, KIDNEY INT, V85, P513, DOI 10.1038/ki.2013.374; O'Brien Noel, 2011, Perspect Vasc Surg Endovasc Ther, V23, P173, DOI 10.1177/1531003511408340; Oderich GS, 2017, J VASC SURG, V65, P1249, DOI 10.1016/j.jvs.2016.09.038; Oezkur M, 2017, KIDNEY BLOOD PRESS R, V42, P456, DOI 10.1159/000479298; Pawlak K, 2010, NEPHRON CLIN PRACT, V115, pC251, DOI 10.1159/000313483; Piechota-Polanczyk A, 2015, EUR J VASC ENDOVASC, V49, P549, DOI 10.1016/j.ejvs.2015.02.011; Price PM, 2009, KIDNEY INT, V76, P604, DOI 10.1038/ki.2009.224; Riambau V, 2017, EUR J VASC ENDOVASC, V53, P4, DOI 10.1016/j.ejvs.2016.06.005; Rodier F, 2007, NUCLEIC ACIDS RES, V35, P7475, DOI 10.1093/nar/gkm744; Saratzis A, 2015, EUR J VASC ENDOVASC, V49, P534, DOI 10.1016/j.ejvs.2015.01.002; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Tshomba Y, 2015, J CARDIOVASC SURG, V56, P687; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Xiong WF, 2006, J VASC SURG, V44, P1061, DOI 10.1016/j.jvs.2006.06.036; Zarbock A, 2016, JAMA-J AM MED ASSOC, V315, P2190, DOI 10.1001/jama.2016.5828	34	0	0	1	2	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0301-1526			VASA	Vasa	FEB	2021	50	2					101	109		10.1024/0301-1526/a000902			9	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	QQ5PH	32815460				2022-04-28	WOS:000624575300004
J	Behrendt, CA; Peters, F				Behrendt, Christian-Alexander; Peters, Frederik			On the rise but still underutilized - why statins are the Achilles' heel of secondary prevention in peripheral arterial disease	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Editorial Material							DECISION; SOCIETY; IMPACT		[Behrendt, Christian-Alexander; Peters, Frederik] Univ Med Ctr Hamburg Eppendorf, Dept Vasc Med, Res Grp GermanVasc, Univ Heart & Vasc Ctr Hamburg, Hamburg, Germany		Behrendt, CA (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Vasc Med, Res Grp GermanVasc, Univ Heart & Vasc Ctr Hamburg, Hamburg, Germany.	behrendt@hamburg.de	Peters, Frederik/AAS-1846-2021	Peters, Frederik/0000-0001-5832-8410			Aboyans V, 2018, EUR J VASC ENDOVASC, V55, P305, DOI 10.1016/j.ejvs.2017.07.018; Behrendt CA, 2019, VASA, V48, P262, DOI 10.1024/0301-1526/a000771; Chiang CE, 2016, J ATHEROSCLER THROMB, V23, P567, DOI 10.5551/jat.31179; Conte MS, 2019, EUR J VASC ENDOVASC, V58, pS1, DOI 10.1016/j.ejvs.2019.05.006; Corriere MA, 2015, J VASC SURG, V62, P1032, DOI 10.1016/j.jvs.2015.04.443; De Martino RR, 2014, J VASC SURG, V59, P1615, DOI 10.1016/j.jvs.2013.12.013; Frank U, 2019, VASA, V48, P7, DOI 10.1024/0301-1526/a000834; Klein-Weigel PF, 2010, VASA, V39, P145, DOI 10.1024/0301-1526/a000020; Kokkinidis DG, 2020, VASC MED, V25, P106, DOI 10.1177/1358863X19894055; Nishimura RA, 2017, CIRCULATION, V135, pE1159, DOI 10.1161/CIR.0000000000000503; Pastori D, 2020, THROMB HAEMOSTASIS, V120, P866, DOI 10.1055/s-0040-1709711; Peters F, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.018338; Peters F, 2020, EUR J VASC ENDOVASC, V60, P421, DOI 10.1016/j.ejvs.2020.05.001; Schwabe U., 2020, ARZNEIVERORDNUNGS RE, DOI [https://doi.org10.1007/978-3-662-62168-4, DOI 10.1007/978-3-662-62168-4]; Stroes ES, 2015, EUR HEART J, V36, P1012, DOI 10.1093/eurheartj/ehv043	15	0	0	1	2	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	MAY	2021	50	3					161	162		10.1024/0301-1526/a000926			2	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QU	33215976	Bronze			2022-04-28	WOS:000695708300001
J	Visona, A; Quere, I; Mazzolai, L; Amitrano, M; Lugli, M; Madaric, J; Prandoni, P				Visona, Adriana; Quere, Isabelle; Mazzolai, Lucia; Amitrano, Maria; Lugli, Marzia; Madaric, Juraj; Prandoni, Paolo		European Soc Vasc Med ESVM	Post-thrombotic syndrome A position paper from European Society of Vascular Medicine	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Review						Thrombosis; deep vein thrombosis; Villalta score; anticoagulant; ultrasound	DEEP-VEIN THROMBOSIS; CATHETER-DIRECTED THROMBOLYSIS; VENOUS THROMBOSIS; COMPRESSION STOCKINGS; PREDICTION MODEL; FOLLOW-UP; PREVENTION; EXERCISE; THERAPY; SURGERY	Post-thrombotic syndrome (PTS) is a chronic venous insufficiency manifestation following an episode of deep-vein thrombosis (DVT). It is an important and frequent long-term adverse event of proximal DVT affecting 20-50% of patients. This position paper integrates data guiding clinicians in deciding PTS diagnosis, treatment and follow-up.	[Visona, Adriana] Azienda ULSS 2 Marca Trevigiana, Angiol Unit, Castelfranco Veneto, Italy; [Quere, Isabelle] Univ Montpellier, Med Vasc, Montpellier, France; [Mazzolai, Lucia] Lausanne Univ Hosp, Heart & Vessel Dept, Div Angiol, Ch Mt Paisible 18, CH-1011 Lausanne, Switzerland; [Amitrano, Maria] Moscati Hosp, Internal Med Unit, Avellino, Italy; [Lugli, Marzia] Hesperia Hosp, Int Ctr Deep Venous Surg, Dept Vasc Surg, Modena, Italy; [Madaric, Juraj] Comenius Univ, Clin Angiol, Bratislava, Slovakia; [Madaric, Juraj] Natl Inst Cardiovasc Dis, Bratislava, Slovakia; [Prandoni, Paolo] Arianna Fdn, Bologna, Italy		Mazzolai, L (通讯作者)，Lausanne Univ Hosp, Heart & Vessel Dept, Div Angiol, Ch Mt Paisible 18, CH-1011 Lausanne, Switzerland.	lucia.mazzolai@chuv.ch	Stanek, Agata/N-8179-2017	Stanek, Agata/0000-0001-6939-9898; Madaric, Juraj/0000-0003-1326-2336			Amin EE, 2018, J THROMB HAEMOST, V16, P1555, DOI 10.1111/jth.14163; Amin EE, 2018, BLOOD, V132, P2298, DOI 10.1182/blood-2018-03-836783; Amin EE, 2018, THROMB HAEMOSTASIS, V118, P1242, DOI 10.1055/s-0038-1655743; Ashrani AA, 2009, J THROMB THROMBOLYS, V28, P465, DOI 10.1007/s11239-009-0309-3; Brandjes DPM, 1997, LANCET, V349, P759, DOI 10.1016/S0140-6736(96)12215-7; Brooks EG, 2009, BLOOD, V114, P1276, DOI 10.1182/blood-2009-03-209981; Caldwell K, 2013, J VASC SURG-VENOUS L, V1, P126, DOI 10.1016/j.jvsv.2012.07.004; Cohen JM, 2012, CHEST, V141, P308, DOI 10.1378/chest.11-1175; Comerota AJ, 2019, CIRCULATION, V139, P1162, DOI 10.1161/CIRCULATIONAHA.118.037425; Dronkers CEA, 2018, THROMB HAEMOSTASIS, V118, P1428, DOI 10.1055/s-0038-1666859; Eklof B, 2004, J VASC SURG, V40, P1248, DOI 10.1016/j.jvs.2004.09.027; Elsharawy M, 2002, EUR J VASC ENDOVASC, V24, P209, DOI 10.1053/ejvs.2002.1665; Enden T, 2012, LANCET, V379, P31, DOI 10.1016/S0140-6736(11)61753-4; Frank U, 2019, VASA, V48, P7, DOI 10.1024/0301-1526/a000834; Galanaud JP, 2018, THROMB RES, V164, P100, DOI 10.1016/j.thromres.2017.07.026; Garcia MJ, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.013398; Ginsberg JS, 2001, ARCH INTERN MED, V161, P2105, DOI 10.1001/archinte.161.17.2105; Haenen JH, 1999, CLIN SCI, V96, P271, DOI 10.1042/CS19980254; Haig Y, 2016, LANCET HAEMATOL, V3, pE64, DOI 10.1016/S2352-3026(15)00248-3; Holmes CE, 2014, VASC MED, V19, P42, DOI 10.1177/1358863X14521883; JOHNSON BF, 1995, J VASC SURG, V21, P307, DOI 10.1016/S0741-5214(95)70271-7; Kahn SR, 2009, J THROMB HAEMOST, V7, P879, DOI 10.1111/j.1538-7836.2009.03294.x; Kahn SR, 2004, J THROMB HAEMOST, V2, P2146, DOI 10.1111/j.1538-7836.2004.00957.x; Kahn SR, 2014, CIRCULATION, V130, P1636, DOI 10.1161/CIR.0000000000000130; Kahn SR, 2014, LANCET, V383, P880, DOI 10.1016/S0140-6736(13)61902-9; Klonizakis M, 2009, MICROVASC RES, V78, P67, DOI 10.1016/j.mvr.2009.03.002; Klonizakis M, 2010, EUR J APPL PHYSIOL, V109, P1221, DOI 10.1007/s00421-010-1471-1; Labropoulos N, 2003, J VASC SURG, V38, P793, DOI 10.1016/S0741-5214(03)00424-5; Lattimer CR, 2014, J VASC SURG-VENOUS L, V2, P8, DOI 10.1016/j.jvsv.2013.06.003; Li RH, 2020, THROMB RES, V196, P340, DOI 10.1016/j.thromres.2020.09.014; Lichtenberg MKW, 2021, VASA, V50, P59, DOI 10.1024/0301-1526/a000875; Maleti O, 2011, EUR J VASC ENDOVASC, V41, P837, DOI 10.1016/j.ejvs.2011.02.013; Meissner MH, 2012, J VASC SURG, V55, P1449, DOI 10.1016/j.jvs.2011.12.081; Mol GC, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2691; Mukhopadhyay S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01348; Nawasrah J, 2021, VASA, V50, P30, DOI 10.1024/0301-1526/a000933; Neglen P, 2000, EUR J VASC ENDOVASC, V20, P560, DOI 10.1053/ejvs.2000.1251; Notten P, 2020, LANCET HAEMATOL, V7, pE40, DOI 10.1016/S2352-3026(19)30209-1; OShaughnessy AM, 1997, INT ANGIOL, V16, P45; Partsch H, 2000, J VASC SURG, V32, P861, DOI 10.1067/mva.2000.110352; Prandoni P, 2004, ANN INTERN MED, V141, P249, DOI 10.7326/0003-4819-141-4-200408170-00004; Prandoni P, 2002, ANN INTERN MED, V137, P955, DOI 10.7326/0003-4819-137-12-200212170-00008; Prandoni P, 2020, INTERN EMERG MED, V15, P447, DOI 10.1007/s11739-019-02215-z; Prandoni P, 2017, THROMB RES, V153, P97, DOI 10.1016/j.thromres.2017.03.022; Prandoni P, 2015, SEMIN THROMB HEMOST, V41, P133, DOI 10.1055/s-0035-1544161; Prandoni P, 2012, BLOOD, V119, P1561, DOI 10.1182/blood-2011-11-391961; Quere I, 2019, J Med Vasc, V44, P28, DOI 10.1016/j.jdmv.2018.12.003; Rabinovich A, 2018, J THROMB HAEMOST, V16, P262, DOI 10.1111/jth.13909; Rabinovich A, 2018, BLOOD, V131, P2215, DOI 10.1182/blood-2018-01-785956; Raju S, 2010, J VASC SURG, V51, P401, DOI 10.1016/j.jvs.2009.08.032; Ramos-Gonzalez E, 2012, COMPLEMENT THER MED, V20, P291, DOI 10.1016/j.ctim.2012.03.005; Razavi MK, 2015, CIRC-CARDIOVASC INTE, V8, DOI 10.1161/CIRCINTERVENTIONS.115.002772; Saggini R, 2009, Int J Immunopathol Pharmacol, V22, P1; Seager MJ, 2016, EUR J VASC ENDOVASC, V51, P100, DOI 10.1016/j.ejvs.2015.09.002; SEVITT S, 1974, J CLIN PATHOL, V27, P517, DOI 10.1136/jcp.27.7.517; Subbiah R, 2016, LANCET HAEMATOL, V3, pE293, DOI 10.1016/S2352-3026(16)30017-5; ten Cate-Hoek AJ, 2018, LANCET HAEMATOL, V5, P25, DOI 10.1016/S2352-3026(17)30227-2; ten Cate-Hoek NJ, 2018, RES PRACT THROMB HAE, V2, P209, DOI 10.1002/rth2.12085; Uhl JF, 2015, PHLEBOLOGY, V30, P180, DOI 10.1177/0268355513517686; Uhl JF, 2013, PHLEBOLOGY, V27, P19; Urbanek T, 2021, VASA, V50, P11, DOI 10.1024/0301-1526/a000932; Van Dongen CJJ, 2005, J THROMB HAEMOST, V3, P939; van Es N, 2014, BLOOD, V124, P1968, DOI [10.1182/blood-2014-04571232, 10.1182/blood-2014-04-571232]; Vedantham S, 2017, NEW ENGL J MED, V377, P2240, DOI 10.1056/NEJMoa1615066; Vedantham S, 2016, VASC MED, V21, P400, DOI 10.1177/1358863X16650747; Villalta S, 1994, HAEMOSTASIS, V24; Welsh JD, 2019, J CLIN INVEST, V129, P5489, DOI 10.1172/JCI124791; Wik HS, 2018, THROMB RES, V164, P110, DOI 10.1016/j.thromres.2017.10.022; Wittens C, 2015, EUR J VASC ENDOVASC, V49, P678, DOI 10.1016/j.ejvs.2015.02.007	69	0	0	0	2	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	SEP	2021	50	5					331	340		10.1024/0301-1526/a000946			10	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6GV	33720757				2022-04-28	WOS:000753511900003
J	O'Sullivan, G				O'Sullivan, Gerard			Percutaneous thrombectomy using a novel single session device for acute iliofemoral deep vein thrombosis	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Iliofemoral deep vein thrombosis; single session mechanical thrombectomy; quality of life	CATHETER-DIRECTED THROMBOLYSIS; QUALITY-OF-LIFE; POSTTHROMBOTIC SYNDROME	A 74-year-old woman presented with acute symptomatic left thigh and calf swelling; imaging demonstrated evidence of occlusive thrombosis from the upper left common iliac vein to the mid-thigh. Single session zero-thrombolysis venous thrombectomy was performed using the ReVene (TM) Thrombectomy Catheter.	[O'Sullivan, Gerard] Univ Hosp Galway, Galway, Ireland		O'Sullivan, G (通讯作者)，Galway Univ Hosp, Intervent Radiol, Newcastle Rd, Galway H91 YR71, Ireland.	gerard.osullivan2@hse.ie					Bozkurt A, 2015, ANN VASC SURG, V29, P670, DOI 10.1016/j.avsg.2014.12.013; Comerota AJ, 2019, CIRCULATION, V139, P1162, DOI 10.1161/CIRCULATIONAHA.118.037425; Comerota AJ, 2012, J VASC SURG, V55, P768, DOI 10.1016/j.jvs.2011.10.032; Crowner JR, 2019, J VASC SURG CASES IN, V5, P302, DOI 10.1016/j.jvscit.2019.03.010; Dopheide JF, 2018, VASA, V47, P56, DOI 10.1024/0301-1526/a000666; Enden T, 2012, LANCET, V379, P31, DOI 10.1016/S0140-6736(11)61753-4; Fleck D, 2017, CARDIOVASC DIAGN THE, V7, pS228, DOI 10.21037/cdt.2017.09.15; Grewal NK, 2010, J VASC SURG, V51, P1209, DOI 10.1016/j.jvs.2009.12.021; Kahn SR, 2008, J THROMB HAEMOST, V6, P1105, DOI 10.1111/j.1538-7836.2008.03002.x; Kahn SR, 2002, ARCH INTERN MED, V162, P1144, DOI 10.1001/archinte.162.10.1144; Kahn SR, 2014, CIRCULATION, V130, P1636, DOI 10.1161/CIR.0000000000000130; Kapadia S, 2017, TXB INTERVENTIONAL C; Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026; Kevane B, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-030059; Lu YM, 2018, CLIN APPL THROMB-HEM, V24, P1134, DOI 10.1177/1076029617739703; Raskob GE, 2014, J THROMB HAEMOST, V12, P1580, DOI 10.1111/jth.12698; Roumen-Klappe EM, 2005, THROMB HAEMOSTASIS, V94, P825, DOI 10.1160/TH05-03-0146; Soosainathan A, 2013, J VASC SURG, V57, P254, DOI 10.1016/j.jvs.2012.09.011; Stain M, 2005, J THROMB HAEMOST, V3, P2671, DOI 10.1111/j.1538-7836.2005.01648.x; Vedantham S, 2017, NEW ENGL J MED, V377, P2240, DOI 10.1056/NEJMoa1615066	20	0	0	1	2	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0301-1526			VASA	Vasa	JAN	2021	50	1			SI		74	77		10.1024/0301-1526/a000928			4	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	PQ4VY	33291997	Bronze			2022-04-28	WOS:000606545800011
J	Bohme, T; Noory, E; Beschorner, U; Lerke, F; Schmidt, A; Scheinert, D; Ito, W; Zeller, T; Rastan, A				Boehme, Tanja; Noory, Elias; Beschorner, Ulrich; Lerke, Frederik; Schmidt, Andrej; Scheinert, Dierk; Ito, Wulf; Zeller, Thomas; Rastan, Aljoscha			Photoablative atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis in instent femoro-popliteal obstructions (PHOTOPAC) A randomized multicentre pilot study	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Peripheral artery occlusive disease; superficial femoral artery; drug coated balloon; instent restenosis; laser atherectomy	IN-STENT RESTENOSIS; SUPERFICIAL FEMORAL-ARTERY; LASER ATHERECTOMY; NITINOL STENTS; EXCIMER-LASER; ANGIOPLASTY; IMPLANTATION; DISEASE; SUPERIORITY; LESIONS	Background: To evaluate the safety and effectiveness of preparing instent femoropopliteal lesion with photoabtative laser atherectomy or plain balloon angioplasty (POBA) prior to drug-coated balloon (DCB) angioplasty. Patients and methods: The prospective, multicenter, randomized study enrolled patients with Rutherford-Becker-class (RBC) 1 to 5 and instent lesions located in superficial femoral artery and/or popliteal artery above the knee joint. Primary endpoint was target lesion percent stenosis at 1 year as determined by the angiographic core-laboratory. Secondary endpoints included procedural success, major adverse event rate, clinical improvement and improvement in ankle-brachial index (ABI), clinically-driven target lesion revascularization (CD-TLR), and primary patency rate at until 2-year follow-up. Results: The study was terminated prior to the enrollment goat due to slow enrollment. Thirty patients were included in the laser plus DCB cohort and 31 patients in the control cohort. Primary endpoint was not significantly different (p=0.331). Procedural success was 83.3% and 87.1% for the laser plus DCB and the control cohort, respectively. Serious adverse events at 30 days and 1-year were not statistically different between the two cohorts. For the ABI, significant improvements were present at discharge as well as at the follow-up visits. This was also evident for the RBC at the follow-up visits. One- and two-year freedom from CD-TLR was 86.7% vs. 87.1%, and 63.6% vs. 72%, respectively. Duplex derived primary patency was 90% at 6-months, 65.5% at one year and 56.5% at two year for the laser cohort and 90.3%, 75.9% and 53.8% for the control cohort. Conclusions: Safety of instent photoablative laser atherectomy followed by DCB angioplasty is confirmed by this study. Due to the small sample size, no benefit over POBA as vessel preparation could be shown.	[Boehme, Tanja; Noory, Elias; Beschorner, Ulrich; Lerke, Frederik; Zeller, Thomas] Univ Heart Ctr Freiburg Bad Krozingen, Dept Angiol, Bad Krozingen, Germany; [Schmidt, Andrej; Scheinert, Dierk] Univ Hosp Leipzig, Leipzig, Germany; [Ito, Wulf] Allgaeu Hosp Grp, Cardiovasc Ctr Oberallgaeu Kempten, Immenstadt, Germany; [Rastan, Aljoscha] Kantonsspital Aarau, Dept Angiol, Med Univ Clin, Aargau, Switzerland		Bohme, T (通讯作者)，Univ Herzzentrum Freiburg Bad Krozingen, Abt Angiol & Kardiol 2, Sudring 15, D-79189 Bad Krozingen, Germany.	tanja.boehme@universitaets-herzzentrum.de		Rastan, Aljoscha/0000-0002-3077-3253			Bosiers M, 2020, J ENDOVASC THER, V27, P287, DOI 10.1177/1526602820902014; Bosiers M, 2015, J ENDOVASC THER, V22, P1, DOI 10.1177/1526602814564385; Bosiers M, 2011, J VASC SURG, V54, P1042, DOI 10.1016/j.jvs.2011.03.272; Bosiers M, 2009, J ENDOVASC THER, V16, P261, DOI 10.1583/08-2676.1; Brodmann M, 2017, JACC-CARDIOVASC INTE, V10, P2113, DOI 10.1016/j.jcin.2017.06.018; Cassese S, 2018, CIRC-CARDIOVASC INTE, V11, DOI 10.1161/CIRCINTERVENTIONS.118.007055; Dake MD, 2011, CIRC-CARDIOVASC INTE, V4, P495, DOI 10.1161/CIRCINTERVENTIONS.111.962324; Dick P, 2009, CATHETER CARDIO INTE, V74, P1090, DOI 10.1002/ccd.22128; Dippel EJ, 2015, JACC-CARDIOVASC INTE, V8, P92, DOI 10.1016/j.jcin.2014.09.009; Feldman DN, 2018, CATHETER CARDIO INTE, V92, P124, DOI 10.1002/ccd.27635; Gandini R, 2013, J ENDOVASC THER, V20, P805, DOI 10.1583/13-4308MR.1; Giannopoulos S, 2020, CARDIOVASC REVASCULA, V21, P771, DOI 10.1016/j.carrev.2019.10.006; Iida O, 2011, J ENDOVASC THER, V18, P753, DOI 10.1583/11-3581.1; Kearney M, 1997, CIRCULATION, V95, P1998, DOI 10.1161/01.CIR.95.8.1998; Kornowski R, 1998, J AM COLL CARDIOL, V31, P224, DOI 10.1016/S0735-1097(97)00450-6; Krankenberg H, 2008, J VASC SURG, V47, P239; Krankenberg H, 2015, CIRCULATION, V132, P2230, DOI 10.1161/CIRCULATIONAHA.115.017364; Laird JR, 2010, CIRC-CARDIOVASC INTE, V3, P267, DOI 10.1161/CIRCINTERVENTIONS.109.903468; Norgren L, 2007, J VASC SURG, V45, pS5, DOI 10.1016/j.jvs.2006.12.037; Schillinger M, 2006, NEW ENGL J MED, V354, P1879, DOI 10.1056/NEJMoa051303; Schmidt A, 2014, J ENDOVASC THER, V21, P52, DOI 10.1583/13-4538R.1; Tepe G, 2020, J ENDOVASC THER, V27, P276, DOI 10.1177/1526602820907917; Tepe G, 2015, CIRCULATION, V131, P495, DOI 10.1161/CIRCULATIONAHA.114.011004; Tosaka A, 2012, J AM COLL CARDIOL, V59, P16, DOI 10.1016/j.jacc.2011.09.036; Zeller T, 2013, JACC-CARDIOVASC INTE, V6, P274, DOI 10.1016/j.jcin.2012.12.118	25	0	0	1	1	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	SEP	2021	50	5					387	393		10.1024/0301-1526/a000959			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6GV	34107772				2022-04-28	WOS:000753511900010
J	Keschenau, PR; Beropoulis, E; Gombert, A; Jacobs, MJ; Torsello, G; Austermann, M; Kotelis, D; Donas, KP				Keschenau, Paula R.; Beropoulis, Efthymios; Gombert, Alexander; Jacobs, Michael J.; Torsello, Giovanni; Austermann, Martin; Kotelis, Drosos; Donas, Konstantinos P.			The role of surgical and total endovascular techniques in the treatment of ruptured juxtarenal aortic aneurysms	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Ruptured aneurysm; abdominal aortic aneurysm; endovascular procedures; vascular grafting	CHIMNEY TECHNIQUE; REPAIR; IMPACT; ENDOGRAFTS; EMERGENCY; TRENDS	Background: Ruptured juxtarenal aortic aneurysms (RJAAA) represent a special challenge in clinical practice, but the evidence to guide therapeutic decision-making is scarce. The aim of this study was to present two different approaches, open surgical (OAR) and chimney endovascular repair (CHEVAR), for treating patients with RJAAA. Patients and methods: This retrospective two-center study included all patients per center undergoing OAR or CHEVAR for RJAAA between February 2008 and January 2020. Juxtarenal aortic aneurysms were defined as having an infrarenal neck of 2-5 mm, measured after three-dimensional reconstruction of the computed tomography angiography scan. Results: 12 OAR patients (10 mate, median age 73 years [58-90 years]) and 6 CHEVAR patients (all mate, median age 74 years [59-83 years]) were included. In the OAR group, the proximal aortic damping was suprarenal in 7 and interrenal in 5 patients. Cold renal perfusion was used in 4 patients, in 2 with suprarenal aortic damping and in 2 with interrenal aortic clamping. 3 CHEVAR patients received a single renal chimney, the other 3 received double renal chimneys. Technical success was 12/12 in the OAR group 5/6 in the CHEVAR group. Inhospital mortality and 30-day mortality were 3/12 after OAR and 0/6 after CHEVAR. 2 OAR patients required transient dialysis. Median in-hospital stay was 14 (10-63) and 8 (6-21) days and median follow-up (FU) was 20 (3-37) and 30 (7-101) months, respectively. No further deaths occurred during FU. One OAR patient and 4 CHEVAR patients required aortic reinterventions. Conclusions: RJAAAs are rare. Both OAR and CHEVAR can represent adequate treatments for RJAAAs. OAR is the traditional approach, but CHEVAR has - in a high-volume center - promising early results with nonetheless a need for continuous FU to prevent reinterventions. Defining the studied aortic pathology precisely is essential for future research in order to draw valid conclusions.	[Keschenau, Paula R.; Gombert, Alexander; Jacobs, Michael J.; Kotelis, Drosos] RWTH Univ Hosp Aachen, European Vasc Ctr Aachen Maastricht, Dept Vasc Surg, Pauwelsstr 30, D-52074 Aachen, Germany; [Beropoulis, Efthymios; Torsello, Giovanni; Austermann, Martin] St Franziskus Hosp Munster, Dept Vasc Surg, Munster, Germany; [Beropoulis, Efthymios; Torsello, Giovanni; Austermann, Martin] St Franziskus Hosp Munster, Inst Vasc Res, Munster, Germany; [Donas, Konstantinos P.] Goethe Univ Frankfurt, Dept Vasc Surg, Asklepios Clin Langen, Langen, Germany; [Donas, Konstantinos P.] Goethe Univ Frankfurt, Res Vasc Ctr, Asklepios Clin Langen, Langen, Germany		Keschenau, PR (通讯作者)，RWTH Univ Hosp Aachen, European Vasc Ctr Aachen Maastricht, Dept Vasc Surg, Pauwelsstr 30, D-52074 Aachen, Germany.	paula.keschenau@rwth-aachen.de					Back MR, 2005, ANN VASC SURG, V19, P648, DOI 10.1007/s10016-005-6843-3; Brossier J, 2013, ANN VASC SURG, V27, P844, DOI 10.1016/j.avsg.2012.05.035; Chaufour X, 2020, EUR J VASC ENDOVASC, V59, P40, DOI 10.1016/j.ejvs.2019.05.010; Dias NV, 2015, J ENDOVASC THER, V22, P105, DOI 10.1177/1526602814564384; Donas KP, 2012, J VASC SURG, V56, P285, DOI 10.1016/j.jvs.2012.01.043; Doonan RJ, 2019, J VASC SURG, V70, P2054, DOI 10.1016/j.jvs.2019.04.464; Greenleaf EK, 2020, J VASC SURG, V71, P1148, DOI 10.1016/j.jvs.2019.06.187; Kinio A, 2020, J VASC SURG, VS0741, P31697; Latz CA, 2020, ANN VASC SURG, VS0890, P30417; Latz CA, 2020, ANN VASC SURG, VS0741, P31089; Park BD, 2013, J AM COLL SURGEONS, V216, P745, DOI 10.1016/j.jamcollsurg.2012.12.028; Suero SR, 2019, ANN VASC SURG, V59, P63, DOI 10.1016/j.avsg.2018.12.089; Steffen M, 2020, LANGENBECK ARCH SURG, V405, P207, DOI 10.1007/s00423-020-01865-4; Suckow BD, 2018, J VASC SURG, V67, P1690, DOI 10.1016/j.jvs.2017.09.046; Sveinsson M, 2021, EUR J VASC ENDOVASC, V61, P550, DOI 10.1016/j.ejvs.2020.12.012; Taneva GT, 2020, J ENDOVASC THER, V27, P902, DOI 10.1177/1526602820948260; Tanious A, 2020, ANN VASC SURG, V62, P63, DOI 10.1016/j.avsg.2019.05.005; Touma J, 2020, EUR J VASC ENDOVASC, V59, P776, DOI 10.1016/j.ejvs.2020.01.040; Varkevisser RRB, 2020, EUR J VASC ENDOVASC, V59, P411, DOI 10.1016/j.ejvs.2019.10.004; Wanhainen A, 2019, EUR J VASC ENDOVASC, V57, P8, DOI 10.1016/j.ejvs.2018.09.020; Yeung KK, 2010, J VASC SURG, V51, P551, DOI 10.1016/j.jvs.2009.09.051	21	1	1	0	1	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	SEP	2021	50	5					356	362		10.1024/0301-1526/a000955			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6GV	34006132				2022-04-28	WOS:000753511900006
J	Qanadli, SD; Rotzinger, D				Qanadli, Salah D.; Rotzinger, David			Lower extremity arterial disease - call for a standardized and comprehensive name of the disease to improve public awareness Comment on Bauersachs et al., pp. 294-300	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Editorial Material									[Qanadli, Salah D.; Rotzinger, David] Univ Hosp Lausanne, Cardiothorac & Vasc Unit, Dept Radiol, Lausanne, Switzerland		Qanadli, SD (通讯作者)，Dept Radiol, Cardiothorac & Vasc Unit, Rue Bugnon 46, CH-1011 Lausanne, Switzerland.	salah.qanadli@chuv.ch					Bauersachs R, 2021, VASA, V50, P294, DOI 10.1024/0301-1526/a000945; Qanadli SD, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.00045	2	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JUL	2021	50	4					249	249		10.1024/0301-1526/a000952			1	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QY	34219472				2022-04-28	WOS:000695708700001
J	Di Pilla, M; Barco, S; Sacco, C; Barosi, G; Lodigiani, C				Di Pilla, Marina; Barco, Stefano; Sacco, Clara; Barosi, Giovanni; Lodigiani, Corrado			Acute limb ischemia in a patient with pre-fibrotic myelofibrosis complicated by heparin-induced thrombocytopenia and thrombosis - case report and systematic review of dabigatran use	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Review						dabigatran etexilate; heparin-induced throm-bocytopenia; myelofibrosis; bleeding; venous thromboem-bolism; acute limb ischemia	ESSENTIAL THROMBOCYTHEMIA; ORAL ANTICOAGULANTS; CLINICAL-COURSE; JAK2	A 49-year-old man was diagnosed with prefibrotic myelofibrosis after acute left lower-limb ischemia requiring amputation and portal vein thrombosis. After surgery he developed heparin-induced thrombocytopenia (HIT) with venous thromboembolism, successfully treated with argatroban followed by dabigatran. Our systematic review of the literature supports the use of dabigatran for suspected HIT.	[Di Pilla, Marina; Sacco, Clara; Lodigiani, Corrado] Humanitas Clin & Res Ctr IRCCS, Thrombosis & Haemorrhag Dis Ctr, Milan, Italy; [Barco, Stefano] Univ Med Ctr Mainz, Ctr Thrombosis & Hemostasis CTH, Mainz, Germany; [Barco, Stefano] Univ Hosp Zurich, Clin Angiol, Zurich, Switzerland; [Barosi, Giovanni] IRCCS Policlin S Matteo Fdn, Pavia, Italy		Lodigiani, C (通讯作者)，Humanitas Res Hosp, Thrombosis & Hemorrhag Dis Unit, Via Alessandro Manzoni 56, I-20089 Rozzano, MI, Italy.	corrado.lodigiani@humanitas.it	Barco, Stefano/V-4901-2017	Barco, Stefano/0000-0002-2618-347X	German Federal Ministry of Education and Research (BMBF)Federal Ministry of Education & Research (BMBF) [01EO1003, 01EO1503]	The work of Stefano Barco is supported by the German Federal Ministry of Education and Research (BMBF 01EO1003 and 01EO1503) .	Anniccherico FJ, 2012, AN SIST SANIT NAVAR, V35, P521, DOI 10.4321/s1137-66272012000300024; Ashrafi F, 2017, J RES PHARM PRACT, V6, P211, DOI 10.4103/jrpp.JRPP_17_54; Barbui T, 2016, THROMB RES, V140, pS71, DOI 10.1016/S0049-3848(16)30102-5; Bircan HA, 2016, EURASIAN J MED, V48, P65, DOI 10.5152/eurasianjmed.2015.95; Cuker A, 2018, BLOOD ADV, V2, P3360, DOI 10.1182/bloodadvances.2018024489; Eshraghi A, 2014, IRANIAN HEART J, V15, P47; Fieland Daniel, 2012, Ann Pharmacother, V46, pe3, DOI 10.1345/aph.1Q474; Goncalves Ricca L, 2016, THROMB RES, V141, pS1; Jeryczynski G, 2017, AM J HEMATOL, V92, P885, DOI 10.1002/ajh.24788; Jozwik A, 2018, ANN TRANSPL, V23, P232, DOI 10.12659/AOT.905868; Lee JK, 2013, J HONG KONG COLL CAR, V21, P15; Mirdamadi A, 2013, ARYA ATHEROSCLER, V9, P112; Nasiripour S, 2019, J CLIN PHARMACOL, V59, P107, DOI 10.1002/jcph.1300; Noel E, 2015, CASE REP HEMATOL, V2015, DOI 10.1155/2015/985253; Rumi E, 2017, ONCOTARGET, V8, P101735, DOI 10.18632/oncotarget.21594; Rumi E, 2014, BLOOD, V123, P1544, DOI 10.1182/blood-2013-11-539098; Sharifi M, 2015, THROMB RES, V135, P607, DOI 10.1016/j.thromres.2015.01.009; Tardy-Poncet B, 2015, THROMB HAEMOSTASIS, V114, P652, DOI 10.1160/TH14-07-0593; Vannucchi AM, 2013, SEMIN THROMB HEMOST, V39, P496, DOI 10.1055/s-0033-1343890; Warkentin TE, 2017, BLOOD, V130, P1104, DOI 10.1182/blood-2017-04-778993	20	1	1	1	2	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0301-1526			VASA	Vasa	FEB	2021	50	2					151	156		10.1024/0301-1526/a000876			6	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	QQ5PH	32597318				2022-04-28	WOS:000624575300011
J	Rammos, C; Steinmetz, M; Johnstone, M; Manzke, A; Lortz, J; Petrikhovich, O; Hendgen-Cotta, U; Janosi, RA; Rassaf, T				Rammos, Christos; Steinmetz, Martin; Johnstone, Mirjam; Manzke, Anna; Lortz, Julia; Petrikhovich, Olga; Hendgen-Cotta, Ulrike; Janosi, Rolf A.; Rassaf, Tienush			The impact of percutaneous peripheral interventions on endothelial function	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Vascular functions; peripheral interventions; endovascular treatment; endothelial dysfunction	FLOW-MEDIATED VASODILATION; CARDIOVASCULAR EVENTS; DYSFUNCTION; ARTERY; ANGIOPLASTY; PACLITAXEL; RESTENOSIS; DELIVERY; DISEASE; BALLOON	Background: Treatment of symptomatic peripheral artery disease (PAD) through endovascular interventions is the primary revascularization strategy. Interventions restore perfusion but may cause severe injury to the vascular endothelium, which regulates vascular tone. Endothelial dysfunction is involved in the progression of cardiovascular disease, with higher incidences of vascular events. We aimed to determine the impact of percutaneous interventions on change in endothelial function. Patients and methods: Endothelial function was determined using flow-mediated dilation (FMD) before, the day after lower limb intervention with paclitaxel-coated balloons or stent guided interventions and after a six-month follow-up in the target limb, control limb and the systemic circulation in 42 PAD patients aged 70.2 +/- 9 years and 66% men. Additionally, macro- and microvascular function were assessed. Results: In PAD patients aged 70.2 +/- 9 years and 66% men, we observed an immediate enhancement of macro-, microvascular and endothelial function after endovascular treatment (FMD of superficial femoral artery (SFA) 3.7 +/- 0.2% to 4.1 +/- 0.1%, n=42, p=0.02), a sustained long-term improvement after 6-months (FMD SFA 3.7 +/- 0.2% to 4.2 +/- 0.1%, n=42, p=0.01), and moreover an improved systemic endothelial function (FMD brachial artery 4.3 +/- 0.1% to 4.7 +/- 0.2, n-42, p=0.01) following peripheral interventions. Subgroup analysis however revealed that following pactitaxel-based percutaneous intervention, the paclitaxel dosage applied was inversely related to the chronic improvement in local endothelial function (r=-0.6, n-22, p=0.005) without evidence for systemic effects (r= -0.25, 13=0.27). Conclusions: We demonstrate an improved local and systemic endothelial function after treatment of atherosclerotic peripheral disease with a distinguished response after endovascular intervention with higher dosage of applied paclitaxel restraining the benefits. Further studies have to determine the optimal interventional strategy with respect to different treatment modalities to maintain vessel functions.	[Rammos, Christos; Steinmetz, Martin; Johnstone, Mirjam; Manzke, Anna; Lortz, Julia; Petrikhovich, Olga; Hendgen-Cotta, Ulrike; Janosi, Rolf A.; Rassaf, Tienush] Univ Duisburg Essen, West German Heart & Vasc Ctr Essen, Dept Cardiol & Vasc Med, Hufelandstr 55, D-45147 Essen, Germany		Rammos, C (通讯作者)，Univ Duisburg Essen, West German Heart & Vasc Ctr Essen, Dept Cardiol & Vasc Med, Hufelandstr 55, D-45147 Essen, Germany.	christos.rammos@uk-essen.de		Rammos, Christos/0000-0003-3468-9945			Allan RB, 2016, INT J VASC MED, V2016, DOI 10.1155/2016/2969740; Caramori PRA, 1999, J AM COLL CARDIOL, V34, P1675, DOI 10.1016/S0735-1097(99)00411-8; Cornelissen A, 2019, J CELL MOL MED, V23, P39, DOI 10.1111/jcmm.13936; Corretti MC, 2002, J AM COLL CARDIOL, V39, P257, DOI 10.1016/S0735-1097(01)01746-6; Das T, 2014, CATHETER CARDIO INTE, V83, P115, DOI 10.1002/ccd.25046; Gimbrone MA, 2016, CIRC RES, V118, P620, DOI 10.1161/CIRCRESAHA.115.306301; Heinen Y, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001472; Heitzer T, 2005, ARTERIOSCL THROM VAS, V25, P1174, DOI 10.1161/01.ATV.0000166516.52477.81; Heitzer T, 2001, CIRCULATION, V104, P2673, DOI 10.1161/hc4601.099485; Herdeg C, 2000, J AM COLL CARDIOL, V35, P1969, DOI 10.1016/S0735-1097(00)00614-8; Holden A, 2019, J ENDOVASC THER, V26, P467, DOI 10.1177/1526602819857241; Katsanos K, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.011245; Kim JW, 2008, JACC-CARDIOVASC INTE, V1, P65, DOI 10.1016/j.jcin.2007.11.002; Kooijman M, 2008, J PHYSIOL-LONDON, V586, P1137, DOI 10.1113/jphysiol.2007.145722; Kullo IJ, 2016, NEW ENGL J MED, V374, P861, DOI 10.1056/NEJMcp1507631; Lortz J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216538; Rammos Christos, 2016, J Heart Valve Dis, V25, P309; Rammos C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151203; Rammos C, 2014, J AM COLL CARDIOL, V63, P1584, DOI 10.1016/j.jacc.2013.08.691; Rammos C, 2013, INT J CARDIOL, V168, P5249, DOI 10.1016/j.ijcard.2013.08.021; Ras RT, 2013, INT J CARDIOL, V168, P344, DOI 10.1016/j.ijcard.2012.09.047; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899; Serruys PW, 2016, LANCET, V388, P2479, DOI 10.1016/S0140-6736(16)32050-5; Tepe G, 2008, NEW ENGL J MED, V358, P689, DOI 10.1056/NEJMoa0706356; Tepe G, 2015, CIRCULATION, V131, P495, DOI 10.1161/CIRCULATIONAHA.114.011004; Van der Heiden K, 2013, CARDIOVASC RES, V99, P269, DOI 10.1093/cvr/cvt090; Verbeke FH, 2011, CLIN J AM SOC NEPHRO, V6, P2009, DOI 10.2215/CJN.01260211; Yeboah J, 2007, CIRCULATION, V115, P2390, DOI 10.1161/CIRCULATIONAHA.106.678276; Zeller T, 2014, J AM COLL CARDIOL, V64, P1568, DOI 10.1016/j.jacc.2014.06.1198	30	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	NOV	2021	50	6					423	430		10.1024/0301-1526/a000963			8	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6JL	34233505				2022-04-28	WOS:000753518900003
J	Behrendt, CA; Peters, F				Behrendt, Christian-Alexander; Peters, Frederik			The paclitaxel files - reasonable doubt or acquittal?	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Editorial Material							COATED DEVICES; BALLOONS		[Behrendt, Christian-Alexander; Peters, Frederik] Univ Med Ctr Hamburg Eppendorf, Univ Heart & Vasc Ctr Hamburg, Res Grp GermanVasc, Dept Vasc Med, Hamburg, Germany		Behrendt, CA (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Res Grp GermanVasc, Dept Vasc Med, Martinistr 52, D-20246 Hamburg, Germany.	behrendt@hamburg.de	Peters, Frederik/AAS-1846-2021; Behrendt, Christian-Alexander/M-2952-2017	Peters, Frederik/0000-0001-5832-8410; Behrendt, Christian-Alexander/0000-0003-0406-3319			Behrendt Christian-Alexander, 2020, Eur J Vasc Endovasc Surg, V59, P587, DOI 10.1016/j.ejvs.2019.12.034; Behrendt CA, 2020, EUR J VASC ENDOVASC, V59, P510, DOI 10.1016/j.ejvs.2020.01.029; Bohme T, 2021, VASA, V50, P132, DOI 10.1024/0301-1526/a000910; Heidemann F, 2020, EUR J VASC ENDOVASC, V60, P549, DOI 10.1016/j.ejvs.2020.06.033; Kaschwich M, 2020, VASA, V49, P493, DOI 10.1024/0301-1526/a000901; Katsanos K, 2020, J VASC INTERV RADIOL, V31, P202, DOI 10.1016/j.jvir.2019.11.015; Katsanos K, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.011245; Dinh L, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa047; Mills JL, 2019, J VASC SURG, V70, P3, DOI 10.1016/j.jvs.2019.05.002; Rocha-Singh KJ, 2020, CIRCULATION, V141, P1859, DOI 10.1161/CIRCULATIONAHA.119.044697; Saratzis A, 2020, EUR J VASC ENDOVASC, V60, P220, DOI 10.1016/j.ejvs.2020.04.008; Schneider PA, 2019, J AM COLL CARDIOL, V73, P2550, DOI 10.1016/j.jacc.2019.01.013; Secemsky EA, 2019, JAMA CARDIOL, V4, P332, DOI 10.1001/jamacardio.2019.0325; Seiffert M, 2020, CLIN RES CARDIOL, V109, P1540, DOI 10.1007/s00392-020-01723-9; Zeller T, 2019, VASA, V48, P109, DOI 10.1024/0301-1526/a000778	15	0	0	0	1	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0301-1526			VASA	Vasa	FEB	2021	50	2					83	84		10.1024/0301-1526/a000912			2	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	QQ5PH	33645235	Bronze			2022-04-28	WOS:000624575300001
J	Blodt, K				Bloedt, Kathrin			A new player in the fight against dyslipidemia-bempedoic acid	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Editorial Material									[Bloedt, Kathrin] Univ Klinikum Ulm, Klin Innere Med 2, Kardiol Angiol, Ulm, Germany		Blodt, K (通讯作者)，Univ Klinikum Ulm, Klin Innere Med 2, Kardiol Angiol, Ulm, Germany.	kathrin.bloedt@uniklinik-ulm.de					Chapman MJ, 2010, PHARMACOL THERAPEUT, V126, P314, DOI 10.1016/j.pharmthera.2010.01.008; Ford ES, 2007, NEW ENGL J MED, V356, P2388, DOI 10.1056/NEJMsa053935; Kausik KR, 2019, NEW ENGL J MED, V380, P1022; Mach F, 2019, ATHEROSCLEROSIS, V290, P140, DOI [10.1016/j.atherosclerosis.2019.08.014, 10.1093/eurheartj/ehz455]	4	0	0	0	0	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0301-1526			VASA	Vasa	FEB	2021	50	2					159	159		10.1024/0301-1526/a000930			1	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	QQ5PH	33645234				2022-04-28	WOS:000624575300014
J	Stoberock, K; Kaschwich, M; Nicolay, SS; Mahmoud, N; Heidemann, F; Riess, HC; Debus, ES; Behrendt, CA				Stoberock, Konstanze; Kaschwich, Mark; Nicolay, Shiva Sophia; Mahmoud, Nazeh; Heidemann, Franziska; Riess, Henrik C.; Debus, Eike Sebastian; Behrendt, Christian-Alexander			The interrelationship between diabetes mellitus and peripheral arterial disease	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Review						Health services research; diabetes; peripheral arterial disease; therapy; outcomes	CRITICAL LIMB ISCHEMIA; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RISK-FACTORS; NONDIABETIC PATIENTS; AMPUTATION RATES; FOOT ULCERS; PREVALENCE; POPULATION; EPIDEMIOLOGY; MORTALITY	This systematic review examined the interrelationship between concomitant diabetes mellitus (DM) and peripheral arterial disease (PAD). The objective was to determine differences in the prevalence as well as in the outcomes in diabetic vs. non-diabetic PAD patients. The current review followed a study protocol that was published online in German in 2017. The search included societal practice guidelines, consensus statements, systematic reviews, meta-analyses, and observational studies published from 2007 to 2020 reporting symptomatic PAD and concomitant DM in patients undergoing invasive opensurgical and endovascular revascularizations. German and English literature has been considered. Eligibility criteria were verified by three independent reviewers. Disagreement was resolved by discussion involving a fourth reviewer. 580 articles were identified. After exclusion of non-eligible studies, 61 papers from 30 countries remained, respectively 850,072 patients. The included studies showed that PAD prevalence differed between diabetic vs. non-diabetic populations (20-50% vs. 10-26%), and further by age, gender, ethnicity, duration of existing diabetes, and geographic region. The included studies revealed worse outcomes regarding perioperative complications, amputation rate, and mortality rate in diabetic patients when compared to non-diabetic patients. In both groups, the amputation rates decreased during the research period. This review emphasizes an interrelationship between PAD and DM. To improve the outcomes, early detection of PAD in diabetic patients, and vice versa, should be recommended. The results of this systematic review may help to update societal practice guidelines.	[Stoberock, Konstanze; Kaschwich, Mark; Nicolay, Shiva Sophia; Mahmoud, Nazeh; Heidemann, Franziska; Riess, Henrik C.; Debus, Eike Sebastian; Behrendt, Christian-Alexander] Univ Med Ctr Hamburg Eppendorf, Dept Vasc Med, Res Grp GermanVasc, Hamburg, Germany		Behrendt, CA (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Vasc Med, Res Grp GermanVasc, Hamburg, Germany.	behrendt@hamburg.de	Behrendt, Christian-Alexander/M-2952-2017	Behrendt, Christian-Alexander/0000-0003-0406-3319			Aarabi G, 2020, VASA, V49, P128, DOI 10.1024/0301-1526/a000846; Aboyans V, 2018, EUR HEART J, V39, P763, DOI 10.1093/eurheartj/ehx095; Ahmad N, 2016, DIABETES VASC DIS RE, V13, P348, DOI 10.1177/1479164116651390; Ali SR, 2018, EUR J VASC ENDOVASC, V56, P401, DOI 10.1016/j.ejvs.2018.05.009; [Anonymous], 2019, IDF DIABETES ATLAS; Arya S, 2018, J VASC SURG, V67, P217, DOI 10.1016/j.jvs.2017.06.101; Becker F, 2011, EUR J VASC ENDOVASC, V42, pS4, DOI 10.1016/S1078-5884(11)60009-9; Behrendt CA, 2019, EUR J VASC ENDOVASC, V57, P658, DOI 10.1016/j.ejvs.2018.10.021; Behrendt CA, 2018, EUR J VASC ENDOVASC, V56, P391, DOI 10.1016/j.ejvs.2018.04.017; Brechow A, 2013, THER ADV ENDOCRINOL, V4, P83, DOI 10.1177/2042018813489719; Bruun C, 2013, DIABETIC MED, V30, P964, DOI 10.1111/dme.12196; Cha JJ, 2020, CARDIOVASC DIABETOL, V19, DOI 10.1186/s12933-020-01072-x; Chang CH, 2019, EUR J VASC ENDOVASC, V57, P527, DOI 10.1016/j.ejvs.2018.11.010; Charles M, 2011, DIABETES CARE, V34, P2244, DOI 10.2337/dc11-0903; Coce Franjo, 2008, Diabetologia Croatica, V37, P47; Collins TC, 2010, VASC HEALTH RISK MAN, V6, P287; Conte MS, 2019, J VASC SURG, V69, p3S, DOI 10.1016/j.jvs.2019.02.016; del Rio VC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186220; Cosentino F, 2020, EUR HEART J, V41, P255, DOI 10.1093/eurheartj/ehz486; Elgzyri T, 2014, EUR J VASC ENDOVASC, V48, P440, DOI 10.1016/j.ejvs.2014.06.041; Elgzyri T, 2013, EUR J VASC ENDOVASC, V46, P110, DOI 10.1016/j.ejvs.2013.04.013; Escobar C, 2011, EUR J INTERN MED, V22, P275, DOI 10.1016/j.ejim.2011.02.001; Eshcol J, 2014, J DIABETES COMPLICAT, V28, P627, DOI 10.1016/j.jdiacomp.2014.04.013; Faglia E, 2011, INT J LOW EXTR WOUND, V10, P152, DOI 10.1177/1534734611417352; Fosse S, 2009, DIABETIC MED, V26, P391, DOI 10.1111/j.1464-5491.2009.02698.x; Frank U, 2019, VASA, V48, P7, DOI 10.1024/0301-1526/a000834; Freisinger E, 2017, CARDIOVASC DIABETOL, V16, DOI 10.1186/s12933-017-0524-8; Fridh EB, 2017, EUR J VASC ENDOVASC, V54, P480, DOI 10.1016/j.ejvs.2017.07.005; Fridh EB, 2018, EUR J VASC ENDOVASC, V56, P681, DOI 10.1016/j.ejvs.2018.06.003; Gazzaruso C, 2013, AGING CLIN EXP RES, V25, P225, DOI 10.1007/s40520-013-0033-x; Gentile F, 2016, EUR J VASC ENDOVASC, V52, P643, DOI 10.1016/j.ejvs.2016.07.013; Gerhard-Herman MD, 2017, CIRCULATION, V135, pE726, DOI 10.1161/CIR.0000000000000471; Giugliano G, 2012, BMC SURG, V12, DOI 10.1186/1471-2482-12-S1-S19; Guerchet M, 2012, EUR J VASC ENDOVASC, V44, P164, DOI 10.1016/j.ejvs.2012.05.019; Heyer K, 2015, EUR J VASC ENDOVASC, V50, P761, DOI 10.1016/j.ejvs.2015.07.033; Hicks CW, 2016, J VASC SURG, V64, P1667, DOI 10.1016/j.jvs.2016.07.107; Hinchliffe RJ, 2012, DIABETES-METAB RES, V28, P179, DOI 10.1002/dmrr.2249; Humphries MD, 2016, J VASC SURG, V64, P1747, DOI 10.1016/j.jvs.2016.06.096; Humphries MD, 2016, ANN VASC SURG, V30, P123, DOI 10.1016/j.avsg.2015.04.089; Icks A, 2011, DIABETES CARE, V34, P1350, DOI 10.2337/dc10-2341; Janas AJ, 2018, CARD J, V10, P1; Jude EB, 2001, DIABETES CARE, V24, P1433, DOI 10.2337/diacare.24.8.1433; Kreutzburg T, 2020, EUR J VASC ENDOVASC, V59, P59, DOI 10.1016/j.ejvs.2019.08.006; Lawall H, 2015, S3 LEITLINIE DIAGNOS, P1; Lazzarini PA, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008544; Liang KW, 2016, ANGIOLOGY, V67, P287, DOI 10.1177/0003319712475074; Lin JH, 2019, CIRC-CARDIOVASC QUAL, V12, DOI 10.1161/CIRCOUTCOMES.118.005273; Londero LS, 2019, EUR J VASC ENDOVASC, V58, P729, DOI 10.1016/j.ejvs.2019.06.007; Mahmoud N., 2020, DIABETES MELLITUS PE, P1; Matsushita K, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012177; Melillo E, 2016, EUR REV MED PHARMACO, V20, P502; Mohammedi K, 2016, DIABETES CARE, V39, P1796, DOI 10.2337/dc16-0588; Mohammedi K, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0446-x; Mueller T, 2016, VASC MED, V21, P445, DOI 10.1177/1358863X16643603; Mueller T, 2014, J VASC SURG, V59, P1291, DOI 10.1016/j.jvs.2013.11.063; Mwebaze RM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105211; Narayanan RML, 2010, ANN ACAD MED SINGAP, V39, P525; Newhall K, 2016, ANN VASC SURG, V30, P292, DOI 10.1016/j.avsg.2015.07.040; Oyelade B. O., 2012, African Journal of Primary Health Care and Family Medicine, V4, P354; Prompers L, 2008, DIABETOLOGIA, V51, P747, DOI 10.1007/s00125-008-0940-0; Rabia K, 2007, Med J Malaysia, V62, P130; Rhee SY, 2007, DIABETES RES CLIN PR, V76, P82, DOI 10.1016/j.diabres.2006.07.029; Rhee SY, 2015, DIABETES METAB J, V39, P283, DOI 10.4093/dmj.2015.39.4.283; Santosa F, 2015, INT WOUND J, V12, P276, DOI 10.1111/iwj.12096; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.g7647, 10.1136/bmj.b2700]; Sirohi P, 2014, J ASS PHYS INDIA, V62, P44; Soyoye DO, 2016, ADV MED, P1; Takahara M, 2010, DIABETES CARE, V33, P2538, DOI 10.2337/dc10-0939; Tavintharan S, 2009, DIABETES VASC DIS RE, V6, P80, DOI 10.1177/1479164109336043; Thiruvoipati T, 2015, WORLD J DIABETES, V6, P961, DOI 10.4239/wjd.v6.i7.961; Tseng CH, 2007, CIRC J, V71, P1131, DOI 10.1253/circj.71.1131; Velescu A, 2016, EUR J VASC ENDOVASC, V51, P696, DOI 10.1016/j.ejvs.2015.12.045; Vitalis A, 2017, EXPERT REV CARDIOVAS, V15, P327, DOI 10.1080/14779072.2017.1305890; Yakubu PD, 2018, INT J CLIN CARDIOL R, V2, P8	74	4	4	1	1	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	SEP	2021	50	5					323	330		10.1024/0301-1526/a000925			8	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6GV	33175668				2022-04-28	WOS:000753511900002
J	Bohme, T				Boehme, Tanja			Doubts reduced - end of paclitaxel discussion in sight	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Editorial Material							COATED BALLOON ANGIOPLASTY; FEMOROPOPLITEAL LESIONS		[Boehme, Tanja] Univ Heart Ctr Freiburg Bad Krozingen, Dept Cardiol & Angiol, D-79189 Bad Krozingen, Germany		Bohme, T (通讯作者)，Univ Heart Ctr Freiburg Bad Krozingen, Dept Cardiol & Angiol, D-79189 Bad Krozingen, Germany.	tanja.boehme@universitaets-herzzentrum.de					Behrendt Christian-Alexander, 2020, Eur J Vasc Endovasc Surg, V59, P587, DOI 10.1016/j.ejvs.2019.12.034; Bohme T, 2021, VASA, V50, P132, DOI 10.1024/0301-1526/a000910; Bohme T, 2020, JACC-CARDIOVASC INTE, V13, P2052, DOI 10.1016/j.jcin.2020.04.050; Katsanos K, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.011245; Nordanstig J, 2020, NEW ENGL J MED, V383, P2538, DOI 10.1056/NEJMoa2005206; Schneider PA, 2019, J AM COLL CARDIOL, V73, P2550, DOI 10.1016/j.jacc.2019.01.013	6	0	0	0	1	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JUL	2021	50	4					319	319		10.1024/0301-1526/a000951			1	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QY	34219473				2022-04-28	WOS:000695708700012
J	Rodway, A; Stafford, M; Wilding, S; Ntagiantas, N; Patsiogiannis, V; Allan, C; Field, B; Clark, J; Casal, FP; Pankhania, A; Loosemore, T; Heiss, C				Rodway, Alexander; Stafford, Michelle; Wilding, Sophie; Ntagiantas, Nikolaos; Patsiogiannis, Vasileios; Allan, Charlotte; Field, Ben; Clark, James; Casal, Felipe Pazos; Pankhania, Ajay; Loosemore, Thomas; Heiss, Christian			Day case angioplasty in a secondary care setting - initial experience	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Day-case angioplasty; critical limb ischaemia; peripheral artery disease; multi-disciplinary	PERIPHERAL ARTERIAL-DISEASE; CRITICAL LIMB ISCHEMIA; ENDOVASCULAR INTERVENTIONS; DISCHARGE; SAFETY; REVASCULARIZATION; FEASIBILITY; PREVALENCE; BYPASS	Background: Peripheral artery disease presents an increasing healthcare burden worldwide. Day-case angioplasty in a secondary care setting can be a safe and effective means of meeting the growing demand for lower limb revascularisation. We evaluated the safety and efficacy of a day-case-based angioplasty service in a UK district general hospital. Patients and methods: Consecutive patients undergoing endovascular revascularisation between August 2018-February 2020 were analysed retrospectively. All patients were discussed at a multi-disciplinary (diabetic foot) team meeting following a day case algorithm. Patient and procedural characteristics, technical success, peri-procedural complications, and 30-day outcome of day-case angioplasties were compared with those requiring overnight stay or were hospitalized. Results: Fifty-seven percent of 138 patients were diabetic, mean age 75 +/- 12 years, 95% had critical limb ischaemia (Fontaine III 12%, IV 83%), and baseline ankle brachial pressure index [ABPI] 0.40 +/- 0.30. Sixty-three patients (45%) were treated as planned day cases, 21 (15%) required overnight admission for social indications. Fifteen (11%) were planned admissions with the need for sequential debridement procedures, and 39 (28%) were already hospitalised at the time of referral to the vascular service. The overall technical success was 92% and not successful procedures mainly occurred in patients > 80 years. The ABPI increased at the initial follow-up to 0.84 +/- 0.18. Fifty-three percent required treatment of > 1 level, 80% included recanalisations of chronic total occlusions, and average total lesion length was 133 +/- 90 mm. Closure devices were employed in all cases. There were no major peri-procedural complications. A single minor access-site related bleeding episode (0.8%) occurred, requiring 24 h observation in hospital. While significantly more wounds had closed in out-patients, the mortality, major amputation and target lesion revascularization did not differ between groups. Conclusions: Safe and effective day-case-based angioplasty can be provided in a secondary care setting for patients with critical limb ischaemia needing complex multi-level procedures.	[Rodway, Alexander; Stafford, Michelle; Wilding, Sophie; Ntagiantas, Nikolaos; Patsiogiannis, Vasileios; Allan, Charlotte; Field, Ben; Clark, James; Casal, Felipe Pazos; Pankhania, Ajay; Loosemore, Thomas; Heiss, Christian] Surrey & Sussex Healthcare NHS Trust, Redhill, Surrey, England; [Wilding, Sophie; Field, Ben; Heiss, Christian] Univ Surrey, Dept Clin & Expt Med, Sect Clin Med, Guildford, Surrey, England; [Ntagiantas, Nikolaos; Patsiogiannis, Vasileios; Loosemore, Thomas] St Georges Univ Hosp NHS Fdn Trust, London, England; [Rodway, Alexander; Allan, Charlotte] Brighton & Sussex Univ Hosp NHS Trust, Brighton, E Sussex, England; [Stafford, Michelle] First Community Hlth & Care, Redhill, Surrey, England		Heiss, C (通讯作者)，Univ Surrey, Clin Med Sect, Dept Clin & Expt Med, Fac Hlth & Med Sci, Stag Hill, Guildford GU2 7XH, Surrey, England.	c.heiss@surrey.ac.uk					Akopian G, 2006, J VASC SURG, V44, P115, DOI 10.1016/j.jvs.2006.03.025; Albert B, 2014, ANN VASC SURG, V28, P137, DOI 10.1016/j.avsg.2013.06.008; Alimi Y, 2019, ANN VASC SURG, V59, P248, DOI 10.1016/j.avsg.2019.05.001; Ansari A, 2020, THER ADV CARDIO DIS, V14, DOI 10.1177/1753944720948651; Bradbury AW, 2010, J VASC SURG, V51, p5S, DOI 10.1016/j.jvs.2010.01.073; Conte MS, 2019, EUR J VASC ENDOVASC, V58, pS1, DOI 10.1016/j.ejvs.2019.05.006; Cox Tiffany, 2015, Surg Technol Int, V27, P32; D'Souza SM, 2018, J ENDOVASC THER, V25, P666, DOI 10.1177/1526602818806691; Frank U, 2019, VASA, V48, P7, DOI 10.1024/0301-1526/a000834; Gouicem D, 2014, ANN VASC SURG, V28, P132, DOI 10.1016/j.avsg.2013.06.007; Hauguel A, 2017, J CARDIOVASC SURG, V58, P293, DOI 10.23736/S0021-9509.17.09879-2; Heiss C, 2019, VASA, V48, P487, DOI 10.1024/0301-1526/a000810; Ireland TVSoGBa, PROV SERV PAT VASC D; Ireland VSoGBa, PER ART DIS QUAL IMP; Janas A, 2018, CATHETER CARDIO INTE, V91, P515, DOI 10.1002/ccd.27338; Jones WS, 2015, J AM COLL CARDIOL, V65, P920, DOI 10.1016/j.jacc.2014.12.048; Kasthuri R, 2007, CLIN RADIOL, V62, P1202, DOI 10.1016/j.crad.2007.05.016; LEMARBRE L, 1987, AM J ROENTGENOL, V148, P1239, DOI 10.2214/ajr.148.6.1239; Lin JH, 2019, CIRC-CARDIOVASC QUAL, V12, DOI 10.1161/CIRCOUTCOMES.118.005273; Malekzadeh S, 2019, DIAGN INTERV IMAG, V100, P347, DOI 10.1016/j.diii.2018.11.009; Maurel B, 2011, ANN VASC SURG, V25, P191, DOI 10.1016/j.avsg.2010.08.007; Miller C, 2019, CLIN RADIOL, V74, P429, DOI 10.1016/j.crad.2019.01.026; Nehler MR, 2014, J VASC SURG, V60, P686, DOI 10.1016/j.jvs.2014.03.290; Prompers L, 2007, DIABETOLOGIA, V50, P18, DOI 10.1007/s00125-006-0491-1; Reinecke H, 2015, EUR HEART J, V36, P932, DOI 10.1093/eurheartj/ehv006; Robertson L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009541.pub2; Song PG, 2019, LANCET GLOB HEALTH, V7, pE1020, DOI 10.1016/S2214-109X(19)30255-4; Spiliopoulos S, 2016, CARDIOVASC INTER RAD, V39, P1684, DOI 10.1007/s00270-016-1436-9; Stegemann E, 2015, AM J CARDIOL, V115, P879, DOI 10.1016/j.amjcard.2015.01.012; Stella J, 2020, VASA, V49, P121, DOI 10.1024/0301-1526/a000831; Tsai TT, 2015, CIRCULATION, V132, P1999, DOI 10.1161/CIRCULATIONAHA.114.013440; Vernet FBM., 2015, 30 ANN M FRENCH SOC; Zayed HA, 2008, INT ANGIOL, V27, P232	33	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	MAY	2021	50	3					202	208		10.1024/0301-1526/a000942			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QU	33599142	Green Submitted, Bronze			2022-04-28	WOS:000695708300007
J	Irakleidis, F; Kyriakides, J; Baker, D				Irakleidis, Foivos; Kyriakides, Jonathon; Baker, Daryll			Aberrant right subclavian artery - a rare congenital anatomical variation causing dysphagia lusoria	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						aberrant right subclavian artery; arteria lusoria; dysphagia lusoria; dysphagia; aortic arch	DIAGNOSIS	An aberrant right subclavian artery (ARSA) is a rare anatomical variation of the aortic arch. Although an incidental finding and asymptomatic in the majority of individuals, an ARSA can cause troubling symptoms during both childhood and in later life. In adulthood, the most common symptom is dysphagia, where the condition is named dysphagia lusoria. In other rare cases it can cause shortness of breath, chronic cough and hoarseness of voice amongst others. We present a case of a 65-year-old female patient who was diagnosed with dysphagia lusoria following a barium swallow examination to investigate a 10-year history of dysphagia. She was further investigated with other imaging modalities to establish her diagnosis. The dysphagia was not progressive, nor did it result in malnutrition, and hence the patient was managed conservatively. There is currently no established guideline to classify the severity of symptoms or radiological findings of this anatomical anomaly. Our case reiterates the importance of such protocols, in order to be able to avoid the risks of an unnecessary surgical procedure, whilst being sure to prevent the undertreatment of affected individuals.	[Irakleidis, Foivos; Kyriakides, Jonathon; Baker, Daryll] Royal Free London NHS Fdn Trust, Dept Vasc Surg, London, England		Irakleidis, F (通讯作者)，Royal Free London NHS Fdn Trust, Dept Vasc Surg, London, England.	georgios.irakleidis@nhs.net		Irakleidis, Foivos/0000-0002-6569-1266			Allen D, 2016, CASE REP CARDIOL, V2016, DOI 10.1155/2016/8079856; Bayford D., 1789, MEMOIRS MED SOC LOND, VII, P251; Febrero B, 2017, GASTROENT HEPAT-BARC, V40, P354, DOI 10.1016/j.gastrohep.2016.03.004; Gong RX, 2014, J SURG RES, V189, P75, DOI 10.1016/j.jss.2014.02.010; Jalaie H, 2014, EUR J VASC ENDOVASC, V48, P521, DOI 10.1016/j.ejvs.2014.06.040; Janssen M, 2000, AM J GASTROENTEROL, V95, P1411; Khanna M, 2013, J COMMUNITY HOSP INT, V3, DOI 10.3402/jchimp.v3i3-4.22091; Levitt B, 2007, DIS ESOPHAGUS, V20, P455, DOI 10.1111/j.1442-2050.2007.00787.x; Mahmodlou Rahim, 2014, J Surg Tech Case Rep, V6, P61, DOI 10.4103/2006-8808.147262; Polguj M, 2014, SCI WORLD J, DOI 10.1155/2014/292734; Popieluszko P, 2018, J VASC SURG, V68, P298, DOI 10.1016/j.jvs.2017.06.097; Salassa JR, 1999, DIGEST DIS, V17, P230, DOI 10.1159/000016941; Song MJ, 2017, ULTRASONOGRAPHY, V36, P278, DOI 10.14366/usg.16046; Still GG, 2018, GLOB PEDIAT HLTH, V5; Williams GD, 1932, ANAT REC, V54, P247, DOI 10.1002/ar.1090540211	15	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	SEP	2021	50	5					394	397		10.1024/0301-1526/a000904			4	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6GV	32815461				2022-04-28	WOS:000753511900011
J	Kronlage, M; Erbel, C; Lichtenberg, M; Heinrich, U; Katus, HA; Frey, N; Giusca, S; Korosoglou, G				Kronlage, Mariya; Erbel, Christian; Lichtenberg, Michael; Heinrich, Ulrike; Katus, Hugo A.; Frey, Norbert; Giusca, Sorin; Korosoglou, Grigorios			Safety and effectiveness of Phoenix atherectomy for endovascular treatment in calcified common femoral artery lesions	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Common femoral artery; rotational atherectomy; endovascular treatment; claudication; critical limb ischemia	DRUG-COATED BALLOON; DIRECTIONAL ATHERECTOMY; OUTCOMES; ANGIOPLASTY	Background: Traditionally endarterectomy has been considered as the gold standard technique for the treatment of common femoral artery (CFA) lesions. The aim of this study is to investigate the procedural safety and mid-term outcomes of minimal invasive Phoenix atherectomy for the treatment of CFA lesions. Patients and methods: Phoenix atherectomy was used for treatment of 61 consecutive, moderately to heavily calcified CFA lesions in 56 patients. Lesions were classified based on the CFA occlusive disease classification (Type I, II&III lesions). Primary endpoints were technical, procedural, and clinical success rate. Safety endpoints (vessel perforation, peripheral embolization) and clinically driven target lesion revascularization (TLR) were also assessed. Results: Of 61 CFA lesions, 58 (95%) exhibited at least moderate/severe calcification (PACSS3 in 38 (62%) and PACSS4 in 20 (33%) cases). Type III lesions were present in 30 (49%), type I/II lesions in 31 (51%) cases. Technical and procedural success was achieved in 30 (49%) and all 61 (100%) lesions, respectively with low complication rates (0% perforation, 2% embolization). Adjunctive treatment after atherectomy was performed using drug-coated balloon (DCB) in 35 (57%) and bait-out stenting in 6 (10%) cases. Target lesion revascularization (TLR) occurred in 4 (7%) cases during a mean follow-up duration of 11 +/- 7months. All patients exhibited clinical improvement at follow-up, showing mean Rutherford category reduction from 3.7 +/- 1.1 to 1.5 +/- 1.1 (p<0.001). Conclusions: The Phoenix device can be used for the effective endovascular treatment of CFA lesions, due to its reasonable safety profile and mid-term results.	[Kronlage, Mariya; Erbel, Christian; Katus, Hugo A.; Frey, Norbert] Univ Hosp Heidelberg, Heidelberg, Germany; [Lichtenberg, Michael] Klinikum Arnsberg, Vasc Ctr, Arnsberg, Germany; [Heinrich, Ulrike] Vasc Med & Gastroenterol, Weinheim, Germany; [Giusca, Sorin; Korosoglou, Grigorios] GRN Hosp Weinheim, Cardiol & Vasc Med, Weinheim, Germany		Korosoglou, G (通讯作者)，GRN Hosp Weinheim, Dept Cariol & Angiol, Rontgenstr 1, D-69469 Weinheim, Germany.	gkorosoglou@hotmail.com	Frey, Norbert/M-7749-2019	Frey, Norbert/0000-0001-7611-378X; Korosoglou, Grigorios/0000-0002-6038-2253	Volcano, Philips	The GRN Hospital Weinheim (G. Korosoglou and S. Giusca) received an institutional research grant from Volcano, Philips.	Azema L, 2011, EUR J VASC ENDOVASC, V41, P787, DOI 10.1016/j.ejvs.2011.02.025; Ballotta E, 2010, SURGERY, V147, P268, DOI 10.1016/j.surg.2009.08.004; Nguyen BN, 2015, J VASC SURG, V61, P1489, DOI 10.1016/j.jvs.2015.01.024; Bohme T, 2020, EUROINTERVENTION; Changal KH, 2019, J INTERV CARDIOL, DOI 10.1155/2019/1593401; Cioppa A, 2017, EUROINTERVENTION, V12, P1789, DOI 10.4244/EIJ-D-15-00187; Davis T, 2017, VASCULAR, V25, P563, DOI 10.1177/1708538117712383; Fowkes FGR, 2017, NAT REV CARDIOL, V14, DOI 10.1038/nrcardio.2016.179; Fujihara M, 2017, J ENDOVASC THER, V24, P367, DOI 10.1177/1526602817698634; Giusca S, 2021, HEART VESSELS, V36, P366, DOI 10.1007/s00380-020-01695-w; Giusca S, 2020, HEART VESSELS, V35, P346, DOI 10.1007/s00380-019-01498-8; Goueffic Y, 2017, JACC-CARDIOVASC INTE, V10, P1344, DOI 10.1016/j.jcin.2017.03.046; Krankenberg H, 2019, INTERNIST, V60, P1235, DOI 10.1007/s00108-019-00695-x; Lichtenberg M, 2019, J CARDIOVASC SURG, V60, P205, DOI 10.23736/S0021-9509.19.10844-0; Nasr B, 2020, ANN VASC SURG, V64, P2, DOI 10.1016/j.avsg.2019.10.031; Nasr B, 2017, ANN VASC SURG, V40, P10, DOI 10.1016/j.avsg.2016.07.088; Norgren L, 2007, INT ANGIOL, V26, P81; Rocha-Singh KJ, 2014, CATHETER CARDIO INTE, V83, pE212, DOI 10.1002/ccd.25387; Rutherford RB, 1997, J VASC SURG, V26, P517, DOI 10.1016/S0741-5214(97)70045-4; Sartipy F, 2018, EUR J VASC ENDOVASC, V55, P529, DOI 10.1016/j.ejvs.2018.01.019; Shammas NW, 2020, VASC HEALTH RISK MAN, V16, P67, DOI 10.2147/VHRM.S242291; Shishehbor MH, 2016, CIRCULATION, V134, P2008, DOI 10.1161/CIRCULATIONAHA.116.022546; Stavroulakis K, 2018, J ENDOVASC THER, V25, P92, DOI 10.1177/1526602817748319; Zeller T, 2017, CIRC-CARDIOVASC INTE, V10, DOI 10.1161/CIRCINTERVENTIONS.116.004848	24	1	1	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	SEP	2021	50	5					378	386		10.1024/0301-1526/a000960			9	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6GV	34155913				2022-04-28	WOS:000753511900009
J	Rammos, C; Rassaf, T				Rammos, Christos; Rassaf, Tienush			Insight in the treatment of iatrogenic femoral artery pseudoaneurysms Comment on Herold et al., pp. 231-239	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Editorial Material							GUIDED THROMBIN INJECTION; COMPRESSION; MANAGEMENT; REPAIR		[Rammos, Christos; Rassaf, Tienush] Univ Duisburg Essen, Dept Cardiol & Vasc Med, West German Heart & Vasc Ctr Essen, Essen, Germany		Rammos, C (通讯作者)，Univ Hosp Essen, Dept Cardiol & Vasc Med, West German Heart & Vasc Ctr Essen, Hufelandstr 55, D-45147 Essen, Germany.	christos.rammos@uk-essen.de					COPE C, 1986, AM J ROENTGENOL, V147, P383, DOI 10.2214/ajr.147.2.383; Dzijan-Horn M, 2014, CIRC-CARDIOVASC INTE, V7, P207, DOI 10.1161/CIRCINTERVENTIONS.113.000836; FELLMETH BD, 1991, RADIOLOGY, V178, P671, DOI 10.1148/radiology.178.3.1994400; Herold J, 2021, VASA, V50, P231, DOI 10.1024/0301-1526/a000935; Lonn L, 2004, J ENDOVASC THER, V11, P570, DOI 10.1583/03-1181.1; Luedde M, 2007, ANGIOLOGY, V58, P435, DOI 10.1177/0003319706294608; Pan M, 1997, AM J CARDIOL, V80, P786, DOI 10.1016/S0002-9149(97)00518-3; Popovic B, 2010, INT J CARDIOL, V141, P75, DOI 10.1016/j.ijcard.2008.11.111; Rammos C, 2018, EUR J MED RES, V23, DOI 10.1186/s40001-018-0324-y; Schneider C, 2009, INT J CARDIOL, V131, P356, DOI 10.1016/j.ijcard.2007.10.052; Steinkamp HJ, 2000, INVEST RADIOL, V35, P186, DOI 10.1097/00004424-200003000-00005; Steinmetz M, 2020, VASA, V49, P463, DOI 10.1024/0301-1526/a000892; Stolt M, 2018, VASA, V47, P177, DOI 10.1024/0301-1526/a000691; Talaie R, 2020, VASC ENDOVASC SURG, V54, P458, DOI 10.1177/1538574420921276; Toursarkissian B, 1997, J VASC SURG, V25, P803, DOI 10.1016/S0741-5214(97)70209-X; Webber GW, 2007, CIRCULATION, V115, P2666, DOI 10.1161/CIRCULATIONAHA.106.681973	16	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	MAY	2021	50	3					163	164		10.1024/0301-1526/a000939			2	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QU	33938229				2022-04-28	WOS:000695708300002
J	Bergere, G; Toquet, C; Hoffmann, C; Bressollette, L; Raimbeau, A; Durant, C; Artifoni, M; Gautier, G; Hersant, J; Connault, J; Pistorius, MA; Espitia, O				Bergere, Guillaume; Toquet, Claire; Hoffmann, Clement; Bressollette, Luc; Raimbeau, Alizee; Durant, Cecile; Artifoni, Mathieu; Gautier, Giovanni; Hersant, Jeanne; Connault, Jerome; Pistorius, Marc-Antoine; Espitia, Olivier			Effect of cannabis consumption on characteristics and evolution of thromboangitis obliterans	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Buerger's disease; thromboangitis obliterans; cannabis	BUERGERS-DISEASE; EXPERIENCE	Background: Thromboangiitis obliterans (TAO) is a distal non atherosclerotic thrombotic vasculitis affecting tobacco smokers. The role of cannabis co-exposure remains controversial. The study aims to assess how cannabis consumption influences clinical presentation and outcome of TAO in tobacco smokers. Patients and methods: TAO patients, according to Papa's criteria, were included in a retrospective bicentric study between the 1(st) January 2003 and the 1(st) march 2020. Clinical characteristics, arterial involvement at TAO diagnosis, vascular event and amputations during follow-up were analyzed according to cannabis consumption. Results: Seventy-three patients with TAO patients were included. Forty-five patients were in Tobacco group (T) and 28 in Tobacco and cannabis group (T&C). Tobacco exposure was less important in T&C group than in T group (19.4 +/- 11.3 vs 31.6 +/- 16.6 pack-years) (p=0.005) and patients in T&C group were younger at TAO diagnosis than in T group (p=0.008). Patients in T&C group presented more claudication (33.3% vs 8.9%, p=0.01) and less upper limbs resting ischemia (25.9% vs 51.1%, p=0.04) than patients in the T group. No differences were found between groups with regard to arterial distribution. Amputation rate for patients who had at least one major or minor amputation did not differ between T and T&C group (25% vs 14.8%, p=0.38). Conclusions: Cannabis consumption was associated with a younger age of TAO onset. However, it does not affect amputation-free survival, Tobacco exposure is less important in T&C patients; data of this bicentric study suggest that cannabis could be a cofactor of tobacco which accelerates TAO onset.	[Bergere, Guillaume; Raimbeau, Alizee; Durant, Cecile; Artifoni, Mathieu; Gautier, Giovanni; Hersant, Jeanne; Connault, Jerome; Pistorius, Marc-Antoine; Espitia, Olivier] CHU Nantes, Dept Internal & Vasc Med, Nantes, France; [Bergere, Guillaume; Raimbeau, Alizee; Durant, Cecile; Artifoni, Mathieu; Gautier, Giovanni; Connault, Jerome; Pistorius, Marc-Antoine; Espitia, Olivier] CHU Nantes, Nantes Vasc Access Unit, UNAV, Nantes, France; [Toquet, Claire] CHU Nantes, Dept Pathol, Nantes, France; [Hoffmann, Clement; Bressollette, Luc] CHU Brest, Dept Vasc Med, EA 3878, GETBO, Brest, France		Espitia, O (通讯作者)，CHU Nantes, Dept Internal Med, 1 Pl Alexis Ricordeau, F-44093 Nantes, France.	olivier.espitia@chu-nantes.fr		Hoffmann, Clement/0000-0002-7037-2198; Luc, Bressollette/0000-0002-8354-469X			Arkkila PET, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-14; Ates A, 2006, INT J CARDIOL, V111, P147, DOI 10.1016/j.ijcard.2005.12.002; Beck F., 2017, OFDT, V119; Cooper LT, 2004, J AM COLL CARDIOL, V44, P2410, DOI 10.1016/j.jacc.2004.09.029; Fazeli B, 2018, ANN VASC SURG, V49, P219, DOI 10.1016/j.avsg.2017.10.022; Galyfos G, 2017, VASA, V46, P471, DOI 10.1024/0301-1526/a000649; Le Joncour A, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.010677; Martin-Blondel G, 2011, ANN VASC SURG, V25, P469, DOI 10.1016/j.avsg.2011.01.007; Modaghegh MHS, 2015, VASCULAR, V23, P519, DOI 10.1177/1708538114552838; Olin JW, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.011214; Olin JW, 2000, NEW ENGL J MED, V343, P864, DOI 10.1056/NEJM200009213431207; Sugimoto M, 2015, SURG TODAY, V45, P466, DOI 10.1007/s00595-014-0904-6	12	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JUL	2021	50	4					301	305		10.1024/0301-1526/a000948			5	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QY	33739143				2022-04-28	WOS:000695708700008
J	Herold, J; Peters, S; Juenger, J; Udelnow, A; Kropf, S; Bauersachs, R; Braun-Dullaeus, R				Herold, Joerg; Peters, Sophie; Juenger, Jonas; Udelnow, Andrej; Kropf, Siegfried; Bauersachs, Rupert; Braun-Dullaeus, Ruediger			High incidence of deep vein thrombosis during the treatment of pseudoaneurysms - a retrospective nonrandomized study	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Deep vein thrombosis; pseudoaneurysm; bleeding; complications; thrombin injection	FEMORAL-ARTERY PSEUDOANEURYSM; PERCUTANEOUS TREATMENT; PULMONARY-EMBOLISM; VENOUS THROMBOSIS; MANAGEMENT; INJECTION; EFFICACY; CLOSURE; CATHETERIZATION; ANGIOGRAPHY	Background: Pseudoaneurysms (PSAs) are concerning complications after arterial invasive interventions. Therapeutic options include manual ultrasound-assisted compression, pressure dressings, surgical intervention and thrombin injection. Compression of neighboring veins is obvious. However, the incidence of deep vein thrombosis (DVT) in patients with PSA has not previously been investigated. Patients and methods: In this retrospective, nonrandomized study 238 patients with PSA were analyzed from 2013 to 2018. In 149 patients, all of the parameters were complete for participating. PSAs were treated according to the local standard therapy with either ultrasound-guided compression followed by compression bandage or thrombin injection. Treatment success was evaluated 24 hours later, and the venous system was examined for the presence of DVT. Results: Peripheral DVT was found in 25.4% patients after ultrasound-assisted compression and subsequent pressure bandages, but only 6.4% of patients had DVT after thrombin injection (p = 0.013). Lower leg veins, particularly veins of the crural muscles, were primarily affected. Significantly more PSAs were successfully treated without the occurrence of DVT in the thrombin injection group compared to the compression group (93.6 vs. 69.0%; p = 0.001). Conclusions: Our study revealed that the use of thrombin injections resulted in a significantly lower rate of postinterventional DVT and a higher total number of successfully treated PSAs compared to compression therapy.	[Herold, Joerg; Bauersachs, Rupert] Klinikum Darmstadt, Dept Vasc Med Angiol, Graferstr 9, D-64287 Darmstadt, Germany; [Herold, Joerg; Braun-Dullaeus, Ruediger] Otto von Guericke Univ, Dept Cardiol & Angiol, Magdeburg, Germany; [Peters, Sophie] Dietrich Bonhoeffer Diakonie Hosp, Dept Surg, Neubrandenburg, Germany; [Juenger, Jonas] Childrens Hosp Prinzessin Margaret, Darmstadt, Germany; [Udelnow, Andrej] Municipal Hosp Brandenburg Havel, Dept Vasc & Endovasc Surg, Brandenburg Med Sch Theodor Fontane, Brandenburg Havel, Germany; [Kropf, Siegfried] Otto von Guericke Univ, Inst Biometry & Med Informat, Magdeburg, Germany		Herold, J (通讯作者)，Klinikum Darmstadt, Dept Vasc Med Angiol, Graferstr 9, D-64287 Darmstadt, Germany.	joerg_herold@hotmail.com					AGRAWAL SK, 1992, J AM COLL CARDIOL, V20, P610, DOI 10.1016/0735-1097(92)90015-F; BABU SC, 1989, J VASC SURG, V10, P113, DOI 10.1067/mva.1989.0100113; Biancari F, 2010, AM HEART J, V159, P518, DOI 10.1016/j.ahj.2009.12.027; Brotman DJ, 2004, SOUTH MED J, V97, P213, DOI 10.1097/01.SMJ.0000105663.01648.25; COPE C, 1986, AM J ROENTGENOL, V147, P383, DOI 10.2214/ajr.147.2.383; Decousus H, 2010, ANN INTERN MED, V152, P218, DOI 10.7326/0003-4819-152-4-201002160-00006; Del Corso A, 2013, CARDIOVASC INTER RAD, V36, P669, DOI 10.1007/s00270-012-0502-1; Di Minno MND, 2016, J THROMB HAEMOST, V14, P964, DOI 10.1111/jth.13279; FELLMETH BD, 1991, RADIOLOGY, V178, P671, DOI 10.1148/radiology.178.3.1994400; Finkelstein A, 2008, AM J CARDIOL, V101, P1418, DOI 10.1016/j.amjcard.2008.01.036; Frank U, 2019, VASA, V48, P7, DOI 10.1024/0301-1526/a000834; Hach-Wunderle V., 2016, VASA, V45, P1; Hamraoui K, 2002, J AM COLL CARDIOL, V39, P1297, DOI 10.1016/S0735-1097(02)01752-7; Herold J, 2019, PHLEBOLOGIE, V47, P319; Hofmann Ilona, 2007, EuroIntervention, V3, P321, DOI 10.4244/EIJV3I3A59; Jain SP, 1996, CATHETER CARDIO DIAG, V39, P317, DOI 10.1002/(SICI)1097-0304(199611)39:3<317::AID-CCD25>3.3.CO;2-U; Kurzawski J, 2020, EUR J VASC ENDOVASC, V59, P1019, DOI 10.1016/j.ejvs.2020.01.009; La Perna L, 2000, CIRCULATION, V102, P2391, DOI 10.1161/01.CIR.102.19.2391; Latib A, 2008, AM J CARDIOL, V102, P1477, DOI 10.1016/j.amjcard.2008.07.038; Loose HW, 1998, BRIT J RADIOL, V71, P1255, DOI 10.1259/bjr.71.852.10318997; Meis A, 2009, J ULTRAS MED, V28, P1151, DOI 10.7863/jum.2009.28.9.1151; PAULSON EK, 1992, AM J ROENTGENOL, V159, P1077, DOI 10.2214/ajr.159.5.1414779; Perler B A, 1993, Cardiovasc Surg, V1, P118; Peters S, 2018, HAMOSTASEOLOGIE, V38, P166, DOI 10.5482/HAMO-17-01-0006; Popovic B, 2010, INT J CARDIOL, V141, P75, DOI 10.1016/j.ijcard.2008.11.111; Schaub F, 1997, J AM COLL CARDIOL, V30, P670, DOI 10.1016/S0735-1097(97)00201-5; Spazier M, 2020, ZBL CHIR, V145, P438, DOI 10.1055/a-1096-1327; Stolt M, 2018, VASA, V47, P177, DOI 10.1024/0301-1526/a000691; Wu AR, 2017, J VASC SURG-VENOUS L, V5, P274, DOI 10.1016/j.jvsv.2016.09.005; Zhang GJ, 1996, SURG TODAY, V26, P683, DOI 10.1007/BF00312084	30	1	1	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	MAY	2021	50	3					231	239		10.1024/0301-1526/a000935			9	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QU	33435750				2022-04-28	WOS:000695708300011
J	van Baalen, EA; Hendriksz, TR; Brans, B; Westenend, PJ; van Bommel, EFH				van Baalen, Eske A.; Hendriksz, Tadek R.; Brans, Boudewijn; Westenend, Pieter J.; van Bommel, Eric F. H.			Intimal angiosarcoma masquerading as retroperitoneal fibrosis	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Primary intimal angiosarcoma; iliac artery; retroperitoneal fibrosis	SARCOMA; THERAPY; AORTA	We present a rare case of intimal angiosarcoma arising from the iliac artery with unusual symptoms and signs mimicking retroperitoneal fibrosis (RPF). This 84-year-old male presented with constitutional symptoms, abdominal pain, increased acute-phase reactant levels, impaired renal function and a CT-documented left-sided parailiac soft-tissue mass with unilateral extrinsic ureteric obstruction. Whole-body F-18-fluorodeoxyglucose positron emission tomography scan showed highly increased FDG-uptake in a horseshoe-like pattern surrounding the left common iliac artery, but no pathologic activity elsewhere. Further diagnostic workup revealed no signs of malignancy. Because of its location, CT-guided biopsy of the mass was precluded. A tentative diagnosis of RPF was made and treatment with Tamoxifen 20 b.i.d. was started. However, his condition gradually deteriorated, eventually succumbing to severe pneumosepsis. Autopsy revealed extensive iliac intimal angiosarcoma with infiltrative expansion to the left ureter and tumor emboli in both lungs. The present case suggests that intimal angiosarcoma should be included in the differential diagnosis of suspected RPF.	[van Baalen, Eske A.; van Bommel, Eric F. H.] Albert Schweitzer Hosp, Dept Internal Med, Dordrecht, Netherlands; [Hendriksz, Tadek R.] Albert Schweitzer Hosp, Radiol, Dordrecht, Netherlands; [Brans, Boudewijn] Albert Schweitzer Hosp, Nucl Med, Dordrecht, Netherlands; [Westenend, Pieter J.] Albert Schweitzer Hosp, Pathol, Dordrecht, Netherlands		van Bommel, EFH (通讯作者)，Dutch Natl Ctr Expertise Retroperitoneal Fibrosis, Dept Internal Med, POB 444, NL-3300 AK Dordrecht, Netherlands.	e.f.h.vanbommel@asz.nl		van Bommel, E.F.H./0000-0002-9803-1715			Alexander J Jeffrey, 2006, Vasc Endovascular Surg, V40, P509; Bode-Lesniewska B, 2013, WHO CLASSIFICATION T, P232; ESMO/European Sarcoma Network Working Group, 2014, ANN ONCOL, V25; Garg N, 2012, J VASC SURG, V55, P1134, DOI 10.1016/j.jvs.2011.08.049; Goldblum JR., 2020, ENZINGER WEISSS SOFT, P591; Ishii A, 2016, INTERNAL MED, V55, P755, DOI 10.2169/internalmedicine.55.5073; Ito K, 2009, ANN NUCL MED, V23, P671, DOI 10.1007/s12149-009-0292-y; Jansen I, 2010, EUR J INTERN MED, V21, P216, DOI 10.1016/j.ejim.2010.02.008; Kano M, 2019, J MED INVESTIG, V66, P205, DOI 10.2152/jmi.66.205; Lee DH, 2013, J CARDIOTHORAC SURG, V8, DOI 10.1186/1749-8090-8-40; Leowardi C, 2005, ANN SURG ONCOL, V12, P1090, DOI 10.1245/ASO.2005.09.002; Nicotera SP, 2009, J VASC SURG, V50, P186, DOI 10.1016/j.jvs.2009.01.014; Pelkmans LG, 2012, NEPHROL DIAL TRANSPL, V27, P2819, DOI 10.1093/ndt/gfr779; Seo H, 2020, VASA, V49, P243, DOI 10.1024/0301-1526/a000818; Staats P, 2014, PATHOLOGY, V46, P596, DOI 10.1097/PAT.0000000000000182; Thalheimer A, 2004, J VASC SURG, V40, P548, DOI 10.1016/j.jvs.2004.06.035; van Bommel EFH, 2013, EUR J INTERN MED, V24, P444, DOI 10.1016/j.ejim.2012.11.010; van Bommel EFH, 2009, MEDICINE, V88, P193, DOI 10.1097/MD.0b013e3181afc420; van Bommel EFH, 2006, ANN INTERN MED, V144, P101, DOI 10.7326/0003-4819-144-2-200601170-00007; Van Dievel J, 2017, ONCOL RES TREAT, V40, P353, DOI 10.1159/000476036	20	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	MAY	2021	50	3					240	243		10.1024/0301-1526/a000889			4	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QU	32657231				2022-04-28	WOS:000695708300012
J	Mohan, V; Sangiorgi, G; Knochel, J; Keo, HH; Schonhofen, J; Schumacher, MC; Schonhofen, H; Kalka, C; Diehm, N				Mohan, Vignes; Sangiorgi, Giuseppe; Knochel, Jonas; Keo, Hak-Hong; Schonhofen, Jan; Schumacher, Martin C.; Schonhofen, Heinz; Kalka, Christoph; Diehm, Nicolas			Frequency and anatomic distribution of arterial obstructions in patients with vasculogenic erectile dysfunction not responding to intracavernous prostaglandin	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						erectile dysfunction; vasculogenic; intracavernous; prostaglandin; arterial obstruction; Alprostadil	INTERNATIONAL INDEX; FUNCTION IIEF; INJECTIONS; SILDENAFIL; THERAPY	Background: The extent of arterial disease in patients with erectile dysfunction (ED) non-responsive to intracavernosal injection of Alprostadil is of importance for therapeutic options. However, published evidence, in particular angiographically validated is scarce. Here we investigated arterial lesion patterns in this specific patient cohort by selective angiography. Patients and methods: A cohort of 239 patients received a clinical and duplex-sonographic workup for ED of suspected vascular origin. Duplex ultrasound of the cavernosal arteries was performed after intracavernosal injection of 10 mu g Alprostadil. Consequently, standardized workup included grading of the erectile and determination of peak systolic velocity (PSV) and end-diastolic velocity (EDV) in both cavernosal arteries. PSV-values below 30 cm/sec indicated reduced arterial flow, whereas EDV-values above 15 cm/sec indicated a venous leak of the pudendal veins. All patients with suspected arterial ED based on duplex sonography underwent contrast-enhanced computed tomography. Endovascular therapy was carried out in ED patients not responsive or with significant side effects to PDE-5-inhibitors or Alprostadil by selective angiographic depiction of erection-related arteries. Results: 54 patients with a mean age of 61.2 (+/- 9.8) years underwent angioplasty of erectionr elated arteries. Out of these 48/54 (89%) patients presented with an erection considered insufficient for penetration (E0-E3) subsequent to intracavernous application of 10 mu g Alprostadil. 14/48 (29%) patients had bilateral arterial obstructions and 34/48 (71%) had unilateral disease. Commonly affected was the internal pudendal artery (n = 31, 65%), followed closely by the common penile artery (n = 30, 64%). The least affected arteries were the dorsal penile (n = 6, 13%), hypogastric (n = 4, 8%), common iliac (n = 4, 8%), cavernosal (n = 4, 8%), and inferior gluteal (n = 1, 2%) arteries. Conclusions: Arterial obstructions amenable to endovascular revascularization are frequent in patients non-responsive to intracavernosal prostaglandin administration. Therapeutic strategies in ED patients non-responsive to conservative measures should therefore consider endovascular treatment opportunities.	[Mohan, Vignes; Knochel, Jonas; Keo, Hak-Hong; Schonhofen, Jan; Kalka, Christoph; Diehm, Nicolas] Vasc Inst Cent Switzerland Aarau & Baden, Aarau, Switzerland; [Sangiorgi, Giuseppe] Univ Tor Vergata, Dept Syst Med, Rome, Italy; [Schumacher, Martin C.] Hirslanden Clin Aarau, Dept Urol, Aarau, Switzerland; [Schonhofen, Heinz] Ctr Radiol Baden, Baden, Switzerland		Mohan, V (通讯作者)，Vasc Inst Cent Switzerland, Aarenaustr 2b, CH-5000 Aarau, Switzerland.	drvignesmohan@gmail.com		Mohan, Vignes/0000-0001-6574-3284	iVascular S. L. U., Barcelona, Spain	Data entry into the present registry was financially supported by iVascular S. L. U., Barcelona, Spain.	Baumann F, 2011, J VASC SURG, V53, P1000, DOI 10.1016/j.jvs.2010.10.076; Biswas S., 2017, MOJ SURG, V5, P196; Bokarica P, 2015, EUR UROL, V68, pE77, DOI 10.1016/j.eururo.2015.06.013; BRODERICK GA, 1993, SEMIN ROENTGENOL, V28, P43, DOI 10.1016/S0037-198X(05)80112-9; Caretta N, 2019, ANDROLOGY-US, V7, P82, DOI 10.1111/andr.12561; Diehm N, 2013, EUR J VASC ENDOVASC, V46, P645, DOI 10.1016/j.ejvs.2013.08.017; Diehm N, 2019, J ENDOVASC THER, V26, P181, DOI 10.1177/1526602819829903; Diehm N, 2018, J ENDOVASC THER, V25, P710, DOI 10.1177/1526602818807704; Diehm N, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14268; Doppalapudi SK, 2019, J VASC INTERV RADIOL, V30, P1251, DOI 10.1016/j.jvir.2019.01.024; Duncan C, 2019, WORLD J UROL, V37, P1007, DOI 10.1007/s00345-019-02727-5; Elhanbly S, 2002, J UROLOGY, V167, P192, DOI 10.1016/S0022-5347(05)65410-9; Esposito K, 2004, JAMA-J AM MED ASSOC, V291, P2978, DOI 10.1001/jama.291.24.2978; Feldman HA, 2000, PREV MED, V30, P328, DOI 10.1006/pmed.2000.0643; Gandaglia G, 2016, EUR UROL, V70, P219, DOI 10.1016/j.eururo.2016.01.054; Ghanem H, 2008, J SEX MED, V5, P1582, DOI 10.1111/j.1743-6109.2007.00665.x; Giuliano F, 2000, J UROLOGY, V164, P708, DOI 10.1016/S0022-5347(05)67286-2; Goldstein I, 2000, SCI AM, V283, P70, DOI 10.1038/scientificamerican0800-70; Varela CG, 2020, AM J ROENTGENOL, V214, P1112, DOI 10.2214/AJR.19.22141; Gutierrez P, 2005, INT J IMPOT RES, V17, P354, DOI 10.1038/sj.ijir.3901290; Hatzichristou D, 2002, J UROLOGY, V168, P615, DOI 10.1016/S0022-5347(05)64690-3; Inman BA, 2009, MAYO CLIN PROC, V84, P108, DOI 10.4065/84.2.108; KIRTLAND SJ, 1988, PROSTAG LEUKOTR ESS, V32, P165, DOI 10.1016/0952-3278(88)90168-8; Lewis RW, 2010, J SEX MED, V7, P1598, DOI 10.1111/j.1743-6109.2010.01778.x; McMahon CN, 2006, BMJ-BRIT MED J, V332, P589, DOI 10.1136/bmj.332.7541.589; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; Rogers JH, 2010, CATHETER CARDIO INTE, V76, P882, DOI 10.1002/ccd.22646; Rosen RC, 2011, EUR UROL, V60, P1010, DOI 10.1016/j.eururo.2011.07.053; Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0; Rosen RC, 2002, INT J IMPOT RES, V14, P226, DOI 10.1038/sj.ijir.3900857; Sangiorgi G, 2020, MINERVA CARDIOANGIOL, DOI [10.23736/S0026-4725.20.05136-1, DOI 10.23736/S0026-4725.20.05136-1]; Sommer F, 2004, DRUG AGING, V21, P555, DOI 10.2165/00002512-200421090-00001; Spiliopoulos S, 2016, J ENDOVASC THER, V23, P878, DOI 10.1177/1526602816669457; Sung HH, 2014, ANDROLOGY-US, V2, P45, DOI 10.1111/j.2047-2927.2013.00155.x; Wespes E, 2006, EUR UROL, V49, P806, DOI 10.1016/j.eururo.2006.01.028	35	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JUL	2021	50	4					306	311		10.1024/0301-1526/a000944			6	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QY	33615871				2022-04-28	WOS:000695708700009
J	Poredos, P; Zlajpah, U; Poredos, P; Mangaroska, AS; Jezovnik, MK				Poredos, Pavel; Zlajpah, Urska; Poredos, Peter; Mangaroska, Ana Spirkoska; Jezovnik, Mateja K.			Use of the walking impairment questionnaire as a measure of functional assessment	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Functional assessment; walk tests; intermittent claudication; treadmill test; ankle-brachial index	ANKLE-BRACHIAL INDEX; PERIPHERAL ARTERIAL-DISEASE; QUALITY-OF-LIFE; 6-MINUTE WALK; EXERCISE PERFORMANCE; THERAPEUTIC TRIALS; TREADMILL WALKING; LEG SYMPTOMS; CAPACITY; IMPROVES	Background: A significant consequence of peripheral arterial disease (PAD) is an impaired functional capacity and deteriorated quality of life. Therefore, our study aimed to investigate the usefulness of a symptom questionnaire and walk tests for the determination of the functional capacity of patients with intermittent claudication. Patients and methods:The study included 53 patients (38 males) with stable claudication distance (50-300m). A detailed history and physical examination, ankle-brachial index (ABI), treadmill exercise test, and 6-minute walk test were performed and compared to walking impairment questionnaire (WIQ). Results:Claudication distance reported from patients' history and 6-minute walk test were significantly correlated with ABI (p=0.033, p=0.044). There were no significant correlations between ABI and treadmill walk test or WIQ. Results of WIQ were significantly correlated with the history and the most of performed walk tests: treadmill initial and maximal claudication distance (p=0.004 and 0.012, respectively) and 6-minute walk test (p=0.026). 6-minute walk test was correlated with maximal claudication distance of treadmill (p=0.018), but not with an initial claudication distance. Conclusions: The validity of WIQ is comparable to walk tests and represents the useful technique for the investigation of the functional capacity of patients with PAD. A self-report based on WIQ enables a longer period of observation. It should be routinely used as a basic diagnostic tool for the estimation of the functional capacity of PAD patients with stable intermittent claudication.	[Poredos, Pavel; Zlajpah, Urska; Mangaroska, Ana Spirkoska] Univ Med Ctr Ljubljana, Dept Vasc Dis, Zaloska C 7, Ljubljana 1525, Slovenia; [Poredos, Pavel; Jezovnik, Mateja K.] Univ Texas Hlth Sci Ctr Houston, Dept Adv Cardiopulm Therapies & Transplantat, Houston, TX 77030 USA; [Poredos, Peter] Univ Med Ctr Ljubljana, Dept Anesthesiol & Intens Care, Ljubljana, Slovenia		Poredos, P (通讯作者)，Univ Med Ctr Ljubljana, Dept Vasc Dis, Zaloska C 7, Ljubljana 1525, Slovenia.	pavel.poredos@kclj.si					Al-Qaisi M, 2009, VASC HEALTH RISK MAN, V5, P833; Brass EP, 2006, J AM COLL CARDIOL, V48, P2539, DOI 10.1016/j.jacc.2006.07.064; Cavalcante BR, 2018, EUR J VASC ENDOVASC, V55, P672, DOI 10.1016/j.ejvs.2018.02.010; Chong PFS, 2002, J VASC SURG, V36, P764, DOI 10.1067/mva.2002.127338; Coyne KS, 2003, J VASC SURG, V38, P296, DOI 10.1016/S0741-5214(03)00312-4; Creager MA, 2011, CIRCULATION, V124, P1765, DOI 10.1161/CIRCULATIONAHA.110.009407; Degischer S, 2002, J VASC SURG, V36, P83, DOI 10.1067/mva.2002.123092; Farkas K, 2020, VASA, V49, P235, DOI 10.1024/0301-1526/a000845; Frans FA, 2013, J VASC SURG, V57, P720, DOI 10.1016/j.jvs.2012.09.044; Fried LP, 1997, J AM GERIATR SOC, V45, P92, DOI 10.1111/j.1532-5415.1997.tb00986.x; Gardner AW, 2007, J VASC SURG, V46, P79, DOI 10.1016/j.jvs.2007.02.037; GARDNER AW, 1991, MED SCI SPORT EXER, V23, P402; Gohil RA, 2013, ANN VASC SURG, V27, P68, DOI 10.1016/j.avsg.2012.05.005; GREIG C, 1993, J AM GERIATR SOC, V41, P15, DOI 10.1111/j.1532-5415.1993.tb05941.x; Hanson LC, 2012, PHYSIOTHER RES INT, V17, DOI 10.1002/pri.513; Hiatt WR, 2014, CIRCULATION, V130, P69, DOI 10.1161/CIRCULATIONAHA.113.007003; Johnston AL, 2019, J VASC SURG, V69, P906, DOI 10.1016/j.jvs.2018.07.039; Kieback AG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224608; Long J, 2004, J VASC SURG, V39, P723, DOI 10.1016/j.jvs.2003.12.006; Mahe G, 2011, J VASC SURG, V54, P1360, DOI 10.1016/j.jvs.2011.05.048; McDermott MM, 2014, CIRCULATION, V130, P61, DOI 10.1161/CIRCULATIONAHA.114.007002; McDermott MM, 2013, JAMA-J AM MED ASSOC, V310, P57, DOI 10.1001/jama.2013.7231; McDermott MM, 2010, J AM GERIATR SOC, V58, P1256, DOI 10.1111/j.1532-5415.2010.02941.x; McDermott MM, 2002, ANN INTERN MED, V136, P873, DOI 10.7326/0003-4819-136-12-200206180-00008; McDermott MM, 2001, JAMA-J AM MED ASSOC, V286, P1599; McDermott MM, 1998, J VASC SURG, V28, P1072, DOI 10.1016/S0741-5214(98)70034-5; McDermott MM, 1999, J GEN INTERN MED, V14, P173, DOI 10.1046/j.1525-1497.1999.00309.x; Mueller T, 2016, VASC MED, V21, P445, DOI 10.1177/1358863X16643603; Murphy TP, 2013, J VASC INTERV RADIOL, V24, P1427, DOI 10.1016/j.jvir.2013.05.057; Nicolai SPA, 2009, J VASC SURG, V50, P89, DOI 10.1016/j.jvs.2008.12.073; Peeters P, 1996, J GERONTOL A-BIOL, V51, pM147, DOI 10.1093/gerona/51A.4.M147; Poredos P, 2020, VASA, V49, P275, DOI 10.1024/0301-1526/a000852; Rantner B, 2017, SCI REP-UK, V7, DOI 10.1038/srep45833; Regensteiner JG, 1996, J VASC SURG, V23, P104, DOI 10.1016/S0741-5214(05)80040-0; REGENSTEINER JG, 1993, ANGIOLOGY, V44, P1, DOI 10.1177/000331979304400101; Regensteiner JG, 1990, J VASC MED BIOL, V2, P142; Sagar SP, 2012, INT J VASC MED, V2012, DOI 10.1155/2012/190641; Tew G, 2013, J VASC SURG, V57, P1227, DOI 10.1016/j.jvs.2012.02.073	38	1	1	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JUL	2021	50	4					286	293		10.1024/0301-1526/a000941			8	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Cardiovascular System & Cardiology	UP9QY	33661020				2022-04-28	WOS:000695708700006
J	Semetaite, A; Muhlberg, KS				Semetaite, Agne; Muehlberg, Katja S.			Does sex really matter? Differences between men and women in repair type and mortality risk after AAA repair	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Editorial Material							SURGERY		[Semetaite, Agne; Muehlberg, Katja S.] Univ Leipzig, Clin Angiol, Dept Internal Med Neurol & Dermatol, Leipzig, Germany		Semetaite, A; Muhlberg, KS (通讯作者)，Univ Leipzig, Clin Angiol, Neurol & Dermatol, Dept Internal Med, Liebigstr 20, D-04103 Leipzig, Germany.	katja.muehlberg@medizin.uni-leipzig.de; katja.muehlberg@medizin.uni-leipzig.de					Hoel AW, 2009, J VASC SURG, V50, P349, DOI 10.1016/j.jvs.2009.01.012; Liu Y, 2020, J VASC SURG, V71, P283, DOI 10.1016/j.jvs.2019.06.105; Lo RC, 2016, J VASC SURG, V63, P839, DOI 10.1016/j.jvs.2015.10.087; Ramkumar N, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.21240; Steinmetz E, 2010, EUR J VASC ENDOVASC, V39, P403, DOI 10.1016/j.ejvs.2009.12.009; Stoberock K, 2018, VASA, V47, P267, DOI 10.1024/0301-1526/a000703	6	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	MAY	2021	50	3					246	247		10.1024/0301-1526/a000943			2	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QU	33938230				2022-04-28	WOS:000695708300014
J	Jia, XM; Sun, C; Tanaka, H; Al Rifai, M; Aguilar, D; Ndumele, C; Selvin, E; Virani, SS; Hoogeveen, RC; Heiss, G; Ballantyne, CM; Nambi, V				Jia, Xiaoming; Sun, Caroline; Tanaka, Hirofumi; Al Rifai, Mahmoud; Aguilar, David; Ndumele, Chiadi; Selvin, Elizabeth; Virani, Salim S.; Hoogeveen, Ron C.; Heiss, Gerardo; Ballantyne, Christie M.; Nambi, Vijay			Association between circulating Galectin-3 and arterial stiffness in older adults Atherosclerosis Risk in Communities (ARIC) Study	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Galectin-3; arterial stiffness; aging	PULSE-WAVE VELOCITY; HEART-FAILURE; BLOOD-PRESSURE; HYPERTENSION; PREDICTION; FIBROSIS; INSIGHTS; DISEASE	Background: Gatectin-3 (gat-3) is a beta-galactoside-binding lectin associated tissue fibrosis and inflammation. There is limited understanding of the relationship between gal-3 and vascular health. Our aim was to assess the association between gat-3 and arterial stiffness in older adults. Methods: We conducted a cross-sectional study of 4275 participants (mean age of 75 years) from the Atherosclerosis Risk in Communities (ARIC) Study. Central arterial stiffness was measured by carotid-femoral pulse wave velocity (cfPWV). We evaluated the association of gat-3 with cfPWV using multivariable linear regression. Results: The median (interquartile range) gal-3 concentration was 16.5 (13.8, 19.8) ng/mL and mean cfPWV was 1163 +/- 303 cm/s. Higher gal-3 concentration was associated with greater central arterial stiffness after adjustment for age, sex, race-center, heart rate, systolic blood pressure, anti-hypertensive medication use, and current smoking status (beta=36.4 cm/s change in cfPWV per tog unit change in gal-3: 95% CI: 7.2, 65.5, p=0.015). The association was attenuated after adjusting for additional cardiovascular risk factors (beta=17.3, 95% CI: -14.4, 49.0). Conclusions: In community-dwelling older adults, gal-3 concentration was associated with central arterial stiffness, likely sharing common pathways with traditional cardiovascular risk factors.	[Jia, Xiaoming; Sun, Caroline; Al Rifai, Mahmoud; Virani, Salim S.; Hoogeveen, Ron C.; Ballantyne, Christie M.; Nambi, Vijay] Baylor Coll Med, 1 Baylor Plaza,521D,MS 285, Houston, TX 77030 USA; [Tanaka, Hirofumi] Univ Texas Austin, Austin, TX 78712 USA; [Aguilar, David] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA; [Ndumele, Chiadi; Selvin, Elizabeth] Johns Hopkins Univ, Baltimore, MD USA; [Virani, Salim S.; Nambi, Vijay] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Heiss, Gerardo] Univ N Carolina, Chapel Hill, NC USA		Nambi, V (通讯作者)，Baylor Coll Med, 1 Baylor Plaza,521D,MS 285, Houston, TX 77030 USA.	vnambi@bcm.edu		Aguilar, David/0000-0002-0916-2722			Aguilar D, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.015405; [Anonymous], 2017, CIRCULATION, V135, P224, DOI 10.1161/CIRCULATIONAHA.116.023361; Ballantyne CM, 2004, CIRCULATION, V109, P837, DOI 10.1161/01.CIR.0000116763.91992.F1; Barman SA, 2018, AM J RESP CRIT CARE, V197, P1488, DOI 10.1164/rccm.201711-2308LE; Ben-Shlomo Y, 2014, J AM COLL CARDIOL, V63, P636, DOI 10.1016/j.jacc.2013.09.063; Calvier L, 2013, ARTERIOSCL THROM VAS, V33, P67, DOI 10.1161/ATVBAHA.112.300569; Ding N, 2020, ARTERIOSCL THROM VAS, V40, P2322, DOI 10.1161/ATVBAHA.120.314824; Fashanu OE, 2017, AM HEART J, V192, P19, DOI 10.1016/j.ahj.2017.07.001; Galis ZS, 2013, HYPERTENSION, V61, P757, DOI 10.1161/HYPERTENSIONAHA.111.00770; Ho JE, 2012, J AM COLL CARDIOL, V60, P1249, DOI 10.1016/j.jacc.2012.04.053; Kucharska-Newton AM, 2010, ACTA DIABETOL, V47, pS161, DOI 10.1007/s00592-009-0157-9; Libhaber E, 2015, HYPERTENSION, V65, P1356, DOI 10.1161/HYPERTENSIONAHA.115.05159; Loehr LR, 2008, AM J CARDIOL, V101, P1016, DOI 10.1016/j.amjcard.2007.11.061; Lopez B, 2015, EUR J HEART FAIL, V17, P385, DOI 10.1002/ejhf.246; Madrigal-Matute J, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000785; Matsushita K, 2017, ATHEROSCLEROSIS, V257, P208, DOI 10.1016/j.atherosclerosis.2016.11.023; McEvoy JW, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003079; Meijers WC, 2014, AM HEART J, V167, P853, DOI 10.1016/j.ahj.2014.02.011; Meyer ML, 2016, AM J HYPERTENS, V29, P114, DOI 10.1093/ajh/hpv079; Mitchell GF, 2010, CIRCULATION, V122, P1379, DOI 10.1161/CIRCULATIONAHA.109.914507; Oikonomou E, 2019, CURR VASC PHARMACOL, V17, P396, DOI 10.2174/1570161116666180703094919; Petrie JR, 2018, CAN J CARDIOL, V34, P575, DOI 10.1016/j.cjca.2017.12.005; Pugliese G, 2015, GLYCOBIOLOGY, V25, P136, DOI 10.1093/glycob/cwu111; Spinetti G, 2008, CARDIOVASC RES, V78, P265, DOI 10.1093/cvr/cvn039; van Vark LC, 2017, J AM COLL CARDIOL, V70, P2378, DOI 10.1016/j.jacc.2017.09.026; Vlachopoulos C, 2010, J AM COLL CARDIOL, V55, P1318, DOI 10.1016/j.jacc.2009.10.061; Weisbrod RM, 2013, HYPERTENSION, V62, P1105, DOI 10.1161/HYPERTENSIONAHA.113.01744; Zhang Q, 2019, BIOMARK MED, V13, P437, DOI 10.2217/bmm-2018-0488	28	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	NOV	2021	50	6					439	445		10.1024/0301-1526/a000968			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6JL	34346252				2022-04-28	WOS:000753518900005
J	Watanabe, T				Watanabe, Takuya			Neopterin derivatives - a novel therapeutic target rather than biomarker for atherosclerosis and related diseases	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Review						neopterin derivatives; atherosclerosis; vascular inflammation; coronary artery disease	NITRIC-OXIDE SYNTHASE; CORONARY-ARTERY-DISEASE; LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; NECROSIS-FACTOR-ALPHA; GTP-CYCLOHYDROLASE-I; SERUM NEOPTERIN; ENDOTHELIAL DYSFUNCTION; PLASMA NEOPTERIN; TETRAHYDROBIOPTERIN SYNTHESIS	This review provides an updated overview of the emerging roles of neopterin derivatives in atherosclerosis. Neopterin, a metabolite of guanosine triphosphate, is produced by interferon-gamma -activated macrophages and is expressed at high levels in atheromatous plaques within the human carotid and coronary arteries as well as in the aorta. Plasma concentrations of neopterin are higher in patients with carotid, cerebral, and coronary artery diseases as well as aortic aneurysm. The concentration of neopterin is positively correlated with the severity of coronary artery disease. However, a prospective cohort study showed that neopterin contributes to protection against plaque formation in carotid arteries in patients with atherosclerosis. Moreover, using both in vitro and in vivo experiments, a recent study has shown the atheroprotective effects of neopterin. Neopterin suppresses the expression of monocyte chemotactic protein-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in endothelial cells, and thereby suppresses the adhesion of monocytes to endothelial cells. It also suppresses the inflammatory phenotype of monocyte-derived macrophages. In addition, neopterin suppresses oxidized low-density lipoprotein-induced foam cell formation in macrophages and the migration and proliferation of vascular smooth muscle cells. Neopterin injection into apolipoprotein E-deficient (Apoe(-/-)) mice suppresses the development of atherosclerotic lesions. A neopterin derivative tetrahydroneopterin (BH4), also known as a cofactor for nitric oxide (NO) synthases, suppresses atherosclerosis and vascular injury-induced neointimal hyperplasia in Apoe(-/-) mice. BH4 administration improves endothelial dysfunction in patients with coronary artery disease. These findings suggest that neopterin production may increase to counteract the progression of atherosclerosis, as neopterin contributes to atheroprotection. Otherwise, the increased neopterin levels in atherosclerosis may reflect a compensatory mechanism associated with inducible NO synthase upregulation in macrophages to supply BH4 for high output NO production caused by decreased endothelial NO synthase in atherosclerosis. Therefore, neopterin derivatives are a novel therapeutic target for atherosclerosis and related diseases.	[Watanabe, Takuya] Ushioda Gen Hosp Clin, Dept Internal Med, Yokohama, Kanagawa, Japan		Watanabe, T (通讯作者)，Ushioda Gen Hosp Clin, Dept Internal Med, Tsurumi Ku, 1-16-1 Honcho Dori, Yokohama, Kanagawa 2300048, Japan.	t-watanabe@ushioda.or.jp					Adachi T, 2007, HEART, V93, P1537, DOI 10.1136/hrt.2006.109736; Ali ZA, 2013, CIRCULATION, V128, pS50, DOI 10.1161/CIRCULATIONAHA.112.000249; Alp NJ, 2004, ARTERIOSCL THROM VAS, V24, P445, DOI 10.1161/01.ATV.0000115637.48689.77; ANDERT SE, 1992, CLIN EXP IMMUNOL, V88, P555; Andrys C, 1999, Acta Medica (Hradec Kralove), V42, P97; Antoniades C, 2007, CIRCULATION, V116, P2851, DOI 10.1161/CIRCULATIONAHA.107.704155; Antoniades C, 2011, CIRCULATION, V124, P1860, DOI 10.1161/CIRCULATIONAHA.111.029272; Arshadi D, 2013, INT IMMUNOPHARMACOL, V17, P763, DOI 10.1016/j.intimp.2013.08.022; Arslan N, 2013, J PEDIATR ENDOCR MET, V26, P1141, DOI 10.1515/jpem-2013-0029; Auer J, 2001, Heart Dis, V3, P297; Avanzas P, 2005, EUR HEART J, V26, P457, DOI 10.1093/eurheartj/ehi111; Balogh A, 2005, BBA-GEN SUBJECTS, V1724, P17, DOI 10.1016/j.bbagen.2005.04.006; Baumgardt SL, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.115.002424; Baxter-Parker G, 2020, FREE RADICAL BIO MED, V152, P142, DOI 10.1016/j.freeradbiomed.2020.03.002; Bendall JK, 2014, ANTIOXID REDOX SIGN, V20, P3040, DOI 10.1089/ars.2013.5566; Bertholet S, 1999, J LEUKOCYTE BIOL, V65, P50, DOI 10.1002/jlb.65.1.50; Bowers Mark C, 2011, Front Biosci (Schol Ed), V3, P1263; Chang P, 2015, BIOCHEM BIOPH RES CO, V463, P1012, DOI 10.1016/j.bbrc.2015.06.051; Chuang SC, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0059-y; Ciecko-Michalska Irena, 2010, Przegl Lek, V67, P1262; Cirillo P, 2006, J THROMB HAEMOST, V4, P2248, DOI 10.1111/j.1538-7836.2006.02125.x; Cunnington C, 2012, CIRCULATION, V125, P1356, DOI 10.1161/CIRCULATIONAHA.111.038919; Demir S, 2019, ACTA CARDIOL, V74, P216, DOI 10.1080/00015385.2018.1478266; Dominguez-Rodriguez A, 2010, ATHEROSCLEROSIS, V211, P574, DOI 10.1016/j.atherosclerosis.2010.04.017; Eltoft A, 2018, ATHEROSCLEROSIS, V271, P1, DOI 10.1016/j.atherosclerosis.2018.02.005; Estevez-Loureiro R, 2009, ATHEROSCLEROSIS, V207, P514, DOI 10.1016/j.atherosclerosis.2009.04.032; Firoz CK, 2015, IUBMB LIFE, V67, P453, DOI 10.1002/iub.1390; Firth CA, 2008, BBA-MOL CELL RES, V1783, P1095, DOI 10.1016/j.bbamcr.2008.02.010; FUCHS D, 1994, KIDNEY INT, pS8; Fukuda Y, 2002, CIRC J, V66, P58, DOI 10.1253/circj.66.58; Gieseg SP, 2008, BRIT J PHARMACOL, V153, P627, DOI 10.1038/sj.bjp.0707408; Gieseg SP, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7070080; Gostner JM, 2016, ATHEROSCLEROSIS, V255, P117, DOI 10.1016/j.atherosclerosis.2016.10.046; Gur DO, 2019, J ATHEROSCLER THROMB, V26, P351, DOI 10.5551/jat.44891; Hajsl M, 2020, METABOLITES, V10, DOI 10.3390/metabo10050208; Hattori Y, 2007, ARTERIOSCL THROM VAS, V27, P865, DOI 10.1161/01.ATV.0000258946.55438.0e; Hermus L, 2011, CLIN BIOCHEM, V44, P1292, DOI 10.1016/j.clinbiochem.2011.08.1141; Herrington W, 2016, CIRC RES, V118, P535, DOI 10.1161/CIRCRESAHA.115.307611; Hoffmann G, 1996, FEBS LETT, V391, P181, DOI 10.1016/0014-5793(96)00729-6; Hoffmann G, 1998, IMMUNOBIOLOGY, V199, P63, DOI 10.1016/S0171-2985(98)80064-8; Hoffmann G, 1998, INT ARCH ALLERGY IMM, V116, P240, DOI 10.1159/000023950; HOMOLKA J, 1992, CLIN INVESTIGATOR, V70, P909; Hong HJ, 2001, HYPERTENSION, V38, P1044, DOI 10.1161/hy1101.095331; Hull M, 2000, ALZ DIS ASSOC DIS, V14, P228, DOI 10.1097/00002093-200010000-00007; Iizuka H, 1996, JPN J PHARMACOL, V72, P375, DOI 10.1254/jjp.72.375; Ishii M, 1998, PHARMACOL TOXICOL, V82, P280, DOI 10.1111/j.1600-0773.1998.tb01574.x; Janmale T, 2015, PTERIDINES, V26, P93, DOI 10.1515/pterid-2015-0004; Janmale TV, 2020, FREE RADICAL RES, V54, P341, DOI 10.1080/10715762.2020.1764948; Jiang X, 2010, KOREAN J PHYSIOL PHA, V14, P177, DOI 10.4196/kjpp.2010.14.3.177; Jinkawa A, 2019, CYTOKINE, V119, P52, DOI 10.1016/j.cyto.2019.03.001; Kase H, 2005, J HYPERTENS, V23, P1375, DOI 10.1097/01.hjh.0000173520.13976.7d; Kim SH, 2011, ARCH PHARM RES, V34, P1571, DOI 10.1007/s12272-011-0920-7; Koglin J, 1998, CIRCULATION, V97, P2059, DOI 10.1161/01.CIR.97.20.2059; KOJIMA S, 1993, FEBS LETT, V329, P125, DOI 10.1016/0014-5793(93)80207-B; Lanser L, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122230; Lee JE, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00043; Liu ZY, 2013, GENET MOL RES, V12, P4222, DOI 10.4238/2013.October.7.8; Luoma JS, 1999, VIRCHOWS ARCH, V434, P561, DOI 10.1007/s004280050384; Mahmoud RAK, 2005, CLIN BIOCHEM, V38, P134, DOI 10.1016/j.clinbiochem.2004.11.002; Marinos RS, 2001, AM J PHYSIOL-HEART C, V281, pH482, DOI 10.1152/ajpheart.2001.281.2.H482; McNeill E, 2012, THROMB HAEMOSTASIS, V108, P832, DOI 10.1160/TH12-06-0424; Miller JD, 2013, ARTERIOSCL THROM VAS, V33, P459, DOI 10.1161/ATVBAHA.112.252700; Moens AL, 2006, ARTERIOSCL THROM VAS, V26, P2439, DOI 10.1161/01.ATV.0000243924.00970.cb; Odegard A, 2007, INT ANGIOL, V26, P219; Oxenkrug G, 2011, Am J Neuroprot Neuroregen, V3, P48; Paladino L, 2017, J GLOB INFECT DIS, V9, P45, DOI 10.4103/jgid.jgid_24_17; Peng QL, 2020, CLIN EXP IMMUNOL, V199, P314, DOI 10.1111/cei.13404; Pergialiotis V, 2018, HYPERTENS PREGNANCY, V37, P220, DOI 10.1080/10641955.2018.1526300; Prebble H, 2018, IMMUNOBIOLOGY, V223, P526, DOI 10.1016/j.imbio.2018.03.002; Punjabi NM, 2007, CHEST, V132, P1124, DOI 10.1378/chest.07-0743; Rao VS, 2011, CARDIOL RES PRACT, V2011, DOI 10.4061/2011/295976; SAKURAI A, 1967, J BIOCHEM, V61, P142, DOI 10.1093/oxfordjournals.jbchem.a128513; Schmidt TS, 2010, CLIN SCI, V119, P131, DOI 10.1042/CS20090559; Schobersberger W, 1995, FEBS LETT, V377, P461, DOI 10.1016/0014-5793(95)01393-8; Schumacher M, 1997, J AM COLL CARDIOL, V30, P703, DOI 10.1016/S0735-1097(97)00172-1; Settergren M, 2009, ATHEROSCLEROSIS, V204, P73, DOI 10.1016/j.atherosclerosis.2008.08.034; Shchepetkina AA, 2017, INT J BIOCHEM CELL B, V87, P27, DOI 10.1016/j.biocel.2017.03.017; Shirai R, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007359; Smukowska-Gorynia A, 2018, RESPIRATION, V96, P222, DOI 10.1159/000488908; Sugioka K, 2010, ATHEROSCLEROSIS, V208, P524, DOI 10.1016/j.atherosclerosis.2009.07.054; Tanaka T, 2004, CIRC J, V68, P114, DOI 10.1253/circj.68.114; Tiefenbacher CP, 2000, CIRCULATION, V102, P2172; Tony AA, 2019, NEUROPSYCH DIS TREAT, V15, P575, DOI 10.2147/NDT.S177726; Ueland T, 2006, EUR J CLIN INVEST, V36, P147, DOI 10.1111/j.1365-2362.2006.01613.x; van Dijk RA, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002860; Vengen IT, 2009, ATHEROSCLEROSIS, V207, P239, DOI 10.1016/j.atherosclerosis.2009.04.003; Watanabe Rena, 2016, JACC Basic Transl Sci, V1, P494, DOI 10.1016/j.jacbts.2016.07.008; Watanabe T, 2013, CURR PROTEIN PEPT SC, V14, P472, DOI 10.2174/13892037113149990064; WEISS G, 1994, ATHEROSCLEROSIS, V106, P263, DOI 10.1016/0021-9150(94)90131-7; Wilcox JN, 1997, ARTERIOSCL THROM VAS, V17, P2479, DOI 10.1161/01.ATV.17.11.2479; Wojciechowska C, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/585067; Worthley MI, 2007, CARDIOVASC RES, V76, P539, DOI 10.1016/j.cardiores.2007.07.009; Yadav AK, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/476979; Yamamoto E, 2016, ESC HEART FAIL, V3, P53, DOI 10.1002/ehf2.12070; Yan JQ, 2013, MOL CELL BIOCHEM, V379, P123, DOI 10.1007/s11010-013-1634-6; Yoshida M, 2003, J CARDIOVASC PHARM, V42, P197, DOI 10.1097/00005344-200308000-00007; Yoshiyama T, 2018, J ATHEROSCLER THROMB, V25, P1105, DOI 10.5551/jat.43166; Zhang YY, 2016, J HUM HYPERTENS, V30, P436, DOI 10.1038/jhh.2015.72; Zhang ZY, 2016, CHINESE MED J-PEKING, V129, P2733, DOI 10.4103/0366-6999.193455; Zouridakis E, 2004, CIRCULATION, V110, P1747, DOI 10.1161/01.CIR.0000142664.18739.92	100	4	4	0	1	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	MAY	2021	50	3					165	173		10.1024/0301-1526/a000903			9	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QU	32924886				2022-04-28	WOS:000695708300003
J	Debus, S; Bauersachs, R; Bonaca, M				Debus, Sebastian; Bauersachs, Rupert; Bonaca, Marc			William R. Hiatt June 1, 1950-December 8, 2020 Obituary	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Biographical-Item									[Bauersachs, Rupert] Klinikum Darmstadt GmbH, Dept Vasc Med, Angiol Vasc Ctr, Grafenstr 9, D-64283 Darmstadt, Germany		Bauersachs, R (通讯作者)，Klinikum Darmstadt GmbH, Dept Vasc Med, Angiol Vasc Ctr, Grafenstr 9, D-64283 Darmstadt, Germany.	bauersachs@em.uni-frankfurt.de					Bonaca MP, 2020, NEW ENGL J MED, V382, P1994, DOI 10.1056/NEJMoa2000052; Hiatt WR, 2017, NEW ENGL J MED, V376, P32, DOI 10.1056/NEJMoa1611688; HIATT WR, PUBLICATION LIST; Owen JP, 2005, COWBOY ETHICS	4	0	0	0	0	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0301-1526			VASA	Vasa	FEB	2021	50	2					157	157		10.1024/0301-1526/a000936			1	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	QQ5PH					2022-04-28	WOS:000624575300012
J	Lichtenberg, M; de Graaf, R; Jalaie, H				Lichtenberg, Michael; de Graaf, Rick; Jalaie, Houman			Acute and chronic venous outflow obstructions - a global burden	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Editorial Material									[Lichtenberg, Michael] Vasc Ctr Arnsberg, Arnsberg, Germany; [de Graaf, Rick] Klinikum Friedrichshafen, Radiol Dept, Friedrichshafen, Germany; [Jalaie, Houman] European Venous Ctr, Aachen, Germany; [Jalaie, Houman] European Venous Ctr, Maastricht, Netherlands		Lichtenberg, M (通讯作者)，Vasc Ctr Arnsberg, Arnsberg, Germany.							0	0	0	0	0	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0301-1526			VASA	Vasa	JAN	2021	50	1			SI		1	1		10.1024/0301-1526/a000931			1	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	PQ4VY	33393382	Bronze			2022-04-28	WOS:000606545800001
J	Nawasrah, J; Zydek, B; Lucks, J; Renczes, J; Haberichter, B; Balaban, U; Schellong, S; Lindhoff-Last, E				Nawasrah, Jamil; Zydek, Barbara; Lucks, Jessica; Renczes, Johannes; Haberichter, Barbara; Balaban, Uemniye; Schellong, Sebastian; Lindhoff-Last, Edelgard			Incidence and severity of postthrombotic syndrome after iliofemoral thrombosis - results of the Iliaca-PTS - Registry	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Deep vein thrombosis; iliofemoral thrombosis; postthrombotic syndrome	QUALITY-OF-LIFE; DETERMINANTS; RELIABILITY; DIAGNOSIS; DISEASE; RISK	Background: Deep venous thrombosis (DVT) and in particular, iliofemoral thrombosis (IFT) can lead to recurrent thrombosis and postthrombotic syndrome (PTS). Data on the prevalence, predictors and outcome of IFT are scarce. Patients and methods: We retrospectively searched our database of outpatients who had presented with DVT and IFT including the iliac veins from 2014 until 2017. In addition, we performed a prospective registry in a subgroup of patients with IFT. These patients received duplex ultrasound, magnetic resonance venography and measurement of symptom-free walking distance using a standardized treadmill ergometry. The severity of PTS was analyzed using the Villalta-Scale (VS) and quality of life was assessed using the VEINES-QOL/Sym Questionnaire. Results: 847 patients were retrospectively identified with DVT and 19.7% (167/847) of these presented with IFT. 50.9% (85/167) of the IFT-patients agreed to participate in the prospective registry. The majority of these patients (76.5%: 65/85) presented with left-sided IFT. In 53.8% (35/65) May-Thurner syndrome was suspected. 27.1% (23/85) underwent invasive therapy. Moderate or severe PTS (VS >= 10) occurred in 10.6% (9/85). The severity of PTS is correlated with a reduced quality of life (rho (CI 95%) = -0.63 (-0.76; -0.46); p < 0.01). None of the patients presented with a venous ulcer at any time. A high body mass index was a significant predictor (OR (CI 95%) = 1.18 (1.05; 1.33), p = 0.007) for the development of clinically relevant PTS (VS >= 10) and venous claudication. Conclusions: Every fifth patient with DVT presented with an IFT. The majority developed left sided IFT. Every 10th patient developed moderate or severe PTS (VS >= 10). A high body mass index was predictive for the development of PTS and venous claudication.	[Nawasrah, Jamil; Renczes, Johannes; Haberichter, Barbara; Lindhoff-Last, Edelgard] Cardiol Angiol Ctr Bethanienhosp CCB, CCB Vasc Ctr, Frankfurt, Germany; [Nawasrah, Jamil] Johannes Gutenberg Univ Mainz, Univ Med Ctr Mainz, Sect Angiol, Dept Cardiol Cardiol 1, Langenbeckstr 1, D-55131 Mainz, Germany; [Zydek, Barbara; Lucks, Jessica; Renczes, Johannes; Lindhoff-Last, Edelgard] Cardiol Angiol Ctr Bethanienhosp CCB, CCB Coagulat Res Ctr, Frankfurt, Germany; [Balaban, Uemniye] Goethe Univ Frankfurt, Inst Biostat & Math Modelling, Frankfurt, Germany; [Schellong, Sebastian] Municipal Hosp Dresden, Med Dept Cardiol & Angiol 2, Dresden, Germany		Nawasrah, J (通讯作者)，Johannes Gutenberg Univ Mainz, Univ Med Ctr Mainz, Sect Angiol, Dept Cardiol Cardiol 1, Langenbeckstr 1, D-55131 Mainz, Germany.	jamil.nawasrah@unimedizin-mainz.de					Bland JM, 2015, BMC CARDIOVASC DISOR, V15, DOI 10.1186/s12872-015-0080-7; Brinegar KN, 2015, WORLD J RADIOL, V7, P375, DOI 10.4329/wjr.v7.i11.375; Broholm R, 2011, J VASC SURG, V54, p18S, DOI 10.1016/j.jvs.2011.06.021; Chitsike RS, 2012, J THROMB HAEMOST, V10, P2039, DOI 10.1111/j.1538-7836.2012.04872.x; Ende-Verhaar YM, 2019, THROMB RES, V177, P102, DOI 10.1016/j.thromres.2019.03.003; Enden T, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002984; Falkensammer J, 2012, INT ANGIOL, V31, P150; Galanaud JP, 2020, J THROMB HAEMOST, V18, P857, DOI 10.1111/jth.14728; Galanaud JP, 2018, THROMB RES, V164, P100, DOI 10.1016/j.thromres.2017.07.026; Gurel K, 2011, EUR J RADIOL, V80, P533, DOI 10.1016/j.ejrad.2010.04.033; Harbin MM, 2020, J THROMB HAEMOST, V18, P534, DOI 10.1111/jth.14707; Kahn SR, 2008, J THROMB HAEMOST, V6, P1105, DOI 10.1111/j.1538-7836.2008.03002.x; Kahn SR, 2009, J THROMB HAEMOST, V7, P884, DOI 10.1111/j.1538-7836.2009.03339.x; Kahn SR, 2002, ARCH INTERN MED, V162, P1144, DOI 10.1001/archinte.162.10.1144; Kahn SR, 2008, ANN INTERN MED, V149, P698, DOI 10.7326/0003-4819-149-10-200811180-00004; Kahn SR, 2006, J CLIN EPIDEMIOL, V59, P1049, DOI 10.1016/j.jclinepi.2005.10.016; Kahn SR, 2016, J THROMB THROMBOLYS, V41, P144, DOI 10.1007/s11239-015-1312-5; Lamping DL, 2003, J VASC SURG, V37, P410, DOI 10.1067/mva.2003.152; McDermott S, 2013, DIAGN INTERV RADIOL, V19, P44, DOI 10.4261/1305-3825.DIR.5939-12.1; Mol GC, 2019, THROMB RES, V173, P35, DOI 10.1016/j.thromres.2018.11.002; Newnham EA, 2007, J AFFECT DISORDERS, V98, P91, DOI 10.1016/j.jad.2006.07.001; Nicolai SPA, 2009, J VASC SURG, V50, P322, DOI 10.1016/j.jvs.2009.01.042; Notten P, 2020, LANCET HAEMATOL, V7, pE40, DOI 10.1016/S2352-3026(19)30209-1; Prandoni P, 2009, BRIT J HAEMATOL, V145, P286, DOI 10.1111/j.1365-2141.2009.07601.x; Rabinovich A, 2018, J THROMB HAEMOST, V16, P262, DOI 10.1111/jth.13909; Rabinovich A, 2017, J THROMB HAEMOST, V15, P230, DOI 10.1111/jth.13569; Rattazzi M, 2015, THROMB RES, V136, P225, DOI 10.1016/j.thromres.2015.05.019; Roberts Lara N, 2014, Haematologica, V99, pe41, DOI 10.3324/haematol.2013.089870; Tick LW, 2008, J THROMB HAEMOST, V6, P2075, DOI 10.1111/j.1538-7836.2008.03180.x; Van Dongen CJJ, 2005, J THROMB HAEMOST, V3, P939; van Korlaar I, 2003, THROMB HAEMOSTASIS, V90, P27; Vedantham S, 2017, NEW ENGL J MED, V377, P2240, DOI 10.1056/NEJMoa1615066	32	1	1	0	1	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0301-1526			VASA	Vasa	JAN	2021	50	1			SI		30	37		10.1024/0301-1526/a000933			8	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	PQ4VY	33393383	Bronze			2022-04-28	WOS:000606545800005
J	Bohme, T; Noory, E; Beschorner, U; Jacques, B; Burgelin, K; Macharzina, R; Kuhn, LM; Nuhrenberg, T; Neumann, FJ; Zeller, T				Boehme, Tanja; Noory, Elias; Beschorner, Ulrich; Jacques, Boerries; Buergelin, Karlheinz; Macharzina, Roland; Kuhn, Lisa-Marie; Nuehrenberg, Thomas; Neumann, Franz-Josef; Zeller, Thomas			Evaluation of mortality following paclitaxel drug-coated balloon angioplasty of femoropopliteal lesions in patients with ulcerations and gangrene - a single center experience	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Drug-coated balloon; femoropopliteal artery; mortality; angioplasty; paclitaxel	PERIPHERAL ARTERY-DISEASE; UNCOATED BALLOON; RESTENOSIS; OUTCOMES; TRIAL	Background: A recent meta-analysis of randomized controlled trials suggested an increased long-term mortality risk following femoropopliteal angioplasty using paclitaxel coated devices. To assess the long-term mortality after paclitaxel drug-coated (DCB) and uncoated balloon angioplasty (POBA) of femoropopliteal lesions in patients with ulcerations and gangrene in real world practice. Patients and methods: A retrospective mortality analysis of patients with at least 3-year follow-up who underwent balloon based endovascular therapy of femoropopliteal lesions was performed. Results: Overall 624 patients with femoropopliteal lesions were included in this study. Of those, 197 patients were treated with POBA without crossover to a paclitaxel coated device during follow-up and 427 patients with DCB angioplasty. Mean follow-up time was 33.3 +/- 25.4 months. Mortality incidence was 81.7% (95% confidence interval [95% CI]: 76.1-86.8) after POBA and 59.0% (95% CI: 54.6-63.9) after DCB (p < 0.001). Multivariate logistic regression analysis revealed type of treatment (POBA vs. DCB, (hazard ratio [HR]: 0.332, 95% CI: 0.215-0.514, p < 0.001), age per year (HR: 1.065, 95% CI: 1.046-1.087, p < 0.001), coronary heart disease (HR: 1.969, 95% CI: 1.323-2.930, p = 0.001), renal insufficiency (HR: 1.583, 95% CI: 1.079-2.323, p = 0.019), stroke (HR: 2.505, 95% CI: 1.431-4.384, p = 0.001) as predictors for all-cause mortality. In the subgroup excluding octogenarians, mortality predictors were type of treatment (HR: 0.463, 95% CI: 0.269-0.796, p = 0.005), age per year (HR: 1.035, 95% CI: 1.002-1.069, p = 0.038), coronary heart disease (HR: 2.082, 95% CI: 1.274-3.400, p = 0.003), stroke (HR: 2.203, 95% CI: 1.156-4.197, p = 0.016) and renal insufficiency (HR: 2.201, 95% CI: 1.357-3.571, p < 0.001). Conclusions: This monocentric retrospective analysis showed no survival disadvantage for patients in Rutherford-Becker stage 5 after treatment with paclitaxel-coated balloons.	[Boehme, Tanja; Noory, Elias; Beschorner, Ulrich; Jacques, Boerries; Buergelin, Karlheinz; Macharzina, Roland; Kuhn, Lisa-Marie; Nuehrenberg, Thomas; Neumann, Franz-Josef; Zeller, Thomas] Univ Heart Ctr Freiburg Bad Krozingen, Dept Cardiol & Angiol 2, Sudring 15, D-79189 Bad Krozingen, Germany		Bohme, T (通讯作者)，Univ Heart Ctr Freiburg Bad Krozingen, Dept Cardiol & Angiol 2, Sudring 15, D-79189 Bad Krozingen, Germany.	tanja.boehme@universitaets-herzzentrum.de					Albrecht T, 2019, CARDIOVASC INTER RAD, V42, P949, DOI 10.1007/s00270-019-02194-w; Albrecht T, 2018, CARDIOVASC INTER RAD, V41, P1008, DOI 10.1007/s00270-018-1940-1; Bailey SR, 2019, J AM COLL CARDIOL, V73, P214, DOI 10.1016/j.jacc.2018.10.002; Cambou JP, 2010, EUR J VASC ENDOVASC, V39, P577, DOI 10.1016/j.ejvs.2010.02.009; Cook Medical, MEDICAL ZILVER PTX D; Dake MD, 2016, CIRCULATION, V133, P1472, DOI 10.1161/CIRCULATIONAHA.115.016900; FDA US, 2018, ELUVIA DRUG ELUTING, P18; FDA US, 2017, STELLAREX 0 035 OTW, P26; FDA US, 2017, LUTONIX 035 DRUG COA, P7; FDA US. IN, 2014, US PACT ADMIRAL PACL, P30; Feldman DN, 2018, CATHETER CARDIO INTE, V92, P124, DOI 10.1002/ccd.27635; Fowkes FGR, 2013, LANCET, V382, P1329, DOI 10.1016/S0140-6736(13)61249-0; Fowkes FG, 2018, ELUVIA DRUG ELUTING, P18; Katsanos K, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.011245; Norgren L, 2007, J VASC SURG, V45, pS5, DOI 10.1016/j.jvs.2006.12.037; Reinecke H, 2015, EUR HEART J, V36, P932, DOI 10.1093/eurheartj/ehv006; Rocha-Singh KJ, 2020, CIRCULATION, V141, P1859, DOI 10.1161/CIRCULATIONAHA.119.044697; Rollins KE, 2013, BRIT J SURG, V100, P1002, DOI 10.1002/bjs.9127; RUTHERFORD RB, 1991, RADIOLOGY, V181, P277, DOI 10.1148/radiology.181.1.1887047; Scheinert D, 2014, JACC-CARDIOVASC INTE, V7, P11, DOI 10.1016/j.jcin.2013.05.022; Schneider PA, 2019, J AM COLL CARDIOL, V73, P2550, DOI 10.1016/j.jacc.2019.01.013; Schroe H, 2018, CATHETER CARDIO INTE, V91, P497, DOI 10.1002/ccd.27348; Takeji Y, 2018, CIRC-CARDIOVASC INTE, V11, DOI 10.1161/CIRCINTERVENTIONS.118.006778; Taylor SM, 2009, J AM COLL SURGEONS, V208, P770, DOI 10.1016/j.jamcollsurg.2009.01.025; Tepe G, 2015, CIRCULATION, V131, P495, DOI 10.1161/CIRCULATIONAHA.114.011004; Tepe G, 2015, JACC-CARDIOVASC INTE, V8, P102, DOI 10.1016/j.jcin.2014.07.023; Werk M, 2008, CIRCULATION, V118, P1358, DOI 10.1161/CIRCULATIONAHA.107.735985; Werk M, 2012, CIRC-CARDIOVASC INTE, V5, P831, DOI 10.1161/CIRCINTERVENTIONS.112.971630	28	5	5	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	FEB	2021	50	2					132	138		10.1024/0301-1526/a000910			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	QQ5PH	33118425				2022-04-28	WOS:000624575300008
J	Jonczy, ML; Thalhammer, C				Jonczy, Malgorzata Lea; Thalhammer, Christoph			Drug-coated balloons - the golden tool for treatment of stenotic lesions in dysfunctional haemodialysis fistulas?	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Editorial Material									[Jonczy, Malgorzata Lea; Thalhammer, Christoph] Canton Hosp Aarau, Univ Hosp, Dept Angiol, Aarau, Switzerland		Thalhammer, C (通讯作者)，Canton Hosp Aarau, Univ Hosp, Dept Angiol, Aarau, Switzerland.	christoph.thalhammer@ksa.ch					Lookstein RA, 2020, NEW ENGL J MED, V383, P733, DOI 10.1056/NEJMoa1914617	1	0	0	0	2	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0301-1526			VASA	Vasa	JAN	2021	50	1			SI		78	78		10.1024/0301-1526/a000916			1	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	PQ4VY	33393385				2022-04-28	WOS:000606545800012
J	Lichtenberg, MKW; Stahlhoff, WF; Stahlhoff, S; Ozkapi, A; Breuckmann, F; de Graaf, R				Lichtenberg, Michael K. W.; Stahlhoff, Wilhelm F.; Stahlhoff, Stefan; Oezkapi, Ahmet; Breuckmann, Frank; de Graaf, Rick			Venovo venous stent for treatment of non-thrombotic or post-thrombotic iliac vein lesions - long-term efficacy and safety results from the Arnsberg venous registry	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						chronic venous disease; endovascular procedures; post-thrombotic syndrome; stents; venous thrombosis	ENDOVASCULAR TREATMENT; DISEASE	Background: Endovascular venous stenting with dedicated venous stents for the treatment of chronic venous outflow obstruction is developing as efficacious alternative to conservative therapy or open surgery. However, so far, mid- and long-term evidence on effectiveness and safety is poor. Patients and methods: The prospective, single-center, observational study enrolled consecutive patients with chronic non-thrombotic iliac vein lesions (NIVL) or post-thrombotic iliofemoral obstructions (PTO). From February 2016 to April 2017, patients underwent implantation of open cell, self-expandable dedicated venous stents. Short-term symptomatic improvement, patency, and complication rate were favorable. Evaluation at 2-years included improvement in the revised venous clinical severity score (rVCSS), patency, stent migration, major target limb events, clinically important pulmonary embolism, major bleeding, and all-cause mortality. Results: A total of 79 patients (57 +/- 16 years, 44 female) were evaluated. At 2 years, rVCCS improved by 4.3 +/- 2.7 (p < 0.001). Substantial clinical improvement of >= 2 score points was achieved in 86.4% (38 of 44) of patients. Improvement was not associated with thrombotic pathogenesis (regression coefficient [B] with PTO = 0.6 [95%CI: -1.1 to 2.3], p = 0.48). At 2 years, all ulcers (in 8 of 79 patients) were healed and none recurred. Two-year primary patency was 95.5% (95%CI: 86.5 to 98.5) with no difference between NIVL- and PTO-patients (log-rank p = 0.83). Target vessel revascularization was conducted in two PTO- and one NIVL-patients in the period of 34 days to 156 days from index procedure, resulting in a secondary patency of 100%. No stent migration, target limb deep vein thrombosis, major amputation, pulmonary embolism, or death occurred. Conclusions: Venovo venous open cell self-expanding stent implantation for chronic outflow obstruction was efficacious and provided a sufficient level of safety throughout 2 years.	[Lichtenberg, Michael K. W.; Stahlhoff, Wilhelm F.; Stahlhoff, Stefan; Oezkapi, Ahmet] Klinikum Arnsberg, Venous Ctr, Arnsberg, Germany; [Breuckmann, Frank] Herz Jesu Krankenhaus Dernbach, Dernbach, Germany; [de Graaf, Rick] Klinikum Friedrichshafen, Dept Radiol, Friedrichshafen, Germany		Lichtenberg, MKW (通讯作者)，Karolinen Hosp, Klinikum Arnsberg, Venous Ctr, Stolte Ley 5, D-59759 Arnsberg, Germany.	klichte@gmx.net			Arnsberg Venous Center	This study was funded by Arnsberg Venous Center.	Black S, 2018, EUR J VASC ENDOVASC, V56, P710, DOI 10.1016/j.ejvs.2018.07.014; Alerany MB, 2014, J VASC SURG-VENOUS L, V2, P2, DOI 10.1016/j.jvsv.2013.07.003; Catarinella FS, 2015, PHLEBOLOGY, V30, P89, DOI 10.1177/0268355515569431; de Wolf MAF, 2013, J VASC SURG-VENOUS L, V1, P146, DOI 10.1016/j.jvsv.2012.07.002; Ignatyev IM, 2019, VASC ENDOVASC SURG, V53, P373, DOI 10.1177/1538574419839256; Kolbel T, 2009, J ENDOVASC THER, V16, P483, DOI 10.1583/09-2719.1; Lichtenberg M, 2018, VASA, V47, P475, DOI 10.1024/0301-1526/a000731; Lichtenberg MKW, 2019, VASA, V48, P175, DOI 10.1024/0301-1526/a000763; Liu ZJ, 2014, ANN VASC SURG, V28, P695, DOI 10.1016/j.avsg.2013.05.019; Qiu P, 2019, EUR J VASC ENDOVASC, V57, P407, DOI 10.1016/j.ejvs.2018.09.022; Raju S, 2014, ANN VASC SURG, V28, P1485, DOI 10.1016/j.avsg.2014.02.026; Razavi MK, 2015, CIRC-CARDIOVASC INTE, V8, DOI 10.1161/CIRCINTERVENTIONS.115.002772; Seager MJ, 2016, EUR J VASC ENDOVASC, V51, P100, DOI 10.1016/j.ejvs.2015.09.002; Stuck AK, 2018, VASA, V47, P319, DOI 10.1024/0301-1526/a000697; Wang WD, 2016, PHLEBOLOGY, V31, P376, DOI 10.1177/0268355515596474; Yin M, 2015, EUR J VASC ENDOVASC, V50, P101, DOI 10.1016/j.ejvs.2015.03.029	16	5	5	0	2	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JAN	2021	50	1			SI		52	58		10.1024/0301-1526/a000893			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	PQ4VY	32697148	Bronze			2022-04-28	WOS:000606545800008
J	D'Oria, M; Ziani, B; Pipitone, MD; Manganotti, P; Mucelli, RP; Gorgatti, F; Riccitelli, F; Zamolo, F; Fisicaro, M; Lepidi, S				D'Oria, Mario; Ziani, Barbara; Pipitone, Marco Damiano; Manganotti, Paolo; Mucelli, Roberta Pozzi; Gorgatti, Filippo; Riccitelli, Francesco; Zamolo, Francesca; Fisicaro, Maurizio; Lepidi, Sandro			Prognostic interaction between age and sex on outcomes following carotid endarterectomy	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Carotid endarterectomy; carotid stenosis; gender; age; outcomes; stroke; survival; cardiovascular	GENDER-DIFFERENCES; FRAILTY; STENOSIS; SOCIETY	Background: The aim of this study was to assess the prognostic interaction between age and sex on peri-operative and follow-up outcomes following elective carotid endarterectomy (CEA) for asymptomatic and symptomatic carotid stenosis. Patients and methods: A retrospective review of all patients admitted to a single vascular unit who underwent elective CEA between January, 2015 and December, 2019 was performed. The primary endpoints of the study were overall survival (from index operation) and cumulative stroke rate at thirty days. Results: A total of 383 consecutive patients were included in this study; of these 254 (66.4%) were males. At baseline, mates were younger (mean age 73.4 +/- 11 vs. 76.3 +/- 10 years, p=.01) and with tower proportion of octogenarians (20.4% vs. 28.7%, p=.05). The rate of stroke in symptomatic and asymptomatic patients (males vs. females) were as follows: a) whole cohort 1.9% vs. 2% (p=1.00) and 2.7% vs. 1.3% (p=.66), respectively; b) >= 80 years old 3.7% vs. 0% (p=1.00) and 4% vs. 5.9% (p=1.00), respectively; c) <80 years old 1.2% vs. 3.3% (p=.47) and 2.5% vs. 0% (p=.55), respectively. The 3-year survival estimates were significantly tower for males (84% vs. 92%, p=.03). After stratification by age groups, males maintained inferior survival rates in the strata aged <80 years (85% vs. 97%, p=.005), white no differences were seen in the strata aged >= 80 years (82% vs. 79%, p=.92). Using multivariate Cox proportional hazards, age (HR: 2.1, 95% CI: 1.29-3.3, p=.002) and mate gender (HR: 2.5, 95% CI: 1.16-5.5, p=.02) were associated with increased hazards of all-cause mortality. Conclusions: In this study of elective CEA for asymptomatic and symptomatic carotid stenosis, similar peri-operative neurologic outcomes were found in both mates and females irrespective of age. Despite being usually older, females have superior long-term survival rates.	[D'Oria, Mario; Ziani, Barbara; Gorgatti, Filippo; Riccitelli, Francesco; Zamolo, Francesca; Lepidi, Sandro] Cattinara Univ Hosp ASUGI, Cardiovasc Dept, Div Vasc & Endovasc Surg, Str Fiume 447, I-34149 Trieste, Italy; [Pipitone, Marco Damiano] Bolzano Reg Hosp, Div Vasc Surg, Bolzano, Italy; [Manganotti, Paolo] Cattinara Univ, Dept Med Surg & Hlth Sci, Clin Unit Neurol, Hosp ASUGI, Trieste, Italy; [Mucelli, Roberta Pozzi] Cattinara Univ, Dept Med Surg & Hlth Sci, Radiol Unit, Hosp ASUGI, Trieste, Italy; [Fisicaro, Maurizio] Maggiore Hosp ASUGI, Cardiovasc Dept, Cardiovasc Hlth Serv Ctr, Trieste, Italy		D'Oria, M (通讯作者)，Cattinara Univ Hosp ASUGI, Cardiovasc Dept, Div Vasc & Endovasc Surg, Str Fiume 447, I-34149 Trieste, Italy.	mario.doria88@outlook.com		Pozzi Mucelli, Roberta/0000-0002-0399-9652; Pipitone, Marco Damiano/0000-0003-1091-0772			[Anonymous], 1995, J NEUROL SCI, V129, P76; Barbey SM, 2019, J VASC SURG, V70, P1831, DOI 10.1016/j.jvs.2019.01.086; Bissacco D, 2020, VASC ENDOVASC SURG, V54, P247, DOI 10.1177/1538574419895378; D'Oria M, 2018, EUR J VASC ENDOVASC, V56, P632, DOI 10.1016/j.ejvs.2018.07.024; Dansey KD, 2020, J VASC SURG, V71, P1587, DOI 10.1016/j.jvs.2019.07.088; Drudi LM, 2019, J VASC SURG, V69, P1989, DOI 10.1016/j.jvs.2018.10.053; Fairweather D, 2014, CLIN MED INSIGHTS-CA, V8, P49, DOI 10.4137/CMC.S17068; Gordon EH, 2017, EXP GERONTOL, V89, P30, DOI 10.1016/j.exger.2016.12.021; Howard DPJ, 2021, LANCET NEUROL, V20, P193, DOI 10.1016/S1474-4422(20)30484-1; Hubbard RE, 2015, INTERD T GERONT GERI, V41, P41, DOI 10.1159/000381161; Maas AHEM, 2010, NETH HEART J, V18, P598, DOI 10.1007/s12471-010-0841-y; Mitnitski A, 2005, J AM GERIATR SOC, V53, P2184, DOI 10.1111/j.1532-5415.2005.00506.x; Naylor AR, 2018, EUR J VASC ENDOVASC, V55, P3, DOI 10.1016/j.ejvs.2017.06.021; Oates CP, 2009, EUR J VASC ENDOVASC, V37, P251, DOI 10.1016/j.ejvs.2008.10.015; Piazza M, 2018, EUR J VASC ENDOVASC, V56, P334, DOI 10.1016/j.ejvs.2018.06.030; Schneider JR, 2017, J VASC SURG, V65, P1643, DOI 10.1016/j.jvs.2016.12.118; Stoberock K, 2016, VASA, V45, P11, DOI 10.1024/0301-1526/a000490; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Timaran CH, 2011, J VASC SURG, V53, P1679, DOI 10.1016/j.jvs.2010.11.122; van Kan GA, 2010, CLIN GERIATR MED, V26, P275, DOI 10.1016/j.cger.2010.02.002; Veraldi GF, 2021, ANN VASC SURG, V72, P627, DOI 10.1016/j.avsg.2020.09.047; Vermeiren S, 2016, J AM MED DIR ASSOC, V17, DOI 10.1016/j.jamda.2016.09.010; von Reutern GM, 2012, STROKE, V43, P916, DOI 10.1161/STROKEAHA.111.636084	23	0	0	1	1	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	NOV	2021	50	6					453	461		10.1024/0301-1526/a000957			9	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6JL	34102866				2022-04-28	WOS:000753518900007
J	Sladojevic, M; Zlatanovic, P; Stanojevic, Z; Koncar, I; Vidicevic, S; Tasic, J; Isakovic, A; Tomic, I; Mutavdzic, P; Stevanovic, K; Trailovic, R; Davidovic, L				Sladojevic, Milos; Zlatanovic, Petar; Stanojevic, Zeljka; Koncar, Igor; Vidicevic, Sasenka; Tasic, Jelena; Isakovic, Aleksandra; Tomic, Ivan; Mutavdzic, Perica; Stevanovic, Ksenija; Trailovic, Ranko; Davidovic, Lazar			Influence of preoperative statins and aspirin administration on biological and magnetic resonance imaging properties in patients with abdominal aortic aneurysm	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Abdominal aortic aneurysm; statins; aspirin; intraluminal thrombus; magnetic resonance imaging	INHIBITORS; THROMBUS; GROWTH; RUPTURE	Background: Main objective of this study was to evaluate the influence of statins and/or acetylsalicylic acid on biochemical characteristics of abdominal aortic aneurysm (AAA) wall and intraluminal thrombus (ILT). Patients and methods: Fifty patients with asymptomatic infrarenal AAA were analyzed using magnetic resonance imaging on T1w sequence. Relative ILT signal intensity (SI) was determined as a ratio between ILT and psoas muscle SI. Samples containing the full ILT thickness and aneurysm wall were harvested from the anterior surface at the level of the maximal diameter. The concentration of enzymes such as matrix metalloproteinase (MMP) 9, MMP2 and neutrophil elastase (NE/ELA) were analyzed in ILT and AAA wall; while collagen type III, elastin and proteoglycan 4 were analyzed in harvested AAA wall. Oxidative stress in the AAA wall was assessed by catalase and malondialdehyde activity in tissue samples. Results: Relative ILT signal intensity (1.09 +/- 0.41 vs 0.89 +/- 0.21, p = 0.013) were higher in non-statin than in statin group. Patients who were taking aspirin had lower relative ILT area (0.89 +/- 0.19 vs 1.13. +/- 0.44, p = 0.016), and lower relative ILT signal intensity (0.85 [0.73-1.07] vs 1.01 [0.84-1.19], p = 0.021) compared to non-aspirin group. There were higher concentrations of elastin in AAA wall among patients taking both of aspirin and statins (1.21 [0.77-3.02] vs 0.78 (0.49-1.05) ng/ml, p = 0.044) than in patients who did not take both of these drugs. Conclusions: Relative ILT SI was lower in patients taking statin and aspirin. Combination of antiplatelet therapy and statins was associated with higher elastin concentrations in AAA wall.	[Sladojevic, Milos; Koncar, Igor; Tomic, Ivan; Stevanovic, Ksenija; Davidovic, Lazar] Univ Belgrade, Sch Med, Belgrade, Serbia; [Sladojevic, Milos; Zlatanovic, Petar; Koncar, Igor; Isakovic, Aleksandra; Tomic, Ivan; Mutavdzic, Perica; Stevanovic, Ksenija; Trailovic, Ranko; Davidovic, Lazar] Clin Ctr Serbia, Clin Vasc & Endovasc Surg, Dr Koste Todorovica St 8, Belgrade 11000, Serbia; [Stanojevic, Zeljka; Vidicevic, Sasenka; Tasic, Jelena; Isakovic, Aleksandra] Univ Belgrade, Sch Med, Inst Med & Clin Biochem, Belgrade, Serbia		Zlatanovic, P (通讯作者)，Clin Ctr Serbia, Clin Vasc & Endovasc Surg, Dr Koste Todorovica St 8, Belgrade 11000, Serbia.	petar91goldy@gmail.com		Zlatanovic, Petar/0000-0001-5340-2079; Davidovic, Lazar/0000-0002-0529-2378	Ministry of Education, Science and Technological Development of the Republic of SerbiaMinistry of Education, Science & Technological Development, Serbia [175008, III 41025]	This article is part of scientific research projects (No. 175008 and No. III 41025) supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia.	BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dawson JA, 2011, EUR J VASC ENDOVASC, V41, P28, DOI 10.1016/j.ejvs.2010.08.023; Devasagayam TPA, 2003, INDIAN J BIOCHEM BIO, V40, P300; Evans J, 2007, EUR J VASC ENDOVASC, V34, P302, DOI 10.1016/j.ejvs.2007.04.011; GOTH L, 1991, CLIN CHIM ACTA, V196, P143, DOI 10.1016/0009-8981(91)90067-M; Kajimoto K, 2009, ATHEROSCLEROSIS, V206, P505, DOI 10.1016/j.atherosclerosis.2009.03.028; Kalyanasundaram A, 2006, J VASC SURG, V43, P117, DOI 10.1016/j.jvs.2005.08.007; Karmonik C, 2013, MAGN RESON MED, V69, P1438, DOI 10.1002/mrm.24376; Khan JA, 2012, ANN VASC SURG, V26, P322, DOI 10.1016/j.avsg.2011.08.015; Li X, 2019, VASA, V48, P115, DOI 10.1024/0301-1526/a000749; Lindholt JS, 2013, CURR VASC PHARMACOL, V11, P305, DOI 10.2174/1570161111311030005; Mastoraki ST, 2012, ANN VASC SURG, V26, P250, DOI 10.1016/j.avsg.2011.09.003; Nchimi A, 2010, RADIOLOGY, V254, P973, DOI 10.1148/radiol.09090657; Nguyen VL, 2014, EUR J VASC ENDOVASC, V48, P676, DOI 10.1016/j.ejvs.2014.04.025; Oesterle A, 2017, CIRC RES, V120, P229, DOI 10.1161/CIRCRESAHA.116.308537; Owens AP, 2015, ARTERIOSCL THROM VAS, V35, P2032, DOI 10.1161/ATVBAHA.115.305537; Piechota-Polanczyk A, 2015, EUR J VASC ENDOVASC, V49, P549, DOI 10.1016/j.ejvs.2015.02.011; Piechota-Polanczyk A, 2012, EUR J VASC ENDOVASC, V44, P133, DOI 10.1016/j.ejvs.2012.04.020; Rengier F, 2014, VASA, V43, P6, DOI 10.1024/0301-1526/a000324; Sakalihasan Natzi, 2004, Semin Vasc Surg, V17, P144, DOI 10.1053/j.semvascsurg.2004.03.002; Salata K, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.008657; Stanojevic Z, 2020, J VASC SURG; Staub D, 2013, VASA, V42, P17, DOI 10.1024/0301-1526/a000244; Sweeting MJ, 2012, BRIT J SURG, V99, P655, DOI 10.1002/bjs.8707; Thompson A, 2010, J VASC SURG, V52, P55, DOI 10.1016/j.jvs.2010.02.012; Touat Z, 2006, AM J PATHOL, V168, P1022, DOI 10.2353/ajpath.2006.050868; van der Meij E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053882; Wilson WRW, 2005, EUR J VASC ENDOVASC, V30, P259, DOI 10.1016/j.ejvs.2005.02.044; Yoshimura K, 2015, INT J MOL SCI, V16, P11213, DOI 10.3390/ijms160511213	29	1	1	1	2	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	FEB	2021	50	2					116	124		10.1024/0301-1526/a000895			9	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	QQ5PH	32669062				2022-04-28	WOS:000624575300006
J	Urbanek, T; Labropoulos, N				Urbanek, Tomasz; Labropoulos, Nicos			Can we predict and prevent the postthrombotic syndrome?	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Review						Deep vein thrombosis; postthrombotic syndrome; risk factors prevention	DEEP-VEIN THROMBOSIS; CATHETER-DIRECTED THROMBOLYSIS; COMPRESSION STOCKINGS; VENOUS THROMBOSIS; K ANTAGONISTS; RISK; THROMBOEMBOLISM; RIVAROXABAN; VALIDATION; VILLALTA	Postthrombotic syndrome (PTS) remains one of the major late complications of deep vein thrombosis (DVT) with a reported prevalence from 10 to 50%. Many factors were found to be related with the development and severity of PTS such as ipsilateral recurrent DVT, advanced age, obesity, ilio-femoral DVT and primary chronic venous disease presence. Some PTS prediction models have been proposed based on risk factor weight. However, it is still difficult to predict which patient with DVT will develop PTS and thus, the clinical application of these models remains limited. Among the identified problems the heterogeneity of the DVT patient population together with the variety of PTS clinical presentations and difficulties concerning PTS severity assessment should be mentioned. Difficulties on the implementation of the specific and objective PTS identification method have also the significant influence on the research focusing on PTS prevention modalities including risk factor modification, compression treatment, anticoagulation and invasive DVT treatment. In this review, the current approach and knowledge on PTS prediction and prevention are presented, including the conservative and invasive DVT treatment possibilities.	[Urbanek, Tomasz] Med Univ Silesia, Dept Gen & Vasc Surg, Ziolowa 45-47, PL-40750 Katowice, Poland; [Labropoulos, Nicos] SUNY Stony Brook, Dept Surg, Stony Brook Univ Hosp, Sch Med, Stony Brook, NY 11794 USA		Urbanek, T (通讯作者)，Med Univ Silesia, Dept Gen & Vasc Surg, Ziolowa 45-47, PL-40750 Katowice, Poland.	urbanek.tom@interia.pl		Labropoulos, Nicos/0000-0002-3984-1582			Amin EE, 2018, BLOOD, V132, P2298, DOI 10.1182/blood-2018-03-836783; Amin EE, 2018, THROMB HAEMOSTASIS, V118, P1242, DOI 10.1055/s-0038-1655743; Andreozzi GM, 2015, CIRCULATION, V132, P1891, DOI 10.1161/CIRCULATIONAHA.115.016930; Appelen D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004174.pub3; Audu CO, 2020, J VASC SURG-VENOUS L, V8, P299, DOI 10.1016/j.jvsv.2019.09.008; Blattler W, 2003, INT ANGIOL, V22, P393; Bouman AC, 2012, J THROMB HAEMOST, V10, P1532, DOI 10.1111/j.1538-7836.2012.04798.x; Bradbury C, 2020, BRIT J HAEMATOL, V188, P962, DOI 10.1111/bjh.16275; Brandjes DPM, 1997, LANCET, V349, P759, DOI 10.1016/S0140-6736(96)12215-7; Cheung YW, 2016, THROMB HAEMOSTASIS, V116, P733, DOI 10.1160/TH16-01-0041; Cohen AT, 2007, THROMB HAEMOSTASIS, V98, P756, DOI 10.1160/TH07-03-0212; Comerota AJ, 2019, CIRCULATION, V139, P1162, DOI 10.1161/CIRCULATIONAHA.118.037425; Comerota AJ, 2016, PHLEBOLYMPHOLOGY, V23, P76; Denny N, 2018, Acute Med, V17, P99; Eklof B, 2009, J VASC SURG, V49, P498, DOI 10.1016/j.jvs.2008.09.014; Enden T, 2012, LANCET, V379, P31, DOI 10.1016/S0140-6736(11)61753-4; Engelberger RP, 2017, J THROMB HAEMOST, V15, P1351, DOI 10.1111/jth.13709; Engelberger RP, 2015, CIRC-CARDIOVASC INTE, V8, DOI 10.1161/CIRCINTERVENTIONS.114.002027; Engeseth M, 2019, THROMB RES, V184, P62, DOI 10.1016/j.thromres.2019.10.018; Fahrni J, 2013, VASA, V42, P161, DOI 10.1024/0301-1526/a000264; Foegh P, 2017, EUR J VASC ENDOVASC, V53, P419, DOI 10.1016/j.ejvs.2016.12.023; Galanaud JP, 2020, J THROMB HAEMOST, V18, P3309, DOI 10.1111/jth.15091; Galanaud JP, 2020, J THROMB HAEMOST, V18, P857, DOI 10.1111/jth.14728; Galanaud JP, 2016, J VASC SURG-VENOUS L, V4, P531, DOI 10.1016/j.jvsv.2015.08.005; Ginsberg JS, 2000, ARCH INTERN MED, V160, P669, DOI 10.1001/archinte.160.5.669; Haig Y, 2016, LANCET HAEMATOL, V3, pE64, DOI 10.1016/S2352-3026(15)00248-3; Hsu C, 2019, J VASC SURG-VENOUS L, V7, P169, DOI 10.1016/j.jvsv.2018.10.020; Hull RD, 2013, CLIN APPL THROMB-HEM, V19, P476, DOI 10.1177/1076029613481845; Hull RD, 2011, AM J MED, V124, P756, DOI 10.1016/j.amjmed.2011.02.033; Jayaraj A, 2014, ANN VASC SURG, V28, P313, DOI 10.1016/j.avsg.2012.11.014; Jeraj L, 2017, THROMB RES, V157, P46, DOI 10.1016/j.thromres.2017.05.029; Kahn SR, 2009, J THROMB HAEMOST, V7, P879, DOI 10.1111/j.1538-7836.2009.03294.x; Kahn SR, 2006, J THROMB HAEMOST, V4, P907, DOI 10.1111/j.1538-7836.2006.01824.x; Kahn SR, 2008, ANN INTERN MED, V149, P698, DOI 10.7326/0003-4819-149-10-200811180-00004; Kahn SR, 2020, J VASC SURG-VENOUS L, V8, P8, DOI 10.1016/j.jvsv.2019.03.023; Kahn SR, 2016, HEMATOL-AM SOC HEMAT, P413, DOI 10.1182/asheducation-2016.1.413; Kahn SR, 2016, J THROMB THROMBOLYS, V41, P144, DOI 10.1007/s11239-015-1312-5; Kahn SR, 2014, CIRCULATION, V130, P1636, DOI 10.1161/CIR.0000000000000130; Kahn SR, 2014, LANCET, V383, P880, DOI 10.1016/S0140-6736(13)61902-9; Kearon C, 2020, BLOOD, V135, P317, DOI 10.1182/blood.2019002364; Kessinger CW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116621; Kolbach DN, 2005, EUR J VASC ENDOVASC, V30, P404, DOI 10.1016/j.ejvs.2005.06.006; Labropoulos N, 2008, J VASC SURG, V48, P407, DOI 10.1016/j.jvs.2008.03.016; Labropoulos N, 2014, LANCET, V384, P129, DOI 10.1016/S0140-6736(14)61159-4; Li RH, 2020, THROMB RES, V196, P340, DOI 10.1016/j.thromres.2020.09.014; Luzzi R, 2014, CLIN APPL THROMB-HEM, V20, P594, DOI 10.1177/1076029614533143; San Norberto EM, 2016, VASA, V45, P133, DOI 10.1024/0301-1526/a000507; Martinez C, 2018, PULM CIRC, V8, DOI 10.1177/2045894018791358; Mean M, 2018, THROMB HAEMOSTASIS, V118, P1419, DOI 10.1055/s-0038-1661392; Meissner MH, 2012, J VASC SURG, V55, P1449, DOI 10.1016/j.jvs.2011.12.081; Mulloy B, 2016, PHARMACOL REV, V68, P76, DOI 10.1124/pr.115.011247; Notten P, 2020, THROMB HAEMOSTASIS, V120, P1188, DOI 10.1055/s-0040-1713171; Notten P, 2020, LANCET HAEMATOL, V7, pE40, DOI 10.1016/S2352-3026(19)30209-1; Partsch H, 2018, THROMB HAEMOSTASIS, V118, P1130, DOI 10.1055/s-0038-1660859; Poredos P, 2018, INT ANGIOL, V37, P261, DOI 10.23736/S0392-9590.18.04001-4; Prandoni P, 2005, J THROMB HAEMOST, V3, P401, DOI 10.1111/j.1538-7836.2004.01106.x; Prandoni P, 2004, ANN INTERN MED, V141, P249, DOI 10.7326/0003-4819-141-4-200408170-00004; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Prandoni P, 2015, SEMIN THROMB HEMOST, V41, P133, DOI 10.1055/s-0035-1544161; Rabe E, 2018, PHLEBOLOGY, V33, P163, DOI 10.1177/0268355516689631; Rabinovich A, 2018, J THROMB HAEMOST, V16, P262, DOI 10.1111/jth.13909; Rabinovich A, 2017, J THROMB HAEMOST, V15, P230, DOI 10.1111/jth.13569; Rabinovich A, 2014, J THROMB HAEMOST, V12, P14, DOI 10.1111/jth.12447; Rabinovich A, 2013, INT J VASC MED, V2013, DOI 10.1155/2013/643036; Rabinovich A, 2015, J VASC SURG-VENOUS L, V3, P347, DOI 10.1016/j.jvsv.2015.04.005; Rabinovich A, 2014, POL ARCH MED WEWN, V124, P410, DOI 10.20452/pamw.2353; Rabinovich A, 2014, THROMB HAEMOSTASIS, V111, P1031, DOI 10.1160/TH13-11-0931; Raskob GE, 2014, J THROMB HAEMOST, V12, P1580, DOI 10.1111/jth.12698; Rattazzi M, 2015, THROMB RES, V136, P225, DOI 10.1016/j.thromres.2015.05.019; Soares RD, 2019, SURGERY, V166, P1076, DOI 10.1016/j.surg.2019.05.030; Soosainathan A, 2013, J VASC SURG, V57, P254, DOI 10.1016/j.jvs.2012.09.011; Strijkers RHW, 2012, PHLEBOLOGY, V27, P130, DOI [10.1258/phleb.2011.012S02, 10.1258/phleb.2011.012s02]; ten Cate-Hoek AJ, 2018, LANCET HAEMATOL, V5, P25, DOI 10.1016/S2352-3026(17)30227-2; Utne KK, 2016, THROMB HAEMOSTASIS, V115, P361, DOI [10.1160/TH15-04-0318, 10.1160/th15-04-0318]; Van der Velden SK, 2014, PHLEBOLOGY, V29, P580, DOI 10.1177/0268355513515859; van Rij AM, 2013, ANN VASC SURG, V27, P924, DOI 10.1016/j.avsg.2012.09.018; Vedantham S, 2017, NEW ENGL J MED, V377, P2240, DOI 10.1056/NEJMoa1615066; Villalta S, 1994, HAEMOSTASIS, V24, p158a; Widmer L, 1981, KORONAIRE HERZKRANKH; Wik HS, 2018, THROMB RES, V164, P110, DOI 10.1016/j.thromres.2017.10.022; Yamaki T, 2011, EUR J VASC ENDOVASC, V41, P126, DOI 10.1016/j.ejvs.2010.09.018; Yusuf Hussain R., 2012, Morbidity and Mortality Weekly Report, V61, P401; Zhang Z, 2019, J ARTHROPLASTY, V34, P560, DOI 10.1016/j.arth.2018.10.013	83	1	1	0	1	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JAN	2021	50	1			SI		11	21		10.1024/0301-1526/a000932			11	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	PQ4VY	33393384				2022-04-28	WOS:000606545800003
J	Lichtenberg, M; Stahlhoff, S; Ozkapi, A; de Graaf, R				Lichtenberg, Michael; Stahlhoff, Stefan; Ozkapi, Ahmet; de Graaf, Rick			Braided nitinol stent for chronic iliofemoral venous disease - the real-world BLUEFLOW registry	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Chronic venous disease; endovascular procedures; post-thrombotic syndrome; stents; venous thrombosis	ILIAC VEIN; COMPRESSION; EPIDEMIOLOGY; SAFETY	Background: In patients with iliofemoral chronic venous disease (CVD) secondary to post-thrombotic or non-thrombotic obstruction, venous outflow obstruction after adequate anticoagulation alone is still frequent and post-thrombotic syndrome is a common complication. Thus, we aimed to evaluate mid-term effectiveness and safety of a novel braided venous stent for venous outflow obstruction treatment. Patients and methods: Consecutive patients who underwent venous recanalization with a new braided, closed cell, venous stent for non- or post-thrombotic CVD were eligible for inclusion in our retrospective, observational study. Effectiveness outcomes were primary patency and change in the revised venous clinical severity score (rVCSS) and the clinical score of the comprehensive classification system for chronic venous disease (CEAP) at 6- and 12-month follow-up. Safety outcomes were recurrent DVT, clinically driven target vein revascularization, index limb major amputation, or death. Results: A total of 67 participants (50.7% female, aged 46.7 +/- 18.1 years) who underwent blueflow Venous Stent implantation between February 2018 and March 2019 were enrolled. Primary patency of the target segment was present in 91.7% (95%CI: 76.8-97.7) of participants at the 6-month examination and in 79.8% (95%CI: 66.4-93.2) at the 12-month examination. Twelve-month primary patency was 91.7% (95%CI: 76.0-100) in non-thrombotic, and 72.6% (95%CI: 53.9-91.3) in postthrombotic disease (tog-rank p=0.14). Median rVCSS improved from 8 (interquartile range [IQR]: 9-7) at baseline to 4 (IQR: 6.3-2.8) at 12 months (p<0.001) with a substantial clinical improvement of >= 2 points in 86.1% (31 of 36 participants). No significant association of rVCSS improvement with thrombotic pathogenesis could be found. Median clinical CEAP score improved from 3 (IQR: 3-3) to 2 (IQR: 3-2), p>0.001. No safety signal occurred. Conclusions: blueflow Venous Stent implantation for the treatment of iliofemoral CVD was associated with promising patency and favorable clinical improvement over the mid-term.	[Lichtenberg, Michael; Stahlhoff, Stefan; Ozkapi, Ahmet] Klinikum Hochsauerland, Vasc Ctr Arnsberg, Arnsberg, Germany; [de Graaf, Rick] Klinikum Friedrichshafen, Radiol Dept, Friedrichshafen, Germany		Lichtenberg, M (通讯作者)，Klinikum Hochsauerland, Vasc Ctr Arnsberg, Arnsberg, Germany.	klichte@gmx.net					Dabir D, 2018, CARDIOVASC INTER RAD, V41, P942, DOI 10.1007/s00270-018-1916-1; de Wolf MAF, 2015, EUR J VASC ENDOVASC, V50, P518, DOI 10.1016/j.ejvs.2015.05.011; Kahn SR, 2014, LANCET, V383, P880, DOI 10.1016/S0140-6736(13)61902-9; Lichtenberg M, 2018, VASA, V47, P475, DOI 10.1024/0301-1526/a000731; Lichtenberg M, 2018, VASA, V47, P259, DOI 10.1024/0301-1526/a000696; Lichtenberg MKW, 2021, VASA, V50, P52, DOI 10.1024/0301-1526/a000893; Liu ZJ, 2014, ANN VASC SURG, V28, P695, DOI 10.1016/j.avsg.2013.05.019; Neglen P, 2008, J VASC SURG, V48, P1255, DOI 10.1016/j.jvs.2008.06.035; Oguzkurt L, 2008, J VASC INTERV RADIOL, V19, P366, DOI 10.1016/j.jvir.2007.09.007; Razavi MK, 2015, CIRC-CARDIOVASC INTE, V8, DOI 10.1161/CIRCINTERVENTIONS.115.002772; Razavi MK, 2019, CIRC-CARDIOVASC INTE, V12, DOI 10.1161/CIRCINTERVENTIONS.119.008268; Sista AK, 2015, RADIOLOGY, V276, P30, DOI 10.1148/radiol.2015132603; Van Dongen CJJ, 2005, J THROMB HAEMOST, V3, P939; van Vuuren TMAJ, 2018, J VASC SURG-VENOUS L, V6, P321, DOI 10.1016/j.jvsv.2017.09.013; White RH, 2003, CIRCULATION, V107, pI4, DOI 10.1161/01.CIR.0000078468.11849.66; Wong P, 2012, PHLEBOLOGY, V27, P2, DOI 10.1258/phleb.2012.012S31	16	0	0	2	3	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	SEP	2021	50	5					372	377		10.1024/0301-1526/a000953			6	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6GV	33955794				2022-04-28	WOS:000753511900008
J	Klein-Weigel, PF; Elitok, S; Ruttloff, A; Reinhold, S; Nielitz, J; Steindl, J; Lutfi, P; Rehmenklau-Bremer, L; Hillner, B; Fuchs, H; Wrase, C; Herold, T; Beyer, L				Klein-Weigel, Peter Franz; Elitok, Saban; Ruttloff, Andreas; Reinhold, Sabine; Nielitz, Jessica; Steindl, Julia; Lutfi, Philippe; Rehmenklau-Bremer, Lars; Hillner, Birgit; Fuchs, Heiko; Wrase, Christian; Herold, Thomas; Beyer, Lukas			Inferior vena cava-syndrome	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Review						Inferior vena cava syndrome; tumor compression; inferior vena cava thrombosis; Budd-Chiari syndrome; venous stenting; catheter-directed thrombolysis; thrombaspiration	BUDD-CHIARI-SYNDROME; LONG-TERM OUTCOMES; STENT PLACEMENT; ENDOVASCULAR TREATMENT; ASPIRATION THROMBECTOMY; RHEOLYTIC THROMBECTOMY; CONGENITAL-ANOMALIES; COMPUTED-TOMOGRAPHY; VEIN THROMBOSIS; VENOUS OUTFLOW	Inferior vena cava syndrome (IVCS) is caused by agenesis, compression, invasion, or thrombosis of the IVC, or may be associated with Budd-Chiari syndrome. Its incidence and prevalence are unknown. Benign IVCS is separated from malignant IVCS. Both cover a wide clinical spectrum reaching from asymptomatic to highly symptomatic cases correlated to the underlying cause, the acuity, the extent of the venous obstruction, and the recruitment and development of venous collateral circuits. Imaging is necessary to determine the underlying cause of IVCS and to guide clinical decisions. Interventional therapy has changed the therapeutic approach in symptomatic patients. This article provides an overview over IVCS and focuses on interventional therapeutic methods and results.	[Klein-Weigel, Peter Franz; Ruttloff, Andreas; Reinhold, Sabine; Nielitz, Jessica; Steindl, Julia; Lutfi, Philippe] Ernst von Bergmann Klinikum Potsdam, Angiol Interdisciplinary Ctr Vasc Dis, Potsdam, Germany; [Elitok, Saban] Ernst von Bergmann Klinikum Potsdam, Nephrol, Endokrinol Diabetol, Potsdam, Germany; [Fuchs, Heiko; Wrase, Christian; Beyer, Lukas] Ernst von Bergmann Klinikum Potsdam, Diagnost & Intervent Radiol, Potsdam, Germany; [Rehmenklau-Bremer, Lars; Hillner, Birgit; Herold, Thomas] Helios Klinikum Buch, Inst Radiodiagnost, Berlin, Germany		Klein-Weigel, PF (通讯作者)，Klinikum Ernst von Bergmann, Klin Angiol, Charlottenstr 72, D-14467 Potsdam, Germany.	peter.klein-weigel@klinikumevb.de	Beyer, Lukas/B-2496-2019	Beyer, Lukas/0000-0002-2498-920X			Ageno W, 2017, THROMB HAEMOSTASIS, V117, P794, DOI 10.1160/TH16-10-0781; Al-Hakim R, 2014, J VASC INTERV RADIOL, V25, P933, DOI 10.1016/j.jvir.2014.01.019; Alghulayqah A, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006751; Alkhalili E, 2016, ANN VASC SURG, V33, P245, DOI 10.1016/j.avsg.2015.10.016; Alkhouli M, 2016, JACC-CARDIOVASC INTE, V9, P629, DOI 10.1016/j.jcin.2015.12.268; Alkhouli M, 2015, CIRC-CARDIOVASC INTE, V8, DOI 10.1161/CIRCINTERVENTIONS.114.001882; Alkhouli M, 2014, INT J CARDIOL, V177, P742, DOI 10.1016/j.ijcard.2014.08.010; Balraj P, 2017, ANN VASC SURG, V40, DOI 10.1016/j.avsg.2016.07.068; Bangash HK, 2017, UROL CASE REP, V15, P56, DOI 10.1016/j.eucr.2017.09.004; Barge TF, 2020, VASC ENDOVASC SURG, V54, P297, DOI 10.1177/1538574419900613; Barrette LX., 2020, ANN VASC SURG, VS0890, P30160; Bass YE, 2000, RADIOGRAPHICS, V20, P639, DOI 10.1148/radiographics.20.3.g00ma09639; Bi YH, 2019, J LAPAROENDOSC ADV S, V29, P309, DOI 10.1089/lap.2018.0385; Boozari B, 2008, J HEPATOL, V49, P572, DOI 10.1016/j.jhep.2008.04.025; Nicolau PB, 2017, AM J GASTROENTEROL, V112, P984, DOI 10.1038/ajg.2017.132; Brountzos EN, 2004, CARDIOVASC INTER RAD, V27, P129, DOI 10.1007/s00270-003-0009-x; Chee YL, 2001, BRIT J HAEMATOL, V114, P878, DOI 10.1046/j.1365-2141.2001.03025.x; Chen ZK, 2018, RADIOL MED, V123, P799, DOI 10.1007/s11547-018-0907-2; Cheng DL, 2019, CARDIOVASC INTER RAD, V42, P1311, DOI 10.1007/s00270-019-02267-w; Cheng DL, 2018, EXP THER MED, V16, P4141, DOI 10.3892/etm.2018.6708; Cheung CKM, 2018, ARCH MED SCI, V14, P251, DOI 10.5114/aoms.2018.72247; Chick JFB, 2018, TECH VASC INTERV RAD, V21, P92, DOI 10.1053/j.tvir.2018.03.005; Chick JFB, 2017, J VASC INTERV RADIOL, V28, P933, DOI 10.1016/j.jvir.2017.04.017; Das CJ, 2018, CLIN RADIOL, V73, P610, DOI 10.1016/j.crad.2018.02.003; Dass P, 2015, VASCULAR, V23, P545, DOI 10.1177/1708538114560454; Delis KT, 2007, ANN SURG, V245, P130, DOI 10.1097/01.sla.0000245550.36159.93; Devcic Z, 2016, J VASC INTERV RADIOL, V27, P1350, DOI 10.1016/j.jvir.2016.02.030; Ding PX, 2018, EUR J VASC ENDOVASC, V55, P545, DOI 10.1016/j.ejvs.2017.12.016; Ding PX, 2019, CARDIOVASC INTER RAD, V42, P1398, DOI 10.1007/s00270-019-02292-9; Ding PX, 2019, LIVER INT, V39, P1577, DOI 10.1111/liv.14114; Ding PX, 2016, J GASTROEN HEPATOL, V31, P222, DOI 10.1111/jgh.13025; Dinglasan LAV, 2012, J VASC INTERV RADIOL, V23, P181, DOI 10.1016/j.jvir.2011.10.023; Dopheide JF, 2018, VASA, V47, P56, DOI 10.1024/0301-1526/a000666; Eleid MF, 2014, CATHETER CARDIO INTE, V83, pE105, DOI 10.1002/ccd.25062; Epelboym Y, 2020, CLIN IMAG, V59, P95, DOI 10.1016/j.clinimag.2019.09.015; Erben Y, 2018, J VASC SURG-VENOUS L, V6, P173, DOI 10.1016/j.jvsv.2017.10.017; Erhamamci S, 2015, REV ESP MED NUCL IMA, V34, P287, DOI [10.1016/j.remn.2015.04.002, 10.1016/j.remnie.2015.07.016]; Faraoun SA, 2015, ABDOM IMAGING, V40, P1500, DOI 10.1007/s00261-015-0380-5; Ferraris M, 2019, J VASC SURG-VENOUS L, V7, P547, DOI 10.1016/j.jvsv.2018.10.023; Fletcher WS, 1998, ARCH SURG-CHICAGO, V133, P935, DOI 10.1001/archsurg.133.9.935; Friedman T, 2017, SEMIN INTERVENT RAD, V34, P398, DOI 10.1055/s-0037-1608863; Fu YF, 2015, RADIOL MED, V120, P1094, DOI 10.1007/s11547-015-0554-9; GABRIELE OF, 1967, AMER J ROENTGENOL RA, V100, P417, DOI 10.2214/ajr.100.2.417; Gagne-Loranger M, 2016, EUR J CARDIO-THORAC, V50, P317, DOI 10.1093/ejcts/ezw023; Gai YH, 2014, J CLIN ULTRASOUND, V42, P134, DOI 10.1002/jcu.22107; Georgiou NA, 2015, EMERG RADIOL, V22, P677, DOI 10.1007/s10140-015-1333-6; Ghandour A, 2016, CARDIOVASC DIAGN THE, V6, P482, DOI 10.21037/cdt.2016.11.18; Grotta O, 2017, EUR J VASC ENDOVASC, V54, P620, DOI 10.1016/j.ejvs.2017.07.003; Grus Tomas, 2017, Prague Med Rep, V118, P69, DOI 10.14712/23362936.2017.6; Guerra A, 2008, ACTA RADIOL, V49, P700, DOI 10.1080/02841850802064995; Hedgire SS, 2017, ABDOM RADIOL, V42, P1096, DOI 10.1007/s00261-016-0964-8; Huang QX, 2016, CIRC-CARDIOVASC INTE, V9, DOI 10.1161/CIRCINTERVENTIONS.115.003104; Kandpal H, 2008, RADIOGRAPHICS, V28, P669, DOI 10.1148/rg.283075101; Karaosmanoglu AD, 2019, ABDOM RADIOL, V44, P2988, DOI 10.1007/s00261-019-02100-5; Kaufman LB, 2005, AM J ROENTGENOL, V185, P717, DOI 10.2214/ajr.185.3.01850717; KNODEL DH, 1988, SOUTHERN MED J, V81, P1193; Kolluri R, 2017, J VASC SURG-VENOUS L, V5, P358, DOI 10.1016/j.jvsv.2017.01.017; Kuetting D, 2017, CARDIOVASC INTER RAD, V40, P1873, DOI 10.1007/s00270-017-1740-z; Labropoulos N, 2007, J VASC SURG, V46, P101, DOI 10.1016/j.jvs.2007.02.062; Li L W, 2019, Beijing Da Xue Xue Bao Yi Xue Ban, V51, P678, DOI 10.19723/j.issn.1671-167X.2019.04.014; Li QY, 2020, INT BRAZ J UROL, V46, P92, DOI [10.1590/S1677-5538.IBJU.2019.0304, 10.1590/s1677-5538.ibju.2019.0304]; Li TX, 2010, J VASC SURG, V52, P1242, DOI 10.1016/j.jvs.2010.05.098; Li WD, 2016, INT ANGIOL, V35, P605; Lichtenberg M, 2019, VASA, V48, P341, DOI 10.1024/0301-1526/a000779; Lin EP, 2007, J ULTRAS MED, V26, P885, DOI 10.7863/jum.2007.26.7.885; Low R N, 2000, Oncology (Williston Park), V14, P5; McAree BJ, 2013, VASC MED, V18, P32, DOI 10.1177/1358863X12471967; McDevitt JL, 2019, VASC MED, V24, P349, DOI 10.1177/1358863X19834354; Meng XC, 2016, J VASC INTERV RADIOL, V27, P1592, DOI 10.1016/j.jvir.2016.04.019; MISSAL ME, 1965, ANN INTERN MED, V62, P133, DOI 10.7326/0003-4819-62-1-133; Moore RD, 2013, AM J MED SCI, V346, P521, DOI 10.1097/MAJ.0b013e3182a55a96; Mukund A, 2018, J VASC INTERV RADIOL, V29, P790, DOI 10.1016/j.jvir.2018.01.781; Murakami N, 2019, GYNECOL ONCOL REP, V27, P19, DOI 10.1016/j.gore.2018.12.002; Murata M, 2018, UROL CASE REP, V20, P72, DOI 10.1016/j.eucr.2018.07.004; Nakashima J, 1997, Int J Urol, V4, P441, DOI 10.1111/j.1442-2042.1997.tb00282.x; Neglen P., 2009, INNOVATIVE TREATMENT, P253; Neglen P, 2007, J VASC SURG, V46, P979, DOI 10.1016/j.jvs.2007.06.046; Neglen P, 2011, J VASC SURG, V54, P153, DOI 10.1016/j.jvs.2010.11.117; Notten P, 2020, LANCET HAEMATOL, V7, pE40, DOI 10.1016/S2352-3026(19)30209-1; Ollivier-Hourmand I, 2018, DIGEST LIVER DIS, V50, P931, DOI 10.1016/j.dld.2018.04.004; Osborne T, 2019, OXF MED CASE REP, P282, DOI 10.1093/omcr/omz053; Osman S, 2013, CURR PROBL DIAGN RAD, V42, P191, DOI 10.1067/j.cpradiol.2013.02.001; Parmar Kalpesh, 2020, Trauma Case Rep, V25, P100282, DOI 10.1016/j.tcr.2020.100282; Partovi S, 2017, VASA, V46, P121, DOI 10.1024/0301-1526/a000593; Patel Shyam A, 2015, J Med Case Rep, V9, P204, DOI 10.1186/s13256-015-0696-3; Petik B, 2016, J BELG SOC RADIOL, V100, DOI 10.5334/jbr-btr.975; Petik B, 2015, INSIGHTS IMAGING, V6, P631, DOI 10.1007/s13244-015-0431-z; Piciucchi S, 2014, INSIGHTS IMAGING, V5, P619, DOI 10.1007/s13244-014-0351-3; Rajani R, 2009, LIVER INT, V29, P253, DOI 10.1111/j.1478-3231.2008.01838.x; Raju S, 2006, J VASC SURG, V44, P820, DOI 10.1016/j.jvs.2006.05.054; Ren JZ, 2013, VASC ENDOVASC SURG, V47, P232, DOI 10.1177/1538574413478495; Rigatelli G, 2006, J ENDOVASC THER, V13, P373, DOI 10.1583/05-1735.1; Ruggeri M, 2001, LANCET, V357, P441, DOI 10.1016/S0140-6736(00)04010-1; Sangster GP, 2016, ABDOM RADIOL, V41, P1411, DOI 10.1007/s00261-016-0735-6; Sashi R, 1997, MAGN RESON IMAGING, V15, P1099, DOI 10.1016/S0730-725X(97)00160-4; Schwein Adeline, 2018, Methodist Debakey Cardiovasc J, V14, P208, DOI 10.14797/mdcj-14-3-208; Sebastian T, 2019, THROMB HAEMOSTASIS, V119, P2064, DOI 10.1055/s-0039-1697955; Sebastian T, 2018, J VASC SURG-VENOUS L, V6, P312, DOI 10.1016/j.jvsv.2017.11.012; Shammas NW, 2018, J INVASIVE CARDIOL, V30, P452; Shi WY, 2017, THROMB RES, V149, P9, DOI 10.1016/j.thromres.2016.07.010; Shindo S, 2007, ABDOM IMAGING, V32, P754, DOI 10.1007/s00261-007-9184-6; Shukuzawa Kota, 2017, Case Rep Vasc Med, V2017, P8172549, DOI 10.1155/2017/8172549; Smillie RP, 2015, RADIOGRAPHICS, V35, P578, DOI 10.1148/rg.352140136; SONIN AH, 1992, RADIOGRAPHICS, V12, P309, DOI 10.1148/radiographics.12.2.1561419; Stuck AK, 2018, VASA, V47, P319, DOI 10.1024/0301-1526/a000697; Tufano A, 2020, INT J CARDIOL, V305, P115, DOI 10.1016/j.ijcard.2020.01.013; Valla DC, 2018, HEPATOL INT, V12, pS168, DOI 10.1007/s12072-017-9810-5; Van Wettere M, 2018, ABDOM RADIOL, V43, P1896, DOI 10.1007/s00261-017-1447-2; Wang RH, 2013, EXP THER MED, V5, P1254, DOI 10.3892/etm.2013.961; Wang WD, 2018, J VASC SURG-VENOUS L, V6, P788, DOI 10.1016/j.jvsv.2018.08.002; Wang ZG, 2005, ANZ J SURG, V75, P55, DOI 10.1111/j.1445-2197.2005.03135.x; White JA, 2009, CIRCULATION, V120, P1722, DOI 10.1161/CIRCULATIONAHA.109.866400; Wong PC, 2019, HONG KONG MED J, V25, P48, DOI 10.12809/hkmj187491; Ye K, 2016, EUR J VASC ENDOVASC, V52, P839, DOI 10.1016/j.ejvs.2016.08.050; Zaghlool DS, 2016, INT J ANGIOL, V25, P203, DOI 10.1055/s-0036-1580698; Zhang CQ, 2003, WORLD J GASTROENTERO, V9, P2587; Zhang LJ, 2007, ABDOM IMAGING, V32, P495, DOI 10.1007/s00261-006-9137-5; Zhang QQ, 2014, EUR J VASC ENDOVASC, V47, P550, DOI 10.1016/j.ejvs.2014.01.014; Zhang W, 2018, WORLD J GASTROENTERO, V24, P1134, DOI 10.3748/wjg.v24.i10.1134	119	0	0	1	3	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JUL	2021	50	4					250	264		10.1024/0301-1526/a000919			15	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QY	33459041				2022-04-28	WOS:000695708700002
J	Fukaya, E; Welden, S; Bukari, A; Khan, Z; Leeper, N; Mohler, E				Fukaya, Eri; Welden, Scott; Bukari, Abdallah; Khan, Zeeshan; Leeper, Nicholas; Mohler, Emile			Incentivizing physical activity through activity monitoring interventions in PAD - a pilot study	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Peripheral artery disease (PAD); exercise therapy; home-based; activity monitoring; financial incentive	PERIPHERAL ARTERY-DISEASE; EXERCISE; CLAUDICATION	Background: There is ample evidence to show that supervised exercise is efficacious and cost effective for improving claudication symptoms in patients with peripheral artery disease (PAD). Home based exercise therapy can be an effective alternative to supervised exercise however, the results of this is variable depending on the level of motivation and engagement of the patient. Patients and methods: We performed a pilot study in 41 patients to determine whether a home based exercise program with the use of an activity tracking device with personalized feedback and financial incentives can increase daily activity, improve walking and sustain engagement in the exercise regimen in patients with PAD. In this randomized pilot study, the patients in the study group were fitted with an activity monitoring device and given behavioral monitoring, motivational updates and feedback regarding their exercise program. This study group was further divided in to two groups. One half of these patients in the study group were also given financial incentives if they reached their set targets. The control group wore the device with no feedback or ability to see their number of steps walked. Results: Results showed that at the end of the 12 week period, patients in the study groups walked more compared to the controls and the financial incentive structure resulted in an additional 38-63% increase in average daily steps. Conclusions: This pilot study revealed that a home-based exercise program with activity monitoring, feedback and financial incentives resulted increased daily steps, 6-minute walking distance and overall compliance with the program in PAD patients with claudication.	[Fukaya, Eri; Leeper, Nicholas] Stanford Univ, Stanford, CA 94305 USA; [Welden, Scott] Univ Penn, Philadelphia, PA 19104 USA; [Bukari, Abdallah] Univ Pittsburgh, Pittsburgh, PA USA; [Khan, Zeeshan] Rowan Univ, Glassboro, NJ USA		Fukaya, E (通讯作者)，300 Pasteur Dr Alway M103A, Stanford, CA 94305 USA.	efukaya@stanford.edu					Allison MA, 2007, AM J PREV MED, V32, P328, DOI 10.1016/j.amepre.2006.12.010; Braunholtz DA, 2001, J CLIN EPIDEMIOL, V54, P217, DOI 10.1016/S0895-4356(00)00305-X; Chokshi NP, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009173; Collins TC, 2011, DIABETES CARE, V34, P2174, DOI 10.2337/dc10-2399; Gardner AW, 2019, J VASC SURG, V70, P1280, DOI 10.1016/j.jvs.2018.12.056; Gardner AW, 2018, VASC MED, V23, P349, DOI 10.1177/1358863X18762599; Gardner AW, 2015, VASA, V44, P405, DOI 10.1024/0301-1526/a000464; Gardner AW, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001107; Gardner AW, 2011, CIRCULATION, V123, P491, DOI 10.1161/CIRCULATIONAHA.110.963066; Golbidi S, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/789607; Haff N, 2015, AM J HEALTH PROMOT, V29, P314, DOI 10.4278/ajhp.140714-LIT-333; Halpern SD, 2015, N ENGL J MED; Jain A, 2013, J AM COLL CARDIOL, V61, P1820, DOI 10.1016/j.jacc.2013.01.060; Leng GC, 2000, COCHRANE DB SYST REV; Lewis ZH, 2016, GAMES HEALTH J, V5, P93, DOI 10.1089/g4h.2015.0078; Liu TY, 2019, PREV MED REP, V14, DOI 10.1016/j.pmedr.2019.100841; McDermott MM, 2018, JAMA-J AM MED ASSOC, V319, P1665, DOI 10.1001/jama.2018.3275; McDermott MM, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000711; McDermott MM, 2001, JAMA-J AM MED ASSOC, V286, P1599; McDermott MM, 2004, JAMA-J AM MED ASSOC, V292, P453, DOI 10.1001/jama.292.4.453; McDermott MM, 2015, J AM HEART ASS, V4; Murphy TP, 2008, J VASC SURG, V47, P1356, DOI 10.1016/j.jvs.2007.12.048; Murphy TP, 2012, CIRCULATION, V125, P130, DOI 10.1161/CIRCULATIONAHA.111.075770; Norgren L, 2007, EUR J VASC ENDOVASC, V33, pS5, DOI 10.1016/j.ejvs.2006.09.024; Rajani NB, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027883; Rogers T, 2014, JAMA-J AM MED ASSOC, V311, P2065, DOI 10.1001/jama.2014.3485; Rosenthal R, 1968, URBAN REV, V3, P16, DOI [10.1007/BF02322211, DOI 10.1007/BF02322211]; Stein RA, 2015, ARTERIOSCL THROM VAS, V35, P206, DOI 10.1161/ATVBAHA.114.304161; Treat-Jacobson D, 2019, CIRCULATION, V140, pE700, DOI 10.1161/CIR.0000000000000727; Volpp KG, 2014, JAMA-J AM MED ASSOC, V311, P909, DOI 10.1001/jama.2014.418; Volpp KG, 2008, JAMA-J AM MED ASSOC, V300, P2631, DOI 10.1001/jama.2008.804	31	2	2	1	4	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	FEB	2021	50	2					145	150		10.1024/0301-1526/a000924			6	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	QQ5PH	33150850				2022-04-28	WOS:000624575300010
J	Zhang, HJ; Yin, DX; Zhao, Y; Li, YZ; Yao, DJ; Sun, DJ				Zhang, Hanji; Yin, Dexin; Zhao, Yue; Li, Yezhou; Yao, Dejiang; Sun, Dajun			Relationship between total plasma homocysteine and the risk of aneurysms - a meta-analysis	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						aneurysms; homocysteine (Hcy) level; smoking; hypertension; hyperhomocysteinemia (HHcy); meta-analysis	ABDOMINAL AORTIC-ANEURYSM; LOW FOLATE CONCENTRATIONS; VASCULAR-DISEASE; HYPERHOMOCYSTEINAEMIA; ASSOCIATION; METHIONINE	Our meta-analysis focused on the relationship between homocysteine (Hcy) level and the incidence of aneurysms and looked at the relationship between smoking, hypertension and aneurysms. A systematic literature search of Pubmed, Web of Science, and Embase databases (up to March 31, 2020) resulted in the identification of 19 studies, including 2,629 aneurysm patients and 6,497 healthy participants. Combined analysis of the included studies showed that number of smoking, hypertension and hyperhomocysteinemia (HHcy) in aneurysm patients was higher than that in the control groups, and the total plasma Hcy level in aneurysm patients was also higher. These findings suggest that smoking, hypertension and HHcy may be risk factors for the development and progression of aneurysms. Although the heterogeneity of meta-analysis was significant, it was found that the heterogeneity might come from the difference between race and disease species through subgroup analysis. Large-scale randomized controlled studies of single species and single disease species are needed in the future to supplement the accuracy of the results.	[Zhang, Hanji; Yin, Dexin; Zhao, Yue; Li, Yezhou; Sun, Dajun] Jilin Univ, China Japan Union Hosp, Dept Vasc Surg, 126 Xiantai Ave, Changchun 130033, Jilin, Peoples R China; [Yao, Dejiang] Wuhan Univ, Ctr Hosp Enshi Tujia & Miao Autonomous Prefecture, Dept Surg 3, Dept Chinese Med, Enshi City, Hubei, Peoples R China		Sun, DJ (通讯作者)，Jilin Univ, China Japan Union Hosp, Dept Vasc Surg, 126 Xiantai Ave, Changchun 130033, Jilin, Peoples R China.	djvaso@163.com					Boczar KE, 2018, CAN J CARDIOL, V34, P362, DOI 10.1016/j.cjca.2017.12.031; Boese AC, 2017, AM J PHYSIOL-HEART C, V313, pH524, DOI 10.1152/ajpheart.00217.2016; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brunelli T, 2000, J VASC SURG, V32, P531, DOI 10.1067/mva.2000.107563; Caldwell S, 2001, BRIT J SURG, V88, P609, DOI 10.1046/j.1365-2168.2001.01757-30.x; Cao H, 2014, VASA, V43, P181, DOI 10.1024/0301-1526/a000347; Cao H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085831; Davies MJ, 1998, CIRCULATION, V98, P193, DOI 10.1161/01.CIR.98.3.193; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fan YC, 2019, J VASC RES, V56, P230, DOI 10.1159/000501313; Filardo G, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001835.pub3, 10.1002/14651858.CD001835.pub4]; Fu Yi, 2018, Br J Pharmacol, V175, P1173, DOI 10.1111/bph.13988; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Katsiki N, 2017, CURR PHARM DESIGN, V23, P3224, DOI 10.2174/1381612823666170317124913; Kuivaniemi H, 2015, EXPERT REV CARDIOVAS, V13, P975, DOI 10.1586/14779072.2015.1074861; Kumar A, 2017, NUTR METAB, V14, DOI 10.1186/s12986-017-0233-z; Lindberg S, 2016, EUR CYTOKINE NETW, V27, P75, DOI 10.1684/ecn.2016.0381; Lindqvist M, 2012, AM J CARDIOVASC DIS, V2, P318; Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep17966; Liu Z, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01238; Makrygiannis G, 2014, ANN VASC SURG, V28, P1946, DOI 10.1016/j.avsg.2014.07.008; Portillo F, 2020, BIOCHIMIE, V173, P33, DOI 10.1016/j.biochi.2020.02.015; Ren JR, 2017, J STROKE CEREBROVASC, V26, P2720, DOI 10.1016/j.jstrokecerebrovasdis.2017.01.001; Roohi J, 2017, J NUTR, V147, P1290, DOI 10.3945/jn.117.251173; Rosi J, 2018, WORLD NEUROSURG, V119, pE272, DOI 10.1016/j.wneu.2018.07.132; Sbarouni E, 2013, INT J CARDIOL, V168, P463, DOI 10.1016/j.ijcard.2012.09.127; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.g7647, 10.1136/bmj.b2700]; Siennicka A, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3205324; Skovierova H, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101733; Sofi F, 2005, THROMB HAEMOSTASIS, V94, P1094, DOI 10.1160/TH05-06-0431; Spark JI, 2003, EUR J VASC ENDOVASC, V26, P558, DOI 10.1016/S1078-5884(03)00381-2; Tsarouhas K, 2011, THROMB RES, V128, pE95, DOI 10.1016/j.thromres.2011.07.008; Turhan H, 2005, INT J CARDIOL, V104, P158, DOI 10.1016/j.ijcard.2004.10.025; Turkmen S, 2014, EUR REV MED PHARMACO, V18, P1661; Wang Q, 2020, NEUROSURG REV, V43, P1127, DOI 10.1007/s10143-019-01138-9; Warsi AA, 2004, EUR J VASC ENDOVASC, V27, P75, DOI 10.1016/j.ejvs.2003.09.001; Wong YYE, 2013, J VASC SURG, V58, P364, DOI 10.1016/j.jvs.2013.01.046; Yuan HF, 2016, HEART SURG FORUM, V19, pE224, DOI 10.1532/hsf.1415; Zaykova E, 2003, KLIN BIOCH METABOLIS, V11, P190	39	0	0	1	2	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	FEB	2021	50	2					110	115		10.1024/0301-1526/a000891			6	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	QQ5PH	32933402				2022-04-28	WOS:000624575300005
J	Augustin, AM; Dalla Torre, G; Kocot, A; Bley, TA; Kalogirou, C; Kickuth, R				Augustin, Anne Marie; Dalla Torre, Giulia; Kocot, Arkadius; Bley, Thorsten Alexander; Kalogirou, Charis; Kickuth, Ralph			Endovascular therapy of arterioureteral fistulas	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Angiography; arterioureteral fistula; embolisation; endovascular; interventional radiology; urinary tract	URETEROILIAC ARTERY FISTULA; URETEROARTERIAL FISTULA; URETERAL FISTULA; MANAGEMENT; DIAGNOSIS; ANEURYSM; STENT	Background: Arterioureteral fistulas (AUFs) are severe pathologies of different origin and with increasing incidence frequently appear in patients with underlying extensive malignancy and after pelvic surgery. AUF therapy is challenging since symptoms are frequently non-specific and patients are often unsuitable surgical candidates due to comorbidities. Since experiences with endovascular treatment strategies are limited, the feasibility, effectiveness, and safety were evaluated in a consecutive case series. Patients and methods: A retrospective analysis of five patients with endovascular AUF exclusion was performed. Probable predisposing factors for an AUF included history of pelvic malignancy with oncologic surgery in four patients, radiotherapy in four patients, and indwelling ureteral stents in four patients. Clinical presentation, diagnostic management, and site of fistula were assessed. Furthermore, technical and clinical success as well as complications were evaluated. Results: All patients presented with gross haematuria. In four patients, haematuria occurred during endoscopic ureteral stent manipulation. Affected vessels were the internal pudendal artery in one, intrarenal segmental artery and external iliac artery in two, and internal iliac artery in another two patients. Treatment included coil embolisation (n = 2), plug embolisation (n = 3), particulate embolisation (n = 1), and covered stent implantation (n = 2). Technical success was achieved in all procedures. In two cases, re-intervention was necessary due to AUF recurrence, resulting in a clinical success rate of 60.0%. One major complication class D was documented. Conclusions: AUFs can be treated effectively and safely using endovascular techniques. Diagnostic and therapeutic management of this rare entity requires a high level of awareness for potential risk factors as well as an optimal multidisciplinary coordination.	[Augustin, Anne Marie; Dalla Torre, Giulia; Bley, Thorsten Alexander; Kickuth, Ralph] Univ Hosp Wurzburg, Dept Diagnost & Intervent Radiol, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany; [Kocot, Arkadius; Kalogirou, Charis] Univ Hosp Wurzburg, Dept Urol & Paediat Urol, Wurzburg, Germany		Augustin, AM (通讯作者)，Univ Hosp Wurzburg, Dept Diagnost & Intervent Radiol, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany.	augustin_a@ukw.de		Augustin, Anne Marie/0000-0002-3541-5287			Batter SJ, 1996, UROLOGY, V48, P481, DOI 10.1016/S0090-4295(96)00202-6; Bergqvist D, 2001, EUR J VASC ENDOVASC, V22, P191, DOI 10.1053/ejvs.2001.1432; Darcy M, 2009, TECH VASC INTERV RAD, V12, P216, DOI 10.1053/j.tvir.2009.09.005; Das A, 2016, VASCULAR, V24, P203, DOI 10.1177/1708538115585261; Fox JA, 2011, J UROLOGY, V185, P945, DOI 10.1016/j.juro.2010.10.062; Gibbons M, 1998, J UROLOGY, V159, P2083, DOI 10.1016/S0022-5347(01)63260-9; Hausegger KA, 1996, ROFO FORTSCHR RONTG, V164, P525, DOI 10.1055/s-2007-1015703; Inoue T, 2002, INT J UROL, V9, P120, DOI 10.1046/j.1442-2042.2002.00433.x; Kerns DB, 1996, J VASC SURG, V24, P680, DOI 10.1016/S0741-5214(96)70084-8; Krambeck AE, 2005, UROLOGY, V66, P990, DOI 10.1016/j.urology.2005.05.036; Luther B, 2014, AKTUEL UROL, V45, P204, DOI 10.1055/s-0034-1376953; Madoff DC, 2004, AM J ROENTGENOL, V182, P1241, DOI 10.2214/ajr.182.5.1821241; Okada T, 2013, CARDIOVASC INTER RAD, V36, P950, DOI 10.1007/s00270-012-0534-6; Patel D, 2014, SAGE OPEN MED CASE R, V2, DOI 10.1177/2050313X14548094; QUILLIN SP, 1994, AM J ROENTGENOL, V162, P873, DOI 10.2214/ajr.162.4.8141010; RENNICK JM, 1976, J UROLOGY, V116, P111, DOI 10.1016/S0022-5347(17)58704-2; Sacks David, 2003, J Vasc Interv Radiol, V14, pS199; SHARMA SK, 1988, J UROLOGY, V139, P355, DOI 10.1016/S0022-5347(17)42413-X; Tselikas L, 2013, Diagn Interv Imaging, V94, P311, DOI 10.1016/j.diii.2012.10.005; van den Bergh RCN, 2009, UROLOGY, V74, P251, DOI 10.1016/j.urology.2008.12.011; van Kelckhoven BJ, 2007, CARDIOVASC INTER RAD, V30, P774, DOI 10.1007/s00270-007-9013-x; Vandersteen DR, 1997, J UROLOGY, V158, P754, DOI 10.1016/S0022-5347(01)64307-6	22	2	2	1	1	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	MAY	2021	50	3					193	201		10.1024/0301-1526/a000922			9	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QU	33140697				2022-04-28	WOS:000695708300006
J	Dakhel, A; Zarrouk, M; Ekelund, J; Acosta, S; Miftaraj, M; Eliasson, B; Svensson, AM; Gottsater, A				Dakhel, Ardwan; Zarrouk, Moncef; Ekelund, Jan; Acosta, Stefan; Miftaraj, Mervete; Eliasson, Bjorn; Svensson, Ann-Marie; Gottsater, Anders			Higher long-term cardiovascular morbidity after open surgery for intermittent claudication caused by infrainguinal atherosclerotic disease in patients with diabetes - a nationwide observational cohort study	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Diabetes mellitus; intermittent claudication; peripheral arterial disease; open surgery; long-term follow-up	PERIPHERAL ARTERIAL-DISEASE; RISK-FACTORS; OUTCOMES; REVASCULARIZATION; POPULATION; MELLITUS; PREVALENCE; MORTALITY; ISCHEMIA; THERAPY	Background: Diabetes mellitus (DM) is a risk factor for peripheral arterial disease (PAD). Indications for open surgery in infrainguinal intermittent claudication (IC) are limited, and reports are lacking regarding outcomes in DM patients. Study aims were to compare short and long-term effects on major adverse cardiovascular events (MACE), acute myocardial infarction (AMI), stroke, major amputation, and mortality after infrainguinal open surgery for IC in patients with and without DM, and to evaluate relationships between glycaemic control and outcomes. Methods: Nationwide observational cohort study of all patients registered in the Swedish Vascular Registry after planned infrainguinal open surgery for IC from January 1(st) 2010 to December 31(st) 2014. Patients registered in the National Diabetes Registry were compared with patients without diabetes by propensity score adjusted comparison of MACE, AMI, stroke, major amputation, and mortality. Results: After 30 days, there were no differences in MACE, AMI, stroke, major amputation, or mortality between patients with (n = 323, mean age 70.5 [SD 7.4] years, 92 [28.5%] females) and without (n = 679, mean age 69.7 years [SD 11.2], 234 [34.5%] females) DM. At last follow-up after median 5.2 years, patients with DM showed higher rates of MACE (Hazard ratio [HR] 1.33, confidence interval [CI] 1.08-1.62; p < 0.01), and AMI (HR 2.21, CI 1.46-3.35; p < 0.01) than patients without diabetes. Among DM patients, higher glycated haemoglobin (HbA1c) was associated with higher rates of MACE (HR 1.02, CI 1.00-1.03; p = 0.02), stroke (HR 1.05, CI 1.00-1.11; p = 0.04), and total mortality (HR 1.03, CI 1.01-1.06; p < 0.01), during follow-up, whereas duration of diabetes was associated with higher rate of major amputation (HR 1.08, CI 1.02-1.15; p < 0.01). Conclusions: DM patients showed higher rates of MACE and AMI in propensity score adjusted analysis five years after planned infrainguinal open surgery for IC. Higher HbA1c was associated with MACE, stroke, and total mortality in patients with DM, whereas longer duration of DM was associated with major amputation.	[Dakhel, Ardwan; Zarrouk, Moncef; Acosta, Stefan; Gottsater, Anders] Lund Univ, Skane Univ Hosp, Dept Vasc Dis, S-20502 Malmo, Sweden; [Ekelund, Jan; Miftaraj, Mervete; Eliasson, Bjorn; Svensson, Ann-Marie] Swedish Natl Diabet Register, Gothenburg, Sweden; [Svensson, Ann-Marie] Univ Gothenburg, Inst Med, Dept Mol & Clin Med, Gothenburg, Sweden		Dakhel, A (通讯作者)，Lund Univ, Skane Univ Hosp, Dept Vasc Dis, S-20502 Malmo, Sweden.	ardwan.dakhel@gmail.com		Acosta, Stefan/0000-0002-3225-0798; Dakhel, Ardwan/0000-0003-3500-4530			Aboyans V, 2017, KARDIOL POL, V75, P1065, DOI 10.5603/KP.2017.0216; Arya S, 2018, J VASC SURG, V67, P217, DOI 10.1016/j.jvs.2017.06.101; Behrendt CA, 2020, EUR J VASC ENDOVASC, V60, P873, DOI 10.1016/j.ejvs.2020.08.027; Clark N, 2003, DIABETES CARE, V26, P3333; Darling JD, 2018, J VASC SURG, V67, P1159, DOI 10.1016/j.jvs.2017.06.119; de Ferranti SD, 2014, DIABETES CARE, V37, P2843, DOI 10.2337/dc14-1720; Djerf H, 2020, EUR J VASC ENDOVASC, V59, P817, DOI 10.1016/j.ejvs.2019.11.023; Djerf H, 2020, CIRC-CARDIOVASC INTE, V13, DOI 10.1161/CIRCINTERVENTIONS.119.008450; Eliasson B, 2014, DIABETES RES CLIN PR, V106, pS291, DOI 10.1016/S0168-8227(14)70732-6; Emilsson L, 2015, J INTERN MED, V277, P94, DOI 10.1111/joim.12303; Fowkes FGR, 2013, LANCET, V382, P1329, DOI 10.1016/S0140-6736(13)61249-0; Fridh EB, 2017, EUR J VASC ENDOVASC, V54, P480, DOI 10.1016/j.ejvs.2017.07.005; Hageman D, 2017, VASC MED, V22, P21, DOI 10.1177/1358863X16674071; Liang P, 2018, J VASC SURG, V68, P487, DOI 10.1016/j.jvs.2017.11.081; Ludvigsson JF, 2016, EUR J EPIDEMIOL, V31, P125, DOI 10.1007/s10654-016-0117-y; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Marso SP, 2016, NEW ENGL J MED, V375, P311, DOI 10.1056/NEJMoa1603827; Merlo J, 2000, EUR J EPIDEMIOL, V16, P235, DOI 10.1023/A:1007634722658; Nordanstig J, 2014, CIRCULATION, V130, P939, DOI 10.1161/CIRCULATIONAHA.114.009867; Rawshani A, 2017, NEW ENGL J MED, V376, P1407, DOI 10.1056/NEJMoa1608664; Sigvant B, 2007, J VASC SURG, V45, P1185, DOI 10.1016/j.jvs.2007.02.004; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Strain WD, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933-018-0703-2; Troeng T, 2008, EUR J VASC ENDOVASC, V36, P705, DOI 10.1016/j.ejvs.2008.08.017; Tsai TT, 2015, CIRCULATION, V132, P1999, DOI 10.1161/CIRCULATIONAHA.114.013440; Vijan S, 1997, J GEN INTERN MED, V12, P567, DOI 10.1046/j.1525-1497.1997.07111.x; Wallaert JB, 2012, J VASC SURG, V56, P1317, DOI 10.1016/j.jvs.2012.04.011; Wettermark B, 2007, PHARMACOEPIDEM DR S, V16, P726, DOI 10.1002/pds.1294; Wieker CM, 2016, J VASC SURG, V64, P995, DOI 10.1016/j.jvs.2016.04.036; Yang SL, 2017, J DIABETES, V9, P133, DOI 10.1111/1753-0407.12474	30	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	MAY	2021	50	3					224	230		10.1024/0301-1526/a000929			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QU	33334201				2022-04-28	WOS:000695708300010
J	Gahwiler, R; Hirschmuller, A; Grumann, T; Isaak, A; Thalhammer, C				Gaehwiler, Roman; Hirschmueller, Anja; Grumann, Thorsten; Isaak, Andrej; Thalhammer, Christoph			Exercise induced leg pain due to endofibrosis of external iliac artery	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Review						endofibrosis; iliac artery; endurance athlete; sports medicine	RECOGNIZING VASCULAR CAUSES; INTERMITTENT CLAUDICATION; FLOW LIMITATIONS; SMOOTH-MUSCLE; OBSTRUCTION; COMPLAINTS; DIAGNOSIS; STENOSIS	Due to monotonous movement patterns, muscular hypertrophy, and increased cardiac output peripheral vasculature of athletes are subject to extreme stresses during athletic performance. Individuals suffering from exercise induced non-traumatic lower leg pain may display underlying vascular pathology such as external iliac artery endofibrosis. Therefore, it is essential in the course of to discriminate vascular from non-vascular findings and prime the correct diagnostic path within the course of clinical examination. In this regard, interdisciplinary thinking and profound knowledge in exercise-associated pathologies of the musculoskeletal, nervous and vascular system is indispensable. Consequently, provocation testing displays an indispensable diagnostic tool and has to be continued until symptoms occur, or complete exhaustion is attained. Finally, selective assessment of conservative and surgical treatment options, as well as its ethical evaluation, are of major importance in order to protect, preserve and promote the health and physical integrity of our patients who are keen to perform.	[Gaehwiler, Roman; Thalhammer, Christoph] Cantonal Hosp Aarau, Univ Hosp, Dept Angiol, Aarau, Switzerland; [Gaehwiler, Roman] Danube Univ Krems, Dept Hlth & Med, Krems An Der Donau, Austria; [Hirschmueller, Anja] ALTIUS Swiss Sportmed Ctr AG, Rheinfelden, Switzerland; [Hirschmueller, Anja] Albert Ludwigs Univ Freiburg, Fac Med, Med Ctr, Dept Orthoped & Trauma Surg, Freiburg, Germany; [Grumann, Thorsten] Cantonal Hosp Lucerne, Dept Angiol, Lucern, Switzerland; [Isaak, Andrej] Cantonal Hosp Aarau, Dept Vasc Surg, Aarau, Switzerland		Gahwiler, R (通讯作者)，Cantonal Hosp Aarau, Dept Angiol, Tellstr 25, CH-5001 Aarau, Switzerland.	roman.gaehwiler@ksa.ch		Gahwiler, Roman/0000-0003-2026-1606			Akuthota V, 2009, NERVE VASCULAR INJUR; Alimi YS, 2004, EUR J VASC ENDOVASC, V28, P513, DOI 10.1016/j.ejvs.2004.08.008; Arko FR, 2001, J VASC SURG, V33, P935, DOI 10.1067/mva.2001.115162; Baggish AL, 2017, CIRCULATION, V135, P1991, DOI 10.1161/CIRCULATIONAHA.116.026945; Bender MHM, 2012, EUR J VASC ENDOVASC, V43, P472, DOI 10.1016/j.ejvs.2012.01.004; Bender MHM, 2004, SPORTS MED, V34, P427, DOI 10.2165/00007256-200434070-00002; BRAY AE, 1992, J VASC SURG, V15, P664, DOI 10.1016/0741-5214(92)90013-X; Brearley S, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2681; Chevalier J M, 1986, Ann Vasc Surg, V1, P297, DOI 10.1007/BF02732562; Cunningham KS, 2005, LAB INVEST, V85, P9, DOI 10.1038/labinvest.3700215; Feugier P, 2004, ACTA CHIR BELG, V104, P635, DOI 10.1080/00015458.2004.11679635; Ford SJ, 2003, EUR J VASC ENDOVASC, V26, P629, DOI 10.1016/j.ejvs.2003.08.003; Gahwiler R, 2019, SWISS SPORTS EXERCIS, V67, P5; Hinchliffe RJ, 2016, EUR J VASC ENDOVASC, V52, P90, DOI 10.1016/j.ejvs.2016.04.004; Howard AQ, 2013, J VASC SURG, V58, P1657, DOI 10.1016/j.jvs.2013.01.027; Janmaat ML, 2010, BLOOD, V115, P1453, DOI 10.1182/blood-2009-07-230870; Khaira HS, 1996, EUR J VASC ENDOVASC, V11, P499, DOI 10.1016/S1078-5884(96)80189-4; Masmoudi S, 2002, Rev Med Liege, V57, P135; Okazaki Jin, 2011, Ann Vasc Dis, V4, P143, DOI 10.3400/avd.cr.10.01027; Peach G, 2012, EUR J VASC ENDOVASC, V43, P208, DOI 10.1016/j.ejvs.2011.11.019; Peake LK, 2018, EUR J VASC ENDOVASC, V55, P577, DOI 10.1016/j.ejvs.2018.01.018; Politano AD, 2012, J VASC SURG, V55, P1338, DOI 10.1016/j.jvs.2011.11.106; Posthuma JJ, 2019, J VASC SURG, V69, P1243, DOI 10.1016/j.jvs.2018.05.220; Reddy MK, 2007, J CARDIOVASC PHARM T, V12, P237, DOI 10.1177/1074248406297326; ROUSSELET MC, 1990, HUM PATHOL, V21, P524, DOI 10.1016/0046-8177(90)90009-T; Scavee V, 2003, J VASC SURG, V38, P180, DOI 10.1016/S0741-5214(03)00123-X; Schep G, 1999, INT J SPORTS MED, V20, P421; Schep G, 2001, Eur J Ultrasound, V14, P129, DOI 10.1016/S0929-8266(01)00154-9; Schep G, 2002, LANCET, V359, P466, DOI 10.1016/S0140-6736(02)07675-4; Schep G, 2002, INT J SPORTS MED, V23, P322, DOI 10.1055/s-2002-33142; Schep G, 2002, INT J SPORTS MED, V23, P313, DOI 10.1055/s-2002-33141; SHAHIDI NT, 1973, NEW ENGL J MED, V289, P72, DOI 10.1056/NEJM197307122890205; Sullivan J, 2019, J VASC SURG CASES IN, V5, P58, DOI 10.1016/j.jvscit.2018.11.008; Tannsjo T., 2009, HUMAN ENHANCEMENT, P315; Taylor AJ, 2001, MANUAL THER, V6, P48, DOI 10.1054/math.2000.0382; Vink A, 2008, J VASC SURG, V48, P1458, DOI 10.1016/j.jvs.2008.07.057; WALDER J, 1985, HELV CHIR ACTA, V51, P793; Wang LW, 2002, J CARDIOVASC PHARM, V40, P841, DOI 10.1097/00005344-200212000-00005	38	1	1	2	5	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	FEB	2021	50	2					92	100		10.1024/0301-1526/a000909			9	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	QQ5PH	32930655	Bronze			2022-04-28	WOS:000624575300003
J	Rocha, MA; Marques, ESS; Leao, LRD; Magdalena, TRF; Dorea, AA; Yamauchi, FI; Wolosker, N; Tachibana, A				Rocha, Marcelo Assis; Marques, Eduardo Saltao Silva; Leao, Layra Ribeiro de Sousa; Magdalena, Thiago Raspa Freitas; Dorea, Aline Andrade; Yamauchi, Fernando Ide; Wolosker, Nelson; Tachibana, Adriano			Prevalence, growth rate and complications of splenic artery aneurysms in chronic liver disease patients	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Splenic artery; aneurysm; liver diseases; hypertension; portal; liver transplantation	MANAGEMENT; CIRRHOSIS; BRAZIL	Background: Chronic liver disease (CLD) patients are at greater risk for developing splenic artery aneurysm (SAA). Treatment for aneurysms > 2.5 cm in this population is considered. However, the procedure might be challenging in CLD patients, and complications may interfere in liver transplantation. We, therefore, sought to estimate the prevalence, growth rate and complications of SAA in patients with CLD. As secondary objective, we sought to evaluate whether those features differ in pre and post transplantation follow-up and among aneurysms with diameters greater or less than 2.5 cm at diagnosis. Patients and methods: We searched for the terms "SAA" and "CLD" on CT or MRI reports from January 2009 to December 2016. Patients with single examination or less than 6 months follow-up were excluded. Results: Fifty nine out of 2050 CLD patients presented SAA (prevalence of 2.9%). Fifteen patients were excluded (due to exclusion criteria). Forty-four CLD patients (mean age 55.9 years) presented 76 SAA (follow-up median of 27.2 months). Aneurysms presented mean size of 1.5 +/- 0.74 cm at diagnosis and growth rate of 0.12 +/- 0.14 cm/y. Two (4.5%) patients presented mild complications (aneurysm thrombosis). No significant differences were observed in the growth rates of aneurysms < 2.5 cm and similar to 2.5 cm or in the initial size and growth rates of aneurysms of patients submitted to and not submitted to liver transplantation. Conclusions: The estimated prevalence of SAA in patients with DLC in the Brazilian population is 2.9% (CI95% 2.2-3.6%). Although SAA in CLD patients are less likely to remain stable and grow faster than in general population, aneurysms are usually diagnosed at smaller size and complications are rare. These findings might support conservative management with close surveillance, especially in smaller aneurysms.	[Rocha, Marcelo Assis; Marques, Eduardo Saltao Silva; Leao, Layra Ribeiro de Sousa; Magdalena, Thiago Raspa Freitas; Dorea, Aline Andrade; Yamauchi, Fernando Ide; Wolosker, Nelson; Tachibana, Adriano] Hosp Israelita Albert Einstein, Sao Paulo, Brazil		Rocha, MA (通讯作者)，Hosp Israelita Albert Einstein, Diagnost Imaging, Ave Albert Einstein,627, BR-05652900 Sao Paulo, Brazil.	massisrocha@gmail.com		Assis Rocha, Marcelo/0000-0002-0312-4821			Abbas MA, 2002, ANN VASC SURG, V16, P442, DOI 10.1007/s10016-001-0207-4; Aday U, 2017, CASE REP SURG, V2017, DOI 10.1155/2017/8716962; Asthana S, 2010, CLIN TRANSPLANT, V24, P691, DOI 10.1111/j.1399-0012.2009.01192.x; AYALON A, 1988, TRANSPLANTATION, V45, P386, DOI 10.1097/00007890-198802000-00028; Barrionuevo P, 2019, J VASC SURG, V70, P1694, DOI 10.1016/j.jvs.2019.02.024; BEDFORD PD, 1960, GUT, V1, P312, DOI 10.1136/gut.1.4.312; Bjorck M, 2017, EUR J VASC ENDOVASC, V53, P460, DOI 10.1016/j.ejvs.2017.01.010; Chaer RA, 2020, J VASC SURG, V72, p3S, DOI 10.1016/j.jvs.2020.01.039; de Carvalho JR, 2017, ANN HEPATOL, V16, P893, DOI 10.5604/01.3001.0010.5280; Erben Y, 2018, J VASC SURG, V68, P1079, DOI 10.1016/j.jvs.2017.12.057; Ha JF, 2009, EUR J OBSTET GYN R B, V146, P133, DOI 10.1016/j.ejogrb.2009.05.034; Kaya M, 2016, INDIAN J GASTROENTER, V35, P201, DOI 10.1007/s12664-016-0670-z; Kobori L, 1997, J HEPATOL, V27, P890, DOI 10.1016/S0168-8278(97)80327-3; KREEL L, 1974, AUSTRALAS RADIOL, V18, P432; Lee PC, 1999, J AM COLL SURGEONS, V189, P483, DOI 10.1016/S1072-7515(99)00168-4; Maggi U, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029544; Moon DB, 2009, LIVER TRANSPLANT, V15, P1535, DOI 10.1002/lt.21885; Paranagua-Vezozzo DC, 2014, ANN HEPATOL, V13, P386, DOI 10.1016/S1665-2681(19)30845-2; PUTTINI M, 1982, J CARDIOVASC SURG, V23, P490; Robertson AJ, 1999, TRANSPLANT INT, V12, P68, DOI 10.1111/j.1432-2277.1999.tb00578.x; Sunagozaka H, 2006, LIVER INT, V26, P291, DOI 10.1111/j.1478-3231.2005.01231.x; Venturini M, 2018, PHARMACOL RES, V135, P127, DOI 10.1016/j.phrs.2018.07.023; Zeng DB, 2013, WORLD J GASTROENTERO, V19, P1292, DOI 10.3748/wjg.v19.i8.1292	23	0	0	0	1	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0301-1526			VASA	Vasa	FEB	2021	50	2					139	144		10.1024/0301-1526/a000915			6	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	QQ5PH	33115387				2022-04-28	WOS:000624575300009
J	Langhoff, R; Behne, A; Boral, M; Hardung, D				Langhoff, Ralf; Behne, Andrea; Boral, Mehmet; Hardung, David			Ladies and Gentlemen	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			German	Editorial Material																		0	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	SEP	2021	50			106			4	4		10.1024/0301-1526/a000974			1	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6KD		Bronze			2022-04-28	WOS:000753520700001
J	Kontogeorgi, E; Sagris, M; Kokkinidis, DG; Hasemaki, N; Tsakotos, G; Tsapralis, D; Kakisis, JD; Schizas, D				Kontogeorgi, Evangelia; Sagris, Marios; Kokkinidis, Damianos G.; Hasemaki, Natasha; Tsakotos, Georgios; Tsapralis, Dimitrios; Kakisis, John D.; Schizas, Dimitrios			Abdominal aortic aneurysms and abdominal wall hernias - a systematic review and meta-analysis	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Review						Abdominal wall hernia; abdominal aortic aneurysm; screening	SIMPLE RENAL CYSTS; INGUINAL-HERNIA; ASSOCIATION; PREVALENCE; DISEASE; MEN; MORTALITY; RISK; GENE; MASS	Background: Abdominal wall hernias (AWHs) share common epidemiological characteristics with abdominal aortic aneurysms (AAAs), typically presenting in male population and older ages. Prior reports have associated those two disease entities. Our objective was to perform a systematic review and meta-analysis and examine whether AAA rates are higher among patients with AWH vs controls and whether the incidence of AWH was higher among patients with AAA vs patients without AAA. Methods: We performed a systematic review and meta-analysis according to the PRISMA guidelines. The Medline database was searched up to July 31, 2020. A random effects meta-analysis was performed. Results: In total, 17 articles and 738,972 participants were included in the systematic review, while 107,578 patients were eligible for the meta-analysis. Among four studies investigating the incidence of AAA in patients with hernias, AAA was more common in patients with hernias, compared to patients without hernias. [OR: 2.53, 95% CI: 1.24-5.16, I-2=81.6%]. Among thirteen studies that compared patients with known AAA vs no AAA, the incidence of hernias was higher in patients with AAA, compared with patients without AAA [OR: 2.27, 95% CI: 1.66-3.09, I-2=84.6%]. Conclusions: Our study findings indicate that a strong association between AWH and AAA exists. AWHs could therefore be used as an additional selection criterion for screening patients for AAA, apart from age, gender, family history and smoking.	[Kontogeorgi, Evangelia; Sagris, Marios; Kokkinidis, Damianos G.; Hasemaki, Natasha; Schizas, Dimitrios] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Surg 1, Athens, Greece; [Tsakotos, Georgios] Natl & Kapodistrian Univ Athens, Sch Med, Dept Anat & Surg Anat, Athens, Greece; [Tsapralis, Dimitrios] Gen Hosp Ierapetra, Dept Surg, Ierapetra, Greece; [Kakisis, John D.] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Dept Vasc Surg, Athens, Greece		Schizas, D (通讯作者)，Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Surg 1, Athens, Greece.	schizasad@gmail.com					Adye B, 1998, AM J SURG, V175, P400; Altobelli E, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15122805; Anderson O, 2008, ANN ROY COLL SURG, V90, P386, DOI 10.1308/003588408X285937; Antoniou GA, 2011, INT ANGIOL, V30, P123; Antoniou GA, 2013, VASCULAR, V21, P1, DOI 10.1258/vasc.2011.oa0322; Antoniou GA, 2011, J VASC SURG, V54, P1175, DOI 10.1016/j.jvs.2011.02.065; Antoszewska Magdalena, 2013, Pol Przegl Chir, V85, P271, DOI 10.2478/pjs-2013-0041; Ashton HA, 2002, LANCET, V360, P1531, DOI 10.1016/S0140-6736(02)11522-4; Aune D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32100-2; BAIRD PA, 1995, LANCET, V346, P601, DOI 10.1016/S0140-6736(95)91436-6; Bloemen A, 2019, HERNIA, V23, P1199, DOI 10.1007/s10029-019-02067-8; CANNON DJ, 1984, ARCH SURG-CHICAGO, V119, P387; COLLIN J, 1988, LANCET, V2, P613; Corrado G, 2016, INT J CARDIOVAS IMAG, V32, P1213, DOI 10.1007/s10554-016-0911-3; Donahue Timothy R, 2006, Hernia, V10, P478, DOI 10.1007/s10029-006-0146-7; Gertz SD, 2015, AM J CARDIOL, V115, P399, DOI 10.1016/j.amjcard.2014.11.012; Gindera LB, 2015, MINERVA CHIR, V70, P409; Golledge J, 2008, ANZ J SURG, V78, P1034, DOI 10.1111/j.1445-2197.2008.04728.x; HALL KA, 1995, AM J SURG, V170, P572, DOI 10.1016/S0002-9610(99)80018-X; Henriksen NA, 2013, BRIT J SURG, V100, P1478, DOI 10.1002/bjs.9257; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Holland AJA, 2009, ANZ J SURG, V79, P497, DOI 10.1111/j.1445-2197.2009.04961.x; Hung KC., 2020, J THORAC CARDIOV SUR; Jacomelli J, 2016, BRIT J SURG, V103, P1125, DOI 10.1002/bjs.10173; Karthikesalingam A, 2014, LANCET, V383, P963, DOI 10.1016/S0140-6736(14)60109-4; Legg JS, 2016, RADIOL TECHNOL, V88, P145; Lehnert B, 1992, Ann Vasc Surg, V6, P134, DOI 10.1007/BF02042733; Lindholt JS, 2010, BRIT J SURG, V97, P826, DOI 10.1002/bjs.7001; Lindholt JS, 1997, BRIT J SURG, V84, P40; Megalopoulos A, 2019, BIOMED PAP, V163, P247, DOI 10.5507/bp.2018.077; Muller Verena, 2019, Aorta (Stamford), V7, P108, DOI 10.1055/s-0039-1692456; Musella M, 2001, J AM COLL SURGEONS, V193, P392, DOI 10.1016/S1072-7515(01)01003-1; Norman PE, 2007, CONNECT TISSUE RES, V48, P125, DOI 10.1080/03008200701331524; Olsson C, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001040; Pafili K, 2015, J DIABETES COMPLICAT, V29, P1330, DOI 10.1016/j.jdiacomp.2015.08.011; Pannu R, 2012, ANGIOLOGY, V63, P146, DOI 10.1177/0003319711409922; Papadimitriou D, 2002, VASA-J VASCULAR DIS, V31, P111, DOI 10.1024/0301-1526.31.2.111; Pitoulias GA, 2012, WORLD J SURG, V36, P1953, DOI 10.1007/s00268-012-1628-7; Pleumeekers HJCM, 1999, BRIT J SURG, V86, P1155, DOI 10.1046/j.1365-2168.1999.01213.x; Pleumeekers HJCM, 1999, INT J EPIDEMIOL, V28, P682, DOI 10.1093/ije/28.4.682; Raffetto JD, 2003, J VASC SURG, V37, P1150, DOI 10.1016/S0741-5214(03)00147-2; Raffort J, 2018, CARDIOVASC RES, V114, P1702, DOI 10.1093/cvr/cvy174; Sakalihasan N, 2005, LANCET, V365, P1577, DOI 10.1016/S0140-6736(05)66459-8; Schmitz-Rixen T, 2016, LANGENBECK ARCH SURG, V401, P275, DOI 10.1007/s00423-016-1401-8; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.g7647, 10.1136/bmj.b2700]; Spencer C, 2003, ANZ J SURG, V73, P787, DOI 10.1046/j.1445-2197.2003.02796.x; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; Takagi H, 2015, INT ANGIOL, V34, P219; Thompson AR, 2008, EUR J VASC ENDOVASC, V35, P19, DOI 10.1016/j.ejvs.2007.07.022; Virgilio E, 2017, VASC MED, V22, P164, DOI 10.1177/1358863X16679747; Wanhainen A, 2016, CIRCULATION, V134, P1141, DOI 10.1161/CIRCULATIONAHA.116.022305	51	2	2	2	2	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JUL	2021	50	4					270	279		10.1024/0301-1526/a000947			10	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QY	33739140				2022-04-28	WOS:000695708700004
J	Blinc, A; Sabovic, M; Ksela, J; Puscenik, L; Perme, MP; Mijovski, MB				Blinc, Ales; Sabovic, Miso; Ksela, Jus; Puscenik, Lara; Perme, Maja Pohar; Mijovski, Mojca Bozic			Galectin-3 is not predictive of cardiovascular events in patients with peripheral artery disease	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Letter									[Blinc, Ales; Sabovic, Miso; Mijovski, Mojca Bozic] Univ Med Ctr Ljubljana, Dept Vasc Dis, Zaloska 7, Ljubljana 1525, Slovenia; [Blinc, Ales; Sabovic, Miso] Univ Ljubljana, Div Internal Med, Fac Med, Ljubljana, Slovenia; [Ksela, Jus] Univ Med Ctr Ljubljana, Dept Cardiovasc Surg, Ljubljana, Slovenia; [Ksela, Jus] Univ Med Ctr Ljubljana, Div Surg, Fac Med, Ljubljana, Slovenia; [Puscenik, Lara; Mijovski, Mojca Bozic] Univ Ljubljana, Fac Pharm, Ljubljana, Slovenia; [Perme, Maja Pohar] Univ Ljubljana, Fac Med, Inst Biostat & Med Informat, Ljubljana, Slovenia		Blinc, A (通讯作者)，Univ Med Ctr Ljubljana, Dept Vasc Dis, Zaloska 7, Ljubljana 1525, Slovenia.	ales.blinc@kclj.si		Blinc, Ales/0000-0002-7538-1595			Blinc A, 2017, INT ANGIOL, V36, P216, DOI 10.23736/S0392-9590.16.03731-7; Dong R, 2018, INT J MOL MED, V41, P599, DOI 10.3892/ijmm.2017.3311; Fort-Gallifa I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050973; Mortensen MB, 2019, J AM COLL CARDIOL, V74, P1, DOI 10.1016/j.jacc.2019.04.049; Varasteh Z, 2021, THERANOSTICS, V11, P1864, DOI 10.7150/thno.50247	5	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	MAY	2021	50	3					244	245		10.1024/0301-1526/a000940			2	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QU	33559502				2022-04-28	WOS:000695708300013
J	Toh, MR; Damodharan, K; Lim, HHMN; Tang, TY				Toh, Ming Ren; Damodharan, Karthikeyan; Lim, Han Hui Mervin Nathan; Tang, Tjun Yip			Computed tomography venography versus intravascular ultrasound in the diagnosis of iliofemoral vein stenosis	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						IIliac vein stenosis; computed tomography; intravascular ultrasonography	COMPRESSION; OBSTRUCTION; THROMBOSIS	Background: Iliofemoral vein stenosis can cause debilitating chronic venous disease. Diagnostic tools include both computed tomography venography (CTV) and intravascular ultrasonography (IVUS). We aim to compare the diagnostic performance of CTV and IVUS. Patients and methods: We performed a retrospective study of patients with chronic venous disease presenting with iliac vein compression or post-thrombotic limb symptoms, excluding those with acute deep vein thrombosis, high anaesthesia risk, or who had contrast allergy. All patients received CTV before IVUS, as part of the diagnostic work-up and intervention. The cross-sectional area (CSA) of iliofemoral vein segments obtained from both studies were compared against reference CSAs to derive percentage stenosis. A 50% reduction in CSA was considered significant. Results: We studied 50 patients between May 2018 and April 2019. 58% of patients had severe disease CEAP C5-6. 48% of patients had at least one vein segment with significant stenosis. The left proximal common iliac vein was the most commonly stenosed vein segment (n = 12, 24% on IVUS). CSA measurements from CTV were greater than those of IVUS, with a correlation coefficient of 0.57 (p < 0.005). Conversely, percentage stenosis measured on CTV was lower than on IVUS, with approximately one-third of significant stenosis missed on CTV (58 veins from CTV vs. 78 from IVUS, p < 0.005). With IVUS as the gold standard, CTV has low sensitivity (37.2%, 95% CI 26.5-48.9) and high specificity (92.5%, 95% CI 89.3-94.9) in detecting significant stenosis. Conclusions: CTV has limited diagnostic performance in identifying iliofemoral vein stenosis. Patients with normal CTV findings should proceed with IVUS imaging if the clinical features are supportive of iliofemoral vein stenosis.	[Toh, Ming Ren; Tang, Tjun Yip] Duke NUS Med Sch, Singapore, Singapore; [Damodharan, Karthikeyan] Sengkang Gen Hosp, Dept Radiol, Singapore, Singapore; [Lim, Han Hui Mervin Nathan] Yong Yoo Ling Sch Med, Singapore, Singapore; [Tang, Tjun Yip] Singapore Gen Hosp, Dept Vasc Surg, Level 5,Acad 20 Coll Rd, Singapore 169856, Singapore		Tang, TY (通讯作者)，Singapore Gen Hosp, Dept Vasc Surg, Level 5,Acad 20 Coll Rd, Singapore 169856, Singapore.	tang.tjun.yip@singhealth.com.sg			Department of Radiology, Singapore General Hospital; Seng Kang Hospital	We would like to thank the Department of Radiology, Singapore General Hospital, and Seng Kang Hospital for their support and the patients for their participation in the study. We thank Dr. John Carson Allen for his advice on the statistical analysis of this study.	Brazeau NF, 2013, VASA, V42, P96, DOI 10.1024/0301-1526/a000252; Butros SR, 2013, BRIT J RADIOL, V86, DOI 10.1259/bjr.20130284; Chamarthy MR, 2017, J CLIN INTERV RADIOL, V1, P23; Chung JW, 2004, J VASC INTERV RADIOL, V15, P249, DOI 10.1097/01.RIV.0000109402.52762.8D; COCKETT FB, 1967, BRIT MED J, V2, P14, DOI 10.1136/bmj.2.5543.14; Ezhumalai B, 2018, IHJ CARDIOVASCULAR C, V2, P73, DOI DOI 10.1016/J.IHJCCR.2018.01.010; Fronek A, 2001, J VASC SURG, V33, P1050, DOI 10.1067/mva.2001.113496; Gagne PJ, 2017, J VASC SURG-VENOUS L, V5, P678, DOI 10.1016/j.jvsv.2017.04.007; Kibbe MR, 2004, J VASC SURG, V39, P937, DOI 10.1016/j.jvs.2003.12.032; Marston W, 2011, J VASC SURG, V53, P1303, DOI 10.1016/j.jvs.2010.10.120; Marteslo JP, 2020, ULTRASOUND MED BIOL, V46, P216, DOI 10.1016/j.ultrasmedbio.2019.10.010; McLafferty Robert B, 2012, Semin Intervent Radiol, V29, P10, DOI 10.1055/s-0032-1302446; Neglen P, 2003, J VASC SURG, V38, P879, DOI 10.1016/S0741-5214(03)01020-6; Neglen P, 2002, J VASC SURG, V35, P694, DOI 10.1067/mva.2002.121127; Oguzkurt L, 2005, EUR J RADIOL, V55, P421, DOI 10.1016/j.ejrad.2004.11.002; Oguzkurt L, 2007, DIAGN INTERV RADIOL, V13, P152; Raju S, J VASC SURG VENOUS L; Rossi FH, 2020, J VASC SURG-VENOUS L, V8, P413, DOI 10.1016/j.jvsv.2019.09.015; Rossi FH, 2018, J VASC SURG-VENOUS L, V6, P183, DOI 10.1016/j.jvsv.2017.11.003; Rossi Fabio Henrique, 2014, J. vasc. bras., V13, P306, DOI 10.1590/1677-5449.0067; Sermsathanasawadi N, 2019, J VASC SURG-VENOUS L, V7, P441, DOI 10.1016/j.jvsv.2018.10.021; Tang TY, 2019, J THROMB THROMBOLYS, V47, P328, DOI 10.1007/s11239-019-01817-w	22	2	2	0	1	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JAN	2021	50	1			SI		38	44		10.1024/0301-1526/a000920			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	PQ4VY	33153399				2022-04-28	WOS:000606545800006
J	[Anonymous]				[Anonymous]			Angiology Abstracts	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Meeting Abstract																		0	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	NOV	2021	50			107			8	34					27	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6KL					2022-04-28	WOS:000753521600002
J	Kolouschek, A; Weiss, N				Kolouschek, Anne; Weiss, Norbert			4PEPS-a new pretest probability score to reduce imaging testing for suspected pulmonary embolism?	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Editorial Material							MANAGEMENT		[Kolouschek, Anne; Weiss, Norbert] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Univ Ctr Vasc Med, Dresden, Germany; [Kolouschek, Anne; Weiss, Norbert] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Med 3, Sect Angiol, Dresden, Germany		Kolouschek, A (通讯作者)，Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Univ Ctr Vasc Med, Dresden, Germany.; Kolouschek, A (通讯作者)，Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Med 3, Sect Angiol, Dresden, Germany.	anne.kolouschek@ukdd.de					Kline JA, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.119.005753; Righini M, 2014, JAMA-J AM MED ASSOC, V311, P1117, DOI 10.1001/jama.2014.2135; Roy PM, 2021, JAMA CARDIOL; van der Hulle T, 2017, LANCET, V390, P289, DOI 10.1016/S0140-6736(17)30885-1; Wells PS, 1998, ANN INTERN MED, V129, P997, DOI 10.7326/0003-4819-129-12-199812150-00002	5	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	SEP	2021	50	5					398	399		10.1024/0301-1526/a000962			2	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6GV	34482762				2022-04-28	WOS:000753511900012
J	Sigala, F; Galyfos, G; Koniaris, E; Barkolias, C; Artsitas, S; Zografos, K; Filis, K; Zografos, G; Alexakis, N				Sigala, Fragiska; Galyfos, George; Koniaris, Efthimios; Barkolias, Christos; Artsitas, Sotirios; Zografos, Konstantinos; Filis, Konstantinos; Zografos, Georgios; Alexakis, Nikolaos			Epithelioid hemangioendothelioma of the retroperitoneum - a rare vascular tumor	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Epithelioid hemangioendothelioma; retroperitoneal; vascular tumor		Epithelioid hemangioendothelioma (EHE) is a rare vascular tumor, affecting the liver, the lungs and the bones most frequently. It has a heterogenous clinical presentation and there is no consensus on optimal treatment. This report aims to present a rare case of a retroperitoneal EHE and to discuss on proper management.	[Sigala, Fragiska; Galyfos, George; Koniaris, Efthimios; Barkolias, Christos; Artsitas, Sotirios; Zografos, Konstantinos; Filis, Konstantinos; Zografos, Georgios; Alexakis, Nikolaos] Natl Kapodistrian Univ Athens, Hippocrat Hosp, Dept Propedeut Surg 1, Athens, Greece		Galyfos, G (通讯作者)，114 Vasilissis Sofias Ave, Athens 11527, Greece.	georgegalyfos@hotmail.com	Filis, Konstantinos/AAA-7139-2022	Galyfos, George/0000-0002-6077-007X			Amin RMS, 2006, RESPIROLOGY, V11, P818, DOI 10.1111/j.1440-1843.2006.00923.x; Antonescu C, 2014, MODERN PATHOL, V27, pS30, DOI 10.1038/modpathol.2013.176; Balraj P, 2017, ANN VASC SURG, V40, DOI 10.1016/j.avsg.2016.07.068; Deyrup AT, 2008, AM J SURG PATHOL, V32A, P924, DOI 10.1097/PAS.0b013e31815bf8e6; Doyle LA, 2016, AM J SURG PATHOL, V40, P94, DOI 10.1097/PAS.0000000000000511; Errani C, 2011, GENE CHROMOSOME CANC, V50, P644, DOI 10.1002/gcc.20886; Flucke U, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-131; Gan L, 2016, ONCOL LETT, V11, P1699, DOI 10.3892/ol.2016.4149; Gaur Sumit, 2012, Cancer Biology Medicine, V9, P133, DOI 10.3969/j.issn.2095-3941.2012.02.010; Guo QY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007345; Iimuro Y, 2012, SURG TODAY, V42, P1026, DOI 10.1007/s00595-012-0173-1; Kim YH, 2010, J THORAC ONCOL, V5, P1107, DOI 10.1097/JTO.0b013e3181e2bc5d; Kitaichi M, 1998, EUR RESPIR J, V12, P89, DOI 10.1183/09031936.98.12010089; Ko Jennifer S, 2015, Surg Pathol Clin, V8, P331, DOI 10.1016/j.path.2015.05.001; Mizota A, 2011, J THORAC ONCOL, V6, P651, DOI 10.1097/JTO.0b013e31820b9e23; Ravi V, 2013, CURR ONCOL REP, V15, P347, DOI 10.1007/s11912-013-0328-2; Requena L, 2013, SEMIN DIAGN PATHOL, V30, P29, DOI 10.1053/j.semdp.2012.01.003; Rosenberg A, 2018, CURR TREAT OPTION ON, V19, DOI 10.1007/s11864-018-0536-y; Salech F, 2011, ANN HEPATOL, V10, P99; Sardaro A, 2014, ONCOL REV, V8, P82, DOI 10.4081/oncol.2014.259; Stacchiotti S, 2016, ANN SURG ONCOL, V23, P2735, DOI 10.1245/s10434-016-5331-z; Studer LL, 2018, ARCH PATHOL LAB MED, V142, P263, DOI 10.5858/arpa.2016-0171-RS; WEISS SW, 1982, CANCER, V50, P970, DOI 10.1002/1097-0142(19820901)50:5<970::AID-CNCR2820500527>3.0.CO;2-Z; Wu X, 2019, EUR J MED RES, V24, DOI 10.1186/s40001-019-0375-8	24	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JUL	2021	50	4					312	316		10.1024/0301-1526/a000898			5	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QY	32697157				2022-04-28	WOS:000695708700010
J	Amendt, K; Zeller, T; Proczka, R; Beschorner, U; Troisi, N; Waliszewski, M; Langhoff, R; Krankenberg, H; Hansch, A; Krcmar, T; Vidjak, V; Nolte-Ernsting, C; Hansen, A; Sigl, M				Amendt, Klaus; Zeller, Thomas; Proczka, Robert; Beschorner, Ulrich; Troisi, Nicola; Waliszewski, Matthias; Langhoff, Ralf; Krankenberg, Hans; Hansch, Andreas; Krcmar, Tomislav; Vidjak, Vinko; Nolte-Ernsting, Claus; Hansen, Alexander; Sigl, Martin			Provisional focal stenting of complex femoropopliteal lesions using the Multi-LOC multiple stent delivery system-12-month results from the LOCOMOTIVE EXTENDED study	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Femoropopliteal lesions; multiple stent delivery system; spot stenting; target lesion revascularisation; patency	FEMORAL-ARTERY; PATENCY RATES; RESTENOSIS; SPOT; REVASCULARIZATION; DEFORMATION; THERAPY; SYSTEM	Background: This study aimed to evaluate a Multiple Stent Delivery System for provisional focal stenting of the femoropopliteal artery. Patient and methods: The LOCOMOTIVE EXTENDED study (Multi-LOC for flOw liMiting Outcomes after plain old balloon angioplasty and/or drug-coated balloon Treatment in the infrainguinal position with the objectIVE to implant multiple stent segments) is a prospective, single-arm, multicentre observational study. The Multi-LOC Multiple Stent Delivery System (B.Braun, Melsungen, Germany) was used for provisional focal stenting of the femoropopliteal artery. We enrolled 357 patients with 449 femoropopliteal lesions; all had flow-limiting dissections or recoil following angioplasty. Eligibility included Rutherford classification 2 to 5 with a de novo or non-stented restenotic femoropopliteal lesion undergoing plain balloon or drug-coated balloon angioplasty. The 6- and 12-month efficacy endpoints encompassed target lesion revascularisation and primary patency rates. Results: The mean patient age was 71 +/- 10 years. The mean lesion length was 16.0 +/- 9.7 cm; 44.5% were TASC II C/D lesions and 31.4% were chronic total occlusions. By operator choice, 45% of the patients underwent drug-coated balloon angioplasty. On average, 4.0 stents (each 13 mm long) were placed in each lesion, resulting in a scaffolding proportion of 56% of the total lesion length with a technical success rate of 98.3%. At 6 and 12 months, the freedom from clinically driven target lesion revascularisation was 95.5% and 88.7% and the primary patency rates were 88.7% and 82.3%, respectively. At 12 months, significant improvements were noted in Rutherford categories and ankle-brachial indices. In multiple regression analyses, both diabetes mellitus and no distal run-off vessel showed a trend toward worse TLR, while other factors such as DCB predilation or the lesion length were not predictive. Conclusions: The LOCOMOTIVE EXTENDED study demonstrated the safety and efficacy of the Multi-LOC stent system for focal provisional stenting of complex femoropopliteal lesions.	[Amendt, Klaus] Diakonissenkrankenhaus Mannheim, Gefasszentrum Oberrhein, Dept Angiol Cardiol & Diabet Associated Dis, Mannheim, Germany; [Zeller, Thomas; Beschorner, Ulrich] Bad Krozingen GmbH, Univ Herzzentrum Freiburg, Bad Krozingen, Germany; [Proczka, Robert] Amer Heart Poland, Ctr Kardiol Jozefow, Jozefow, Poland; [Troisi, Nicola] Nuovo Osped San Giovanni di Dio, Florence, Italy; [Waliszewski, Matthias] B Braun Melsungen AG, Med Sci Affairs, Berlin, Germany; [Waliszewski, Matthias] Charite Univ Med Berlin, Dept Internal Med & Cardiol, Campus Virchow, Berlin, Germany; [Langhoff, Ralf] Sankt Gertrauden Krankenhaus, Dept Angiol, Berlin, Germany; [Krankenberg, Hans] Asklepios Klinikum Hamburg Harburg, Hamburg, Germany; [Hansch, Andreas] Heinrich Braun Klinikum, Zwickau, Germany; [Krcmar, Tomislav] Univ Hosp Ctr Sisters Mercy, Zagreb, Croatia; [Vidjak, Vinko] Univ Hosp Merkur, Zagreb, Croatia; [Nolte-Ernsting, Claus] Evangelisches Krankenhaus Mulheim, Mulheim, Germany; [Hansen, Alexander] Klin Kosching, Kosching, Germany; [Sigl, Martin] Heidelberg Univ, Univ Med Ctr Mannheim UMM, Fac Med, Dept Med 1, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany		Sigl, M (通讯作者)，Heidelberg Univ, Univ Med Ctr Mannheim UMM, Fac Med, Dept Med 1, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	martin.sigl@umm.de		TROISI, Nicola/0000-0002-8779-9120	B. Braun	This study was funded by B. Braun on a milestone basis per included patient and available follow-ups at 6 and 12 months.	Amendt K, 2017, VASA, V46, P452, DOI 10.1024/0301-1526/a000658; Brodmann M, 2020, J VASC SURG, V72, P1636, DOI 10.1016/j.jvs.2020.01.078; de Boer SW, 2019, J CARDIOVASC SURG, V60, P679, DOI 10.23736/S0021-9509.19.11109-3; Deloose K, 2018, J CARDIOVASC SURG, V59, P495, DOI 10.23736/S0021-9509.18.10583-0; Ghriallais RN, 2016, J ENDOVASC THER, V23, P907, DOI 10.1177/1526602816669135; Hong SJ, 2015, JACC-CARDIOVASC INTE, V8, P472, DOI 10.1016/j.jcin.2014.10.016; Iida O, 2015, JACC-CARDIOVASC INTE, V8, P1105, DOI 10.1016/j.jcin.2015.03.022; Iida O, 2014, JACC-CARDIOVASC INTE, V7, P792, DOI 10.1016/j.jcin.2014.01.168; Ko YG, 2019, ANN VASC SURG, V58, P101, DOI 10.1016/j.avsg.2018.11.023; Laxdal E, 2004, EUR J VASC ENDOVASC, V28, P410, DOI 10.1016/j.ejvs.2004.06.010; Lin TC, 2018, J ENDOVASC THER, V25, P313, DOI 10.1177/1526602818771345; Maleckis K, 2018, ANN BIOMED ENG, V46, P684, DOI 10.1007/s10439-018-1990-1; Malyar NM, 2015, VASA, V44, P257, DOI 10.1024/0301-1526/a000440; Nikanorov A, 2013, EUROINTERVENTION, V9, P730, DOI 10.4244/EIJV9I6A117; Olin JW, 2016, J AM COLL CARDIOL, V67, P1338, DOI 10.1016/j.jacc.2015.12.049; Paraskevas KI, 2008, ANN VASC SURG, V22, P481, DOI 10.1016/j.avsg.2007.12.012; Poulson W, 2018, J VASC SURG, V67, P607, DOI 10.1016/j.jvs.2017.01.071; Shammas NW, 2015, J INVASIVE CARDIOL, V27, pE258; Sigl M, 2020, IN VIVO, V34, P433, DOI 10.21873/invivo.11792; Sigl M, 2019, CARDIOVASC INTER RAD, V42, P169, DOI 10.1007/s00270-018-2095-9; Sigl M, 2017, VASA, V46, P446, DOI 10.1024/0301-1526/a000657; Tomoi Y, 2019, J VASC SURG, V70, P1166, DOI 10.1016/j.jvs.2018.12.044	22	1	1	1	2	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	MAY	2021	50	3					209	216		10.1024/0301-1526/a000927			8	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QU	33238823	hybrid			2022-04-28	WOS:000695708300008
J	Woronowicz-Kmiec, S; Betz, T; Topel, I; Brockner, S; Steinbauer, M; Uhl, C				Woronowicz-Kmiec, Sandra; Betz, Thomas; Topel, Ingolf; Brockner, Stefan; Steinbauer, Markus; Uhl, Christian			Short and long-term outcome after common femoral artery hybrid procedure in patients with intermittent claudication and chronic limb threatening ischemia	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Common femoral artery; endarterectomy; endovascular procedures; claudication; critical limb ischemia	LOWER-EXTREMITY; OCCLUSIVE DISEASE; REVASCULARIZATION; ENDARTERECTOMY; ANGIOPLASTY; MANAGEMENT	Background: This study aimed to evaluate the differences between the outcomes of patients with intermittent claudication (IC) and chronic limb threatening ischemia (CLTI) who underwent a hybrid procedure comprising common femoral artery endarterectomy and endovascular therapy. Patients and methods: This was a retrospective single-center study of all patients with peripheral arterial occlusive disease (PAD) who underwent the hybrid procedure between March 2007 and August 2018. The primary endpoint was primary patency after 7 years. The secondary endpoints were primary-assisted patency, secondary patency, limb salvage, and survival. Results: During the follow-up period, 427 limbs in 409 patients were treated. A total of 267 and 160 patients presented with clinical signs of IC and CLTI, respectively. The 30-day mortality was 1.4% (IC: 0% vs. CLTI: 3.8%, p=0.001). The overall 30-day major amputation rate was 1.6% (IC: 0% vs. CLTI: 4.4, p=0.001). The rates of primary and secondary patency after 7 years were 63% and 94%, respectively, in the IC group and 57% and 88%, respectively, in the CLTI group; the difference was not significant. Limb salvage (94% vs. 82%, p=0.000) and survival (58% vs. 29%, p=0.000) were significantly higher in the IC group. In a multivariate analysis, CLTI was the only risk factor for major amputation. CLTI and single vessel run-off were risk factors for death. Statin therapy was a protective factor. Conclusions: The hybrid procedure provides excellent results as a treatment option for multilevel lesions in patients with PAD. However, patients with CLTI had a shorter tong-term survival and tower limb salvage rate.	[Woronowicz-Kmiec, Sandra; Betz, Thomas; Topel, Ingolf; Brockner, Stefan; Steinbauer, Markus; Uhl, Christian] Barmherzige Bruder Hosp Regensburg, Dept Vasc Surg, Prufeninger Str 86, D-93049 Regensburg, Germany		Woronowicz-Kmiec, S (通讯作者)，Barmherzige Bruder Hosp Regensburg, Dept Vasc Surg, Prufeninger Str 86, D-93049 Regensburg, Germany.	woronowiczsandra@gmail.com					Abu Dabrh AM, 2015, J VASC SURG, V62, P1642, DOI 10.1016/j.jvs.2015.07.065; Agha R, 2019, INT J SURG, V72, P156, DOI 10.1016/j.ijsu.2019.11.002; Antoniou GA, 2009, EUR J VASC ENDOVASC, V38, P616, DOI 10.1016/j.ejvs.2009.06.016; Bath J, 2016, VASCULAR, V24, P404, DOI 10.1177/1708538115604929; Bisdas T, 2015, J VASC SURG, V62, P965, DOI 10.1016/j.jvs.2015.04.441; Conte MS, 2019, EUR J VASC ENDOVASC, V58, pS1, DOI 10.1016/j.ejvs.2019.05.006; Diehm C, 2004, ATHEROSCLEROSIS, V172, P95, DOI 10.1016/S0021-9150(03)00204-1; Elbadawy A, 2020, EUR J VASC ENDOVASC, V59, P947, DOI 10.1016/j.ejvs.2020.02.028; Elsherif M, 2018, VASCULAR, V26, P581, DOI 10.1177/1708538118772682; Hata Y, 2020, J ENDOVASC THER, V27, P641, DOI 10.1177/1526602820933880; Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526; Kang JL, 2008, J VASC SURG, V48, P872, DOI 10.1016/j.jvs.2008.05.025; Kasapis C, 2009, CURR CARDIOL REV, V5, P296, DOI 10.2174/157340309789317823; Kuma S, 2016, CIRC J, V80, P964, DOI 10.1253/circj.CJ-15-1177; Lawall H, 2016, VASA, V45, DOI [10.1024/0301-1526/a000579, DOI 10.1024/0301-1526/A000579]; Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4; Muir KB, 2017, ANN VASC SURG, V38, P64, DOI 10.1016/j.avsg.2016.09.008; Mustapha JA, 2017, J CARDIOVASC SURG, V58, P383, DOI 10.23736/S0021-9509.17.09878-0; Nelson PR, 2002, J VASC SURG, V35, P1107, DOI 10.1067/mva.2002.124374; Nishibe T, 2015, ANN VASC SURG, V29, P1501, DOI 10.1016/j.avsg.2015.05.005; Patel MR, 2015, J AM COLL CARDIOL, V65, P931, DOI 10.1016/j.jacc.2014.12.036; Peters AS, 2021, VASA, V50, P217, DOI 10.1024/0301-1526/a000934; Rutherford RB, 1997, J VASC SURG, V26, P517, DOI 10.1016/S0741-5214(97)70045-4; Schillinger M, 2007, CIRCULATION, V115, P2745, DOI 10.1161/CIRCULATIONAHA.107.688341; Siracuse JJ, 2021, J VASC SURG, V74, P499, DOI 10.1016/j.jvs.2020.10.090; Stricker H, 2020, CARDIOVASC INTER RAD, V43, P541, DOI 10.1007/s00270-020-02413-9; Takayama T, 2018, VASC ENDOVASC SURG, V52, P255, DOI 10.1177/1538574418761723; Uhl C, 2021, SCAND J SURG, V110, P400, DOI 10.1177/1457496920907733; Uhl C, 2017, J ENDOVASC THER, V24, P471, DOI 10.1177/1526602817711424; Wieker CM, 2016, J VASC SURG, V64, P995, DOI 10.1016/j.jvs.2016.04.036	30	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	SEP	2021	50	5					363	371		10.1024/0301-1526/a000954			9	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6GV	33973817	Green Submitted			2022-04-28	WOS:000753511900007
J	Peters, AS; Meisenbacher, K; Weber, D; Bisdas, T; Torsello, G; Bockler, D; Bischoff, MS				Peters, Andreas S.; Meisenbacher, Katrin; Weber, Dorothea; Bisdas, Theodosios; Torsello, Giovanni; Boeckler, Dittmar; Bischoff, Moritz S.		CRITISCH Collaborators	Isolated femoral artery revascularisation with or without iliac inflow improvement - a less invasive surgical option in critical limb ischemia	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Critical limb ischemia; femoral artery revascularisation; peripheral artery disease; amputation; reintervention	1ST-LINE TREATMENT STRATEGIES; ISOLATED ENDARTERECTOMY; ENDOVASCULAR TREATMENT; DISEASE; SURGERY; TRIAL; LINE	Background: Isolated femoral artery revascularisation (iFAR) represents a well-established surgical method in the treatment of peripheral arterial disease (PAD) involving common femoral artery disease. Data for iFAR in multilevel PAD are inconsistent, particularly in patients with critical limb ischemia (CLI). The aim of the study was to evaluate the outcome of iFAR in CLI regarding major amputation and reintervention and to identify associated risk factors for this outcome. Patients and methods: The data used have been derived from the German Registry of Firstline Treatment in Critical Limb Ischemia (CRITISCH). A total of 1200 patients were enrolled in 27 vascular centres. This sub-analysis included patients, which were treated with iFAR with/without concomitant iliac intervention. For detection of risk factors for the combined endpoint of major amputation and/or reintervention, selection of variables for multiple regression was conducted using stepwise forward/backward selection by Akaike's information criterion. Results: 95 patients were included (mean age: 72 years +/- 10.82; 64.2% male). Of those, 32 (33.7%) participants reached the combined endpoint. Risk factor analysis revealed continued tobacco use (odds ratio [OR] 2.316, confidence interval [CI] 0.832-6.674), TASC D-lesion (OR: 2.293, CI: 0.869-6.261) and previous vascular intervention in the trial leg (OR: 2.720, CI: 1.037-7.381) to be associated with reaching the combined endpoint. Conclusions: iFAR provides a reasonable, surgical option to treat CLI. Lesion length (TASC D) seems to have a negative impact on outcome. Further research is required to better define the future role of iFAR for combined femoro-popliteal lesions in CLI - best in terms of a randomised controlled trial.	[Peters, Andreas S.; Meisenbacher, Katrin; Boeckler, Dittmar; Bischoff, Moritz S.] Univ Hosp Heidelberg, Dept Vasc & Endovasc Surg Heidelberg, Heidelberg, Germany; [Weber, Dorothea] Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany; [Bisdas, Theodosios; Torsello, Giovanni] St Franziskus Hosp Munster GmbH, Dept Vasc Surg, Munster, Germany		Peters, AS (通讯作者)，Heidelberg Univ, Dept Vasc & Endovasc Surg, Neuenheimer Feld 420, D-69120 Heidelberg, Germany.	andreas1.peters@med.uni-heidelberg.de		Peters, Andreas/0000-0002-1347-7575	German Society of Vascular Surgery and Medicine	The CRITISCH registry is sponsored by the German Society of Vascular Surgery and Medicine (Deutsche Gesellschaft fur Gefa beta chirurgie und Gefa beta medizin).	Abu Dabrh AM, 2015, J VASC SURG, V62, P1642, DOI 10.1016/j.jvs.2015.07.065; Al-Khoury G, 2009, J VASC SURG, V50, P784, DOI 10.1016/j.jvs.2009.05.053; Almasri J, 2019, EUR J VASC ENDOVASC, V58, pS110, DOI 10.1016/j.ejvs.2019.04.013; Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047; Ballotta E, 2010, SURGERY, V147, P268, DOI 10.1016/j.surg.2009.08.004; Ballotta E, 2009, SURGERY, V145, P426, DOI 10.1016/j.surg.2008.12.005; Baumann F, 2011, J VASC SURG, V53, P1000, DOI 10.1016/j.jvs.2010.10.076; Bischoff MS, 2018, LANGENBECK ARCH SURG, V403, P741, DOI 10.1007/s00423-018-1689-7; Bisdas T, 2015, J VASC SURG, V62, P965, DOI 10.1016/j.jvs.2015.04.441; Bonvini RF, 2011, J AM COLL CARDIOL, V58, P792, DOI 10.1016/j.jacc.2011.01.070; Conte MS, 2019, EUR J VASC ENDOVASC, V58, pS1, DOI 10.1016/j.ejvs.2019.05.006; Desai M, 2011, ANGIOLOGY, V62, P119, DOI 10.1177/0003319710381994; Dihlmann S, 2019, PATHOLOGE, V40, P559, DOI 10.1007/s00292-019-00656-z; Farber A, 2019, J VASC SURG, V69, P470, DOI 10.1016/j.jvs.2018.05.255; Goueffic Y, 2017, JACC-CARDIOVASC INTE, V10, P1344, DOI 10.1016/j.jcin.2017.03.046; HEYDEN B, 1979, ZBL CHIR, V104, P519; Kang JL, 2008, J VASC SURG, V48, P872, DOI 10.1016/j.jvs.2008.05.025; Kechagias A, 2008, WORLD J SURG, V32, P51, DOI 10.1007/s00268-007-9309-7; Menard MT, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003219; Nelson PR, 2002, J VASC SURG, V35, P1107, DOI 10.1067/mva.2002.124374; Norgren L, 2007, J VASC SURG, V45, pS5, DOI 10.1016/j.jvs.2006.12.037; Popplewell MA, 2016, TRIALS, V17, DOI 10.1186/s13063-015-1114-2; Stavroulakis K, 2018, J ENDOVASC THER, V25, P320, DOI 10.1177/1526602818771383; Stella J, 2020, VASA, V49, P121, DOI 10.1024/0301-1526/a000831; Uhl C, 2020, ANN VASC SURG, V62, P382, DOI 10.1016/j.avsg.2019.06.011; VOLLMAR JF, 1982, ZBL CHIR, V107, P440; Wieker CM, 2016, J VASC SURG, V64, P995, DOI 10.1016/j.jvs.2016.04.036; Young JC, 2019, J VASC SURG, V70, P1973, DOI 10.1016/j.jvs.2019.02.066	28	1	1	2	3	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	MAY	2021	50	3					217	223		10.1024/0301-1526/a000934			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QU	33435742				2022-04-28	WOS:000695708300009
J	Fitton, CA; Cox, B; Chalmers, JD; Belch, JJF				Fitton, Catherine A.; Cox, Bianca; Chalmers, James D.; Belch, Jill J. F.			An 18 year data-linkage study on the association between air pollution and acute limb ischaemia	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						acute limb ischaemia; pollution; hospital admissions; death	PARTICULATE MATTER; BLOOD MARKERS; RESIDENTIAL EXPOSURE; AMBIENT-TEMPERATURE; INFLAMMATION; THROMBOSIS; DISEASE; MODELS; RISK	Background: There is limited information regarding the effects of air pollutants, such as nitrogen oxides (NOx) nitric oxide (NO2), nitrous oxide (NO) and particulate matter with a diameter smaller than 10 mu m (PM10), on acute limb ischaemia (ALI), a peripheral arterial disease (PAD) often with a poor clinical outcome. Patients and methods: We conducted an 18-year retrospective cohort study using routinely collected healthcare records from Ninevvells Hospital, Dundee, and Perth Royal Infirmary, in Tayside, Scotland, UK from 2000 to 2017. ALI hospitalisation events and deaths were linked to daily NOx, NO2, NO and PM10 levels extracted from publicly available data over this same time period. Distributed tag models were used to estimate risk ratios for ALI hospitalisation and for ALI mortality, adjusting for temperature, humidity, day of the week, month and public holiday. Results: 5,608 hospital admissions in 2,697 patients were identified over the study period (mean age 71.2 years, +/- 11.1). NOx and NO were associated with an increase of ALI hospital admissions on days of exposure to pollutant (p=.018), white PM10 was associated with a cumulative (tag 0-9 days) increase (p=.027) of ALI hospital admissions in our study. There was no increase of ALI mortality associated with pollution levels. Conclusions: ALI hospital admissions were positively associated with ambient NOx and NO on day of high measured pollution levels and a cumulative effect was seen with PM10.	[Fitton, Catherine A.; Chalmers, James D.; Belch, Jill J. F.] Univ Dundee NHS Tayside, Ninewells Hosp, Dundee DD1 9SY, Scotland; [Fitton, Catherine A.; Chalmers, James D.; Belch, Jill J. F.] Univ Dundee NHS Tayside, Ninewells Hosp, Sch Med, Dundee DD1 9SY, Scotland; [Cox, Bianca] Hasselt Univ, Ctr Environm Sci, Diepenbeek, Belgium		Belch, JJF (通讯作者)，Univ Dundee NHS Tayside, Ninewells Hosp, Dundee DD1 9SY, Scotland.; Belch, JJF (通讯作者)，Univ Dundee NHS Tayside, Ninewells Hosp, Sch Med, Dundee DD1 9SY, Scotland.	j.j.f.belch@dundee.ac.uk		Belch, Jill JF/0000-0001-8280-6689	Miller Bequest; Institute for Cardiovascular Research charity	This study was funded by the Miller Bequest and the Institute for Cardiovascular Research charity. We should also like to acknowledge the safe haven, The Health Informatics Centre, University of Dundee, who provided the linkage data.	Armstrong B, 2006, EPIDEMIOLOGY, V17, P624, DOI 10.1097/01.ede.0000239732.50999.8f; Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1; Carvalho H, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020308; Chen SY, 2017, ENVIRON POLLUT, V223, P403, DOI 10.1016/j.envpol.2017.01.037; Chung JW, 2017, STROKE, V48, P17, DOI 10.1161/STROKEAHA.116.015428; Donaldson K, 2001, INT J HYG ENVIR HEAL, V203, P411, DOI 10.1078/1438-4639-00059; Franchini M, 2012, J THROMB HAEMOST, V10, P2438, DOI 10.1111/jth.12006; Franchini M, 2011, BLOOD, V118, P2405, DOI 10.1182/blood-2011-04-343111; Frank U, 2019, VASA, V48, P7, DOI 10.1024/0301-1526/a000834; Gasparrini A, 2010, STAT MED, V29, P2224, DOI 10.1002/sim.3940; Gasparrini A, 2011, J STAT SOFTW, V43, P1, DOI 10.18637/jss.v043.i08; Hampel R, 2015, ENVIRON INT, V82, P76, DOI 10.1016/j.envint.2015.05.008; Hoek G, 2001, EPIDEMIOLOGY, V12, P355, DOI 10.1097/00001648-200105000-00017; Hoffmann B, 2009, EPIDEMIOLOGY, V20, P280, DOI 10.1097/EDE.0b013e3181961ac2; Howard DPJ, 2015, CIRCULATION, V132, P1805, DOI 10.1161/CIRCULATIONAHA.115.016424; Joint FAO/WHO Expert Committee on Food Additives, 2006, World Health Organ Tech Rep Ser, V930, P1; Kloog I, 2016, INT J ENVIRON HEAL R, V26, P572, DOI 10.1080/09603123.2016.1217315; Landrigan PJ, 2018, LANCET, V391, P462, DOI 10.1016/S0140-6736(17)32345-0; Law Y, 2017, ANN VASC SURG, V44, P393, DOI 10.1016/j.avsg.2017.03.189; Manisalidis I, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00014; Mills NL, 2005, CIRCULATION, V112, P3930, DOI 10.1161/CIRCULATIONAHA.105.588962; Munzel T, 2018, EUR HEART J, V39, P3543, DOI 10.1093/eurheartj/ehy481; Nelin TD, 2012, TOXICOL LETT, V208, P293, DOI 10.1016/j.toxlet.2011.11.008; Obara H, 2018, ANN VASC DIS, V11, P443, DOI 10.3400/avd.ra.18-00074; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Ruckerl R, 2014, ENVIRON INT, V70, P32, DOI 10.1016/j.envint.2014.05.013; Shahrbaf MA, 2021, CURR PROB CARDIOLOGY, V46, DOI 10.1016/j.cpcardiol.2020.100649; Viehmann A, 2015, OCCUP ENVIRON MED, V72, P656, DOI 10.1136/oemed-2014-102800; Ward-Caviness CK, 2018, ARTERIOSCL THROM VAS, V38, P275, DOI 10.1161/ATVBAHA.117.310003; Zeger SL, 2000, ENVIRON HEALTH PERSP, V108, P419, DOI 10.2307/3454382	30	0	0	1	1	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	NOV	2021	50	6					462	467		10.1024/0301-1526/a000972			6	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6JL	34743586	hybrid, Green Submitted			2022-04-28	WOS:000753518900008
J	Meuli, L; Yu, LM; Wyss, TR; Schmidli, J; Makaloski, V				Meuli, Lorenz; Yu, Ly-Mee; Wyss, Thomas R.; Schmidli, Juerg; Makaloski, Vladimir			Development and internal validation of a prognostic model for mortality of patients with abdominal aortic aneurysms treated with endovascular	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Abdominal aortic aneurysm; endovascular aortic repair; EVAR; prognostic model; survival after EVAR	LONG-TERM MORTALITY; REPAIR; SURVIVAL; PREDICTORS; OUTCOMES; EVAR; EVENTS	Background: Morbidity and mortality associated with elective endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms (AAA) must be balanced against the impending risk of aneurysm rupture and the estimated remaining lifetime. The aim of this study is to develop and validate a prognostic model for mortality of patients with AAA treated with EVAR. Methods: This retrospective observational study included 251 consecutive patients treated with EVAR for asymptomatic AAA between January 2001 and December 2012 at the University Hospital in Bern, Switzerland. Pre-selection of variables was based on a literature review; least absolute shrinkage and selection operator technique was used for the final variable selection. A Firth's bias reduced Cox proportional hazard model was developed and validated using 10,000 bootstrap samples to predict survival after EVAR. Results: The median follow-up time was 5.3 years (range 0.1 to 15.9). At the study closing date 95% of follow-up information was available. The mortality rates were 31.9% at 5 years and 50.5% at the study closing date, respectively. Identified predictors for overall mortality after EVAR were age, hazard ratio (HR) = 2.24 per 10-year increase (95% CI 1.64 to 3.09), the presence of chronic obstructive pulmonary disease (COPD), HR = 2.22 (95% CI 1.48 to 3.31), and lower estimated glomerular filtration rate, HR = 1.24 per 10 ml/min/1.73 m(2) decrease (95% CI 1.12 to 1.39). The model showed good discrimination ability, Harrell's C = 0.722 (95% CI 0.667 to 0.778) and was very robust in the bootstrap in-sample validation Harrell's C = 0.726 (95% CI 0.662 to 0.788). Conclusion: Higher age, the presence of COPD and impaired kidney function are independent predictors for impaired survival after EVAR. The expected remaining lifetime should be considered in patients with AAA. This prognostic model can help improving patient care; however, external validation is needed prior to clinical implementation.	[Meuli, Lorenz] Univ Hosp Zurich, Dept Vasc Surg, Zurich, Switzerland; [Meuli, Lorenz; Yu, Ly-Mee] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Primary Care Clin Trials Unit, Oxford, England; [Wyss, Thomas R.; Schmidli, Juerg; Makaloski, Vladimir] Univ Bern, Univ Hosp Bern, Inselspital, Dept Cardiovasc Surg, Bern, Switzerland; [Meuli, Lorenz] Kantonsspital St Gallen, Dept Vasc Surg, St Gallen, Switzerland		Meuli, L (通讯作者)，Univ Spital Zurich, Dept Vasc Surg, Ramistr 100, CH-8091 Zurich, Switzerland.	lorenz.meuli@protonmail.ch		Meuli, Lorenz/0000-0001-7493-2319; Yu, Ly-Mee/0000-0003-0331-7364			Barnes M, 2008, EUR J VASC ENDOVASC, V35, P571, DOI 10.1016/j.ejvs.2007.12.003; Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F; Collins GS, 2015, BRIT J SURG, V102, P148, DOI 10.1002/bjs.9736; Concato J, 1995, J CLIN EPIDEMIOL, V48, P1495, DOI 10.1016/0895-4356(95)00510-2; Egorova NN, 2011, J VASC SURG, V54, P1, DOI 10.1016/j.jvs.2010.12.049; Filardo G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001835.pub4; Fitridge RA, 2016, EUR J VASC ENDOVASC, V51, P528, DOI 10.1016/j.ejvs.2015.12.019; Hjellestad ID, 2016, J DIABETES COMPLICAT, V30, P438, DOI 10.1016/j.jdiacomp.2015.12.015; Huang Y, 2015, J VASC SURG, V62, P304, DOI 10.1016/j.jvs.2015.02.039; Jacomelli J, 2016, BRIT J SURG, V103, P1125, DOI 10.1002/bjs.10173; Karthikesalingam A, 2011, EUR J VASC ENDOVASC, V42, P295, DOI 10.1016/j.ejvs.2011.04.022; Khashram M, 2016, EUR J VASC ENDOVASC, V51, P203, DOI 10.1016/j.ejvs.2015.09.007; Khashram M, 2016, VASCULAR, V24, P115, DOI 10.1177/1708538115586682; Kristensen SD, 2014, EUR HEART J, V35, P2383, DOI 10.1093/eurheartj/ehu282; Lee HG, 2013, WORLD J SURG, V37, P680, DOI 10.1007/s00268-012-1863-y; Marques-Rios G, 2018, INT ANGIOL, V37, P277, DOI 10.23736/S0392-9590.18.03988-3; Ohrlander T, 2012, EUR J VASC ENDOVASC, V43, P43, DOI 10.1016/j.ejvs.2011.09.028; Ohrlander T, 2011, VASC MED, V16, P422, DOI 10.1177/1358863X11425713; Oliveira NFG, 2017, J VASC SURG, V65, p17S, DOI 10.1016/j.jvs.2017.03.033; Parkinson F, 2015, J VASC SURG, V61, P1606, DOI 10.1016/j.jvs.2014.10.023; Patel R, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22050; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Roger VL, 2013, CIRC RES, V113, P646, DOI 10.1161/CIRCRESAHA.113.300268; Singh Ritesh, 2011, Perspect Clin Res, V2, P145, DOI 10.4103/2229-3485.86872; Svensjo S, 2014, EUR J VASC ENDOVASC, V47, P37, DOI 10.1016/j.ejvs.2013.10.007; Sweeting MJ, 2017, ANN SURG, V266, P713, DOI 10.1097/SLA.0000000000002392; van Beek SC, 2014, J VASC SURG, V59, P1555, DOI 10.1016/j.jvs.2013.12.043; von Allmen RS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140817	28	0	0	0	1	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	FEB	2021	50	2					125	131		10.1024/0301-1526/a000921			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	QQ5PH	33118475				2022-04-28	WOS:000624575300007
J	Li, X; D'Amico, G; Quintini, C; Uso, TD; Gadani, S; Romero-Marrero, C; Martin, C; Partovi, S				Li, Xin; D'Amico, Giuseppe; Quintini, Cristiano; Uso, Teresa Diago; Gadani, Sameer; Romero-Marrero, Carlos; Martin, Charles, III; Partovi, Sasan			Intravascular ultrasound in the diagnosis and treatment of central venous diseases	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Review						IVUS; IVC filter; central venous disease; venous stenosis or occlusion	INFERIOR VENA-CAVA; MAY-THURNER-SYNDROME; ENDOVASCULAR TREATMENT; OUTFLOW OBSTRUCTION; STENT IMPLANTATION; VENOGRAPHY; PLACEMENT; RECANALIZATION; MANAGEMENT; GUIDANCE	Intravascular ultrasound (IVUS) has been used extensively in coronary applications. Its use in venous applications has increased as endovascular therapy has increasingly become the mainstay therapy for central venous diseases. IVUS has been used for both diagnostic and therapeutic purposes in managing venous stenotic disease, venous occlusive disease, and IVC filter placement and removal. IVUS has been proven to be effective in providing detailed measurement of the venous anatomy, which aid in determining the appropriate size and the approach for venous stent placement. In IVC filter placement, IVUS can provide detailed measurement and guide IVC filter placement in emergent and critical care settings. It also has certain utility in filter removal. At any rate, to date there are only a few studies examining its impact on patient outcomes. Prospective randomized controlled trials are warranted in the future.	[Li, Xin; Gadani, Sameer; Martin, Charles, III; Partovi, Sasan] Cleveland Clin Main Campus, Imaging Inst, Sect Intervent Radiol, 9500 Euclid Ave, Cleveland, OH 44195 USA; [D'Amico, Giuseppe; Quintini, Cristiano; Uso, Teresa Diago] Cleveland Clin, Dept Transplant Surg, Digest Dis & Surg Inst, Cleveland, OH 44106 USA; [Romero-Marrero, Carlos] Cleveland Clin, Inst Digest Dis, Dept Gastroenterol & Hepatol, Cleveland, OH 44106 USA		Partovi, S (通讯作者)，Cleveland Clin Main Campus, Imaging Inst, Sect Intervent Radiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.						Ahmed HK, 2001, J ULTRAS MED, V20, P251, DOI 10.7863/jum.2001.20.3.251; Bertani H, 2004, ABDOM IMAGING, V29, P606, DOI 10.1007/s00261-004-0170-y; Brazeau NF, 2013, VASA, V42, P96, DOI 10.1024/0301-1526/a000252; Brountzos EN, 2004, CARDIOVASC INTER RAD, V27, P129, DOI 10.1007/s00270-003-0009-x; Chacon Lopez-Muniz JI, 1997, AM J CLIN ONCOL-CANC, V20, P293; Chieffo A, 2013, AM HEART J, V165, P65, DOI 10.1016/j.ahj.2012.09.017; Cornman-Homonoff J, 2019, J VASC INTERV RADIOL, V30, P1679, DOI 10.1016/j.jvir.2019.04.035; Dogan OF, 2005, VASA-J VASCULAR DIS, V34, P147, DOI 10.1024/0301-1526.34.2.147; Donaldson J, 2019, AM J ROENTGENOL, V213, P1381, DOI 10.2214/AJR.18.20915; Eder F, 2008, VASA-J VASCULAR DIS, V37, P68, DOI 10.1024/0301-1526.37.1.68; Epelboym Y, 2020, CLIN IMAG, V59, P95, DOI 10.1016/j.clinimag.2019.09.015; Erben Y, 2018, J VASC SURG-VENOUS L, V6, P173, DOI 10.1016/j.jvsv.2017.10.017; Fagedet D, 2013, CARDIOVASC INTER RAD, V36, P140, DOI 10.1007/s00270-011-0310-z; Fan ZG, 2019, ANATOL J CARDIOL, V22, P160, DOI 10.14744/AnatolJCardiol.2019.86598; Finet G, 1998, ULTRASOUND MED BIOL, V24, P793, DOI 10.1016/S0301-5629(98)00041-6; Forauer AR, 2002, J VASC INTERV RADIOL, V13, P523, DOI 10.1016/S1051-0443(07)61535-8; Gagne PJ, 2018, J VASC SURG-VENOUS L, V6, P48, DOI 10.1016/j.jvsv.2017.07.009; Gagne PJ, 2017, J VASC SURG-VENOUS L, V5, P678, DOI 10.1016/j.jvsv.2017.04.007; Gasparis AP, 2009, VASC ENDOVASC SURG, V43, P295, DOI 10.1177/1538574408328666; Gunn AJ, 2013, VASC ENDOVASC SURG, V47, P97, DOI 10.1177/1538574412473186; Han T, 2018, J VASC INTERV RADIOL, V29, P263; Heckmann MB, 2019, VASA, V48, P443, DOI 10.1024/0301-1526/a000793; Hislop S, 2014, J VASC SURG, V59, P1066, DOI 10.1016/j.jvs.2013.10.071; Kalra M, 2003, J VASC SURG, V38, P215, DOI 10.1016/S0741-5214(03)00331-8; Kang J, 2018, J VASC SURG, V68, pE62, DOI 10.1016/j.jvs.2018.06.056; Kardys CM, 2008, SURG OBES RELAT DIS, V4, P50, DOI 10.1016/j.soard.2007.09.015; Karmon Y, 2013, J VASC INTERV RADIOL, V24, P1487, DOI 10.1016/j.jvir.2013.06.012; Katouzian A, 2012, IEEE T INF TECHNOL B, V16, P823, DOI 10.1109/TITB.2012.2189408; Kim TI, 2019, ANN VASC SURG, V54, P118, DOI 10.1016/j.avsg.2018.08.077; Lee Jason T, 2004, Semin Vasc Surg, V17, P110, DOI 10.1053/j.semvascsurg.2004.03.009; Lepper PM, 2011, RESP CARE, V56, P653, DOI 10.4187/respcare.00947; Li X, 2020, INFERIOR VENA CAVA F, P1; Linnemann B, 2012, VASA, V41, P319, DOI 10.1024/0301-1526/a000217; Maehara A, 2017, JACC-CARDIOVASC IMAG, V10, P1487, DOI 10.1016/j.jcmg.2017.09.008; Mako K, 2019, VASA, V48, P381, DOI 10.1024/0301-1526/a000775; Malik AH, 2020, INT J CARDIOL, V299, P100, DOI 10.1016/j.ijcard.2019.07.033; Matthews R, 2008, J CLIN ULTRASOUND, V36, P254, DOI 10.1002/jcu.20389; Montminy ML, 2019, J VASC SURG-VENOUS L, V7, P801, DOI 10.1016/j.jvsv.2019.03.015; Murphy E, 2016, J VASC SURG, V63, p33S, DOI 10.1016/j.jvs.2016.03.216; Neglen P, 2002, J VASC SURG, V35, P694, DOI 10.1067/mva.2002.121127; Pampati R, 2020, JVIR, V30, pS257; Parise H, 2011, AM J CARDIOL, V107, P374, DOI 10.1016/j.amjcard.2010.09.030; Partovi S, 2017, VASA, V46, P121, DOI 10.1024/0301-1526/a000593; Passman M, 2011, VASC DIS MANAG, V8, P57; Prati F, 2015, AM HEART J, V169, P249, DOI 10.1016/j.ahj.2014.11.012; Quintini C, 2009, LIVER TRANSPLANT, V15, P49, DOI 10.1002/lt.21667; Raju S, 2006, J VASC SURG, V44, P820, DOI 10.1016/j.jvs.2006.05.054; Raju S, 2018, PHLEBOLOGY, V33, P451, DOI 10.1177/0268355517718763; Raju S, 2009, J VASC SURG, V50, P360, DOI 10.1016/j.jvs.2009.01.061; Raju S, 2009, J VASC SURG, V49, P511, DOI 10.1016/j.jvs.2008.08.003; Razdan R, 2020, J VASC INTERV RADIOL, V31, pS198; Rosenthal D, 2004, J VASC SURG, V40, P958, DOI 10.1016/j.jvs.2004.07.048; Rossi FH, 2020, J VASC SURG-VENOUS L, V8, P413, DOI 10.1016/j.jvsv.2019.09.015; Titus JM, 2011, J VASC SURG, V53, P706, DOI 10.1016/j.jvs.2010.09.011; Tsai SC, 2015, VASA, V44, P65, DOI 10.1024/0301-1526/a000408; Vasquez Andres, 2014, Interv Cardiol, V9, P156, DOI 10.15420/icr.2014.9.3.156; Wang X, 2020, ILIAC VEIN STENTING; Woodruff DY, 2013, UROL ONCOL-SEMIN ORI, V31, P517, DOI 10.1016/j.urolonc.2011.03.006	58	0	0	0	2	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0301-1526			VASA	Vasa	JAN	2021	50	1			SI		2	10		10.1024/0301-1526/a000914			9	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	PQ4VY	33138741				2022-04-28	WOS:000606545800002
J	Lange, C; Ngare, N; Hillmeister, P; Bramlage, P; Langhoff, R; Buschmann, I				Lange, Christoph; Ngare, Njeri; Hillmeister, Philipp; Bramlage, Peter; Langhoff, Ralf; Buschmann, Ivo			Impact of chemotherapeutic effects on the pathophysiology of the arterial wall - insights from peripheral arterial disease	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Review						Peripheral arterial desease; chemotherapy; side effects; vascular und targeted therapy	CHRONIC MYELOID-LEUKEMIA; LONG-TERM SURVIVORS; MESENCHYMAL TRANSITION; CARDIOVASCULAR RISK; OCCLUSIVE DISEASE; CANCER; ARTERIOGENESIS; MORBIDITY; HALLMARKS; ETOPOSIDE	Systemic antineoplastic treatment agents represent one of the fastest developing medical fields. Oncological treatment is becoming increasingly individualized and new targets with corresponding agents, are constantly being developed. In tandem with this progress, new combinations and algorithms have evolved and patient's outcome have improved. Expanding tumors rely on a growing neovascular network to maintain their increased metabolism, which is caused by an accelerated reproduction rate. Accordingly, interrupting this supply mechanism is a major component of antineoplastic pharmaceutics and is a hallmark of cancer treatment. With advances in cancer treatment, long-term side effects have become an important consideration, especially in cases of neoplasia in young patients. While neuropathy and cardiotoxicity are well documented, vascular adverse events remain poorly understood. The mutual risk factors, like smoking and increased age, complicate the association between the vascular pathology and the earlier antineoplastic therapy. A deeper understanding of the effects of chemotherapy on peripheral arterial disease could lead to more detailed pathophysiological insight into both maladies and to new treatment options.	[Lange, Christoph] Ctr Anesthesiol, Brandenburg Med Sch, Brandenburg, Germany; [Ngare, Njeri] European Fdn Vasc & Prevent Med, Brandenburg, Germany; [Hillmeister, Philipp; Buschmann, Ivo] Ctr Internal Med 1, Brandenburg Med Sch, Dept Angiol, Brandenburg, Germany; [Bramlage, Peter] Inst Pharmacol & Prevent Med, Cloppenburg, Germany; [Langhoff, Ralf] Sankt Gertrauden Hosp, Vasc Ctr, Dept Angiol, Berlin, Germany		Lange, C (通讯作者)，Stadt Klinikum Brandenburg GmbH, Klin Anasthesiol & Intensivmed, Hochstr 29, D-14770 Brandenburg, Germany.	c.lange@klinikum-brandenburg.de		, Christoph/0000-0003-0119-409X			Bergmann CE, 2006, J LEUKOCYTE BIOL, V80, P59, DOI 10.1189/jlb.0206087; Buschmann I, 2003, MICROCIRCULATION, V10, P371, DOI 10.1038/sj.mn.7800199; de Souza DA, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/142359; DELALLERAMOYA M, 1992, ARTERIOSCLER THROMB, V12, P1363, DOI 10.1161/01.ATV.12.11.1363; Ding Faming, 2015, Zhonghua Xin Xue Guan Bing Za Zhi, V43, P56; Drevs J, 2004, ANTICANCER RES, V24, P1759; Ebisawa S, 2014, CIRC J, V78, P1445, DOI 10.1253/circj.CJ-13-1341; Epstein SE, 2004, CIRCULATION, V109, P2826, DOI 10.1161/01.CIR.0000132468.82942.F5; Erdozain JG, 2014, J RHEUMATOL, V41, P310, DOI 10.3899/jrheum.130817; Evrard SM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11853; Giles FJ, 2013, LEUKEMIA, V27, P1310, DOI 10.1038/leu.2013.69; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hansen CR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020461; Haugnes HS, 2010, J CLIN ONCOL, V28, P4649, DOI 10.1200/JCO.2010.29.9362; Hillmeister P, 2011, CIRC RES, V109, P524, DOI 10.1161/CIRCRESAHA.111.240986; Hoven-Gondrie ML, 2007, ANN SURG ONCOL, V14, P2105, DOI 10.1245/s10434-007-9365-0; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Keeling AN, 2012, VASC MED, V17, P223, DOI 10.1177/1358863X12446213; Kim TD, 2013, LEUKEMIA, V27, P1316, DOI 10.1038/leu.2013.70; Libby P, 2002, NATURE, V420, P868, DOI [10.1038/nature01323, 10.1161/ATVBAHA.108.179705]; Markert A, 2009, INT J CANCER, V124, P722, DOI 10.1002/ijc.23991; Mathews J, 1997, CANCER CHEMOTH PHARM, V40, P19, DOI 10.1007/s002800050619; Mayranpaa MI, 2009, J VASC SURG, V50, P388, DOI 10.1016/j.jvs.2009.03.055; Meijer WT, 1998, ARTERIOSCL THROM VAS, V18, P185, DOI 10.1161/01.ATV.18.2.185; Nguyen L, 2016, J GASTROEN HEPATOL, V31, P1773, DOI 10.1111/jgh.13307; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Parikh PP, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/3750829; Perez C, 1997, J CELL SCI, V110, P337; Persson AB, 2011, VASA, V40, P177, DOI 10.1024/0301-1526/a000092; Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246; Repetto L, 1998, CANCER, V82, P760, DOI 10.1002/(SICI)1097-0142(19980215)82:4<760::AID-CNCR20>3.0.CO;2-V; Semenza GL, 2009, ANN NY ACAD SCI, V1177, P2, DOI 10.1111/j.1749-6632.2009.05032.x; Tini G, 2019, INT J CARDIOL, V281, P133, DOI 10.1016/j.ijcard.2019.01.082; Tulsyan Nirman, 2006, Expert Opin Emerg Drugs, V11, P75, DOI 10.1517/14728214.11.1.75; van den Belt-Dusebout AW, 2007, J CLIN ONCOL, V25, P4370, DOI 10.1200/JCO.2006.10.5296; Vasu S, 2013, J CARDIOVASC MAGN R, V15, DOI 10.1186/1532-429X-15-66; Vaughn DJ, 2008, CANCER-AM CANCER SOC, V112, P1949, DOI 10.1002/cncr.23389; Wethal T, 2007, J Cancer Surviv, V1, P8, DOI 10.1007/s11764-007-0012-3	38	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JUL	2021	50	4					265	269		10.1024/0301-1526/a000923			5	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QY	33140700				2022-04-28	WOS:000695708700003
J	Branzan, D; Geisler, A; Steiner, S; Lautenschlaeger, T; Doss, M; Matschuck, M; Scheinert, D; Schmidt, A				Branzan, Daniela; Geisler, Antonia; Steiner, Sabine; Lautenschlaeger, Tina; Doss, Markus; Matschuck, Manuela; Scheinert, Dierk; Schmidt, Andrej			Stroke rate after thoracic endovascular aortic repair using de-airing of stentgrafts with high-volume of saline solution	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Air embolism; flushing technique; aortic aneurysm; aorta; neurological complications	NEUROLOGIC COMPLICATIONS; REPORTING STANDARDS; SOCIETY; MANAGEMENT; ARTERY	Background: Our aim was to determine the rate of ischemic stroke following thoracic endovascular aortic repair (TEVAR) after reducing gas volume released during stentgraft deployment by de-airing of thoracic stentgrafts with high-volume of 0.9% heparinized saline solution. Patients and methods: A single center retrospective analysis of all consecutive patients undergoing TEVAR from 2014 to 2019 was performed. All thoracic stentgrafts were flushed with 120 ml 0.9% heparinized saline solution before implantation, according to our institutional protocol. Endpoints were in-hospital rates of ischemic stroke and spinal cord ischemia (SCI), and all-cause mortality. Results: One hundred and fifty-four patients (mean age: 66.8 +/- 13.6 years, 64.9% males) were treated with TEVAR during the study period. Indications for treatment were thoracic aortic aneurysms (n = 75, 48.7%), acute type B aortic dissections (n = 46, 29.9%), aortic arch aneurysms and penetrating aortic ulcers (n = 28, 18.2%), and blunt traumatic aortic injuries (n = 5, 3.2%). Timing of procedure was urgent in 75 patients (48.7%). Proximal landing zone were zone 0-1-2 (n = 75, 48.7%), zone 3 (n = 66, 42.9%) and zone 4 (n = 13, 8.4%). Supra-aortic vessels were revascularized with custom-made fenestrated stentgrafts in 9 patients (5.8%), using chimney technique in 4 patients (2.6%), and with debranching procedures in 19 patients (12.3%). Left subclavian artery was covered without revascularization in 46 patients (29.9%). In-hospital stroke occurred in two patients (1.3%) and SCI in another two patients (1.3%). In-hospital mortality rate was 0.6%. No further in-hospital events were noted. Conclusions: De-airing of stentgrafts with high-volume of 0.9% heparinized saline solution seems to be safe and can be used as an adjunct to keep occurrence of neurological events after TEVAR as low as possible.	[Branzan, Daniela; Geisler, Antonia; Lautenschlaeger, Tina; Doss, Markus] Univ Hosp Leipzig, Dept Vasc Surg, Leipzig, Germany; [Steiner, Sabine; Matschuck, Manuela; Scheinert, Dierk; Schmidt, Andrej] Univ Hosp Leipzig, Dept Intervent Angiol, Leipzig, Germany		Branzan, D (通讯作者)，Univ Hosp Leipzig, Vasc Surg, Liebigstr 20,Haus 4, D-04103 Leipzig, Germany.	daniela.branzan@medizin.uni-leipzig.de		Geisler, Antonia Alina/0000-0002-9237-5680			Branzan D, 2019, EUR J VASC ENDOVASC, V58, P344, DOI 10.1016/j.ejvs.2019.01.011; Branzan D, 2018, EUROINTERVENTION, V14, P828, DOI 10.4244/EIJ-D-18-00200; Branzan D, 2018, EUR J VASC ENDOVASC, V56, P561, DOI 10.1016/j.ejvs.2018.07.003; Buth J, 2007, J VASC SURG, V46, P1103, DOI 10.1016/j.jvs.2007.08.020; Czerny M, 2019, EUR J CARDIO-THORAC, V55, P133, DOI 10.1093/ejcts/ezy313; Fattori R, 2006, J THORAC CARDIOV SUR, V132, P332, DOI 10.1016/j.jtcvs.2006.03.055; Fillinger MF, 2010, J VASC SURG, V52, P1022, DOI 10.1016/j.jvs.2010.07.008; Gerriets T, 2010, EUR HEART J, V31, P360, DOI 10.1093/eurheartj/ehp178; Grover G, 2018, J VASC SURG, V68, P1656, DOI 10.1016/j.jvs.2017.11.098; Inci K, 2016, SAGE OPEN MED, V4, DOI 10.1177/2050312116682130; Kolbel T, 2016, J ENDOVASC THER, V23, P393, DOI 10.1177/1526602816633705; Lansky AJ, 2017, J AM COLL CARDIOL, V69, P679, DOI 10.1016/j.jacc.2016.11.045; Lombardi JV, 2020, J VASC SURG, V71, P723, DOI 10.1016/j.jvs.2019.11.013; Lombardi JV, 2014, J VASC SURG, V59, P1544, DOI 10.1016/j.jvs.2013.12.038; Melissano G, 2012, EUR J VASC ENDOVASC, V43, P269, DOI 10.1016/j.ejvs.2011.12.009; Patterson BO, 2014, J VASC SURG, V60, P1491, DOI 10.1016/j.jvs.2014.08.114; Perera AH, 2018, BRIT J SURG, V105, P366, DOI 10.1002/bjs.10718; Piazza M, 2019, EUR J VASC ENDOVASC, V58, P512, DOI 10.1016/j.ejvs.2019.05.011; Riambau V, 2017, EUR J VASC ENDOVASC, V53, P4, DOI 10.1016/j.ejvs.2016.06.005; Riambau V, 2011, J VASC SURG, V53, P565, DOI 10.1016/j.jvs.2010.09.050; Rylski B, 2020, INTERACT CARDIOV TH, V30, P293, DOI 10.1093/icvts/ivz261; Swerdlow NJ, 2020, J VASC SURG, V72, P1593, DOI 10.1016/j.jvs.2020.02.015; Tsilimparis N, 2018, J VASC SURG, V68, P1324, DOI 10.1016/j.jvs.2018.02.027	23	1	1	1	1	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	MAY	2021	50	3					186	192		10.1024/0301-1526/a000937			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QU	33559507				2022-04-28	WOS:000695708300005
J	Bashar, K; Shalan, A; Ali, SS; Tang, T; Tiwari, A				Bashar, Khalid; Shalan, Ahmed; Ali, Sana Sharafat; Tang, Tjun; Tiwari, Alok			Endovascular versus medical treatment of venous compression syndrome of the iliac vein - a systematic review	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Review						Venous; stent; May-Thurner; NIVL	EDITORS CHOICE; THROMBOSIS; OUTCOMES; SECONDARY; DISEASE; THROMBECTOMY; QUALITY; LESIONS	The treatment of non-thrombotic iliac vein lesions (NIVL) remains debatable with many advocating conservative treatments, whilst others offering venous stenting. The objective of this review was to systematically assess the treatment options for symptomatic iliac vein compression syndrome (IVCS) in patients without evidence of thrombotic disease at the time of diagnosis. An online search of published literature looking for randomised controlled trials and observational studies that evaluated the treatment for symptomatic NIVL was performed. Nine studies were included with a total 953 patients of which 782 patients had NIVL. Patency rates ranged between 94.8%-100% in the first month, 88.2%-94.1% in six months and 73.4%-98% in 12 months, in patients with NIVL post stenting. Longer follow-up of up to 5 years shows promising patency rates of 94% in patients with IVCS. Patients with IVCS are likely to benefit from a combination of endovenous treatment at the time of diagnosis including stent placement to maintain lumen patency and prevent recurrent deep venpus thrombosis and/or postthrombotic syndrome.	[Bashar, Khalid; Shalan, Ahmed; Ali, Sana Sharafat; Tiwari, Alok] Univ Hosp Birmingham, Dept Vasc Surg, Birmingham, W Midlands, England; [Tang, Tjun] Singapore Gen Hosp, Dept Vasc Surg, Singapore, Singapore		Tiwari, A (通讯作者)，Univ Hosp Birmingham NHS Fdn Trust, Dept Vasc Surg, Mindelsohn Way, Birmingham B15 2WB, W Midlands, England.	alok.tiwari@uhb.nhs.uk		Tiwari, Alok/0000-0003-4465-0251			Akers DL, 1996, J VASC SURG, V24, P477, DOI 10.1016/S0741-5214(96)70205-7; COCKETT FB, 1965, BRIT J SURG, V52, P816, DOI 10.1002/bjs.1800521028; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Ehrich WE, 1943, AM HEART J, V26, P18; Elsharawy MA, 2008, SAUDI MED J, V29, P603; Enden T, 2012, LANCET, V379, P31, DOI 10.1016/S0140-6736(11)61753-4; Esposito A, 2020, EUR J VASC ENDOVASC, V60, P118, DOI 10.1016/j.ejvs.2020.03.020; Hager ES, 2013, J VASC SURG-VENOUS L, V1, P270, DOI 10.1016/j.jvsv.2012.11.002; Heller T, 2019, ROFO-FORTSCHR RONTG, V191, P1107, DOI 10.1055/a-0959-6230; Hung JB, 2013, AM J EMERG MED, V31, DOI 10.1016/j.ajem.2012.05.029; Kahn SR, 2008, J THROMB HAEMOST, V6, P1105, DOI 10.1111/j.1538-7836.2008.03002.x; Kolbach DN, 2005, EUR J VASC ENDOVASC, V30, P404, DOI 10.1016/j.ejvs.2005.06.006; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]; Liu ZJ, 2014, ANN VASC SURG, V28, P695, DOI 10.1016/j.avsg.2013.05.019; Lou WS, 2009, KOREAN J RADIOL, V10, P135, DOI 10.3348/kjr.2009.10.2.135; Mako K, 2019, VASA, V48, P381, DOI 10.1024/0301-1526/a000775; MAY R., 1957, ANGIOLOGY, V8, P419, DOI 10.1177/000331975700800505; McMurrich JP, 1908, AM J MED SCI, V135, P342, DOI 10.1097/00000441-190803000-00004; MCMURRICH JP, 1906, BRIT MED J, V2, P1699; Meissner MH, 2002, J VASC SURG, V36, P889, DOI 10.1067/mva.2002.128637; Meng QY, 2011, CHINESE MED J-PEKING, V124, P3281, DOI 10.3760/cma.j.issn.0366-6999.2011.20.013; Mickley V, 1998, J VASC SURG, V28, P492, DOI 10.1016/S0741-5214(98)70135-1; Neglen P, 2000, EUR J VASC ENDOVASC, V20, P560, DOI 10.1053/ejvs.2000.1251; ODONNELL TF, 1977, J SURG RES, V22, P483, DOI 10.1016/0022-4804(77)90030-0; Plate G, 1997, EUR J VASC ENDOVASC, V14, P367, DOI 10.1016/S1078-5884(97)80286-9; Raju S, 2006, J VASC SURG, V44, P136, DOI 10.1016/j.jvs.2006.02.065; Razavi MK, 2015, CIRC-CARDIOVASC INTE, V8, DOI 10.1161/CIRCINTERVENTIONS.115.002772; Rohr Aaron, 2020, Radiol Case Rep, V15, P201, DOI 10.1016/j.radcr.2019.11.013; Rollo JC, 2017, J VASC SURG-VENOUS L, V5, P667, DOI 10.1016/j.jvsv.2017.02.009; Sang HF, 2019, PHLEBOLOGY, V34, P40, DOI 10.1177/0268355518764989; Seager MJ, 2016, EUR J VASC ENDOVASC, V51, P100, DOI 10.1016/j.ejvs.2015.09.002; Soosainathan A, 2013, J VASC SURG, V57, P254, DOI 10.1016/j.jvs.2012.09.011; STRANDNESS DE, 1983, JAMA-J AM MED ASSOC, V250, P1289, DOI 10.1001/jama.250.10.1289; Stuck AK, 2018, VASA, V47, P319, DOI 10.1024/0301-1526/a000697; van Vuuren TMAJ, 2017, EUR J VASC ENDOVASC, V54, P495, DOI 10.1016/j.ejvs.2017.06.023; Vasquez MA, 2010, J VASC SURG, V52, P1387, DOI 10.1016/j.jvs.2010.06.161; Villalta S, 1994, HAEMOSTASIS, V24, p158a; Wang WD, 2016, PHLEBOLOGY, V31, P376, DOI 10.1177/0268355515596474; Ye KC, 2012, J VASC INTERV RADIOL, V23, P497, DOI 10.1016/j.jvir.2011.12.021	39	1	1	0	2	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JAN	2021	50	1			SI		22	29		10.1024/0301-1526/a000911			8	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	PQ4VY	33047662				2022-04-28	WOS:000606545800004
J	Fernandez-Alvarez, V; Nieto, CS; Alvarez, FL				Fernandez-Alvarez, Veronica; Suarez Nieto, Carlos; Lopez Alvarez, Fernando			Arterial stiffness as an ultrasound biomarker of radiation-induced carotid artery disease	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Arterial stiffness; atherosclerosis; carotid artery; framingham risk score; radiotherapy	NECK-CANCER PATIENTS; CHILDHOOD-CANCER; NASOPHARYNGEAL CARCINOMA; CARDIOVASCULAR EVENTS; HEAD; STENOSIS; RADIOTHERAPY; RISK; SURVIVORS; PREDICTION	Background: Radiation-induced carotid artery disease (RICAD) is an important issue in head and neck cancer (HNC) survivors after radiotherapy (RT). The risk of cerebrovascular disease in these patients is doubted. The aim of this study was to assess the effect of RT on carotid artery stiffness in HNC patients. Patients and methods: Conventional arterial stiffness parameters were measured in a total of 50 HNC survivors treated with RT for at least 5 years and compared to 50 unirradiated HNC patients. Elastic modulus (Ep) and Beta stiffness index (beta) were measured in proximal, mid and distal common carotid artery (CCA). Results: The mean age of the subjects was 68 +/- 9 years (range: 44-84) in the irradiated group and 67 +/- 10 years (range: 45-85) in the control group. The RT group was treated with a mean radiation exposure of 60.3 +/- 6.7 Gy (range: 44-72) in the neck. Carotid stiffness parameters showed significant group differences: Ep in the RT group was 2.329 +/- 1.222 vs 1.742 +/- 828 in the non-RT group (p =0.006) and beta index in the RT group was 23 +/- 11 vs 15 +/- 8 in the non-RT group (p<0.001). Radiation-induced carotid stiffness was quantified and cervical exposure to RT increased Ep in 575 kPa (p=0.014) and beta in 7 units (p<0.003). Conclusions: Ep and beta index could be suitable ultrasound biomarkers of radiation-induced atherosclerosis in HNC survivors. Further prospective studies are needed to feature RICD in this setting.	[Fernandez-Alvarez, Veronica] Hosp Univ Cabuenes, Dept Vasc & Endovasc Surg, Gijon, Spain; [Suarez Nieto, Carlos; Lopez Alvarez, Fernando] CIBERONC, Inst Oncol Asturias IUOPA, Inst Invest Sanitaria Principado Asturias ISPA, Oviedo, Spain; [Lopez Alvarez, Fernando] Hosp Univ Cent Asturias, Dept Otolaryngol, Oviedo, Spain		Fernandez-Alvarez, V (通讯作者)，Calle Gloria Fuertes 22,4 Ctr, Gijon 33204, Spain.	veronicafdezalvarez@hotmail.com	López, Fernando/AAC-3488-2021	López, Fernando/0000-0001-7019-9746; Fernandez-Alvarez, Veronica/0000-0002-6345-9279			Bjallmark A, 2010, EUR J ECHOCARDIOGR, V11, P630, DOI 10.1093/ejechocard/jeq033; Brown PD, 2005, INT J RADIAT ONCOL, V63, P1361, DOI 10.1016/j.ijrobp.2005.05.046; Carpenter DJ, 2018, ORAL ONCOL, V80, P9, DOI 10.1016/j.oraloncology.2018.02.021; Cheng SWK, 2004, J VASC SURG, V39, P409, DOI 10.1016/j.jvs.2003.08.031; Cheng SWK, 1999, AM J SURG, V178, P323, DOI 10.1016/S0002-9610(99)00184-1; Dorth JA, 2014, HEAD NECK-J SCI SPEC, V36, P215, DOI 10.1002/hed.23280; Fernandez-Alvarez V, 2018, STRAHLENTHER ONKOL, V194, P699, DOI 10.1007/s00066-018-1304-4; Giannarelli C, 2012, ATHEROSCLEROSIS, V223, P372, DOI 10.1016/j.atherosclerosis.2012.05.027; Gujral DM, 2014, CLIN ONCOL-UK, V26, P94, DOI 10.1016/j.clon.2013.10.002; Gujral DM, 2016, ANGIOLOGY, V67, P266, DOI 10.1177/0003319715589520; Hobbelen PHF, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0091910, 10.1371/journal.pone.0087348, 10.1371/journal.pone.0096514, 10.1371/journal.pone.0103267, 10.1371/journal.pone.0103480, 10.1371/journal.pone.0105072, 10.1371/journal.pone.0113637, 10.1371/journal.pone.0095422, 10.1371/journal.pone.0087588, 10.1371/journal.pone.0110033, 10.1371/journal.pone.0103535, 10.1371/journal.pone.0107196, 10.1371/journal.pone.0095536, 10.1371/journal.pone.0099366, 10.1371/journal.pone.0093049]; Kim HL, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00041; Krystal JI, 2015, PEDIATR BLOOD CANCER, V62, P1832, DOI 10.1002/pbc.25547; Lee YJ, 2009, NUTR METAB CARDIOVAS, V19, P3, DOI 10.1016/j.numecd.2008.02.003; Liao W, 2019, RADIOTHER ONCOL, V133, P167, DOI 10.1016/j.radonc.2018.11.013; Meeske KA, 2009, PEDIATR BLOOD CANCER, V53, P615, DOI 10.1002/pbc.22111; Mitchell GF, 2010, CIRCULATION, V121, P505, DOI 10.1161/CIRCULATIONAHA.109.886655; Mozos I, 2017, ONCOTARGETS THER, V10, P1381, DOI 10.2147/OTT.S126852; Muhammad IF, 2017, DIABETES CARE, V40, P1739, DOI 10.2337/dc17-1071; Myung Yusik, 2012, J Cardiovasc Ultrasound, V20, P134, DOI 10.4250/jcu.2012.20.3.134; Naylor AR, 2018, EUR J VASC ENDOVASC, V55, P3, DOI 10.1016/j.ejvs.2017.06.021; Plummer C, 2011, STROKE, V42, P2410, DOI 10.1161/STROKEAHA.111.615203; Qiu Y, 2010, SCAND J IMMUNOL, V72, P425, DOI 10.1111/j.1365-3083.2010.02456.x; Ricotta JJ, 2011, J VASC SURG, V54, pE1, DOI 10.1016/j.jvs.2011.07.031; Smith GL, 2008, J CLIN ONCOL, V26, P5119, DOI 10.1200/JCO.2008.16.6546; Steele SR, 2004, AM J SURG, V187, P594, DOI 10.1016/j.amjsurg.2004.01.014; Thalhammer C, 2015, VASA, V44, P23, DOI 10.1024/0301-1526/a000403; Trojanowski P, 2019, TRANSL ONCOL, V12, P1026, DOI 10.1016/j.tranon.2019.05.001; Valentin ML, 2020, VASA, V49, P467, DOI 10.1024/0301-1526/a000896; van Leeuwen-Segarceanu EM, 2013, LEUKEMIA LYMPHOMA, V54, P1734, DOI 10.3109/10428194.2012.748906; Vatanen A, 2015, PEDIATR BLOOD CANCER, V62, P2000, DOI 10.1002/pbc.25616; Vlachopoulos C, 2010, J AM COLL CARDIOL, V55, P1318, DOI 10.1016/j.jacc.2009.10.061; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Yuan C, 2017, ULTRASCHALL MED, V38, P190, DOI 10.1055/s-0034-1399293; Zaletel LZ, 2018, RADIOL ONCOL, V52, P136, DOI 10.2478/raon-2018-0006	35	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	SEP	2021	50	5					348	355		10.1024/0301-1526/a000956			8	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6GV	34102858				2022-04-28	WOS:000753511900005
J	Pakeliani, D; Lachat, M; Blohme, L; Kobayashi, M; Chaykovska, L; Pfammatter, T; Puippe, G; Veith, FJ; Pecoraro, F				Pakeliani, D.; Lachat, M.; Blohme, L.; Kobayashi, M.; Chaykovska, L.; Pfammatter, T.; Puippe, G.; Veith, F. J.; Pecoraro, F.			Improved technique for sheath supported contralateral limb gate cannulation in endovascular abdominal aortic aneurysm repair (vol 49, pg 39, 2020)	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Correction																	Pakeliani D, 2020, VASA, V49, P39, DOI 10.1024/0301-1526/a000820	1	0	0	0	0	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0301-1526			VASA	Vasa	FEB	2021	50	2					158	158		10.1024/0301-1526/a000938			1	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	QQ5PH		Bronze			2022-04-28	WOS:000624575300013
J	Wang, X; Yu, C; Chen, GJ; Hong, Y; Zhou, B; Ge, J; Liu, TE				Wang, Xiang; Yu, Chong; Chen, Guojun; Hong, Yi; Zhou, Bin; Ge, Jin; Liu, Tuoen			Iliac vein stenting guided by intravascular ultrasound without iodinated contrast medium	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						intravascular ultrasound; endovascular therapy; stent; iliac vein compression syndrome; angioplasty; May-Thurner syndrome	STENOSIS	Iliac vein compression syndrome, also known as May-Thurner Syndrome, is a type of vein reflux disorders which is often ignored due to lack of efficient diagnostic methods. The traditional gold standard of diagnosis is venography, but this has been challenged and largely replaced by intravascular ultrasound (IVUS). Here we report a case that a patient suffered with iodine anaphylaxis was successfully performed iliac vein stenting guided by using IVUS alone. This case provides the evidence that IVUS can offer necessary information for physicians in the diagnosis and treatment of iliac vein compression. We also find that balloon dilatation notch cannot precisely reflect the whole lesion, indicating it may be unreliable for diagnosis. Differ from the commonly accepted opinion, we find that comparing to IVUS, the notch of balloon dilatation cannot completely reflect the extent of lesion narrowness. Thus, we think the notch should not be used as a reference for seriousness of the lesion, and the diagnosis of stenosis cannot be ruled out even if there is no presence of notch.	[Wang, Xiang; Yu, Chong; Chen, Guojun; Hong, Yi; Zhou, Bin; Ge, Jin] Tongji Univ, Dept Vasc Surg, Affiliated East Hosp, Shanghai, Peoples R China; [Liu, Tuoen] West Virginia Sch Osteopath Med, Dept Biomed Sci, 400 Lee St North, Lewisburg, WV 24901 USA		Liu, TE (通讯作者)，West Virginia Sch Osteopath Med, Dept Biomed Sci, 400 Lee St North, Lewisburg, WV 24901 USA.	tliu@osteo.wvsom.edu					Ashar Rajiv M, 2002, J Interv Cardiol, V15, P101, DOI 10.1111/j.1540-8183.2002.tb01040.x; DeRubertis BG, 2012, J VASC SURG, V56, P580, DOI DOI 10.1016/J.JVS.2012.05.024; Gagne PJ, 2018, J VASC SURG-VENOUS L, V6, P48, DOI 10.1016/j.jvsv.2017.07.009; Gagne PJ, 2017, J VASC SURG-VENOUS L, V5, P678, DOI 10.1016/j.jvsv.2017.04.007; Hameed M, 2017, PHLEBOLOGY, V32, P440, DOI 10.1177/0268355516680458; Hingorani A., 2010, J VASC SURG, V52, P804, DOI DOI 10.1016/J.JVS.2010.06.029; Jeanneret C, 2019, VASA, V48, P377, DOI 10.1024/0301-1526/a000794; Kibbe MR, 2004, J VASC SURG, V39, P937, DOI 10.1016/j.jvs.2003.12.032; Mahnken AH, 2014, CARDIOVASC INTER RAD, V37, P889, DOI 10.1007/s00270-014-0875-4; Mako K, 2019, VASA, V48, P381, DOI 10.1024/0301-1526/a000775; Mousa AY, 2013, ANN VASC SURG, V27, P984, DOI 10.1016/j.avsg.2013.05.001; Murphy E, 2016, J VASC SURG, V63, p33S, DOI 10.1016/j.jvs.2016.03.216; Neglen P, 2002, J VASC SURG, V35, P694, DOI 10.1067/mva.2002.121127; Neglen P, 2007, J VASC SURG, V46, P979, DOI 10.1016/j.jvs.2007.06.046; Raju S, 2018, PHLEBOLOGY, V33, P451, DOI 10.1177/0268355517718763; Raju S, 2014, J VASC SURG-VENOUS L, V2, P260, DOI 10.1016/j.jvsv.2013.12.004; Raju S, 2014, J VASC SURG-VENOUS L, V2, P52, DOI 10.1016/j.jvsv.2013.01.005; Raju S, 2013, J VASC SURG, V57, P1163, DOI 10.1016/j.jvs.2012.11.084; Sharafuddin MJ, 2017, J VASC SURG, V66, P618, DOI 10.1016/j.jvs.2017.03.446	19	1	1	0	0	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0301-1526			VASA	Vasa	JAN	2021	50	1			SI		68	73		10.1024/0301-1526/a000873			6	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	PQ4VY	32552609				2022-04-28	WOS:000606545800010
J	Belch, JJF; Brodmann, M; Baumgartner, I; Binder, CJ; Casula, M; Heiss, C; Kahan, T; Parini, P; Poredos, P; Catapano, AL; Tokgozoglu, L				Belch, Jill J. F.; Brodmann, Marianne; Baumgartner, Iris; Binder, Christoph J.; Casula, Manuela; Heiss, Christian; Kahan, Thomas; Parini, Paolo; Poredos, Pavel; Catapano, Alberico L.; Tokgozoglu, Lale			Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Review						Peripheral arterial disease; lipid lowering; treatment targets	DUAL ANTIPLATELET THERAPY; CARDIOVASCULAR-DISEASE; INTERMITTENT CLAUDICATION; STATIN THERAPY; WALKING PERFORMANCE; MODIFYING THERAPY; RISK POPULATION; DOUBLE-BLIND; CORONARY; METAANALYSIS	Patients with peripheral arterial disease (PAD) are at very high risk of cardiovascular events, but risk factor management is usually suboptimal. This Joint Task Force from the European Atherosclerosis Society and the European Society of Vascular Medicine has updated evidence on the management on dyslipidaemia and thrombotic factors in patients with PAD. Guidelines recommend a low-density lipoprotein cholesterol (LDLC) goal of more than 50% reduction from baseline and <1.4 mmol/L (<55 mg/dL) in PAD patients. As demonstrated by randomized controlled trials, lowering LDL-C not only reduces cardiovascular events but also major adverse limb events (MALE), including amputations, of the order of 25%. Addition of ezetimibe or a PCSK9 inhibitor further decreases the risk of cardiovascular events, and PCSK9 inhibition has also been associated with reduction in the risk of MALE by up to 40%. Furthermore, statin- based treatment improved walking performance, including maximum walking distance, and pain-free walking distance and duration. This Task Force recommends strategies for managing statin-associated muscle symptoms to ensure that PAD patients benefit from lipidlowering therapy. Antiplatelet therapy, either daily clopidogrel 75 mg or the combination of aspirin 100 mg and rivaroxaban (2 x 2.5 mg) is also indicated to prevent cardiovascular events. Dual pathway inhibition (aspirin and rivaroxaban) may be considered following revascularization, taking into account bleeding risk. This Joint Task Force believes that adherence with these recommendations for lipid-lowering and antithrombotic therapy will improve the morbidity and mortality in patients with PAD.	[Belch, Jill J. F.] Univ Dundee, Ninewells Hosp, Ninewells Hosp & Med Sch, Inst Cardiovasc Res, Dundee, Scotland; [Brodmann, Marianne] Med Univ, Div Angiol, Graz, Austria; [Baumgartner, Iris] Univ Bern, Bern Univ Hosp, Swiss Cardiovasc Ctr, Div Angiol, Bern, Switzerland; [Binder, Christoph J.] Med Univ Vienna, Dept Lab Med, Vienna, Austria; [Casula, Manuela] Univ Milan, Dept Pharmacol & Biomol Sci, Epidemiol & Prevent Pharmacol Serv SEFAP, Milan, Italy; [Casula, Manuela; Catapano, Alberico L.] IRCCS MultiMed, Milan, Italy; [Heiss, Christian] Univ Surrey, Dept Clin & Expt Med, Guildford, Surrey, England; [Heiss, Christian] Surrey & Sussex Healthcare NHS Trust, East Surrey Hosp, Redhill, Surrey, England; [Kahan, Thomas] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Div Cardiovasc Med, Stockholm, Sweden; [Parini, Paolo] Karolinska Inst, Dept Med, Stockholm, Sweden; [Parini, Paolo] Karolinska Inst, Dept Lab Med, Stockholm, Sweden; [Parini, Paolo] Karolinska Univ Hosp, Theme Inflammat & Ageing, Stockholm, Sweden; [Poredos, Pavel] Univ Med Ctr Ljubljana, Dept Vasc Dis, Ljubljana, Slovenia; [Catapano, Alberico L.] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy; [Tokgozoglu, Lale] Hacettepe Univ, Dept Cardiol, Fac Med, TR-06230 Ankara, Turkey		Tokgozoglu, L (通讯作者)，Hacettepe Univ, Dept Cardiol, Fac Med, TR-06230 Ankara, Turkey.; Belch, JJF (通讯作者)，Univ Dundee, Inst Cardiovasc Res, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland.	j.j.f.belch@dundee.ac.uk		Belch, Jill JF/0000-0001-8280-6689			Aboyans V, 2017, KARDIOL POL, V75, P1065, DOI 10.5603/KP.2017.0216; Anand SS, 2018, LANCET, V391, P219, DOI 10.1016/S0140-6736(17)32409-1; Annemans L, 2018, EUR HEART J, V39, P2546, DOI 10.1093/eurheartj/ehx710; Aronow WS, 2003, AM J CARDIOL, V92, P711, DOI 10.1016/S0002-9149(03)00833-6; Aung PP, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000123.pub2; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Belch JJF, 2010, J VASC SURG, V52, P825, DOI 10.1016/j.jvs.2010.04.027; Belch JJF, 2003, ARCH INTERN MED, V163, P884, DOI 10.1001/archinte.163.8.884; Berger JS, 2009, JAMA-J AM MED ASSOC, V301, P1909, DOI 10.1001/jama.2009.623; Bonaca MP, 2020, NEW ENGL J MED, V382, P1994, DOI 10.1056/NEJMoa2000052; Bonaca MP, 2018, LANCET DIABETES ENDO, V6, P934, DOI 10.1016/S2213-8587(18)30290-0; Bonaca MP, 2018, CIRCULATION, V137, P338, DOI 10.1161/CIRCULATIONAHA.117.032235; Bonaca MP, 2016, J AM COLL CARDIOL, V67, P2719, DOI 10.1016/j.jacc.2016.03.524; Bonaca MP, 2013, CIRCULATION, V127, P1522, DOI 10.1161/CIRCULATIONAHA.112.000679; Boren J, 2020, EUR HEART J, V41, P2313, DOI 10.1093/eurheartj/ehz962; Boren J, 2016, CURR OPIN LIPIDOL, V27, P473, DOI 10.1097/MOL.0000000000000330; Bregar U, 2009, VASA-J VASCULAR DIS, V38, P155, DOI 10.1024/0301-1526.38.2.155; Bruckert E, 2005, CARDIOVASC DRUG THER, V19, P403, DOI 10.1007/s10557-005-5686-z; Cacoub PP, 2009, EUR HEART J, V30, P192, DOI 10.1093/eurheartj/ehn534; Cannon CP, 2015, NEW ENGL J MED, V372, P2387, DOI 10.1056/NEJMoa1410489; Castano G, 2003, ANGIOLOGY, V54, P25, DOI 10.1177/000331970305400104; Chen DC, 2017, AM J CARDIOL, V119, P1146, DOI 10.1016/j.amjcard.2016.12.023; Chowdhury R, 2013, EUR HEART J, V34, P2940, DOI 10.1093/eurheartj/eht295; Cohen JD, 2012, J CLIN LIPIDOL, V6, P208, DOI 10.1016/j.jacl.2012.03.003; CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; Criqui MH, 2015, CIRC RES, V116, P1509, DOI 10.1161/CIRCRESAHA.116.303849; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Diehm C, 2004, ATHEROSCLEROSIS, V172, P95, DOI 10.1016/S0021-9150(03)00204-1; Dopheide JF, 2018, J CLIN LIPIDOL, V12, P711, DOI 10.1016/j.jacl.2018.02.013; Droz-Perroteau C, 2019, THERAPIE, V74, P459, DOI 10.1016/j.therap.2019.02.001; Eikelboom JW, 2017, NEW ENGL J MED, V377, P1319, DOI 10.1056/NEJMoa1709118; Ference BA, 2018, J AM COLL CARDIOL, V72, P1141, DOI 10.1016/j.jacc.2018.06.046; Ference BA, 2017, EUR HEART J, V38, P2459, DOI 10.1093/eurheartj/ehx144; Frank U, 2019, VASA, V48, P7, DOI 10.1024/0301-1526/a000834; Franzone A, 2016, JAMA CARDIOL, V1, P795, DOI 10.1001/jamacardio.2016.2811; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gerhard-Herman MD, 2017, CIRCULATION, V135, pE686, DOI 10.1161/CIR.0000000000000470; Gudbjartsson DF, 2019, J AM COLL CARDIOL, V74, P2982, DOI 10.1016/j.jacc.2019.10.019; Heart Protection Study Collaborat, 2007, J AM COLL CARDIOL, V49, P311, DOI 10.1016/j.jacc.2006.08.052; Johansson L, 2009, ANGIOLOGY, V60, P539, DOI 10.1177/0003319708324925; Joosten MM, 2012, JAMA-J AM MED ASSOC, V308, P1660, DOI 10.1001/jama.2012.13415; Jukema JW, 2019, J AM COLL CARDIOL, V74, P1167, DOI 10.1016/j.jacc.2019.03.013; Klarin D, 2019, NAT MED, V25, P1274, DOI 10.1038/s41591-019-0492-5; Kokkinidis DG, 2020, VASC MED, V25, P106, DOI 10.1177/1358863X19894055; Krauss RM, 2010, CURR OPIN LIPIDOL, V21, P305, DOI 10.1097/MOL.0b013e32833b7756; Kuiper JG, 2017, CLIN THER, V39, P819, DOI 10.1016/j.clinthera.2017.03.001; KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011; Landmesser U, 2018, EUR HEART J, V39, P1131, DOI 10.1093/eurheartj/ehx549; Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4; Lotteau S, 2019, JACC-BASIC TRANSL SC, V4, P509, DOI 10.1016/j.jacbts.2019.03.012; Mach F, 2020, EUR HEART J, V41, P111, DOI [10.1093/eurheartj/ehz455, 10.15829/1560-4071-2020-3826]; McDermott MM, 2003, ARCH INTERN MED, V163, P2157, DOI 10.1001/archinte.163.18.2157; Mehta SR, 2018, J AM COLL CARDIOL, V71, P303, DOI [10.1016/j.jacc.2018.03.008, 10.1016/j.jacc.2017.12.001]; Mohler ER, 2003, CIRCULATION, V108, P1481, DOI 10.1161/01.CIR.0000090686.57897.F5; Momsen AH, 2009, EUR J VASC ENDOVASC, V38, P463, DOI 10.1016/j.ejvs.2009.06.002; Mondillo S, 2003, AM J MED, V114, P359, DOI 10.1016/S0002-9343(03)00010-X; Narula N, 2018, J AM COLL CARDIOL, V72, P2152, DOI 10.1016/j.jacc.2018.08.002; Nordestgaard BG, 2016, CIRC RES, V118, P547, DOI 10.1161/CIRCRESAHA.115.306249; Parker BA, 2013, CIRCULATION, V127, P96, DOI 10.1161/CIRCULATIONAHA.112.136101; Pastori D, 2020, THROMB HAEMOSTASIS, V120, P866, DOI 10.1055/s-0040-1709711; Pedersen TR, 1998, AM J CARDIOL, V81, P333, DOI 10.1016/S0002-9149(97)00904-1; Pradhan AD, 2018, CIRCULATION, V138, P141, DOI [10.1161/CIRCULATIONAHA.118.034645, 10.1161/CIRCULATIONAHA.118.035432]; Ramos R, 2016, J AM COLL CARDIOL, V67, P630, DOI 10.1016/j.jacc.2015.11.052; Rein P, 2015, ATHEROSCLEROSIS, V239, P299, DOI 10.1016/j.atherosclerosis.2015.01.021; Reinecke H, 2015, EUR HEART J, V36, P932, DOI 10.1093/eurheartj/ehv006; Rizzo M, 2008, ATHEROSCLEROSIS, V197, P237, DOI 10.1016/j.atherosclerosis.2007.03.034; Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI [10.4997/JRCPE.2017.212, 10.1056/NEJMoa1615664]; Sartipy F, 2018, EUR J VASC ENDOVASC, V55, P529, DOI 10.1016/j.ejvs.2018.01.019; Schwartz GG, 2018, NEW ENGL J MED, V379, P2097, DOI 10.1056/NEJMoa1801174; Schwartz GG, 2020, CIRCULATION, V141, P1608, DOI 10.1161/CIRCULATIONAHA.120.046524; Silbernagel G, 2015, DIABETES VASC DIS RE, V12, P146, DOI 10.1177/1479164114560342; Stroes ES, 2015, EUR HEART J, V36, P1012, DOI 10.1093/eurheartj/ehv043; Tarver T, 2012, J CONS HLTH INTERNET, V16, P366, DOI 10.1080/15398285.2012.701177; Teramoto T, 2016, ATHEROSCLEROSIS, V251, P248, DOI 10.1016/j.atherosclerosis.2016.07.001; Tunstall-Pedoe H, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005967; Ward NC, 2019, CIRC RES, V124, P328, DOI 10.1161/CIRCRESAHA.118.312782; Weir-McCall JR, 2016, INT J CARDIOVAS IMAG, V32, P825, DOI 10.1007/s10554-016-0842-z; Welten GMJM, 2008, J AM COLL CARDIOL, V51, P1588, DOI 10.1016/j.jacc.2007.11.077; Zhang HB, 2013, ANN INTERN MED, V158, P526, DOI 10.7326/0003-4819-158-7-201304020-00004	80	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	NOV	2021	50	6					401	411		10.1024/0301-1526/a000969			11	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6JL	34743585	Green Submitted, hybrid, Green Published			2022-04-28	WOS:000753518900001
J	Kotov, A; Peters, F; Debus, ES; Zeller, T; Heider, P; Stavroulakis, K; Remig, J; Gussmann, A; Hoffmann, J; Friedrich, O; Nolte, T; Behrendt, CA				Kotov, Artur; Peters, Frederik; Debus, Eike Sebastian; Zeller, Thomas; Heider, Peter; Stavroulakis, Konstantinos; Remig, Juergen; Gussmann, Andreas; Hoffmann, Johannes; Friedrich, Oliver; Nolte, Thomas; Behrendt, Christian-Alexander			The prospective GermanVasc cohort study Endovascular and open-surgical treatment of symptomatic peripheral artery disease	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Health services research; peripheral artery disease; intermittent claudication; chronic limb-threatening ischaemia; endovascular techniques; bypass surgery	REVASCULARIZATION; EPIDEMIOLOGY; OUTCOMES; LESSONS; IMPACT	Background: Previous observational studies reported a wide variation and possible room for improvement in the treatment of patients suffering from symptomatic peripheral artery disease (PAD). Yet, systematic assessment of everyday clinical practice is lacking. A Gererat Data Protection Regulation (GDPR) compliant registry was developed and used to collect comprehensive data on clinical treatment and outcomes regarding PAD in Germany. Here, we report baseline characteristics of patients prospectively enrolled until the end of 2020. Methods: The GermanVasc registry study is a prospective longitudinal multicentre cohort study. Between 1st May 2018 and 31st December 2020, invasive endovascular, open-surgical, and hybrid revascularisations of patients suffering from chronic symptomatic PAD were prospectively included after explicit informed consent (NCT03098290). For ensuring high quality of the data, we performed comprehensive risk-based and random-sample external and internal validation. Results: In total, 5608 patients from 31 study centres were included (34% females, median 69 years). On-site monitoring visits were performed at least once in all centres. The proportion of chronic limb threatening ischaemia was 30% and 13% were emergent admissions. 55% exhibited a previous revascularisation. Endovascular techniques made 69% among all documented invasive procedures (n=6449). Thirty-five percent were classified as patients with severe systemic disease, and 3% exhibited a constant threat to life according to the American Society of Anaesthesiologists classification. The risk profile comprised of 75% former or current smokers, 36% diabetes mellitus, and in 30% a current ischemic heart disease was present. At discharge, 93% of the patients received antiplatelets and 77% received statins. Conclusions: The GermanVasc registry study provides insights into real-world practice of treatment and outcomes of 5,608 patients with symptomatic PAD in Germany. The cohort covers a broader range of disease severity and types of interventions than usually found in trials. In future studies, comparative outcomes will be analysed in more detail.	[Kotov, Artur; Peters, Frederik; Debus, Eike Sebastian; Behrendt, Christian-Alexander] Univ Med Ctr Hamburg Eppendorf, Res Grp German Vasc, Martinistr 52, D-20246 Hamburg, Germany; [Zeller, Thomas] Univ Heart Ctr Freiburg Bad Krozingen, Bad Krozingen, Germany; [Heider, Peter] Isar Clin Munich, Munich, Germany; [Stavroulakis, Konstantinos] St Franziskus Hosp GmbH, Munster, Germany; [Remig, Juergen] Bonn Community Hosp, Haus St Petrus, Bonn, Germany; [Gussmann, Andreas] HELIOS Clin Ctr Berlin Buch, Berlin, Germany; [Hoffmann, Johannes] Contilia Elisabeth Hosp Essen, Essen, Germany; [Friedrich, Oliver] GFO Clin Bonn Operating St Marien, Bonn, Germany; [Nolte, Thomas] Bad Bevensen Heart & Vasc Ctr, Bad Bevensen, Germany		Behrendt, CA (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Res Grp German Vasc, Martinistr 52, D-20246 Hamburg, Germany.	behrendt@hamburg.de	Stavroulakis, Konstantinos/AGY-2739-2022; Behrendt, Christian-Alexander/M-2952-2017	Stavroulakis, Konstantinos/0000-0002-9775-9210; Peters, Frederik/0000-0001-5832-8410; Behrendt, Christian-Alexander/0000-0003-0406-3319	Innovations Fund of the German Federal Joint Committee [01VSF16008, 01VSF18085]	The IDOMENEO and RABATT studies were funded by the Innovations Fund of the German Federal Joint Committee (grant number 01VSF16008, grant number 01VSF18085, PI: CAB).	Aboyans V, 2017, KARDIOL POL, V75, P1065, DOI 10.5603/KP.2017.0216; Bavendiek K, 2019, IFIP ADV INF COMM TE, V562, P345, DOI 10.1007/978-3-030-22312-0_24; Behrendt CA, 2018, GEFASSCHIRURGIE, V23, P32, DOI 10.1007/s00772-018-0387-7; Behrendt CA, 2020, EUR J VASC ENDOVASC, V60, P720, DOI 10.1016/j.ejvs.2020.07.078; Behrendt CA, 2020, EUR J VASC ENDOVASC, V60, P873, DOI 10.1016/j.ejvs.2020.08.027; Behrendt Christian-Alexander, 2020, Eur J Vasc Endovasc Surg, V59, P587, DOI 10.1016/j.ejvs.2019.12.034; Behrendt CA, 2020, EUR J VASC ENDOVASC, V59, P510, DOI 10.1016/j.ejvs.2020.01.029; Behrendt CA, 2019, EUR J VASC ENDOVASC, V57, P816, DOI 10.1016/j.ejvs.2019.02.023; Behrendt CA, 2020, GESUNDHEITSWESEN, V82, pS94, DOI 10.1055/a-0883-5098; Behrendt CA, 2019, VASA, V48, P262, DOI 10.1024/0301-1526/a000771; Behrendt CA, 2018, EUR J VASC ENDOVASC, V56, P217, DOI 10.1016/j.ejvs.2018.04.006; Bisdas T, 2015, J VASC SURG, V62, P965, DOI 10.1016/j.jvs.2015.04.441; Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2; Frank U, 2019, VASA, V48, P7, DOI 10.1024/0301-1526/a000834; Gerhard-Herman MD, 2017, CIRCULATION, V135, pE726, DOI 10.1161/CIR.0000000000000471; Gray WK, 2020, EUR J VASC ENDOVASC, V60, P711, DOI 10.1016/j.ejvs.2020.07.015; Hunt BD, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1968-6; Janssen F, 2020, TOB CONTROL; Kreutzburg T, 2020, EUR J VASC ENDOVASC, V59, P59, DOI 10.1016/j.ejvs.2019.08.006; Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4; Malyar N, 2020, VASA, V49, P382, DOI 10.1024/0301-1526/a000882; Menard MT, 2014, SEMIN VASC SURG, V27, P82, DOI 10.1053/j.semvascsurg.2015.01.003; Petersen T, 2019, DUD, V43, P507, DOI [10.1007/s11623-019-1153-z, DOI 10.1007/S11623-019-1153-Z]; Renteria E, 2016, TOB CONTROL, V25, P551, DOI 10.1136/tobaccocontrol-2015-052265; Riess HC, 2018, VASA, V47, P491, DOI 10.1024/0301-1526/a000720; von Elm E, 2007, LANCET, V370, P1453, DOI [10.2471/BLT.07.045120, 10.1016/j.jclinepi.2007.11.008, 10.1371/journal.pmed.0040296]	26	3	3	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	NOV	2021	50	6					446	452		10.1024/0301-1526/a000966			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6JL	34279120	hybrid			2022-04-28	WOS:000753518900006
J	Lavier, J; Bouzourene, K; Millet, G; Rosenblatt-Velin, N; Mazzolai, L; Pellegrin, M				Lavier, J.; Bouzourene, K.; Millet, G.; Rosenblatt-Velin, N.; Mazzolai, L.; Pellegrin, M.			Angiology Abstracts	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article																		0	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	NOV	2021	50			107			8	34					27	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6KL					2022-04-28	WOS:000753521600001
J	Bradley, NA; Roxburgh, C; Khan, F; Guthrie, G				Bradley, Nicholas Andrew; Roxburgh, Campbell; Khan, Faisel; Guthrie, Graeme			Postimplantation syndrome in endovascular aortic aneurysm repair - a systematic review	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Review						Aneurysm; EVAR; postimplantation syndrome	HUMAN-ENDOTHELIAL-CELLS; INFLAMMATORY RESPONSE; INTERLEUKIN-6 RELEASE; II ENDOLEAKS; GRAFT; PROCALCITONIN; INFECTION; EVAR; IL-6; EXPRESSION	Postimplantation syndrome (PIS) following endovascular aortic aneurysm repair (EVAR) is a poorly understood phenomenon occurring in the early post-operative course. The underlying aetiology, risk factors, clinical sequalae, and treatment options, are largely unknown. The lack of any standardised diagnostic criteria limits current research in this field. The MEDLINE database was interrogated using a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) search strategy. Five search terms were used; "postimplantation syndrome" AND "aneurysm", AND "infection", AND "complications", AND "biomarkers", AND "outcomes". 19 studies were included in the review process, reporting a 17.4%-39.0% incidence of PIS. IL-6 was the most commonly elevated biomarker in PIS vs. non-PIS patients. There was a higher incidence of PIS in patients who received polyester rather than expanded-polytetrafluoroethylene (ePTFE) grafts. There was a lower rate of type 2 endoleaks observed in patients who developed PIS. Early major adverse cardiovascular events (MACE) were higher in PIS patients, however there were no studies reporting long-term MACE. Length of stay was higher in PIS patients. Current data support the role of IL-6 as being key to the development of PIS following EVAR. Further work describing the effect that PIS has on long-term clinical outcomes is needed. Lack of standardised diagnostic criteria limit the reporting of PIS between centres, the criteria proposed by this review may resolve this.	[Bradley, Nicholas Andrew; Guthrie, Graeme] Ninewells Hosp & Med Sch, Dundee, Scotland; [Roxburgh, Campbell] Glasgow Royal Infirm, Acad Dept Surg, Glasgow, Lanark, Scotland; [Khan, Faisel] Univ Dundee, Sch Med, Dundee, Scotland		Bradley, NA (通讯作者)，Ninewells Hosp & Med Sch, Dept Vasc Surg, James Arrot Dr, Dundee DD2 1SY, Scotland.	nicholasbradley@nhs.net		Bradley, Nicholas/0000-0002-6588-2636; Khan, Faisel/0000-0002-9889-0229			Arnaoutoglou E, 2015, EUR J VASC ENDOVASC, V49, P175, DOI 10.1016/j.ejvs.2014.12.006; Arnaoutoglou E, 2016, J VASC SURG, V63, P1248, DOI 10.1016/j.jvs.2015.11.043; Arnaoutoglou E, 2011, INTERACT CARDIOV TH, V12, P609, DOI 10.1510/icvts.2010.256784; Asarias JR, 2011, J INVEST SURG, V24, P87, DOI 10.3109/08941939.2010.548904; Ashton HA, 2002, BMJ-BRIT MED J, V325, P1135; Bacchiega BC, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005038; Brewster DC, 2003, J VASC SURG, V37, P1106, DOI 10.1067/mva.2003.363; Capoccia L, 2016, ANN VASC SURG, V30, P198, DOI 10.1016/j.avsg.2015.07.017; Chi LQ, 2001, J INTERF CYTOK RES, V21, P231, DOI 10.1089/107999001750169871; Choke E, 2004, J CARDIOVASC SURG, V45, P349; Comstedt P, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-67; Cosford PA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002945.pub2; de la Motte L, 2014, ANN SURG, V260, P540, DOI 10.1097/SLA.0000000000000895; Dijkstra ML, 2020, J VASC SURG, V71, P780, DOI 10.1016/j.jvs.2019.04.486; Dua A, 2014, J VASC SURG, V59, P1512, DOI 10.1016/j.jvs.2014.01.007; Fardet L, 2014, DRUGS, V74, P1731, DOI 10.1007/s40265-014-0282-9; Gelfand DV, 2006, ANN VASC SURG, V20, P69, DOI 10.1007/s10016-005-9382-z; Grygiel-Gorniak Bogna, 2015, Reumatologia (Warsaw), V53, P207, DOI 10.5114/reum.2015.53998; Hodes GE, 2016, NEUROBIOL STRESS, V4, P15, DOI 10.1016/j.ynstr.2016.03.003; Isselbacher EM, 2005, CIRCULATION, V111, P816, DOI 10.1161/01.CIR.0000154569.08857.7A; Ito E, 2018, ANN VASC DIS, V11, P520, DOI 10.3400/avd.oa.18-00058; Jeong MJ, 2019, EUR RADIOL, V29, P6591, DOI 10.1007/s00330-019-06306-5; JOHNSTON KW, 1991, J VASC SURG, V13, P452, DOI 10.1067/mva.1991.26737; Julian PT., 2011, COCHRANE HDB SYSTEMA; Kahlberg A, 2016, J VASC SURG, V64, P313, DOI 10.1016/j.jvs.2016.04.008; Kakisis JD, 2014, J VASC SURG, V60, P1140, DOI 10.1016/j.jvs.2014.05.041; Kwon TW, 2016, MED US, V95; Lee JH, 2018, J CARDIOTHORAC SURG, V13, DOI 10.1186/s13019-018-0712-y; Li HL, 2018, ANN VASC SURG, V51, P306, DOI 10.1016/j.avsg.2018.02.038; Lo RC, 2016, J VASC SURG, V63, P895, DOI 10.1016/j.jvs.2015.10.088; MAY LT, 1989, BIOCHEM BIOPH RES CO, V159, P991, DOI 10.1016/0006-291X(89)92206-7; Moulakakis KG, 2013, J VASC SURG, V57, P668, DOI 10.1016/j.jvs.2012.09.034; Mutlu GM, 2007, J CLIN INVEST, V117, P2952, DOI 10.1172/JCI30639; Nano G, 2014, ANN VASC SURG, V28, P1409, DOI 10.1016/j.avsg.2014.03.001; Ng MKC, 2004, HEART, V90, P829, DOI 10.1136/hrt.2003.031492; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; Plaisance KI, 2000, ARCH INTERN MED, V160, P449, DOI 10.1001/archinte.160.4.449; PODOR TJ, 1989, ANN NY ACAD SCI, V557, P374; SAKAMOTO K, 1994, CYTOKINE, V6, P181, DOI 10.1016/1043-4666(94)90040-X; Sartipy F, 2015, VASC ENDOVASC SURG, V49, P79, DOI 10.1177/1538574415595209; Sartipy F, 2014, ANN VASC SURG, V28, P866, DOI 10.1016/j.avsg.2013.11.011; Sarwar N, 2012, LANCET, V379, P1205, DOI 10.1016/S0140-6736(11)61931-4; Schuetz P, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-107; Schuetz P, 2010, EXPERT REV ANTI-INFE, V8, P575, DOI [10.1586/eri.10.25, 10.1586/ERI.10.25]; Senchenkova EY, 2013, AM J PATHOL, V183, P173, DOI 10.1016/j.ajpath.2013.03.014; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.g7647, 10.1136/bmj.b2700]; Shukuzawa K, 2019, J VASC SURG, V70, P181, DOI 10.1016/j.jvs.2018.10.062; Silveira Fábio Porto, 2012, Rev. Col. Bras. Cir., V39, P33; Silverberg D, 2006, J VASC SURG, V44, P453, DOI 10.1016/j.jvs.2006.04.058; SIRONI M, 1989, J IMMUNOL, V142, P549; Storck M, 2001, Vasc Surg, V35, P23, DOI 10.1177/153857440103500105; Strohmayer EA, 2011, ENDOCRIN METAB CLIN, V40, P409, DOI 10.1016/j.ecl.2011.01.011; Swartbol P, 1998, J VASC SURG, V28, P664, DOI 10.1016/S0741-5214(98)70092-8; Swartbol P, 1997, J BIOMED MATER RES, V36, P400, DOI 10.1002/(SICI)1097-4636(19970905)36:3<400::AID-JBM15>3.0.CO;2-H; Swerdlow NJ, 2019, CIRC RES, V124, P647, DOI 10.1161/CIRCRESAHA.118.313186; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; Thompson MM, 2003, BRIT J SURG, V90, P897, DOI 10.1002/bjs.4280; Ultee KHJ, 2018, EUR J VASC ENDOVASC, V56, P794, DOI 10.1016/j.ejvs.2018.06.009; Velazquez OC, 1999, AM J SURG, V178, P185, DOI 10.1016/S0002-9610(99)00144-0; Venkiteshwaran A, 2009, MABS-AUSTIN, V1, P432, DOI 10.4161/mabs.1.5.9497; Voute MT, 2012, J VASC SURG, V56, P1503, DOI 10.1016/j.jvs.2012.06.072; Wainstein MV, 2017, DIABETOL METAB SYNDR, V9, DOI 10.1186/s13098-017-0266-5; White Sarah B, 2009, Semin Intervent Radiol, V26, P33, DOI 10.1055/s-0029-1208381; Yan SL, 2014, INFLAMM BOWEL DIS, V20, P353, DOI 10.1097/01.MIB.0000440614.83703.84	64	2	2	1	2	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	MAY	2021	50	3					174	185		10.1024/0301-1526/a000913			12	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QU	33138736				2022-04-28	WOS:000695708300004
J	Lichtenberg, MKW; Stahlhoff, S; Mlynczak, K; Golicki, D; Gagne, P; Razavi, MK; de Graaf, R; Kolluri, R; Kolasa, K				Lichtenberg, Michael K. W.; Stahlhoff, Stefan; Mlynczak, Katarzyna; Golicki, Dominik; Gagne, Paul; Razavi, Mahmood K.; de Graaf, Rick; Kolluri, Raghu; Kolasa, Katarzyna			Endovascular mechanical thrombectomy versus thrombolysis in patients with iliofemoral deep vein thrombosis - a systematic review and meta-analysis	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Review						Thrombectomy; iliofemoral deep venous thrombosis; thrombolytic therapy; hematuria; hemolysis; post-thrombotic syndrome; pulmonary embolism	CATHETER-DIRECTED THROMBOLYSIS; VENOUS THROMBOSIS; POSTTHROMBOTIC SYNDROME; VALVE FUNCTION; ANTICOAGULATION; ANGIOJET; THERAPY; LYSIS; RISK	Background: This study sought to compare effectiveness and safety of percutaneous mechanical thrombectomy (PMT) and thrombolysis alone (THR) in patients with acute or subacute iliofemoral deep vein thrombosis (IfDVT). Patients and methods: Observational and randomized trials, published between January 2001 to February 2019 were identified by searching MEDLINE. Studies on deep venous thrombosis (DVT) treated with either THR or PMT adjunctive to conventional anticoagulation and compressive intervention were included. Meta-analysis of proportions was conducted to assess effectiveness outcomes of successful lysis and primary patency, post-thrombotic syndrome (PTS), valvular reflux, recurrent DVT, as well as safety outcomes of major bleeding, hematuria, and pulmonary embolism. Results: Of 77 identified records, 17 studies including 1417 patients were eligible. Pooled proportion of successful lysis was similar between groups (THR: 95 % [I-2 = 68.4 %], PMT 96 %, [I-2 = 0 %]; Q(bet) [Cochran's Q between groups] 0.3, p = 0.61). However, pooled proportion of 6-month primary patency was lower after THR than after PMT (68 % [I-2 = 15.6 %] versus 94 %; Q(bet) 26.4, p < 0.001). Considerable heterogeneity within groups did not allow for between-group comparison of PTS and recurrent DVT. Major bleeding was more frequent after THR than after PMT (6.0 % [I-2 = 0 %] versus 1.0 % [I-2 = 0 %]; Q(bet) 12.3, p < 0.001). Incidence of hematuria was lower after THR as compared to PMT (2 % [I-2 = 56 %] versus 91.3 % [I-2 = 91.7 %]; Q(bet) 714, p < 0.001). Incidences of valvular reflux and pulmonary embolism were similar across groups (THR: 61 % versus PMT: 53 %; Q(bet) 0.7, p = 0.39 and THR: 2 % versus PMT: 1 %; Q(bet) 1.1, p = 0.30, respectively). Conclusions: In patients with iliofemoral DVT, percutaneous mechanical thrombectomy was associated with a higher cumulative 6-month primary patency and a lower incidence of major bleeding compared to thrombolysis alone. Risk of hemolysis from mechanical thrombectomy needs further consideration.	[Lichtenberg, Michael K. W.; Stahlhoff, Stefan] Klinikum Arnsberg, Venous Ctr, Angiol Clin, Arnsberg, Germany; [Mlynczak, Katarzyna; Golicki, Dominik] Med Univ Warsaw, Dept Expt & Clin Pharmacol, Warsaw, Poland; [Mlynczak, Katarzyna; Golicki, Dominik] HealthQuest, Warsaw, Poland; [Gagne, Paul] Vasc Experts, Darien, CT USA; [Razavi, Mahmood K.] St Joseph Hosp, Heart & Vasc Ctr, Orange, CA USA; [de Graaf, Rick] Clin Ctr Friedrichshafen, Clin Diagnost & Intervent Radiol Nucl Med, Friedrichshafen, Germany; [Kolluri, Raghu] Ohio Hlth Heart & Vasc, Columbus, OH USA; [Kolasa, Katarzyna] Kozminski Univ, Hlth Econ & Healthcare Management Div, Warsaw, Poland		Lichtenberg, MKW (通讯作者)，Klinikum Arnsberg, Arnsberg Venous Ctr, Angiol Clin, Stolte Ley 5, D-59759 Arnsberg, Germany.	klichte@gmx.net	Golicki, Dominik/N-5656-2018	Golicki, Dominik/0000-0001-7741-4760	Arnsberg Venous Center	This study was funded by Arnsberg Venous Center.	AbuRahma AF, 2001, ANN SURG, V233, P752, DOI 10.1097/00000658-200106000-00004; Bashir R, 2014, JAMA INTERN MED, V174, P1494, DOI 10.1001/jamainternmed.2014.3415; Borenstein M., 2009, INTRO META ANAL; Comerota AJ, 2019, CIRCULATION, V139, P1162, DOI 10.1161/CIRCULATIONAHA.118.037425; Dopheide JF, 2018, VASA, V47, P56, DOI 10.1024/0301-1526/a000666; Elsharawy M, 2002, EUR J VASC ENDOVASC, V24, P209, DOI 10.1053/ejvs.2002.1665; Engelberger RP, 2017, J THROMB HAEMOST, V15, P1351, DOI 10.1111/jth.13709; Engelberger RP, 2015, CIRC-CARDIOVASC INTE, V8, DOI 10.1161/CIRCINTERVENTIONS.114.002027; Escobar GA, 2017, ANN VASC SURG, V42, P238, DOI 10.1016/j.avsg.2016.12.018; Gombert A, 2018, PHLEBOLOGY, V33, P251, DOI 10.1177/0268355517697784; Haig Y, 2016, LANCET HAEMATOL, V3, pE64, DOI 10.1016/S2352-3026(15)00248-3; Haig Y, 2013, J VASC INTERV RADIOL, V24, P17, DOI 10.1016/j.jvir.2012.09.023; Kuo TT, 2017, J CHIN MED ASSOC, V80, P72, DOI 10.1016/j.jcma.2016.08.012; Laiho MK, 2004, EUR J VASC ENDOVASC, V28, P391, DOI 10.1016/j.ejvs.2004.06.007; Lee CY, 2013, J CHIN MED ASSOC, V76, P265, DOI 10.1016/j.jcma.2013.01.006; Lichtenberg M, 2019, VASA, V48, P341, DOI 10.1024/0301-1526/a000779; Liu G, 2018, J ENDOVASC THER, V25, P133, DOI 10.1177/1526602817714570; Mewissen MW, 1999, RADIOLOGY, V211, P39, DOI 10.1148/radiology.211.1.r99ap4739; Morrow KL, 2017, J VASC SURG, V65, P1460, DOI 10.1016/j.jvs.2016.09.047; Murphy EH, 2010, J ENDOVASC THER, V17, P423, DOI 10.1583/10-3088.1; Notten P, 2020, LANCET HAEMATOL, V7, pE40, DOI 10.1016/S2352-3026(19)30209-1; Shen Y, 2019, J VASC SURG-VENOUS L, V7, P29, DOI 10.1016/j.jvsv.2018.06.016; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; Tichelaar VYIG, 2016, CARDIOVASC INTER RAD, V39, P1115, DOI 10.1007/s00270-016-1367-5; Vedantham S, 2017, NEW ENGL J MED, V377, P2240, DOI 10.1056/NEJMoa1615066; Vedantham S, 2016, VASC MED, V21, P400, DOI 10.1177/1358863X16650747; Vogel D, 2012, J VASC SURG, V56, P1351, DOI 10.1016/j.jvs.2012.02.053; Watson L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002783.pub4; Yoon WJ, 2018, ANN VASC SURG, V51, P234, DOI 10.1016/j.avsg.2018.01.081; Zhang XQ, 2014, CARDIOVASC INTER RAD, V37, P958, DOI 10.1007/s00270-013-0747-3	30	7	8	0	4	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0301-1526			VASA	Vasa	JAN	2021	50	1			SI		59	67		10.1024/0301-1526/a000875			9	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	PQ4VY	32449481	Bronze			2022-04-28	WOS:000606545800009
J	Hermann, I; Shchetynska-Marinova, T; Amendt, K; Hohneck, AL; Schonberg, SO; Zollner, FG; Sigl, M				Hermann, Ingo; Shchetynska-Marinova, Tetyana; Amendt, Klaus; Hohneck, Anna-Lena; Schoenberg, Stefan O.; Zoellner, Frank G.; Sigl, Martin			First experiences of local pulse wave velocity measurements in 4D-MRI in focally stented femoropopliteal arteries	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						4D-flow MRI; pulse wave velocity; femoropopliteal artery; stiffness	PRACTICE GUIDELINES; AXIAL-COMPRESSION; RISK-FACTORS; LOWER-LIMB; MANAGEMENT; STIFFNESS; DISEASE; SOCIETY; REVASCULARIZATION; PREVALENCE	Background: In peripheral arterial disease (PAD) the femoropopliteal (FP) artery is the most frequently recanalized lower limb artery. Stent-based interventions change the biomechanical properties of FP arteries. However, no clinical tool for functional imaging is established for quantitative measurements in vivo. Four-dimensional-flow magnetic resonance imaging enables a detailed evaluation of the hemodynamics of the central and - more challenging - the peripheral arteries. The present study aimed to determine the feasibility of assessing pulse wave velocities (PWV) as a marker of vessel stiffness in PAD patients with multiple spot stents and to compare the values with age-matched subjects and young-adult healthy subjects. Patients and methods: Contrast-free 4D-flow MRI was performed in seven PAD patients with focally stented FP arteries, five age-matched subjects after exclusion of PAD, and five young, healthy adults. PWV values were calculated from flow curves by using the foot-to-foot method. Results: Four-D-flow MRI sequences offering high spatial and temporal resolution enables quantification of flow velocity measurements and estimation of PkANs. Assessment of segmental PWV as a surrogate of vascular stiffness in focally stented femoral arteries is feasible. PWV values across all groups were 15.6 +/- 5.2 m/s, 13.3 +/- 4.1 m/s, and 9.9 +/- 2.2 m/s in PAD patients, senior-aged volunteers, and young-adult volunteers respectively. PWV values in PAD patients were similar with those in the senior-aged volunteers group (15.6 +/- 5.2 vs. 13.3 +/- 4.1 years, p=0.43). However, when compared to the young-adult volunteers, PAD patients had a statistically significantly higher mean local PWV (15.6 +/- 5.2 m/s vs. 9.9 +/- 2.2 m/s, p<0.05). Conclusions: Calculating segmental PWV in the femoral arteries is feasible in PAD patients with focally stented FP arteries. PWV values in PAD patients were similar to those in senior-aged volunteers, both of which were higher than in young-adult volunteers.	[Hermann, Ingo; Zoellner, Frank G.] Heidelberg Univ, Med Fac Mannheim, Mannheim Inst Intelligent Syst Med, Comp Assisted Clin Med, Mannheim, Germany; [Shchetynska-Marinova, Tetyana; Amendt, Klaus; Hohneck, Anna-Lena; Sigl, Martin] Heidelberg Univ, Med Fac Mannheim, Univ Med Ctr Mannheim, Dept Med 1, Mannheim, Germany; [Shchetynska-Marinova, Tetyana; Amendt, Klaus; Hohneck, Anna-Lena; Sigl, Martin] DZHK German Ctr Cardiovasc Res, Partner Site Heidelberg Mannheim, Mannheim, Germany; [Schoenberg, Stefan O.] Heidelberg Univ, Dept Clin Radiol & Nucl Med, Univ Med Ctr Mannheim, Med Fac Mannheim, Mannheim, Germany		Sigl, M (通讯作者)，Univ Vasc Ctr Mannheim, Dept Med 1, Sect Chief Angiol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	martin.sigl@umm.de	Zöllner, Frank G./A-2725-2012	Zöllner, Frank G./0000-0003-3405-1394			Amendt K, 2021, VASA, V50, P209, DOI 10.1024/0301-1526/a000927; Ben-Shlomo Y, 2014, J AM COLL CARDIOL, V63, P636, DOI 10.1016/j.jacc.2013.09.063; Bossuyt J, 2015, J HYPERTENS, V33, P1997, DOI 10.1097/HJH.0000000000000655; Bramwell JC, 1922, P R SOC LOND B-CONTA, V93, P298, DOI 10.1098/rspb.1922.0022; BUNTIN CM, 1990, ANN BIOMED ENG, V18, P549, DOI 10.1007/BF02364617; Conte MS, 2015, J VASC SURG, V61, p2S, DOI 10.1016/j.jvs.2014.12.009; Deloose K, 2018, J CARDIOVASC SURG, V59, P495, DOI 10.23736/S0021-9509.18.10583-0; Gerhard-Herman MD, 2017, J AM COLL CARDIOL, V69, pE71, DOI 10.1016/j.jacc.2016.11.007; Hansen TW, 2006, CIRCULATION, V113, P664, DOI 10.1161/CIRCULATIONAHA.105.579342; Hong SJ, 2015, JACC-CARDIOVASC INTE, V8, P472, DOI 10.1016/j.jcin.2014.10.016; Jaff MR, 2015, CATHETER CARDIO INTE, V86, P611, DOI 10.1002/ccd.26122; Kamenskiy A, 2018, ARTERIOSCL THROM VAS, V38, pe48, DOI 10.1161/ATVBAHA.117.310490; Klemm T, 2000, J MAGN RESON IMAGING, V12, P606, DOI 10.1002/1522-2586(200010)12:4<606::AID-JMRI14>3.0.CO;2-J; Ko YG, 2019, ANN VASC SURG, V58, P101, DOI 10.1016/j.avsg.2018.11.023; Lei L, 2019, COMPUT BIOL MED, V104, P205, DOI 10.1016/j.compbiomed.2018.11.019; MacTaggart J, 2019, ANN SURG, V270, P180, DOI 10.1097/SLA.0000000000002747; MacTaggart JN, 2014, J BIOMECH, V47, P2249, DOI 10.1016/j.jbiomech.2014.04.053; Malyar NM, 2015, VASA, V44, P257, DOI 10.1024/0301-1526/a000440; Nabeel PM, 2020, IEEE REV BIOMED ENG, V13, P74, DOI 10.1109/RBME.2019.2931587; Nichols WW, 2011, MCDONALD'S BLOOD FLOW IN ARTERIES: THEORETICAL, EXPERIMENTAL AND CLINICAL PRINCIPLES, 6TH EDITION, P1; Otsuka F, 2013, J CARDIOVASC SURG, V54, P191; Phillips JA, 2018, J ENDOVASC THER, V25, P295, DOI 10.1177/1526602818762805; Poulson W, 2018, J VASC SURG, V67, P607, DOI 10.1016/j.jvs.2017.01.071; Rengier F, 2013, VASA, V42, P395, DOI 10.1024/0301-1526/a000309; Schillaci G, 2013, HYPERTENS RES, V36, P679, DOI 10.1038/hr.2013.47; Schramm KM, 2020, J VASC INTERV RADIOL, V31, P614, DOI 10.1016/j.jvir.2019.10.025; Shige H, 2001, ATHEROSCLEROSIS, V155, P245, DOI 10.1016/S0021-9150(00)00558-X; Shinohara K, 2005, J ATHEROSCLER THROMB, V12, P205, DOI 10.5551/jat.12.205; Sigl M, 2019, CARDIOVASC INTER RAD, V42, P169, DOI 10.1007/s00270-018-2095-9; Song PG, 2019, LANCET GLOB HEALTH, V7, pE1020, DOI 10.1016/S2214-109X(19)30255-4; Tomoi Y, 2019, J VASC SURG, V70, P1166, DOI 10.1016/j.jvs.2018.12.044; van den Berg JC, 2019, CARDIOVASC INTER RAD, V42, P176, DOI 10.1007/s00270-018-2119-5; Watahiki M, 2020, VASC HEALTH RISK MAN, V16, P561, DOI 10.2147/VHRM.S284248; White C, 2007, NEW ENGL J MED, V356, P1241, DOI 10.1056/NEJMcp064483; Williams B, 2018, BLOOD PRESSURE, V27, P314, DOI [10.1080/08037051.2018.1527177, 10.1097/HJH.0000000000001961]; Wohlfahrt P, 2013, HYPERTENS RES, V36, P718, DOI 10.1038/hr.2013.21	36	0	0	0	1	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	NOV	2021	50	6					468	474		10.1024/0301-1526/a000965			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6JL	34269078				2022-04-28	WOS:000753518900009
J	Bauersachs, R; Debus, SE; Zeymer, U; Vogtlander, K; Gay, A				Bauersachs, R.; Debus, S. E.; Zeymer, U.; Vogtlander, K.; Gay, A.			Annual Meeting of the German Society for Angiology Society for Vascular Medicine 2021 Vascular Medicine 2.0-Angiology at the Pulse of Time Abstracts	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article									[Bauersachs, R.] Klinikum Darmstadt GmbH, Klin Gefass Med Angiol, Gefasszentrum, Darmstadt, Germany; [Debus, S. E.] Univ Hamburg Eppendorf, Dept Vasc Med Vasc Surg Angiol Endovasc Therapy, Hamburg, Germany; [Zeymer, U.] Klinikum Stadt Ludwigshafen, Med Klin B, Ludwigshafen, Germany; [Zeymer, U.] Inst Herzinfarktforsch, Ludwigshafen, Germany; [Vogtlander, K.] Bayer AG, Wuppertal, Germany; [Gay, A.] Bayer AG, Berlin, Germany		Bauersachs, R (通讯作者)，Klinikum Darmstadt GmbH, Klin Gefass Med Angiol, Gefasszentrum, Darmstadt, Germany.							0	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	SEP	2021	50			106			8	42					35	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6KD					2022-04-28	WOS:000753520700002
J	Koulouri, A; Darioli, R; Dine Qanadli, S; Katz, E; Eeckhout, E; Mazzolai, L; Depairon, M				Koulouri, Angeliki; Darioli, Roger; Dine Qanadli, Salah; Katz, Eugene; Eeckhout, Eric; Mazzolai, Lucia; Depairon, Michele			The atherosclerosis burden score: Comparison between the atherosclerosis burden score, coronary artery calcium score, carotid intima-media thickness and ankle-brachial index for the prediction of coronary artery disease among asymptomatic subjects	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Framingham risk score; cardiovascular disease prediction; subclinical atherosclerosis imaging	FRAMINGHAM RISK SCORE; CARDIOVASCULAR RISK; SUBCLINICAL ATHEROSCLEROSIS; AMERICAN-COLLEGE; ASSOCIATION; EVENTS; CHOLESTEROL; PROGRESSION; PREVALENCE; MARKERS	Purpose: We carried out this study to evaluate the predictive value of atherosclerosis burden score (ABS) to predict coronary artery disease (CAD) among asymptomatic patients without known cardiovascular disease (CVD), as compared to other imaging or functional techniques, namely coronary artery calcium (CAC) score, carotid intima-media thickness (C-IMT), and ankle brachial index (ABI). Patients and methods: This prospective study included 198 asymptomatic consecutive patients referred for evaluation of their cardiovascular (CV) risk and for therapeutic advice. Traditional CV risk factors, ABS, CAC score, C-IMT, ABI and an ECG-synchronized coronary CT-angiography (CCTA) were performed for each patient. We compared the predictive values of these atherosclerosis markers to detect CAD defined as coronary stenosis >= 30% objectivated by CCTA. Results:Among the whole sample, the area under the receiver-operating characteristic curve (ROC-AUC) was significantly higher for CAC score (0.81, p=0.015) than for ABS, the reference (0.70) but these values were lower for C-IMT (0.60, p=0.16) and particularly for ABI (0.56, p=0.0015). However, among patients at intermediate risk of coronary heart disease (CHD), according to Framingham risk score (FRS), the differences between the ROC-AUC values for ABS (0.70) and CAC score (0.76, p=0.36) were less pronounced. Again, as compared to ABS, the ROC-AUC values were lower for C-IMT (0.60, p=0.21) and ABI (0.57, p=0.06).Conclusions: ABS, an ultrasonographic score based on the assessment of carotid and femoral plaque burden, predicts more accurately CAD than other non-radiation tools analyzed here, and has a similar performance to CAC in patients at intermediate CHD risk. Thus, ABS could be an appropriate non-invasive and safe method to improve the detection of high-risk patients who will benefit from a more intensive therapy for the primary prevention of CVD.	[Koulouri, Angeliki; Mazzolai, Lucia; Depairon, Michele] Univ Hosp CHUV, Angiol, Chemin Mt Paisible 18, CH-1011 Lausanne, Switzerland; [Darioli, Roger] Univ Hosp CHUV, Lipid & Cardiovasc Prevent Unit, Lausanne, Switzerland; [Dine Qanadli, Salah] Univ Hosp CHUV, Diagnost & Intervent Radiol, Lausanne, Switzerland; [Katz, Eugene; Eeckhout, Eric] Univ Hosp CHUV, Cardiol, Lausanne, Switzerland		Depairon, M (通讯作者)，Univ Hosp CHUV, Angiol, Chemin Mt Paisible 18, CH-1011 Lausanne, Switzerland.	michele.depairon@chuv.ch			Emma Muschamp Foundation (Lausanne, Switzerland)	This study was supported by grant from Emma Muschamp Foundation (CH-1003 Lausanne, Switzerland).	Aboyans V, 2012, CIRCULATION, V126, P2890, DOI 10.1161/CIR.0b013e318276fbcb; Allison MA, 2010, AM J EPIDEMIOL, V171, P368, DOI 10.1093/aje/kwp382; Arnett DK, 2019, CIRCULATION, V140, pE596, DOI [10.1161/CIR.0000000000000678, 10.1016/j.jacc.2019.03.009, 10.1161/CIR.0000000000000677, 10.1016/j.jacc.2019.03.010]; Belcaro G, 2001, ATHEROSCLEROSIS, V156, P379, DOI 10.1016/S0021-9150(00)00665-1; Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cosentino F, 2020, EUR HEART J, V41, P255, DOI 10.1093/eurheartj/ehz486; Den Ruijter HM, 2012, JAMA-J AM MED ASSOC, V308, P796, DOI 10.1001/jama.2012.9630; Fernandez-Friera L, 2015, CIRCULATION, V131, P2104, DOI 10.1161/CIRCULATIONAHA.114.014310; Fluss R, 2005, BIOMETRICAL J, V47, P458, DOI 10.1002/bimj.200410135; Fowkes FGR, 2008, JAMA-J AM MED ASSOC, V300, P197, DOI 10.1001/jama.300.2.197; Gepner AD, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005179; Gnanenthiran SR, 2019, EUR HEART J-CARD IMG, V20, P1279, DOI 10.1093/ehjci/jez067; Goff DC, 2014, J AM COLL CARDIOL, V63, P2935, DOI [10.1016/j.jacc.2013.11.005, 10.1161/01.cir.0000437741.48606.98]; HARRIS PJ, 1980, CIRCULATION, V62, P240, DOI 10.1161/01.CIR.62.2.240; Hoo ZH, 2017, EMERG MED J, V34, P357, DOI 10.1136/emermed-2017-206735; Inaba Y, 2012, ATHEROSCLEROSIS, V220, P128, DOI 10.1016/j.atherosclerosis.2011.06.044; Laclaustra M, 2016, J AM COLL CARDIOL, V67, P1263, DOI 10.1016/j.jacc.2015.12.056; Lauer MS, 2007, JAMA-J AM MED ASSOC, V297, P1376, DOI 10.1001/jama.297.12.1376; Lorenz MW, 2010, EUR HEART J, V31, P2041, DOI 10.1093/eurheartj/ehq189; Mach F, 2020, EUR HEART J, V41, P111, DOI [10.1093/eurheartj/ehz455, 10.15829/1560-4071-2020-3826]; MEGNIEN JL, 1992, CIRCULATION, V85, P1799, DOI 10.1161/01.CIR.85.5.1799; Naqvi TZ, 2010, J AM SOC ECHOCARDIOG, V23, P809, DOI 10.1016/j.echo.2010.05.005; Pen A, 2013, EUR HEART J, V34, P1075, DOI 10.1093/eurheartj/ehs473; Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI 10.1093/eurheartj/ehw106; Roth GA, 2015, NEW ENGL J MED, V372, P1333, DOI 10.1056/NEJMoa1406656; Yeboah J, 2015, CIRCULATION, V132, P916, DOI 10.1161/CIRCULATIONAHA.115.016846; Yeboah J, 2012, JAMA-J AM MED ASSOC, V308, P788, DOI 10.1001/jama.2012.9624; Yerly P, 2015, J CARDIOVASC TRANSL, V8, P138, DOI 10.1007/s12265-015-9617-5; Yerly P, 2013, INT J CARDIOVAS IMAG, V29, P589, DOI 10.1007/s10554-012-0124-3	30	1	1	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JUL	2021	50	4					280	285		10.1024/0301-1526/a000949			6	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QY	33789435				2022-04-28	WOS:000695708700005
J	Awouters, J; Jardinet, T; Hiele, M; Laenen, A; Dymarkowski, S; Fourneau, I; Maleux, G				Awouters, Joris; Jardinet, Thomas; Hiele, Martin; Laenen, Annouschka; Dymarkowski, Steven; Fourneau, Inge; Maleux, Geert			Factors predicting long-term outcomes of percutaneous angioplasty and stenting of the superior mesenteric artery for chronic mesenteric ischemia	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Angor; chronic; ischemia; mesenteric; interventional; angioplasty	BARE-METAL STENTS; ENDOVASCULAR TREATMENT; COVERED STENTS; SHEAR-STRESS	Background: To analyse the tong-term outcomes of percutaneous angioplasty and stenting of the superior mesenteric artery (SMA) in the treatment of chronic mesenteric ischemia (CMI), and to assess predictive factors for a better clinical outcome. Patients and methods: Retrospective analysis of 76 consecutive patients, treated percutaneousty for CMI between January 1999 and January 2018 and followed up until the end of 2018. Patients' pre-, peri- and post-interventional clinical and radiological data were gathered from the institutional electronic medical records. The Kaplan Meier method with tog rank test or the Cox model were used to analyse overall survival; the cumulative incidence function with Pepe and Mori test or the Fine and Grey model were used to analyse relapse-free survival, considering death as a competing event. Results: Seventy-six consecutive patients with a mean age of 72 years were included in the study. Catheter-angiography revealed an ostial or non-ostial >90% stenosis in n-23 (29.7%) and n-53 (69.7%) of included patients, respectively. Immediate clinical success was achieved in n-68 (89.5%), and procedural complications were observed in n-13 (17.1%) patients. Long-term follow-up revealed relapse of symptoms in n=21 (28.8%) patients, and overall survival estimates are 81.8%, 57.0% and 28.2% after two, five and ten years of follow-up, respectively. A trend towards longer relapse-free survival was found in the circumferential stenosis group (78.2% at five years) compared with the non-circumferential stenosis group (55.5%) (P=0.063). Conclusions: Angioplasty and stenting of the SMA for CMI is relatively safe and effective despite a substantial number of patients experiencing clinical relapse over time. Patients with focal, circumferential stenosis might have longer relapse-free survival than patients with non-circumferential stenosis.	[Awouters, Joris; Jardinet, Thomas; Dymarkowski, Steven; Maleux, Geert] Univ Hosp Leuven, Dept Radiol, Herestr 49, B-3000 Leuven, Belgium; [Hiele, Martin] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium; [Laenen, Annouschka] Interuniv Inst Biostat & Stat Bioinformat BioStat, Leuven, Belgium; [Fourneau, Inge] Univ Hosp Leuven, Dept Vasc Surg, Leuven, Belgium		Maleux, G (通讯作者)，Univ Hosp Leuven, Dept Radiol, Herestr 49, B-3000 Leuven, Belgium.	geert.maleux@uzleuven.be		Maleux, Geert/0000-0003-0598-0258			AbuRahma AF, 2013, J VASC SURG, V57, P1052, DOI 10.1016/j.jvs.2012.10.082; Ahanchi SS, 2013, J VASC SURG, V57, P1062, DOI 10.1016/j.jvs.2012.10.081; Aschenbach R, 2012, VASA, V41, P425, DOI 10.1024/0301-1526/a000232; Blauw J, 2017, J CARDIOVASC SURG, V58, P321, DOI 10.23736/S0021-9509.16.09829-3; Cardaioli P, 2007, J ENDOVASC THER, V14, P748, DOI 10.1583/1545-1550(2007)14[748:DSFRMA]2.0.CO;2; Chahid T, 2004, CARDIOVASC INTER RAD, V27, P637, DOI 10.1007/s00270-004-0225-z; Daliri A, 2010, VASA, V39, P319, DOI 10.1024/0301-1526/a000056; Fioole B, 2010, J VASC SURG, V51, P386, DOI 10.1016/j.jvs.2009.08.055; Gibbons CP, 2010, SEMIN VASC SURG, V23, P47, DOI 10.1053/j.semvascsurg.2009.12.006; Girault A, 2021, J VASC SURG; Goldman MP, 2017, ANN VASC SURG, V38, P29, DOI 10.1016/j.avsg.2016.08.009; Haben C, 2020, J VASC SURG, V71, P111, DOI 10.1016/j.jvs.2019.01.094; Heiss P, 2008, ROFO-FORTSCHR RONTG, V180, P906, DOI 10.1055/s-2008-1027699; Jundt MC, 2019, CARDIOVASC INTER RAD, V42, P1293, DOI 10.1007/s00270-019-02264-z; Karkkainen JM, 2020, EUR J VASC ENDOVASC, V59, P910, DOI 10.1016/j.ejvs.2020.02.015; LaDisa JF, 2005, J APPL PHYSIOL, V98, P947, DOI 10.1152/japplphysiol.00872.2004; Landis MS, 2005, J VASC INTERV RADIOL, V16, P1319, DOI 10.1097/01.RVI.0000171697.09811.0E; Lee RW, 2008, ANN VASC SURG, V22, P541, DOI 10.1016/j.avsg.2007.09.019; Loffroy R, 2010, ABDOM IMAGING, V35, P306, DOI 10.1007/s00261-009-9515-x; Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035; Malgor RD, 2010, ANN VASC SURG, V24, P1094, DOI 10.1016/j.avsg.2010.07.001; Oderich GS, 2013, J VASC SURG, V58, P1316, DOI 10.1016/j.jvs.2013.05.013; Pillai AK, 2018, J VASC INTERV RADIOL, V29, P642, DOI 10.1016/j.jvir.2017.11.024; Sacks David, 2003, J Vasc Interv Radiol, V14, pS199; Schermerhorn ML, 2009, J VASC SURG, V50, P341, DOI 10.1016/j.jvs.2009.03.004; Turba UC, 2012, EUR RADIOL, V22, P1372, DOI 10.1007/s00330-011-2376-z; van Dijk LJD, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3609-8; Zahringer M, 2007, J ENDOVASC THER, V14, P460, DOI 10.1177/152660280701400405; Zerbib P, 2008, LANGENBECK ARCH SURG, V393, P865, DOI 10.1007/s00423-008-0355-x	29	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	NOV	2021	50	6					431	438		10.1024/0301-1526/a000964			8	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6JL	34231372				2022-04-28	WOS:000753518900004
J	Li, KB; Zemmrich, C; Bramlage, P; Persson, AB; Sacirovic, M; Ritter, O; Buschmann, E; Buschmann, I; Hillmeister, P				Li, Kangbo; Zemmrich, Claudia; Bramlage, Peter; Persson, Anja Bondke; Sacirovic, Mesud; Ritter, Oliver; Buschmann, Eva; Buschmann, Ivo; Hillmeister, Philipp			Effect of ACEI and ARB treatment on nitric oxide-dependent endothelial function	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						flow mediated dilation; nitric oxide; kallikrein-kinin-system; angiotensin-converting-enzyme inhibitors; angiotensin receptor blockers	ANGIOTENSIN-CONVERTING ENZYME; TYPE-2 RECEPTOR; ARTERIOGENESIS; INHIBITION; BIOAVAILABILITY; HYPERTENSION; DYSFUNCTION; GUIDELINES	Background: Angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are widely used as a first-line therapy for the treatment of cardiovascular disease. Here, ACEI modulate the bradykinin receptor (BDKRB1 and BDKRB2) system and NO-dependent endothelial function, thus determining cardiovascular health and regenerative arteriogenesis. The current study aims at evaluating nitric oxide-dependent endothelial function, and gene expression of bradykinin receptors in peripheral blood mononuclear cells (PBMC) from patients with ACEI or ARB treatment. Patients and methods: The WalkByLab has been established to screen cardiovascular patients for peripheral artery disease and coronary artery disease. In total 177 patients from WalkByLab with heterogenous disease and risk status were randomly selected, divided according to their medication history into the following groups: 1. ACEI group, 2. ARB group or 3. non-ACE/ARB group. Total plasma nitrite/nitrate (NO) levels were measured, endothelial function was evaluated by assessing flow meditated dilation (FMD). PBMC were isolated from peripheral whole blood, and gene expression (qRT.PCR) of bradykinin receptors and angiotensin converting enzyme were assessed. Results: Plasma total NO concentration it the ACEI group (24.66 +/- 16.28, mu mol/l) was increased as compared to the ARB group (18.57 +/- 11.58, mu mol/l, P=0.0046) and non-ACE/ARB group (16.83 +/- 8.64, mu mol/l, P=0.0127) in patients between 40 to 90 years of age. However, FMD values (%) in the ACEI group (7.07 +/- 2.40, %) were similar as compared to the ARB (6.35 +/- 2.13, %) and non-ACE/ARB group (6.51 +/- 2.15, %), but significantly negatively correlated with age. Interestingly, BDKRB1 mRNA level was significantly higher and BDKRB2 mRNA level lower in the ACEI group (BDKRB1 3.88-fold +/- 1.05, BDKRB2 0.22-fold +/- 0.04) as compared to the non-ACE/ARB group (BDKRB1 1.00-fold +/- 0.39, P<0.0001, BDKRB2 1.00-fold +/- 0.45, P=0.0136). Conclusions: ACEI treatment enhances total nitrite/nitrate concentration, furthermore, upregulates BDKRB1 in PBMC, but downregulates BDKRB2 mRNA expression. FMD is a strong determinant of vascular aging and is sensitive to underlying heterogenous cardiovascular diseases.	[Li, Kangbo; Sacirovic, Mesud; Buschmann, Ivo; Hillmeister, Philipp] Campus Univ Clin Brandenburg, Ctr Internal Med 1, Deutsch Angiol Zentrum Brandenburg Berlin DAZB, Dept Angiol,Brandenburg Med Sch Theodor Fontane, Brandenburg, Germany; [Li, Kangbo; Persson, Anja Bondke] Charite Univ Med Berlin, Berlin, Germany; [Li, Kangbo; Persson, Anja Bondke] Free Univ Berlin, Berlin, Germany; [Li, Kangbo; Persson, Anja Bondke] Humboldt Univ, Berlin, Germany; [Zemmrich, Claudia; Bramlage, Peter] Inst Pharmacol & Prevent Med, Cloppenburg, Germany; [Ritter, Oliver] Campus Univ Clin Brandenburg, Brandenburg Med Sch Theodor Fontane, Ctr Internal Med 1, Dept Cardiol, Brandenburg, Germany; [Ritter, Oliver; Buschmann, Ivo; Hillmeister, Philipp] Joint Fac Brandenburg Univ Technol Cottbus Senfte, Brandenburg Med Sch Theodor Fontane, Fac Hlth Sci, Cottbus, Germany; [Ritter, Oliver; Buschmann, Ivo; Hillmeister, Philipp] Univ Potsdam, Brandenburg Med Sch Theodor Fontane, Potsdam, Germany; [Buschmann, Eva] Univ Clin Graz, Dept Cardiol, Graz, Austria		Hillmeister, P (通讯作者)，Campus Univ Clin Brandenburg, Dept Angiol, Ctr Internal Med 1, Fac Hlth Sci FGW,Brandenburg Med Sch MHB, Hochstr 29, D-14770 Brandenburg, Germany.; Hillmeister, P (通讯作者)，Campus Univ Clin Brandenburg, WalkByLab, Hochstr 29, D-14770 Brandenburg, Germany.	p.hillmeister@klinikum-brandenburg.de			Ministry of Science, Research and Culture, Federal State of Brandenburg (Ministeriums fur Wissenschaft, Forschung und Kultur des Landes Brandenburg); Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung)Federal Ministry of Education & Research (BMBF); Chinese Scholarship Council (CSC)China Scholarship Council	This study was supported by the Ministry of Science, Research and Culture, Federal State of Brandenburg (Ministeriums fur Wissenschaft, Forschung und Kultur des Landes Brandenburg), the Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung) and the Chinese Scholarship Council (CSC).	Abadir PM, 2006, HYPERTENSION, V48, P316, DOI 10.1161/01.HYP.0000228997.88162.a8; Aboyans V, 2017, KARDIOL POL, V75, P1065, DOI 10.5603/KP.2017.0216; AUCHSCHWELK W, 1993, CARDIOVASC RES, V27, P312, DOI 10.1093/cvr/27.2.312; Bockmann S, 2000, J LEUKOCYTE BIOL, V68, P587; Brix M, 2017, VASA, V46, P37, DOI 10.1024/0301-1526/a000600; Burnier M, 2001, CIRCULATION, V103, P904, DOI 10.1161/01.CIR.103.6.904; Buschmann I, 1999, NEWS PHYSIOL SCI, V14, P121; Buschmann IR, 2003, CIRCULATION, V108, P610, DOI 10.1161/01.CIR.0000074209.17561.99; Carey RM, 2000, HYPERTENSION, V35, P155, DOI 10.1161/01.HYP.35.1.155; Ceconi C, 2007, CARDIOVASC RES, V73, P237, DOI 10.1016/j.cardiores.2006.10.021; Chen JW, 2002, AM J CARDIOL, V90, P974, DOI 10.1016/S0002-9149(02)02664-4; Deanfield JE, 2007, CIRCULATION, V115, P1285, DOI 10.1161/CIRCULATIONAHA.106.652859; Erdos EG, 2010, HYPERTENSION, V55, P214, DOI 10.1161/HYPERTENSIONAHA.109.144600; Giani JF, 2014, J AM SOC NEPHROL, V25, P2752, DOI 10.1681/ASN.2013091030; Hillmeister P, 2020, ACTA PHYSIOL, V228, DOI 10.1111/apha.13445; Hillmeister P, 2011, CIRC RES, V109, P524, DOI 10.1161/CIRCRESAHA.111.240986; Imanishi T, 2008, HYPERTENS RES, V31, P575, DOI 10.1291/hypres.31.575; Ito A, 2002, CIRC J, V66, P811, DOI 10.1253/circj.66.811; Knuuti J, 2020, EUR HEART J, V41, P407, DOI 10.1093/eurheartj/ehz425; Kuhr F, 2010, NEUROPEPTIDES, V44, P145, DOI 10.1016/j.npep.2009.12.004; Manolis AJ, 2010, HYPERTENS RES, V33, P772, DOI 10.1038/hr.2010.82; Maruhashi T, 2013, HEART, V99, P1837, DOI 10.1136/heartjnl-2013-304739; Merino VF, 2009, J MOL MED, V87, P953, DOI 10.1007/s00109-009-0501-0; Perhal A, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00032; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Prior BM, 2003, ENDOTHELIUM-J ENDOTH, V10, P207, DOI 10.1080/10623320390246388; Sancheti S, 2018, INDIAN HEART J, V70, P622, DOI 10.1016/j.ihj.2018.01.008; Shen B, 2007, J AM SOC NEPHROL, V18, P1140, DOI 10.1681/ASN.2006101127; Varin R, 2000, CIRCULATION, V102, P351; Williams B, 2018, BLOOD PRESSURE, V27, P314, DOI [10.1080/08037051.2018.1527177, 10.1097/HJH.0000000000001961]; Wilmink HW, 1999, J AM COLL CARDIOL, V34, P140, DOI 10.1016/S0735-1097(99)00154-0; Wu HY, 2014, CLIN SCI, V126, P441, DOI 10.1042/CS20130204; Yeboah J, 2007, CIRCULATION, V115, P2390, DOI 10.1161/CIRCULATIONAHA.106.678276; Zietzer A, 2017, ACTA PHYSIOL, V220, P251, DOI 10.1111/apha.12820	34	1	1	1	1	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	NOV	2021	50	6					413	422		10.1024/0301-1526/a000971			10	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6JL	34428929	hybrid			2022-04-28	WOS:000753518900002
J	Kalka, C; Surberg, D; Baumgartner, I; Diehm, N; Heiss, C				Kalka, Christoph; Surberg, Denise; Baumgartner, Iris; Diehm, Nicolas; Heiss, Christian			Low carotid intima media thickness excludes lower limb peripheral artery disease	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Letter									[Kalka, Christoph; Surberg, Denise] Marien Hosp, Dept Cardiovasc Med, Bruehl, Germany; [Kalka, Christoph; Diehm, Nicolas] Vasc Ctr Cent Switzerland, Aargau, Switzerland; [Baumgartner, Iris] Inselspital Bern, Dept Angiol, Bern, Switzerland; [Heiss, Christian] Univ Surrey, Dept Clin & Expt Med, Guildford, Surrey, England		Heiss, C (通讯作者)，Univ Surrey, Fac Hlth & Med Sci, Stag Hill, Guildford GU2 7XH, Surrey, England.	c.heiss@surrey.ac.uk		Heiss, Christian/0000-0002-3212-8995			[Anonymous], PER ART DIS DIAGN MA; Bryniarski KL, 2018, POSTEP KARDIOL INTER, V14, P52, DOI 10.5114/aic.2018.74355; Frank U, 2019, VASA, V48, P7, DOI 10.1024/0301-1526/a000834; McGovern A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012801; Song PG, 2019, LANCET GLOB HEALTH, V7, pE1020, DOI 10.1016/S2214-109X(19)30255-4; Vlachopoulos C, 2015, ATHEROSCLEROSIS, V241, P507, DOI 10.1016/j.atherosclerosis.2015.05.007	6	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	JUL	2021	50	4					317	318		10.1024/0301-1526/a000950			2	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	UP9QY	34219474				2022-04-28	WOS:000695708700011
J	Blessing, E; Antaredja, M; Tilemann, L; Oberacker, R				Blessing, Erwin; Antaredja, Muliadi; Tilemann, Lisa; Oberacker, Ralph			Implantation of vascular mimetic implants in challenging chronic total occlusions - Supera (TM) Extreme	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Vascular mimetic implants; peripheral arterial disease; chronic total occlusions	SELF-EXPANDING STENTS; ARTERY-DISEASE; FEMOROPOPLITEAL; OUTCOMES	Standard nitinol stents (SNS), with or without drug eluting technology, are an essential tool within the interventional armamentarium in the treatment of patients with peripheral arterial disease. However, they are plagued by a number of limitations: a.) stent fractures, although observed predominately in first-generation stents, do still occur in state-of-the art stent platforms, b.) lack of radial strength, resulting in inadequate stent expansion, c.) kinking up to a complete collapse of the stent, therefore compromising its use in areas of high mechanical stress such as bending zones. In contrast, the interwoven design of the Supera (TM) stent, also referred to as "vascular mimetic implant", overcomes all of the above limitations of SNS. Several registries and studies not only confirmed its mechanical superiority (lack of stent fractures etc.) but also demonstrated remarkable clinical performance (patency and freedom from target lesion revascularization), despite its use in challenging lesions (calcification etc.) and territories (popliteal arteries etc.). Increasing confidence in the mechanical properties of the Supera (TM) stent platform prompted interventionalists to further "push the limits" of this unique implant. The present article summarizes the clinical data and shows examples of "extreme" applications of this dedicated stent platform.	[Blessing, Erwin; Antaredja, Muliadi; Tilemann, Lisa; Oberacker, Ralph] SRH Klinikum Karlsbad Langensteinbach, Dept Internal Med, Vasc Ctr, Karlsbad, Germany		Blessing, E (通讯作者)，SRH Klinikum Karlsbad Langensteinbach, Guttmann Str 1, D-76307 Karlsbad, Germany.	erwin_blessing@yahoo.de					Aghel A, 2014, EXPERT REV CARDIOVAS, V12, P833, DOI 10.1586/14779072.2014.918505; Bishu K, 2015, VASC HEALTH RISK MAN, V11, P387, DOI 10.2147/VHRM.S70229; Chevalier B, 1998, AM J CARDIOL, V82, P943, DOI 10.1016/S0002-9149(98)00510-4; Dias-Neto M, 2018, J ENDOVASC THER, V25, P334, DOI 10.1177/1526602818763352; Garcia L, 2015, CIRC-CARDIOVASC INTE, V8, DOI 10.1161/CIRCINTERVENTIONS.113.000937; Garcia LA, 2017, CATHETER CARDIO INTE, V89, P1259, DOI 10.1002/ccd.27058; Palena LM, 2018, J ENDOVASC THER, V25, P588, DOI 10.1177/1526602817753388; Palena LM, 2017, CATHETER CARDIO INTE, V89, P910, DOI 10.1002/ccd.26863; Scheinert D, 2005, J AM COLL CARDIOL, V45, P312, DOI 10.1016/j.jacc.2004.11.026; Scheinert D, 2013, JACC-CARDIOVASC INTE, V6, P65, DOI 10.1016/j.jcin.2012.09.011; Werner M, 2014, EUROINTERVENTION, V10, P861, DOI 10.4244/EIJV10I7A147	11	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	NOV	2021	50	6					475	479		10.1024/0301-1526/a000918			5	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6JL	33118474				2022-04-28	WOS:000753518900010
J	Muhlberger, D; Brenner, E; Brockhoff, H; Frings, N; Geier, B; Mumme, A; Reich-Schupke, S; Rohrer, AL; Steffen, HP; Stenger, D; Stucker, M; Hummel, T				Muhlberger, D.; Brenner, E.; Brockhoff, H.; Frings, N.; Geier, B.; Mumme, A.; Reich-Schupke, S.; Rohrer, A. L.; Steffen, H. -P.; Stenger, D.; Stucker, M.; Hummel, T.			External valvuloplasty of the saphenofemoral junction in insufficient great saphenous veins - six weeks results of a prospective multicentre trial (vol 49, pg 411, 2020)	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Correction																	Muhlberger D, 2020, VASA, V49, P411, DOI 10.1024/0301-1526/a000874	1	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	NOV	2021	50	6					480	480		10.1024/0301-1526/a000874			1	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6JL		Bronze			2022-04-28	WOS:000753518900011
J	Moulakakis, KG; Papadoulas, S; Kakisis, JD				Moulakakis, Konstantinos G.; Papadoulas, Spyros; Kakisis, John D.			The role of parallel grafts on the treatment of ruptured juxtarenal aortic aneurysms	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Editorial Material							OPEN REPAIR		[Moulakakis, Konstantinos G.; Papadoulas, Spyros] Patras Univ Hosp, Vasc Surg Dept, Patras, Greece; [Kakisis, John D.] Natl & Kapodistrian Univ Athens, Attikon Teaching Hosp, Sch Med, Dept Vasc Surg, Athens, Greece		Moulakakis, KG (通讯作者)，Patras Univ Hosp, Vasc Surg Dept, Patras, Greece.	konmoulakakis@yahoo.gr					Bin Jabr A, 2016, J VASC SURG, V63, P625, DOI 10.1016/j.jvs.2015.09.023; Chaufour X, 2020, EUR J VASC ENDOVASC, V59, P40, DOI 10.1016/j.ejvs.2019.05.010; Donas KP, 2015, ANN SURG, V262, P546, DOI 10.1097/SLA.0000000000001405; Keschenau PR, 2021, VASA, V50, P356, DOI 10.1024/0301-1526/a000955; Latz CA, 2020, ANN VASC SURG, V68, P34, DOI 10.1016/j.avsg.2020.04.073; Mehta A, 2021, J VASC SURG, V25; Oderich GS, 2021, J VASC SURG, V73, p4S, DOI 10.1016/j.jvs.2020.06.011; Rao R, 2015, J VASC SURG, V61, P242, DOI 10.1016/j.jvs.2014.08.068; Wanhainen A, 2019, EUR J VASC ENDOVASC, V57, P8, DOI 10.1016/j.ejvs.2018.09.020; Zimmermann A, 2021, CHAR CROSS 2021 S 20	10	0	0	0	0	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	SEP	2021	50	5					321	322		10.1024/0301-1526/a000958			2	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	YW6GV	34482763				2022-04-28	WOS:000753511900001
J	Kieback, AG; Gahwiler, R; Thalhammer, C				Kieback, Arne G.; Gaehwiler, Roman; Thalhammer, Christoph			PAD screening: why? whom? when? how? - a systematic review	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Review						Peripheral arterial disease; lower extremity arterial disease; screening; ankle-brachial index; systematic review; claudication	PERIPHERAL ARTERIAL-DISEASE; ANKLE-BRACHIAL INDEX; CORONARY-ARTERY; VASCULAR-DISEASE; CLAUDICATION; PREVALENCE; MORTALITY; DIAGNOSIS; RISK; INTERVENTION	An estimated 237 million people suffer from peripheral arterial disease (PAD), which is associated with high morbidity and mortality, and prevalence is still increasing. Currently, we do not have any randomized trials that compare screening to no screening specifically for PAD in the general population. Presently, PAD screening is not generally established. This systematic review gives an overview of relevant literature and guidelines. Screening usually focuses on ankle-brachial index (ABI)-measurement, which enables detection of asymptomatic and symptomatic PAD, but has limitations in diabetics. There are no sufficient data on PAD screening. Guideline recommendations are heterogeneous. While some advocate no screening until better data are available, most recommend selective screening despite insufficient data on morbidity and mortality reduction in consequence of screening. We support the only evidence-based screening strategy for PAD: combined screening for abdominal aortic aneurysm (AAA), PAD and arterial hypertension in men aged 65-74 according to the VIVA study. We additionally suggest a new simple three-step screening strategy for symptomatic PAD in all individuals aged 40 and older, who see a general practitioner: Asking one question ("Do you have pain or cramps in the legs during normal walking?") followed by physical examination (normal lower extremity pulse status?) in those, whose answer is "yes", and ABI measurement unless all pulses are normal.	[Kieback, Arne G.; Gaehwiler, Roman; Thalhammer, Christoph] Kantonsspital Aarau, Div Angiol, Med Univ Dept, Aargau, Switzerland		Kieback, AG (通讯作者)，Kantonsspital Aarau AG, Div Angiol, Med Univ Dept, Tellstr 25, CH-5000 Aarau, Switzerland.	arne.kieback@ksa.ch					Aboyans V, 2005, J AM COLL CARDIOL, V46, P815, DOI 10.1016/j.jacc.2005.05.066; Aboyans V, 2021, VASA, V50, P85; Aboyans V, 2018, EUR HEART J, V39, P763, DOI 10.1093/eurheartj/ehx095; Alahdab F, 2015, J VASC SURG, V61, p42S, DOI 10.1016/j.jvs.2014.12.008; Anand SS, 2017, LANCET; Bell AD, 2013, INT J CLIN PRACT, V67, P996, DOI 10.1111/ijcp.12148; Bonaca MP, 2020, N ENGL J MED; Collet JP, 2018, INT J CARDIOL, V254, P36, DOI 10.1016/j.ijcard.2017.11.081; Conte MS, 2015, J VASC SURG, V61, p2S, DOI 10.1016/j.jvs.2014.12.009; Diederichsen ACP, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1082-6; Diehm C, 2006, EUR HEART J, V27, P1743, DOI 10.1093/eurheartj/ehl092; Dopheide JF, 2019, EUR HEART J CARDIOVA; Eiberg JP, 2010, EUR J VASC ENDOVASC, V40, P507, DOI 10.1016/j.ejvs.2010.06.002; Espinola-Klein C, 2008, CIRCULATION, V118, P961, DOI 10.1161/CIRCULATIONAHA.107.763227; Fores R, 2014, MED CLIN-BARCELONA, V143, P335, DOI 10.1016/j.medcli.2013.10.029; Forsythe RO, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3277; Frank U, 2019, VASA, V48, P7, DOI 10.1024/0301-1526/a000834; Gerhard-Herman MD, 2017, J AM COLL CARDIOL, V69, pE71, DOI 10.1016/j.jacc.2016.11.007; Hansen TB, 2020, EUR J VASC ENDOVASC; Harrison ML, 2011, BLOOD PRESS MONIT, V16, P138, DOI 10.1097/MBP.0b013e328346a839; Heart Protection Study Collaborati, 2007, J VASC SURG, V45, P645, DOI 10.1016/j.jvs.2006.12.054; Heidrich H, 2004, VASA-J VASCULAR DIS, V33, P63, DOI 10.1024/0301-1526.33.2.63; Hirsch AT, 2001, JAMA-J AM MED ASSOC, V286, P1317, DOI 10.1001/jama.286.11.1317; Hoyer C, 2019, ATHEROSCLEROSIS, V289, P21, DOI 10.1016/j.atherosclerosis.2019.08.005; Itoga NK, 2018, VASC MED, V23, P97, DOI [10.1177/1358863X17745371, 10.1177/1358863x17745371]; Jude EB, 2010, DIABETIC MED, V27, P4, DOI 10.1111/j.1464-5491.2009.02866.x; Kaufmann C, 2013, SWISS MED WKLY, V143, DOI 10.4414/smw.2013.13761; Kayhan A, 2012, EUR J RADIOL, V81, P542, DOI 10.1016/j.ejrad.2011.01.100; Kieback AG, 2012, VASA, V41, P105, DOI 10.1024/0301-1526/a000172; Kieback AG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224608; Lawall H, 2017, VASA, V46, P79, DOI 10.1024/0301-1526/a000603; LENG GC, 1992, J CLIN EPIDEMIOL, V45, P1101, DOI 10.1016/0895-4356(92)90150-L; Lin JS, 2013, ANN INTERN MED, V159, P333, DOI 10.7326/0003-4819-159-5-201309030-00007; Lindholt JS, 2020, CLIN EPIDEMIOL, V12, P95, DOI 10.2147/CLEP.S238502; Lindholt JS, 2017, LANCET, V390, P2256, DOI 10.1016/S0140-6736(17)32250-X; Londero LS, 2016, J VASC SURG, V63, P1305, DOI 10.1016/j.jvs.2015.11.044; Norgren L, 2007, INT ANGIOL, V26, P81; Ramos R, 2011, ATHEROSCLEROSIS, V214, P474, DOI 10.1016/j.atherosclerosis.2010.11.015; Rihal CS, 1999, CIRCULATION, V100, P171, DOI 10.1161/01.CIR.100.2.171; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; Saw J, 2006, J AM COLL CARDIOL, V48, P1567, DOI 10.1016/j.jacc.2006.03.067; Schroder F, 2006, J VASC SURG, V44, P531, DOI 10.1016/j.jvs.2006.05.016; Soejima H, 2010, THROMB HAEMOSTASIS, V104, P1085, DOI 10.1160/TH10-05-0333; Sogaard R, 2018, BRIT J SURG, V105, P1283, DOI 10.1002/bjs.10872; Song PG, 2019, LANCET GLOB HEALTH, V7, pE1020, DOI 10.1016/S2214-109X(19)30255-4; Wilson JMG, 1968, PRINCIPLES PRACTICE; Wohlfahrt P, 2011, INT ANGIOL, V30, P256; Xu DC, 2013, CAN J CARDIOL, V29, P492, DOI 10.1016/j.cjca.2012.06.014; Zhan YQ, 2016, VASA, V45, P31, DOI 10.1024/0301-1526/a000492	49	0	0	3	7	HOGREFE AG-HOGREFE AG SUISSE	BERN	LANGGASSSTRASSE 76, BERN, SWITZERLAND	0301-1526	1664-2872		VASA	Vasa	FEB	2021	50	2					85	91		10.1024/0301-1526/a000897			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	QQ5PH	32674716				2022-04-28	WOS:000624575300002
J	Jalaie, H; Gombert, A; Grommes, J; Schleimer, K; Kurstjens, RLM; de Graaf, R; Wittens, CHA; Razavi, M; Barbati, ME				Jalaie, Houman; Gombert, Alexander; Grommes, Jochen; Schleimer, Karina; Kurstjens, Ralph L. M.; de Graaf, Rick; Wittens, Cees H. A.; Razavi, Mahmood; Barbati, Mohammad Esmaeil			Outcome of stenting in central venous obstruction of benign etiology	VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE			English	Article						Superior vena cava syndrome; endovascular recanalization; venous stenting	VENA-CAVA SYNDROME; ENDOVASCULAR TREATMENT; ANGIOPLASTY; PLACEMENT; STENOSIS; EXPERIENCE; HISTORY	Background: The aim of this study is to evaluate long term outcome in patients treated for benign superior vena cava (SVC) syndrome by endovascular techniques. Patients and methods: Between 2015 and 2018, 62 patients suffering from central venous obstruction of benign etiology underwent balloon angioplasty with stent placement for venous obstruction in our department. Patency was assessed clinically, using duplex ultrasound in all patients or with CT-phlebography in selected cases. Results: Median age was 60 years (23-83), forty-one patients (66%) had central venous devices. Swelling of the arm and face were the main symptoms (71%). During the median follow up of 22 months (9-38), cumulative primary patency was 71% after venous stenting. The cumulative assisted primary and the secondary patency were 85% and 92%, respectively. Conclusions: Recanalization and stenting of central vein obstruction has turned out to be the technique of reference and provides satisfactory mid-term patency rates. After adjusting for the risk factors, presence of AV-fistula remained a significant risk factor for recurrent stenosis or loss of patency after intervention.	[Jalaie, Houman; Gombert, Alexander; Schleimer, Karina; Barbati, Mohammad Esmaeil] Univ Hosp Aachen, Dept Vasc Surg, Aachen, Germany; [Grommes, Jochen] Clin Ctr Rhein Maas, Dept Vasc Surg, Wurselen, Germany; [Kurstjens, Ralph L. M.; Wittens, Cees H. A.] Maastricht Univ Med Ctr, Dept Vasc Surg, Maastricht, Netherlands; [de Graaf, Rick] Clin Ctr Friedrichshafen, Dept Radiol & Intervent Radiol, Friedrichshafen, Germany; [Razavi, Mahmood] St Joseph Heart & Vasc Ctr, Orange, CA USA		Barbati, ME (通讯作者)，Univ Hosp RWTH, Vasc Surg, Pauwelsstr 30, D-52072 Aachen, Germany.	mbarbati@ukaachen.de	Barbati, Mohammad Esmaeil/F-5529-2016	Barbati, Mohammad Esmaeil/0000-0003-0709-8533			Bakken AM, 2007, J VASC SURG, V45, P776, DOI 10.1016/j.jvs.2006.12.046; Baltayiannis N, 2005, J BUON, V10, P377; Molinelli LB, 2018, EUR J VASC ENDOVASC, V55, P292, DOI 10.1016/j.ejvs.2017.09.006; Barshes NR, 2007, VASCULAR, V15, P314, DOI 10.2310/6670.2007.00067; BEATHARD GA, 1992, KIDNEY INT, V42, P1390, DOI 10.1038/ki.1992.431; Breault S, 2017, EUR RADIOL, V27, P97, DOI 10.1007/s00330-016-4354-y; Brown KT, 2005, CARDIOVASC INTER RAD, V28, P372, DOI 10.1007/s00270-004-0001-0; Byrd CL, 2002, PACE, V25, P804, DOI 10.1046/j.1460-9592.2002.t01-1-00804.x; Clark K, 2017, J VASC INTERV RADIOL, V28, P602, DOI 10.1016/j.jvir.2016.12.1222; Courtheoux P, 2003, ANN THORAC SURG, V75, P158, DOI 10.1016/S0003-4975(02)04293-5; DAVIDSON CJ, 1991, KIDNEY INT, V40, P91, DOI 10.1038/ki.1991.185; de Graaf R, 2015, CARDIOVASC INTER RAD, V38, P1198, DOI 10.1007/s00270-015-1068-5; Epstein LM, 1999, CIRCULATION, V100, P516, DOI 10.1161/01.CIR.100.5.516; KOVALIK EC, 1994, KIDNEY INT, V45, P1177, DOI 10.1038/ki.1994.156; Lee T, 2014, J VASC ACCESS, V15, P298, DOI 10.5301/jva.5000212; MacRae JM, 2005, ASAIO J, V51, P77, DOI 10.1097/01.MAT.0000151921.95165.1E; Mallios A, 2015, ANN VASC SURG, V29, DOI 10.1016/j.avsg.2015.04.064; Mezzano D, 2001, KIDNEY INT, V60, P1844, DOI 10.1046/j.1523-1755.2001.00998.x; Monaco RG, 2003, EUR J CARDIO-THORAC, V24, P208, DOI 10.1016/S1010-7940(03)00293-8; Oderich GSC, 2000, J VASC SURG, V32, P760, DOI 10.1067/mva.2000.107988; Oguzkurt L, 2005, EUR J RADIOL, V55, P237, DOI 10.1016/j.ejrad.2004.11.006; Rice TW, 2006, MEDICINE, V85, P37, DOI 10.1097/01.md.0000198474.99876.f0; Rizvi AZ, 2008, J VASC SURG, V47, P372, DOI 10.1016/j.jvs.2007.09.071; Schmidli J, 2018, EUR J VASC ENDOVASC, V55, P757, DOI 10.1016/j.ejvs.2018.02.001; Sfyroeras GS, 2017, EUR J VASC ENDOVASC, V53, P238, DOI 10.1016/j.ejvs.2016.11.013; Smayra T, 2001, CARDIOVASC INTER RAD, V24, P388, DOI 10.1007/s00270-001-0055-1; Surowiec Scott M, 2004, Vasc Endovascular Surg, V38, P349, DOI 10.1177/153857440403800407; Tan GM, 2019, EUR J VASC ENDOVASC, V57, P417, DOI 10.1016/j.ejvs.2018.10.009; Thony F, 1999, EUR RADIOL, V9, P965, DOI 10.1007/s003300050777; Wilkoff BL, 2009, HEART RHYTHM, V6, P1085, DOI 10.1016/j.hrthm.2009.05.020; Wilson E, 2002, CLIN ONCOL-UK, V14, P228, DOI 10.1053/clon.2002.0088; Wilson LD, 2007, NEW ENGL J MED, V356, P1862, DOI 10.1056/NEJMcp067190	32	0	0	0	0	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0301-1526			VASA	Vasa	JAN	2021	50	1			SI		45	51		10.1024/0301-1526/a000917			7	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	PQ4VY	33112212				2022-04-28	WOS:000606545800007
